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Plant natural products are a valuable source of compounds with a healthy potential effect on
living organisms, including animals and humans. These natural compounds are commonly called
phytochemicals, specifically indicating their origin from the plant kingdom. It is frequently reported
that phytochemicals merge with phytotherapeutics, which are molecules with a keen effect on health.
This Special Issue entitled “Biological and Pharmacological Activity of Plant Natural Compounds” focused
its attention on such plant-derived products and aimed to expand our knowledge on bioactive effects
in preclinical models.
This Special Issue consisted of 4 reviews and 11 research articles that substantially contributed to
the mission of Molecules, i.e., to increase scientists’ and readers’ perspectives and knowledge on plant
natural products.
The first review evaluated Tabebuia impetiginosa (Mart. ex DC.) Mattos, an Amazonian plant
traditionally used against fever, malaria, bacterial and fungal infections, and skin diseases [1]. The
work emphasized that the main effect of this plant could derive from its anti-inflammatory activity
together with the presence of immunomodulatory compounds. In addition, the authors suggested that
even if the biological effects of T. impetiginosa are clearly detectable, future research needs to better
characterize its mechanisms of action, which until now remain elusive.
The comprehensive work of De Carvalho and collaborators explored the phytochemical
composition, biological and toxicological properties of four fruit species, i.e., Talisia esculenta, Brosimum
gaudichaudii, Genipa americana, and Bromelia antiacantha [2]. They reported that these plants demonstrated
anti-inflammatory, antitumor, and photosensitizing properties, in addition to providing key molecules
with pharmacological and healthy activity.
Another review investigated the wide spectrum of biological activities of epigallocatechin gallate
(EGCG), the main bioactive component of tea [3]. The mechanism of action along with signaling
pathways and its pharmacological properties (antioxidative, anti-inflammatory, and antitumor) were
reported, suggesting that EGCG could play a key role in the future treatment or prevention of cancer.
Interestingly, the work of Diniz and co-authors evaluated the antidepressant effects of cinnamic
acids [4]. Such molecules, as reported in different animal model experiments of behavioral disorders,
indicated their potential applicability as antidepressant drugs, given their low costs in certain cases.
Cinnamic acids could have a future in the treatment of depression and other psychiatric conditions.
In addition to reviews, 11 preclinical studies were performed, ranging from the pharmacological
effects to the biological impact on cell processes and/or signaling pathways.
Mahonia aquifolium (Pursh) Nutt. is a plant with potential anticancer effects. It has been studied in
association with doxorubicin in lung cell models demonstrating stimulating antiproliferative results [5].
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M. aquifolium extract showed apoptosis activation, cell cycle modulation, and a decrease in the invasion
process. Furthermore, the synergistic effects of this plant extract and doxorubicin (with the subsequent
decrease in toxic effects) suggested its potential application in higher models.
Seeds of Pharbitis nil (L.) Choisy, a traditional plant used in East Asia to treat inflammation and
cancer, were used in cell models of colorectal cancer to evaluate the antiproliferative effects of the
purified extract [6]. Cell cycle modulation and apoptosis induction were observed, with changes in
the RAS/ERK and AKT/mTOR pathways. In addition, the extract preserved muscle cell function,
suggesting the seeds of P. nil as a promising novel nature-derived drug against colorectal cancer.
Four different secoiridoids were studied for their potential anticancer effects on human epidermoid
carcinoma (A431) and non-small cell lung cancer (A549) cell lines [7]. One of these compounds,
multifloroside showed the highest inhibitory activity against A431 cells, with the ability to suppress
colony formation, induce S cell cycle arrest, and increase reactive oxygen species (ROS) production
and mitochondrial membrane potential.
A work on the phenolic compounds from 18 different Hibiscus acetosella accessions were assessed
for their antibacterial activity and antioxidant activity (associated with the level of anthocyanins) [8].
For the first time, the antibacterial activity of H. acetosella was shown on the Gram-negative Pseudomonas
aeruginosa and on the Gram-positive Staphylococcus aureus, reserving an antimicrobial perspective in
higher organisms for these compounds.
Another work evaluated the influence of maltodextrin and inulin (used as a carrier) on the
quantitative and qualitative composition of the polyphenolic profile of Amelanchier alnifolia Nutt. fruit,
juice, and pomace powders, in order to study the polyphenol profile and antioxidant properties [9].
The results showed the strong effect of the processing and matrix composition on the preservation
of the antioxidant properties of A. alnifolia. The authors claimed that properly designed high-quality
powders are necessary to obtain valuable nutraceutical additives for future use in humans.
Ageratina havanensis (Kunth) R. M. King and H. Robinson was used as a basis to compare the
quantitative chemical composition of extracts in its flowering and vegetative stages [10]. This plant,
typical to the Caribbean and Texas, was also studied for its antioxidant activity and to evaluate its
effects on P-glycoprotein (P-gp) function. The results showed the content of major flavonoids of A.
havanensis, its antioxidant effects, and the ability to inhibit P-gp. Thus, this plant species is a source of
new potential inhibitors for drug efflux.
In an animal study, Wali and colleagues showed the protective effect of zingerone (ZIN) against
lipopolysaccharide-induced oxidative stress, DNA damage, and cytokine storm [11]. They reported
the strong antioxidative effect of ZIN, with the restoration of plasma enzymes and attenuated plasma
proinflammatory cytokines and sepsis biomarkers. Thus, ZIN appears to be a convincing candidate for
validation in future clinical trials for its anti-inflammatory and antioxidant properties.
Similar to ZIN, juglone (5-hydroxyl-1,4-naphthoquinone), a well known black walnut (Juglans
nigra) derivative, was evaluated as an anti-inflammatory compound in a mouse macrophage cell model
(J774.1 cells) [12]. The results showed that juglone could reduce inflammatory cytokine production and
NLRP3 inflammasome activation in macrophages, indicating this molecule to be a possible therapeutic
tool to control inflammation.
Another potential anti-inflammatory compound was nootkatone (NTK), a sesquiterpenoid found
in the essential oils of many species of the Citrus genus, tested in mice models of acute and chronic
inflammation [13]. The authors reported that NTK was effective in reducing IL1-β and TNF-α
production, COX-2 activity, and that it could antagonize the H1 receptor in acute assays. However,
further studies are necessary to understand its mechanism of action in chronic inflammation.
Furthermore, renal diseases were investigated in in vivo models. Hlophe et al. analyzed the
effects of a plant-derived lanosteryl triterpene, known as RA-3 [14]. The compound was able to
reduce blood urea nitrogen, creatinine, uric acid, and xanthine oxidase biomarkers in rats, suggesting
antihyperuricemic and nephroprotective properties. Moreover, antioxidant status with a decrease in
malondialdehyde content was observed, again indicating the potential role of RA-3 in renal diseases.
2
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Hesperidin (HSP), one of the principal bioflavonoids of Citrus fruits, was extracted from orange
bagasse and tested to eliminate dark eye circles in in vitro artificial 3D skin [15]. The most effective
methods for HSP nanonization were explored, and this nanonized compound was found to be the
most skin-friendly and could be potentially used in cosmetics.
Overall, this Special Issue significantly contributes to stressing the importance of the biological
and pharmacological activities of plant natural compounds. The aforementioned preclinical results
revealed novel molecules with exciting properties that could potentially be useful for further human
studies, for nutritional purpose, and for therapeutic aid.
Funding: This research received no external funding.
Conflicts of Interest: The authors declare no conflict of interest.
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Abstract: Tabebuia impetiginosa, a plant native to the Amazon rainforest and other parts of Latin
America, is traditionally used for treating fever, malaria, bacterial and fungal infections, and skin
diseases. Additionally, several categories of phytochemicals and extracts isolated from T. impetiginosa
have been studied via various models and displayed pharmacological activities. This review aims
to uncover and summarize the research concerning T. impetiginosa, particularly its traditional uses,
phytochemistry, and immunopharmacological activity, as well as to provide guidance for future
research. A comprehensive search of the published literature was conducted to locate original
publications pertaining to T. impetiginosa up to June 2020. The main inquiry used the following
keywords in various combinations in titles and abstracts: T. impetiginosa, Taheebo, traditional uses,
phytochemistry, immunopharmacological, anti-inflammatory activity. Immunopharmacological
activity described in this paper includes its anti-inflammatory, anti-allergic, anti-autoimmune,
and anti-cancer properties. Particularly, T. impetiginosa has a strong effect on anti-inflammatory
activity. This paper also describes the target pathway underlying how T. impetiginosa inhibits the
inflammatory response. The need for further investigation to identify other pharmacological activities
as well as the exact target proteins of T. impetiginosa was also highlighted. T. impetiginosa may provide
a new strategy for prevention and treatment of many immunological disorders that foster extensive
research to identify potential anti-inflammatory and immunomodulatory compounds and fractions
as well as to explore the underlying mechanisms of this herb. Further scientific evidence is required
for clinical trials on its immunopharmacological effects and safety.
Keywords: Tabebuia impetiginosa; Taheebo; traditional uses; immunopharmacology; immunological
disorders
1. Introduction
Historically, people have used natural products such as plants, animals, microorganisms, and other
biological resources to assuage and cure diseases [1]. Many of the commercial drugs (such as atropine,
teniposide, aescin, digoxin, silymarin, and so on) available today were initially developed from
plants and other biological resources used in traditional medicines [2,3]. Therefore, knowledge of the
traditional use of natural products plays a large role in drug discovery and development.
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Tabebuia impetiginosa (Mart. Ex DC. Mattos) is a plant belonging to the family Bignoniaceae,
which is mainly distributed in the Amazon rainforest and other tropical regions of Central and Latin
America [4]. It is not only a decorative plant but also has high pharmaceutical value. T. impetiginosa has
been used as a traditional medicine to treat various diseases and has antinociceptive, anti-edematogenic,
antibiotic, and antidepressant effects [5–7]. Moreover, the inner bark of this tree can be made into
poultice or concentrated tea to treat various skin inflammatory diseases [8]. Several categories of
compounds have been isolated and identified from T. impetiginosa, principally quinones, flavonoids,
naphthoquinones, and benzoic acids [9–12]. In recent years, many investigations have demonstrated
that extracts or compounds isolated from T. impetiginosa reveal an extensive range of pharmacological
activities such as anti-obesity, antifungal, anti-psoriatic, antioxidant, anti-inflammatory, and anti-cancer
activities [4,7,13–18]. It is particularly prominent in immunopharmacology. Typically, the mechanism
of anti-inflammatory activity of extract from the inner bark of Tabebuia was studied through a molecular
biological approach. Nevertheless, the clinical applications of T. impetiginosa have been poorly
researched, and there is a void of information on its mechanisms of action.
As far as we know, no review in the literature provides a comprehensive summary of T. impetiginosa.
Thus, in an attempt to provide a basis for the in-depth exploration and clinical application of this
plant, we reviewed the traditional medicinal uses, botany, immunopharmacology, phytochemistry,
and ethnopharmacology of T. impetiginosa, in addition to perspectives and possible directions of future
research. Furthermore, this review will be conducive to identifying the information gaps important for
future research into T. impetiginosa.
2. Methodology
A scientific literature review regarding the traditional uses, phytochemistry, anti-inflammatory,
anti-cancer, antioxidant, and anti-autoimmune disease activities of T. impetiginosa was performed using
bibliographic databases. Keywords used for this study were ‘anti-inflammatory,’ ‘T. impetiginosa,’
‘Taheebo,’ and other names synonymous with Taheebo. Research articles were chosen if they tested a
compound isolated from T. impetiginosa and investigated the related pharmacological activity. Studies
using in vitro assays included inhibition of nitric oxide, oxidative enzymes, or cytokines. In vivo trials
were included if they used antigens to induce ear edema, arthritis, or colitis in inflammatory animal
models. Websites, articles, and scientific papers were used as sources of information on historical uses,
components, taxonomy, and morphology of T. impetiginosa. Other sites, including mapchart.net, were
used to create a distribution map of T. impetiginosa.
3. Taxonomy and Botanical Traits
3.1. Taxonomy
T. impetiginosa is also known as Handroanthus impetiginosus (Mart. ex Dc.) Mattos as accepted
on the website www.theplantlist.org [19]. There are 17 valid synonymous names for Handroanthus
impetiginosus (Mart. ex Dc.) Mattos and one invalid synonymous name (Tecoma impetiginosa Mart.).
Synonymous names for Handroanthus impetiginosus (Mart. ex DC.) Mattos within one confidence
level are T. ipe var. integra (Sprague) Sandwith, Tecoma avellanedae var. alba Lillo, Tecoma ipe var.
integra Sprague, Tecoma ipe var. integrifolia Hassl., and Tecoma ipe f. leucotricha Hassl. Synonymous
names for Handroanthus impetiginosus (Mart. ex DC.) Mattos within three confidence levels are
Gelseminum avellanedae (Lorentz ex Griseb.) Kuntze, Handroanthus avellanedae (Lorentz ex Griseb.)
Mattos, T. avellanedae (Lorentz ex Griseb.), T. dugandii Standl., T. impetiginosa (Mart. ex DC.) Standl.,
T. nicaraguensis S.F. Blake, T. palmeri Rose, T. schunkevigoi D.R. Simpson, Tecoma adenophylla Bureau
and K. Schum, Tecoma avellanedae (Lorentz ex Griseb.) Speg., Tecoma impetiginosa Mart. ex DC.,
and Tecoma integra (Sprague) Hassl (The Plant List, 2013) (Table 1). This paper will use the name
T. impetiginosa (Mart. ex DC.) Standl and present it as T. impetiginosa. T. impetiginosa is a member of
family Bignoniaceae, genus Tabebuia, and species impetiginosa as written in NCBI: txid429701. Its genus
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name is derived from a native language of Brazil, while the species name is derived from the Latin
word impetigo, a common and highly contagious skin infection. It was so named because people
believed that this plant could be used to treat impetigo [20].
Table 1. Synonymous names for Tabebuia impetiginosa from The Plant List, 2013.
Synonym Name Remarks
Handroanthus impetiginosus (Mart. ex Dc.) Mattos Accepted name
Tabebuia ipe var. integra (Sprague) Sandwith One confidence level
Tecoma avellanedae var. alba Lillo One confidence level
Tecoma ipe var. integra Sprague One confidence level
Tecoma ipe var. integrifolia Hassl. One confidence level
Tecoma ipe f. leucotricha Hassl. One confidence level
Gelseminum avellanedae (Lorentz ex Griseb.) Kuntze Three confidence levels
Handroanthus avellanedae (Lorentz ex Griseb.) Mattos Three confidence levels
Tabebuia avellanedae Lorentz ex Griseb. Three confidence levels
Tabebuia dugandii Standl. Three confidence levels
Tabebuia impetiginosa (Mart. ex DC.) Standl. Three confidence levels
Tabebuia nicaraguensis S.F. Blake Three confidence levels
Tabebuia palmeri Rose Three confidence levels
Tabebuia schunkevigoi D.R. Simpson Three confidence levels
Tecoma adenophylla Bureau and K. Schum Three confidence levels
Tecoma avellanedae (Lorentz ex Griseb.) Speg. Three confidence levels
Tecoma impetiginosa Mart. ex DC. Three confidence levels
Tecoma integra (Sprague) Hassl Three confidence levels
Tecoma impetiginosa Mart Invalid name
3.2. Botanical Traits
T. impetiginosa is also known as pink trumpet tree or purple trumpet tree due to its flower color [21].
In English, it is called Ipe, Taheebo (ant wood), and purple tabebuia. In French, it is known as Poui,
while its Spanish names include Lapacho negro, lapacho, and quebracho. In German, the common
name is Lapachobaum, Trompetenbaum, and Feenkraut. In Portuguese, this plant is recognized as
Pau d’arco (bow tree), Ipe-roxo (red thick bark), and Ipe [19,20]. T. impetiginosa is well known due
to its conspicuous appearance. This deciduous species can grow to a height of 30 m and sheds its
leaves during the dry season. The palmately compound and serrated leaves are green and arranged in
opposite or subopposite pairs. The leaf shape is elliptic or oblong with pinnate or banchidodrome
venation. Showy purple, dark pink, or pink flowers appear in spring. The calyx is campanulate to
tubular with five lobes and is trumpet shaped. Its fruit is contained in a pod and is comprised of an
elongated cylindrical capsule with thin seeds [21,22].
3.3. Distribution
T. impetiginosa is a tree found in South and Central America and in some parts of North America.
Information on the distribution of this species was obtained from www.tropicos.org [23] and a review
paper on red lapacho [20]. Although it is best known for its presence in the Amazon rainforest, it is
also found in Argentina, Bolivia, Brazil, Colombia, Costa Rica, Ecuador, El Salvador, French Guiana,
Guatemala, Honduras, Mexico, Nicaragua, Panama, Paraguay, Peru, Suriname, Trinidad and Tobago,
and Venezuela, as shown in Figure 1 and Table 2.
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Figure 1. Distribution map of Tabebuia impetiginosa.
Table 2. Geographical distribution of Tabebuia impetiginosa.
Species Distribution
Tabebuia avellanedae Lorentz ex Griseb. Argentina
Handroanthus avellanedae (Lorentz ex Griseb.) Mattos Bolivia
Bignonia heptaphylla Vell. Brazil
Handroanthus impetiginosus (Mart. ex DC.) Mattos Bolivia, Brazil, Mexico
Gelseminum avellanedae (Lorentz ex Griseb.) Kuntze Bolivia
Tabebuia avellanedae var. paulensis Toledo Brazil
Tabebuia dugandii Standl. Colombia
Tabebuia eximia (Miq.) Sandwith Bolivia, Panama
Tabebuia heptaphylla (Vell.) Toledo Argentina, Bolivia, Brazil, Paraguay
Tabebuia hypodictyon (A. DC.) Standl. Bolivia, Panama
* Tabebuia ipe (Mart.) Standl. Panama
Tabebuia ipe var. integra (Sprague) Sandwith Bolivia, Paraguay
Tabebuia nicaraguensis S.F. Blake Nicaragua
Tabebuia palmeri Rose Costa Rica, El Salvador, Guatemala, Honduras,Mexico, Nicaragua, Panama
Tabebuia schunkevigoi D.R. Simpson Peru
Tecoma adenophylla Bureau ex K. Schum. Brazil
Tecoma avellanedae (Lorentz ex Griseb.) Speg. Honduras
Tecoma avellanedae var. alba Lillo Argentina
Tecoma eximia Miq. Brazil
Tecoma hassleri Sprague Paraguay
! Tecoma heptaphylla (Vell.) Mart. Panama
Tecoma hypodictyon A. DC. Brazil
** Tecoma impetiginosa Mart. Panama
!Tecoma impetiginosa Mart. ex DC. Brazil
Tecoma impetiginosa var. lepidota Bureau Brazil
Tecoma integra (Sprague) Chodat Bolivia, Panama
Tecoma ipe fo. leucotricha Hassl. Paraguay
** Tecoma ipe Mart. Bolivia, Panama
Tecoma ipe var. integra Sprague Paraguay
Tecoma ipe var. integrifolia Hassl. Bolivia
Tecoma ochracea Cham. Brazil
! = legitimate, * = illegitimate, ** = invalid.
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4. Traditional Uses
T. impetiginosa has been used traditionally to treat cancer [24], obesity [25], depression [26], viral,
fungal, and bacterial infections [27], and inflammatory symptoms such as pain [28], arthritis [15],
colitis [29], and prostatitis since the Inca civilization. The Callawaya Tribe makes a concentrated tea
out of the tree’s inner bark for treating skin inflammatory diseases [8]. Moreover, it can be used as an
astringent and diuretic [30]. Caribbean folk healers utilize the bark and leaves of T. impetiginosa to
cure toothaches, backaches, and sexually transmitted diseases [31]. Latino and Haitian populations
were also reported to use this plant for the treatment of infectious disease [32]. Brazilian people have
traditionally used this plant for anti-inflammatory, analgesic, and antiophidic purposes against snake
venom [33]. Traditional healers in Brazil prescribed T. impetiginosa for cancer and tumor prevention or
treatment; 69.05% for the treatment of tumors and cancer in general and 30.95% for specific tumors
or cancers [34]. Such ethnomedicinal uses of T. impetiginosa led us to pay attention to it for a full
understanding of its immunopharmacological properties for the future development of an effective
drug against ethnopharmacologically targeted diseases with this plant.
5. Phytochemistry
Several categories of phytochemicals have been identified in the leaves, bark, and wood of
T. impetiginosa. From T. impetiginosa bark, 19 glycosides comprised of four iridoid glycosides, two lignan
glycosides, two isocoumarin glycosides, three phenylethanoid glycosides, and eight phenolic glycosides
were methanol-extracted [35]. Major constituents of T. impetiginosa are furanonaphthoquinones,
naphthoquinones, anthraquinones (e.g., anthraquinone-2-carboxylic acid (Compound 1 in Figure 2)),
quinones, benzoic acid, flavonoids, cyclopentene dialdehydes, coumarins, iridoids, and phenolic
glycosides [4,8,36]. The presence of naphthoquinones attracted scientific attention, with lapachol
(2) and β-lapachone (3) especially piquing the interest of professionals in the medical field. Lapachol
inhibits proliferation of tumor cells, while β-lapachone exhibits strong toxicity in murine and human
cells. Lapachol has been shown to reduce the number of tumors caused by doxorubicin in Drosophila
melanogaster heterozygous for the tumor suppressor gene. Lapachol can also decrease the invasion of
HeLa cells, which could represent an interesting scaffold for the development of novel antimetastatic
compounds [4].
Fatty acids, especially oleic acid (4), palmitic acid (5), and linoleic acid (6), are found in the
bark of T. impetiginosa. Free sugars also were identified in the bark, with glucose being the most
abundant, followed by fructose and sucrose. Organic acids, especially oxalic acid (7), are present,
as well as the fat-soluble alcohols α-tocopherol (8) and γ-tocopherol (9). α-Tocopherol can reduce
cardiovascular disease risk and neurodegenerative disorders [4]. In addition, T. impetiginosa has some
volatile constituents that exhibit antioxidant activity. The major volatile constituents in T. impetiginosa
include 4-methoxybenzaldehyde (10), 4-methoxyphenol (11), 5-allyl-1,2,3-trimethoxybenzene (12),
1-methoxy-4-(1E)-1-propenylbenzene (13), and 4-methoxybenzyl alcohol (14) [37].
Cyclopentene derivatives are secondary metabolites of plants, and this constituent from
T. impetiginosa contained six known cyclopentenyl esters (avallaneine A–F (15–20)), two new
cyclopentyl esters (avallaneine G (21) and H (22)), and two known cyclopentenyl esters. These
cyclopentene derivatives may provide a significant anti-inflammatory effect on the lipopolysaccharide
(LPS)-mediated inflammatory response by blocking the production of NO and PGE2; therefore, it is
important to determine the molecular mechanism whereby cyclopentenyl esters from T. impetiginosa
inhibit inflammatory responses [16]. Moreover, Koyama et al. [38] isolated two cyclopentene
dialdehydes, 2-formyl-5-(4′-methoxybenzoyloxy)-3-methyl-2-cyclopentene-1-acetaldehyde (23) and
2-formyl-5-(3′,4′-dimethoxybenzoyloxy)-3-methyl-2-cyclopentene-1-acetaldehyde (24), that exert
anti-inflammatory activity in human leukocytes. Thus, it is necessary to further investigate
their activities.
9
Molecules 2020, 25, 4294
 
 
Figure 2. Chemical structures of Tabebuia impetiginosa-derived components.
6. Pharmacological Activities
Previous research has indicated various pharmacological effects of T. impetiginosa and its crude
extracts and chemical compounds in a series of in vitro and animal models. It exhibits antibacterial,
antioxidant, antifungal, antinociceptive, antidiabetic, anti-edema, anti-inflammatory, and anti-cancer
activities at different concentrations or doses. The main pharmacological activities of extracts or
compounds isolated from T. impetiginosa reported in in vitro and in vivo studies are briefly summarized
in Table 3 and described in detail in the following subsections.
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6.1. Anti-inflammatory Activity
6.1.1. Regulation of Inflammatory Mediators.
T. impetiginosa can alter the expression of signaling molecules involved in the inflammation
process, including nitric oxide (NO), prostaglandin (PGE2), and leukotriene B4 (LTB4) [8,15,28]. NO is
essential for maintaining homeostasis and protecting human hosts and provides immunosuppressive
effects as well as immunopathological and immunoprotective activities [44]. PGE2 is a mediator
of inflammation, especially in diseases such as rheumatoid arthritis and osteoarthritis, playing
an important role in stimulating the inflammatory response, facilitating tissue regeneration,
and maintaining homeostasis [45]. LTB4, a pro-inflammatory lipid mediator, is synthesized from
arachidonic acid, expressed on many inflammatory and immune cells, and is a powerful chemokine
that promotes migration of macrophages and neutrophils to tissues [46]. T. impetiginosa can also
inhibit the proinflammatory cytokines interleukin (IL)-1β and IL-6 [15,47]. IL-1β has an important
homeostatic function; however, overproduction of IL-1β can result in pathophysiological changes
related to pain and inflammation [48]. Likewise, IL-6 is a pro-inflammatory mediator with pleiotropic
effects on immune response, inflammation, and hematopoiesis, but excessive production of IL-6 can
cause various diseases [49]. In addition, the mRNA expressions of IL-1β and inflammatory genes
inducible NO synthase (iNOS) and cyclooxygenase (COX)-2 were markedly decreased when treated
with T. impetiginosa [8,15,28,47]. Information gained from in vitro and in vivo models provided insights
to other researchers for further investigation. Some focused on macrophages, the main cells involved
in inflammation, while others focused on neutrophils, the most abundant blood leukocytes, and their
role in defense against pathogens [50,51]. Previously, Byeon et al. [8] discovered that suppression of
PGE2 production negatively regulated the macrophage-mediated inflammatory response. Similarly,
Suzuki et al. [52] found that T. impetiginosa repressed neutrophil activation. Interestingly, T. impetiginosa
did not inhibit the migration of neutrophils but instead inhibited the reactive oxygen species (ROS)
produced by migrating neutrophils. The ROS produced from normal cellular metabolism play an
important role in the signaling pathways of plant and animal cells in response to environmental
changes [53], and future studies should investigate their mechanisms and active substances in the
context of neutrophil functional modulation.
Our body has two protective effects against infections in the form of innate and adaptive immune
cells. Adaptive immune cells include T and B cells, while innate immune cells include macrophages,
dendritic cells, and other cell types. Dendritic cells are the most effective antigen presenting cells due to
their ability to express high levels of major histocompatibility complex II (MHC II), cluster differentiation
80 (CD80), and CD86 that are required for antigen presentation. This expression allows dendritic cells
to effectively trigger an immune response [54]. Dendritic cells are predominantly found in two forms,
mature and immature. Mature dendritic cells are important for stimulating the T cell immune response,
while immature dendritic cells support T cell tolerance [55]. Previous research has discovered that the
water extract of T. impetiginosa impacted dendritic cells by upregulating the expression of MHC II and
CD86, the markers of dendritic cell maturation, but had no effect on production of pro-inflammatory
cytokines. On the other hand, dendritic cells can affect the differentiation of CD4+ T cells, which are
important for adaptive immunity, while treatment with T. impetiginosa can induce differentiation of
CD4+ T cells, resulting in induction of Th2 and differentiation of regulatory T cells. The expansion of
regulatory T and Th2 cells may suppress the Th1 response, thereby preventing dextran sulfate sodium
(DSS)-induced colitis in mice [29].
6.1.2. Effects on Inflammatory Signaling
When pattern recognition receptors (PRRs) interact with pathogen-associated molecular patterns
(PAMPs) or damage-associated molecular patterns (DAMPs), intracellular signal transduction pathways
are induced to activate and translocate transcription factors such as nuclear factor (NF)-κB, activator
protein (AP)-1, signal transducer and activator of transcription 3 (STAT3), and interferon regulatory
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factor 3 (IRF3) into the nucleus to stimulate the expression of pro-inflammatory genes, thereby
producing an inflammatory response [56]. NF-κB is one of the transcription factors that expresses
pro-inflammatory genes and is involved in both innate and adaptive immune responses. NF-κB can be
activated through canonical and non-canonical signaling pathways. The canonical NF-κB pathway is
mostly involved in immune response, while the non-canonical NF-κB pathway is only involved in
parts of the adaptive immune system [57].
Park et al. [15] used an immunoblotting technique to show that the ethanol extract of T. impetiginosa
suppressed the activation of Src and spleen tyrosine kinase (Syk). Furthermore, to determine the direct
molecular targets, they conducted kinase assays and found that both Syk and Src were suppressed
by T. impetiginosa [46]. However, Byeon et al. [8] discovered that the water extract of T. impetiginosa
did not function in the NF-κB pathway due to non-inhibition of phospho-IκB and the upstream
molecules that activate phosphorylation of IκB and AKT. Results from Park et al. [15] showed inhibition
of phospho-IκB, even though they did not assess AKT expression. However, phospho-Syk and
phospho-Src upstream of AKT were inhibited by ethanol extracts of T. impetiginosa. These results
could vary depending on the proportion of active components contained in extracts using different
solvents [58].
Park et al. [59] investigated the effect of anthraquinone, a main component of T. impetiginosa. They
specifically focused on anthraquinone-2-carboxlic acid (9,10-dihydro-9,10-dioxo-2-anthracenecarboxylic
acid) (AQCA: 1) and discovered through immunoblotting that an inhibitor of IκB (IKK) and IκBα
decreased when treated with 100 μM of AQCA in LPS-induced RAW264.7 cells. They repeated the
kinase assay and found that Syk and Src were inhibited by treatment with AQCA [59].
Another pathway, the mitogen-activated protein kinase (MAPK) pathway, activates the activator
protein (AP)-1 transcription factor that can lead to expression of pro-inflammatory genes. The MAPK
pathway consists of three families: extracellular-signal-regulated kinases (ERKs), c-Jun N-terminal
kinases (JNKs)/stress-activated protein kinases (SAPKs), and p38s. ERKs can be divided into two
subgroups: classic ERKs that include ERK1 and ERK2 and larger ERKs such as ERK5. Classic ERKs are
mainly responsible for cell growth, survival, differentiation, and development. JNK family members,
which include JNK1, JNK2, and JNK3, are stress-activated [60].
Anthraquinone-2-carboxlic acid (AQCA) was identified as one of the major anthraquinones
in T. impetiginosa. Administration of AQCA to mice treated with HCl/EtOH and aspirin resulted
in reduced expression of phospo-p38 and interleukin 1 receptor associated kinase 1 (IRAK1) [61].
Treatment with AQCA reduced the expression of phospo-p38, c-JNK, mitogen-activated protein kinase
3/6 (MKK3/6), and transforming growth factor β-activated kinase (TAK1) in RAW264.7 cells. However,
the expression of ERK was not inhibited. The upstream level of TAK1 was inhibited, as evidenced by
degradation of IRAK1. These findings were confirmed using a conventional kinase assay with purified
enzyme, and results showed potent suppression of IRAK1 by AQCA. Transfection was performed
using HEK293 cells with the IRAK1 gene to validate the results, and treatment with AQCA suppressed
phosphorylation of p38 protein without altering FLAG and IRAK1 protein levels. Taken together,
these findings suggest that downregulation of IRAK1 by AQCA contributes to an anti-inflammatory
effect [59]. Results are summarized in a pathway chart (Figure 3).
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Figure 3. Inhibitory targets of Tabebuia impetiginosa in the NF-κB and AP-1 pathways.
6.2. Anti-Cancer Activity
T. impetiginosa exhibits inhibitory effects on the growth of several human tumor cell lines,
such as breast carcinoma (MCF-7), lung carcinoma (NCI-H460), cervical carcinoma (HeLa), and
hepatocellular carcinoma (HepG2), and the GI50 values (corresponding to a sample concentration
achieving 50% growth inhibition in human tumor cell lines) were 1.21, 1.03, 0.91, and 1.10 μg/mL,
respectively [4]. Woo et al. [42] reported that β-lapachone isolated from T. avellanedae significantly
inhibited the proliferation of human hepatoma cell line HepG2 by inducing apoptosis, which is
associated with upregulation of pro-apoptotic Bax and downregulation of anti-apoptotic Bcl-2 and
Bcl-XL expression, proteolytic activation of caspase-3 and -9, as well as degradation of poly (ADP-ribose)
polymerase protein.
In a human breast carcinoma derived estrogen receptor (ER+) MCF-7 cells model, Taheebo
showed antiproliferative effects by upregulating xenobiotic metabolism-specific genes (dual specific
phosphatase genes) and apoptosis-specific genes and by downregulating estrogen response and cell
cycle regulatory genes [24]. Particularly, Taheebo treatment upregulated the dual specific phosphatase
(DUSP) gene family and downregulated cyclin A and cdk2, indicating that Taheebo also inhibited the
MAPK signaling pathway and phosphorylation of the ER N-terminal AF-1 domain [24]. Junior et al. [62]
found that the anti-cancer activity of T. impetiginosa was correlated with the presence of lapachol
and β-lapachone in its constitution. It is noteworthy that T. impetiginosa not only displayed growth
inhibition against various tumor cell lines in vitro but also prolonged the duration of survival in a
number of mouse models in vivo. For example, Queiroz et al. [63] examined the effects of T. avellanedae
(30–500 mg/kg) and the naphtoquinone β-lapachone (1–5 mg/kg) in Ehrlich’s ascites tumor-bearing
mice. They observed that T. avellanedae administration prolonged the lifespan of tumor-bearing mice by
increasing the number of bone marrow granulocyte-macrophage colony-forming units and reducing
colony-stimulating activity levels; the optimal biologically active dose was 120 mg/kg. In addition,
Tahara et al. [14] found that naphthoquinones isolated from T. avellanedae markedly blocked the STAT3
pathway while reducing hyperactivation of these signals as well as inhibited growth of cancer cell lines.
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6.3. Anti-Autoimmune Diseases
Recent research has shown that T. impetiginosa has effects on various autoimmune diseases such
as psoriasis, osteoarthritis, allergy, and inflammatory bowel disease. Suo et al. [41] found that five
novel compounds isolated from the water extract of Taheebo had strong anti-inflammatory activity but
displayed weak or no effect on anti-allergic and antioxidant activities. Muller et al. [64] reported that
Lapacho, a common constituent in the inner bark of T. impetiginosa, suppressed growth of the human
keratinocyte cell line (HaCaT) and could be promising as an effective anti-psoriatic agent. In addition, it
has been reported that T. impetiginosa bark extracts significantly inhibited the growth of some bacterial
species associated with gastrointestinal disease and diarrhea, implying their suitability for prophylactic
therapeutic usage [7]. Park et al. [15] examined the effect of T. avellanedae on monoiodoacetate-induced
osteoarthritis in a Sprague-Dawley rat model. They observed that T. avellanedae administration
ameliorated osteoarthritis symptoms by decreasing the serum levels of proinflammatory cytokines
and inflammatory mediators, such as PGE2, LTB4, and IL-1β [15]. De Miranda et al. [5] further
investigated its effects using animal models and described anti-edematogenic and antinociceptive
effects of T. impetiginosa in rat paw edema induced by carrageenan. In this study, an aqueous extract
containing a 200 mg/kg dose ameliorated rat paw edema in a way similar to indomethacin, the control
drug. However, at a dose of 400 mg/kg, the edema was not reduced, suggesting that the edema-reducing
compounds were competing with other constituents and nullifying any edema-reducing effect.
Lee et al. [28] investigated the analgesic and anti-inflammatory effects of T. impetiginosa, especially
with regard to osteoarthritis. In this study, the analgesic effects were tested using pain threshold
methods assessed by a hot plate test. A T. impetiginosa ethanol extract-treated group showed a significant
analgesic effect at 200 mg/kg compared with a control group treated with diclofenac. Using an acetic
acid-induced writhing response, they confirmed results from previous experiments that 100–400 mg/kg
of T. impetiginosa ethanol extract significantly inhibited the number of writhes compared to the control
group. This analgesic model used acetic acid because it causes inflammatory pain by increasing capillary
permeability, and the hot plate-induced pain indicated narcotic involvement. Anti-inflammatory activity
was assessed using acetic acid-induced vascular permeability, 12-O-tetradecanoylphorbol-13-acetate
(TPA)-induced ear edema, arachidonic acid-induced mouse ear edema, and carrageenan-induced paw
edema. Most of the group treated with T. impetiginosa exhibited reduced inflammation at a dose of
100–400 mg/kg, including suppression of ear weight and thickness, inhibition of ear inflammation,
and reduction of edema in a TPA-induced ear edema test volume [28]. Byeon et al. [8] performed a
similar study using a hot water extract and tested the edema model with different inducers. They
found that prostaglandin E2 (PGE2) production was blocked and edema symptoms were reduced
when treated with T. impetiginosa. However, in this study, T. impetiginosa only affected arachidonic
acid-induced ear edema.
Park et al. [29] investigated the effect of T. impetiginosa on a DSS-induced colitis mouse model.
They discovered that T. impetiginosa protected the colon from inflammation by reducing mucosal
edema loss, epithelial crypts, and inflammatory cell infiltration. In addition, the use of T. impetiginosa
in traditional arthritis medicines led researchers to perform experiments in an osteoarthritis model.
Park et al. [46] used an ethanol extract of T. impetiginosa in the form of Tabetri™ (Ta-EE) in a
monoiodoacetate-induced osteoarthritic mouse model. They compared the pain indicator of a
mechanical paw withdrawal threshold to Von Frey stimuli and found that pain was significantly
increased in osteoarthritic rats, which was suppressed by Ta-EE. Moreover, they also compared the
results to those of methylsulfonylmethane (MSM) and Pc-LE and found that Ta-EE produced results
comparable to those of these anti-inflammatory agents. Interestingly, results with Ta-EE were not
dose-dependent, indicating that Ta-EE can be used in small doses. The osteoarthritic rats showed
no weight loss, indicating no toxicity or side effects regarding weight loss or appetite caused by
Ta-EE treatments. To investigate further, they measured the degradation of articular cartilage in rats
administered Ta-EE and found it to be dramatically inhibited. Strangely, the chondroprotective effect
of Ta-EE was better than that of MSM at 60 and 120 mg/kg doses in a dose-dependent manner.
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7. Clinical Trials
In recent years, along with thorough research, some of the principal active components of
T. impetiginosa have been used in clinical research. For example, β-lapachone, mainly distributed in
heartwood of T. impetiginosa, has entered into phase 2 clinical trials for treatment of squamous cell
carcinoma, and 2-acetylnaphtho (2,3-β) furan-4,9-dione, also referred to as STAT3 inhibitor BBI608
(Napabucacin), was developed by Boston Biomedical Inc [14].
8. Conclusions
In this paper, we summarized the traditional uses, botanical traits, phytochemistry,
and pharmacological activities of T. impetiginosa with collation and analysis of relevant studies.
T. impetiginosa has been used as a traditional medicine in Central and South America to treat edema,
arthritis, diuretic, and infections. Based on its traditional use, in vivo and in vitro experiments
examining its pharmacological potential have been conducted. In vivo experiments were conducted
using edema, osteoarthritis, animal paw edema, and writhing (and other) models to screen effects
of T. impetiginosa. Moreover, there are numerous studies confirming that extracts or compounds
isolated from T. impetiginosa have various pharmacological activities such as anti-obesity, antibacterial,
antifungal, antiviral, anti-psoriatic, antioxidant, anti-inflammatory, and anti-cancer activities.
Currently, substantial progress has been made in exploration of the phytochemistry and
pharmacological activity of T. impetiginosa. Nonetheless, there are still challenges and gaps in
published research papers that should be further explored to establish its clinical application value.
Firstly, the extracts and compounds isolated from T. impetiginosa possess multiple pharmacological
activities, though most functional mechanisms remain unclear and need to be further explored through
in vivo and in vitro experiments. Furthermore, most studies on T. impetiginosa are still in the in vitro
and in vivo mouse model stages. Toxicological research can be conducted on other animals such as
rabbits in the future to evaluate its safety, which will pave the way for further clinical trials. In addition,
further comprehensive experiments are needed to enrich the data and discover other pharmacological
uses of T. impetiginosa and to find the exact mechanisms by which its extracts bind to target proteins.
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Abstract: Fruit plants have been widely used by the population as a source of food, income and in
the treatment of various diseases due to their nutritional and pharmacological properties. The aim
of this study was to review information from the most current research about the phytochemical
composition, biological and toxicological properties of four fruit species widely used by the world
population in order to support the safe medicinal use of these species and encourage further studies
on their therapeutic properties. The reviewed species are: Talisia esculenta, Brosimum gaudichaudii,
Genipa americana, and Bromelia antiacantha. The review presents the botanical description of these
species, their geographical distribution, forms of use in popular medicine, phytochemical studies and
molecules isolated from different plant organs. The description of the pharmacological mechanism of
action of secondary metabolites isolated from these species was detailed and toxicity studies related
to them were reviewed. The present study demonstrates the significant concentration of phenolic
compounds in these species and their anti-inflammatory, anti-tumor, photosensitizing properties,
among others. Such species provide important molecules with pharmacological activity that serve
as raw materials for the development of new drugs, making further studies necessary to elucidate
mechanisms of action not yet understood and prove the safety for use in humans.
Keywords: plant secondary metabolites; natural compounds; biological activity; phytochemistry;
pharmacological activity; plant side effects; Talisia esculenta; Brosimum gaudichaudii; Genipa americana;
Bromelia antiacantha
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1. Introduction
The Cerrado is one of the most important and extensive Brazilian biomes, with a great richness of
plant species that are used as food and therapeutic agents, highlighting their medicinal, sociocultural
and nutritional importance, which make them attractive for research and commercialization [1].
The Brazilian population has great range of cultural knowledge about native plants, which are used
in the treatment of diseases. These medicinal plants present molecules with pharmacological properties
which expand the possibilities for the development of drugs and/or nutraceuticals. However, despite the
great Brazilian biodiversity in species considered medicinal, research is still incipient, requiring active
investigations on the phytochemical constituents present in these plants, as well as their pharmacological
or nutritional properties [2].
Climatic factors directly affect the production of fruits and phytochemical constituents by plants,
since water availability in the Cerrado is reduced over a period that can vary from two to five months.
Some species adapt to reduced water availability in soil and increased temperature, being called
sclerophyll plants. These plants make up the Cerrado vegetation, which is characterized by the
presence of shrubs, grasses and trees with deep roots to facilitate water absorption; in the dry season,
some species lose their leaves in an attempt to save water [3].
Given these environmental conditions to which Cerrado plants are exposed, another way to
mitigate the damage caused by climate changes is the production of bioactive molecules that act
in the defense of the plant against harmful agents. These compounds are alternative sources for
the formulation of new products, not only in the pharmaceutical industry, but also in the food
industry. In addition to climatic conditions associated with different geographic regions, factors such
as cultivation, harvest time and growth stage of the collected plant can also change the concentration
of these compounds [4].
Some Cerrado fruit species are used as functional foods, with fruits and seeds being the most
used parts. The therapeutic and nutritional properties associated with these foods are constantly
investigated through scientific studies, which highlight the high concentration of phenolic compounds
found in these species, normally produced in response to water scarcity, intense exposure to solar
radiation, attack of herbivores and infections by fungi, which are conditions common to Cerrado plants.
The sale of parts of these plants for fresh consumption or therapeutic purposes has great prominence
in the economy as source of livelihood for workers in regions covered by this biome [5].
Studies that have assessed the biological activity, toxicity and phytochemical composition of
plants native to the Cerrado can contribute to ensuring the effectiveness and safety in the use of such
species, favoring the healthy consumption of fruits and by-products, also encouraging further studies
on the therapeutic properties of substances isolated from these plants, which are of great importance
for popular medicine, nutrition and income in various regions of the world. In this sense, the aim of
this study was to review the current literature to gather detailed and accurate information about the
phytochemical, pharmacological and toxicological aspects of the following fruit plants: Talisia esculenta,
Brosimum gaudichaudii, Genipa americana, Bromelia antiacantha.
2. Fruit Plants from the Brazilian Cerrado
Cerrado is considered the second largest Brazilian biome, only behind the Amazon, accounting for
around 23% of the national territory and extending into 11 of the country’s states. With abundant flora
and fauna diversity, this biome has been annually targeted by deforestation caused by the expansion of
agribusiness, livestock and urbanization, which already occupy 50% of the biome’s extension [6].
The multiplicity of Cerrado plant species is superior to that found in other regions of the
world, with shrub, liana and herbaceous plants, and the registered number reaches 12,669 species,
of which, some stand out for their relevant pharmacological and nutritional properties, which play an
important role in the commercial activities of regions where they are found. In addition, fruits of these
plants also contribute to the promotion and development of family farming, generating income for
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communities through the preparation of sweets, ice cream, flavorings for alcoholic distillates and other
by-products [7–9].
Fruits produced by Cerrado species are known not only for their flavor and aroma, which are generally
striking, but also for their high concentrations of carotenoids, phenolic compounds, vitamins and minerals,
whose antioxidant power is desired in the food and pharmaceutical industry. The identification and
quantification of these components allow the assessment of their nutritional value and, consequently,
the production and commercialization of by-products with guaranteed quality [10].
However, for the study of properties attributed to the phytochemical constituents found in fruits
of these species, the correct identification of species must be performed by a botanist. Such species have
their classification based on botanical nomenclatures, followed by norms created by an international
commission of scientists, which are described in the International Botanical Nomenclature Code,
which aims to guarantee the universality of names given to taxa. In this code, plants are categorized
into Phylum, Class, Order, Family, Genus and species [11,12].
3. Sapindaceae Family
The Sapindaceae family belongs to the order of Sapindales angiosperm plants, has 141 genera and
approximately 2000 identified species, 28 genera and about 418 species being native to Brazil. It is
predominantly found in tropical and subtropical climates, with rare occurrence of some genera in
countries with temperate climate [13]. This family is morphologically characterized by the presence
of shrubs, lianas with tendrils and trees, whose leaves can be alternate or opposite, composed,
trifoliate, unifoliated, pinnate or webbed, with present or absent stipules and unisexual and monoic
flowers [14]. In addition, this plant family has species with edible fruits with industrial potential,
for example, Litchichinensis Sonn. (lychee), Melicoccus bijugatus Jacq. (mamoncillo or Spanish lime),
Nephelium lappaceum L. (rambutão) and Talisia esculenta (A. St. Hil) Radlk. (pitomba). Other species
have known medicinal and ichthyotoxic properties, such as species of the genera Paullinia L. and
Serjania Mill., and there are those that can be simply ornamental, such as Paullinia pinnata L. and
P. elegans (cipó-timbó). The flowers of these species are usually tetrameric or pentameric, with an
extra-stamen nectary, that is, located between the androceu and the perianth. Fruits can be dehiscent
or indehiscent, ranging from berries and capsules to schizocarps [15–17].
3.1. Genus Talisia and Species Talisia esculenta
The genus Talisia was first described by Aublet in 1775. Soon after, in 1778, following up on
Aublet’s findings, Rodlkofer carried out several studies on this genus. About 10 species of the
genus Talisia have nutritional properties, including Talisia esculenta (popularly known as “pitombeira”,
although the name is also used for other species of the same genus, such as T. acutifolia Raldk, T. cerasina
(Benth). Radlk. and T. cupularis Radlk., all from the Amazon [14]).
The species has characteristics that help it adapt to areas along the margins of water courses,
such as rapid growth and large seed production, which are dispersed with high water content, that is,
recalcitrant seeds, which should be sown quickly, as they are only viable for a short time in the
environment [18].
Fruits produced by this species are consumed by humans and birds, with economic importance
attributed to their nutritional properties and characteristic flavor, desired in regional cuisine, being used in
the manufacture of pulps, jams, sweets, and jellies. In addition, the wood derived from the trunks is used
in the manufacture of furniture and decorative objects, while leaves and seeds have been investigated
in several studies due to their reported therapeutic properties based on their popular use [19].
3.1.1. Geographic Distribution and Popular Use
T. esculenta although native to Brazil, has a cosmopolitan distribution and occurs in several other
countries such as Bolivia, Paraguay, Colombia, Ecuador, Peru and Argentina, where the climate is
favorable for its development [20]. It can be found in the native and wild state or cultivated and despite
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being a tropical climate plant, it adapts well to subtropical areas, with preference for alluvial soils in
valley bottoms. Its flowering occurs from August to October and the fruit maturation occurs between
January and March, which may vary according to the region in which the species is found [21,22].
The use of T. esculenta by the population is mainly for food and medicinal purposes. The fruit
is commonly used for fresh consumption or in the form of by-products. The other plant parts are
associated with therapeutic purposes, such as leaves, which are popularly used for back pain and
rheumatism, seeds for diarrhea, dehydration and as astringents and barks for kidney problems [9,23].
The therapeutic use of teas made from the leaves can vary according to the region. An example
was reported in an ethnobotanical study of species with medicinal use, which describes the use of
T. esculenta leaves tea as antihypertensive, a property little mentioned by the inhabitants of other
regions of the country [24]. Regarding the form of preparation, tea is usually obtained from freshly
harvested or dried plant parts produced through the method of infusion or decoction, using leaves to
prepare tea by infusion, while seeds and bark are used to prepare tea by decoction. Some studies point
out a concern in relation to the hygiene of plant parts to be used and the way they are dried and stored,
which can favor contamination or proliferation of deteriorating microorganisms [25,26].
In the preparation of teas using the infusion method, the popularly used solvent is boiling water,
in which the vegetable is immersed for about 30 min. After this time, the tea is leached and cooled
until it reaches an ideal temperature for consumption. Unlike infusion, in decoction, which is the
most widely used form of tea preparation, the vegetable is in direct contact with water throughout
the process, from heating to boiling; then the tea is leached and cooled to be consumed. A negative
consequence associated with these methods is the degradation of some thermolabile compounds that
do not resist exposure to intense heat [27].
3.1.2. Botanical Aspects
T. esculenta is an arboreal fruit plant of some 6–12 m in height, with terrestrial roots and aerial and
erect cylindrical stems of dark and lenticelous in color; leaves are composite and alternate, with 2 to
4 pairs of leaflets, with petioles of 3–10 cm in length and a petiole of 1–5 mm and simple non-glandular
trichomes on their surface. In addition, as to morphology, leaves are classified in oblong shape,
acuminated apex, rounded or obtuse base and venation is of peninerval type [20,28].
Inflorescences are composed, of the thyrsus type, that is, forming racemes of crests. Flowers are
white, aromatic, diclamid, with pedicels up to 4 mm in length, gamosepal, with five elliptical sepals
and dialipetal, with five petals. Classification regarding sexual characteristics is not well defined,
with monoclinous flowers, that is, hermaphrodites, or diclinous, which are unisexual male or female.
They present about eight filiform and hairy stamens, oblong and apiculate anthers, trifid stigmas and
ovoid ovary, tricarpellar and trilocular [14,20].
Fruit production occurs annually, about ten years after planting, and it is possible to harvest ten
to twenty fruits in each raceme. Fruits are generally monospermic, globose, fleshy, drupe type and
when ripe they have approximately 2.5 cm in diameter and the color of the epicarp changes from
green to brown. The pulp of the ripe fruit has bittersweet flavor and its color varies from white to
transparent [29].
Seeds are elongated, reddish in color immediately after harvest and dark after drying. They are
surrounded by a pinkish-white aryl, which must be removed before planting, as it can harm germination.
Regarding seed viability, it is about 15 days in the environment, but if stored in polyethylene package
with 50% relative humidity under refrigeration (approx. 18 ◦C), they can remain viable for up to
25 days. Seed dispersion enables species maintenance; however, it is still not clear which agent is
responsible for dissemination, since the fruits attract several animals [18,30,31].
3.1.3. Phytochemical Aspects
Table 1 presents a summary of phytochemical studies carried out with different T. esculenta organs,
as well as the structures of isolated substances.
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Phytochemical investigations include the in-depth study of the target species, as well as extractive
and separation methods, purification and structural determination of isolated chemical constituents [37].
Cerrado species are known to have significant amount of phenolic compounds in their composition,
which are bioactive substances widely distributed in nature and derive from two biosynthetic routes,
that of shikimic acid and that of acetyl-CoA, being divided into two large groups, phenolic acids and
flavonoids, commonly found in fruits and vegetables [38].
To date, there is scarcity of studies on the bioactive compounds present in T. esculenta, mainly
for roots and stems. [39] determined the centesimal composition of T. esculenta fruits. The average
values found after triplicate analysis, were: 56.35 kcal/100 g of energy value, 83.16 g/100g of moisture,
1.15 g/100 g of proteins, 0.19 g/100 of lipids, 12.51 g/100 g of carbohydrates, 2.40 g/100 g dietary fiber
and 0.61 g/100 g of fixed mineral residue. In addition, the analysis revealed 26.7 mg/100 g of calcium,
0.84 mg/100 g of zinc and 0.60 mg/100 g of iron, 0.0 mg/100 g of copper and 10.8 mg/100 g of magnesium.
The phosphorus concentration was considered insignificant [40].
In a study on fruits and seeds in which extraction was performed using the technique of maceration
in acetone and methanol, quinic (9), gallic (5) and p-coumaric (8) acids, in addition to epicatechin (4)
and catechin (3), were identified in the ketone extract of the pulp, the latter being also found in the pulp
methanolic extract. In the ketone extract of the fruit bark, naringenin (7), catechin (3) and epicatechin
(4) were detected, not identified in the methanolic extract of the fruit bark. For seeds, epicatechin (4),
catechin (3), naringenin (7) and luteolin (6) were found in the ketone extract (6) and in the methanolic
naringenin extract (7) and luteolin (6) [33].
Other phytochemical findings of this species were analyzed using 5:95 hydroalcoholic extract
(v/v, water, ethanol) from fruits, followed by evaporation and collection of the lipophilic fraction, which
was homogenized in hexane. High mirecetin (1) and quercetin (2) concentrations were determined,
approximately 89.90 mg/100 g and 30.20 mg/100 g, respectively, which are associated with possible
antioxidant and antiproliferative properties [36].
Furthermore, the analysis of the methanolic extract of the pulp of T. esculenta fruits showed the
presence of flavonoids and phenolic acids. The following 12 phenolic compounds were found: gallic
acid (5), chlorogenic acid (13), catechin (3), epicatechin (4), caffeic acid (12), serum acid (16), p-coumaric
acid (8), rutin (10), ferulic acid (15), quercetin (2), eriodicthiol (14) and acacetin (11); and the cyclitol
quinic acid (9). This study identified 27 aromatic compounds, including esters, alcohols, aldehydes,
hydrocarbons, fatty acids and terpenoids such as monoterpenolinalol (18) and the sesquiterpene
β-bisabolene (17) [35].
In this sense, in order to investigate the phytochemical composition of T. esculenta leaves and stem,
hydroalcoholic extract was produced, which, after analysis and characterization, allowed identifying
derivatives of flavonoids, benzoic and cinnamic acids, fragments of aglycones, quercetin (2) and
dicaffeoylquinic acid (24), which compounds being given the ability to influence renal hemodynamics
and induce diuretic response in normotensive and spontaneously hypertensive Wistar rats [35].
Junior (2019) analyzed the hydroalcoholic extract of T. esculenta leaves and identified some
compounds such as quinic acid (9), caffeic acid (12), gallic acid (5), which are classified as phenolic
acids, in addition to flavonoids such as catechin (3), rutin (10), acacetin (11) and quercetin (2), which are
associated with antioxidant and anti-inflammatory properties [36].
3.1.4. Pharmacological Studies
Flavonoids, phytochemicals present in different T. esculenta parts have pharmacological properties
that are the focus of several studies, in which, among others, the anti-inflammatory, antioxidant
and anti-tumor properties associated with these compounds are described. A study analyzed
the anti-inflammatory activity of some flavonoids with a focus on the possible regulatory role in
the activation of NLRP3 inflammasome. The mechanism proposed for inhibiting activation by
flavonoids was based on the regulation of the expression of inflammasome components such as
the amino-terminal pyrin domain (PYD), which interacts with the ASC pyrin domain (caspase
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recruitment domain) to initiate the assembly of the inflammasome; the central nucleotide binding and
oligomerization domain (NACHT), which has the ATPase activity necessary for NLRP3 oligomerization
after activation; and C-terminal leucine-rich repeat (LRR) domain, whose function has not yet been
identified. These changes can prevent its assembly and lead to inhibition of caspase-1 activation and,
consequently, maturation and secretion of pro-inflammatory cytokines [41,42].
Luteolin (6), a flavonoid found in T. esculenta seeds, has anti-inflammatory activity attributed
to its ability to reduce the generation of reactive oxygen species (ROS) and inhibit the activation
of NLRP3 inflammasome. Previous studies have described some Pattern-Recognition Receptors
(PRR) located in the cytoplasm of cells, such as dendritic cells and macrophages, which are also
involved in the induction of inflammatory responses [43]. Among these receivers, some belong to
the family of NOD-like receptors (NRLs). NLRs are a large family of intracellular PRRs with similar
structure [44,45]. Among the various types of NLRs, NLRP3 is recognized for responding to various
stimuli, being responsible for the inflammasome activation (NLRP3 inflammasome), involved in the
recruitment and activation of caspase-1 (pro-caspase 1) in association with the ASC adapter protein [46].
The role of activated caspase-1 is crucial for the conversion of pro-interleukin 1 beta (pro-IL-1β) and
pro-interleukin 18 (pro-IL-18) into their mature and biologically active forms [47]. Thus, luteolin (6)
is able to reduce the expression of interleukin-1 beta (IL-1β), a cytokine with a primary role in the
inflammatory response, and interleukin-8 (IL-8), a chemokine that stimulates migration of immune
cells. Another anti-inflammatory flavonoid found in T. esculenta seeds is rutin (10), which promotes
the inhibition of the NLRP3 inflammasome activation through the negative regulation of the NLRP3,
ASC and caspase-1 expression and reduced production of IL-1β and interleukin-18 (IL-18), which is
also known as an interferon-γ inducing factor (IFN-γ) [41,48].
A previous study revealed the immunoregulatory properties of naringenin (7), a flavonoid also
found in T. esculenta seeds. This compound promotes the inhibition of nuclear transcription factor
kappa B (NF-κB), mitogen-activated protein kinase (MAPK) and reduces the production of tumor
necrosis factor alpha (TNF-α) and interleukin-6 (IL-6), a pro-inflammatory cytokine [49].
Jhang et. al. [50] analyzed the therapeutic potential of catechin (3) and gallic acid (5), both found in
T. esculenta fruits and possible anti-inflammatory properties were found. After subcutaneous injection
in mice, whose inflammation was stimulated by the administration of monosodium urate (MSU),
significant reduction in the production and secretion of IL-1β and IL-6 was observed. The secretion
of IL-1β was modulated through two pathways that include the NF-κB pathway, which provides
pro-IL-1β and the NLRP3 inflammasome pathway, which promotes the release of IL-1β from pro-IL-1β.
The study demonstrated that catechin (3) and gallic acid (5) have potent activity to eliminate superoxide
anions, consequently inhibiting MSU-induced IL-1β secretion and NLRP3 inflammasome activation.
Catechin (3) also regulated the oxidative stress status in mitochondria through positive regulation
of thioredoxin (TRX) and deglycase protein DJ-1 (DJ-1) and these effects prevented mitochondrial
damage caused by MSU attack. These results suggest that catechin intake has potential to prevent
acute gout attacks. In addition, researchers have demonstrated the role of these compounds on the
intracellular calcium concentration, which is high during the inflammatory process, with significant
reduction in calcium concentration by catechin (3), but not by gallic acid (5) (Figure 1a,b).
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Figure 1. Molecular mechanism of flavonoids in inflammasome regulation: (a) Studies suggest that
oxidative stress is an important mediator of monosodiumurate (MSU) induced inflammation [51].
The formation of reactive oxygen species (ROS) induces nuclear translocation of Nuclear Factor-kappa
B (NF-kB) via phosphorylation by IkB kinase, which binds to target DNA that regulates Pro-IL-1β
and Pro-IL-8 gene expression. In addition, ROS dissociates the thioredoxin (TRX) and thioredoxin
interaction protein (TXNIP) conjugation [52], and released TXNIP further recruits and binds to NLRP3
inflammasome, leading to the release of IL-1β [53] and IL-8. NLRP3 inflammasome consists of NLRP3,
caspase recruitment domain (ASC), and pro-caspase-1. Mitochondrial ROS (MtROS) is also associated
with NLRP3 inflammasome activation [53]. In the process of NLRP3 inflammasome activation,
activated caspase-1 transforms pro-IL-1b and pro-IL-18 into mature IL-1b and IL-18, resulting in the
release of inflammatory cytokines; (b) Flavonoid uptake occurs either via passive diffusion through the
cell membrane, or through membrane bound transport proteins. Cut circles indicate different points
of flavonoid action, inhibiting the process of inflammasome formation with subsequent inhibition of
inflammatory events [54]. Phenolic compounds block the inflammatory process by inhibiting ROS
formation, thereby reducing the formation of pro-inflammatory cytokines. The nature and position of
substituents in relation to the hydroxyl group affect the activity of polyphenols. The easily ionizable
carboxylic group contributes to the efficient hydrogen donation tendency of phenolic acids [55]. Gallic acid
has high antioxidant activity rate. This is due to a beneficial influence of carboxylate on the antioxidant
activity of phenolic acids [56]. The tricyclic structure of flavonoids, such as catechin, determines their
antioxidant effect. Phenolic quinoid tautomerism and the localization of electrons over the aromatic system
eliminate reactive oxygen species. These aromatic rings directly neutralize free radicals and increase
antioxidant defense [57]; (c) DAMPs/PAMPs bind to their receptor on the cell membrane and activate a
signaling cascade. As a consequence, activation and formation of NRLP3 inflammasome occur, where
the formation of active caspase-1 catalyzes the cleavage and secretion of mature IL-1β and IL-18, leading
to propagate inflammation [54]. ASC, caspase recruitment domain; C-JUN/JNK, c-Jun N-terminal
Kinase; CARD, caspase recruitment domain; DAMPs, damage-associated molecular patterns; IκB,
inhibitor of κB; IKKα, IkBkinase α; IKKβ, IkBkinase β; IL-1β, Interleukin 1-beta; IL-8, Interleukin 8; LRR,
leucine-rich repeats; MAP3Ks, mitogen-activated protein 3 kinases; MEK, mitogen-activated protein
kinase; MKK4, mitogen-activated protein kinasekinase 4; MKK7, mitogen-activated protein kinase
kinase 7; MtROS, Mitochondrial ROS; MSU, monosodiumurate; NACHT, central nucleotide-binding and
oligomerization domain; NEMO, NF-kappa-B essential modulator; NF-KB, Nuclear Factor-kappa B; p38a,
p38 kinase α; p50, NF-KB, Nuclear Factor-kappa B 1 (NF-KB1); p65, RelA; PAMPs, pathogen-associated
molecular patterns; PYD, pyrin domain; ROS, reactive oxygen species; TXNIP, thioredoxin interaction
protein; TRX, thioredoxin; TXNIP, thioredoxin interaction protein.
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For the inflammasome activation, danger signals such as Damage-Associated Molecular Patterns
(DAMPs) or Pathogen-Associated Molecular Patterns (PAMPs) bind to PRRs on the cell membrane and
trigger the activation of a signaling cascade, which includes the activation of NF-κB, MAPK and MAPK
activating protein kinase (MEK), leading to activation and assembly of the inflammasome, a protein
complex where active caspase-1 catalyzes the cleavage and secretion of IL-1β and IL-18, important
pro- inflammatory signaling gents. In this context, flavonoids cross the membrane through passive or
facilitated diffusion using membrane-bound transport proteins. In the cell, different flavonoids act in
the same pathway or in different pathways, blocking the formation of inflammasome and consequently
inhibiting the inflammatory process (Figure 1c) [54].
The flavonoid quercetin (2), found in T. esculenta fruits, has anti-dyslipidemic activity, which is
also associated with inflammation, since the accumulation of lipids is a factor that contributes to the
inflammatory response and inflammasome formation. Quercetin (2) acts by suppressing the NLRP3
expression, inhibiting caspase-1 and the production of IL-1β, also reducing the levels of lipids, more
specifically triacylglycerols [58].
In addition, quercetin (2) also has antioxidant activity, which is mainly mediated by its effects on
glutathione (GSH), enzyme activity, signal transduction pathways and ROS. Increase in GSH levels
in rats was observed after quercetin administration (2), which increases the antioxidant capacity of
these animals, since GSH acts as hydrogen donor in the reaction of conversion of hydrogen peroxide
into water, catalyzed by superoxide dismutase (SOD), reducing its toxicity. Quercetin (2) also acts by
increasing the expression of endogenous antioxidant enzymes, including catalase (CAT) and glutathione
peroxidase (GPx). In signal transduction pathways, quercetin (2) acts in the regulation of kinase
protein activated by AMP (AMPK) and MAPK, stimulated by ROS, promoting antioxidant defense and
maintaining the oxidative balance, since ROS lead to the activation of several pro-inflammatory and
apoptotic signaling events mediated by p53, a cell cycle regulatory protein (Figure 2). Also, quercetin (2)
inhibits the p38MAPK/inducible nitric oxide synthase (iNOS) signaling pathways, negative regulation
of NF-κB levels and positive regulation of SOD activity to promote antioxidant activity [59].
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Figure 2. Antioxidant effect of quercetin on enzyme activity, signal transduction pathways
and reactive oxygen species (ROS). Several conditions and environmental factors can increase
ROS production. Besides, the mitochondrial electron transport chain is an important source
of intracellular ROS generation. Flavonoid uptake occurs either via passive diffusion through
cell membrane, or through membrane bound transport proteins [54]. After entering the cell,
quercetin acts through the regulation of the enzyme-mediated antioxidant defense system and the
non-enzymatic antioxidant defense system. Nuclear factor erythroid 2–related factor 2 (NRF2),
AMP-activated protein kinase (AMPK), and mitogen-activated protein kinase (MAPK) pathways
induced by ROS to promote the antioxidant defense system and maintain oxidative balance can
also be regulated by phenolic compounds such as quercetin [59]. Through the neutralizing effect
of ROS, quercetin can develop important anti-inflammatory effect due to inhibition of the Nuclear
Factor-kappa B (NF-KB) pathway, preventing the activation of NRLP3 inflammasome (shown in
Figure 1B). Through the p53 pathway, ROS induce apoptotic events. Therefore, quercetin can prevent
apoptosis induced by excess ROS. In addition, it enhances the production of Apurinic/apyrimidinic
Endonuclease 1/ Redox Effector Factor 1 (APE1/Ref1), activation of various signaling events and
the NF-E2-related factor (NRF2)-mediated activation of genes, containing antioxidant response
elements (ARE) and NF-κB [60–64]. AMPK, AMP-activated protein kinase; AP-1, activator protein
1; APE1, Apurinic/apyrimidinic endonuclease 1; ARE, antioxidant response element; Bax, BCL2
Associated X; CAT, catalase; CREB, cAMP-response element binding protein; EGR1, Early Growth
Response 1; ERK, Extracellular signal-regulated kinase; GSH, glutathione; GSHPx, Glutathione
peroxidase; IκB, κB inhibitor; JNK, c-Jun N-terminal Kinase; KEAP1, Kelch-like ECH-associated
protein 1; Maf, musculoaponeurotic fibrosarcoma; MAPK, mitogen-activated protein kinase; MtROS,
Mitochondrial ROS; NF-KB, Nuclear Factor-kappa B; Nrf2, nuclear factor erythroid 2–related
factor 2; PDGFR, Platelet-derived growth factor receptors; PI3K, phosphatidylinositol-3-kinase;
Ref-1, redox effector factor 1; ROS, reactive oxygen species; SOD, Superoxide dismutase.
p-Coumaric acid (8), identified in T. esculenta fruits, presents a phenyl hydroxyl group in its
molecular structure, capable of promoting the neutralization of free radicals such as superoxide anion
2,2-diphenyl-1-picrylhydrazyl-hydrate (DPPH) and hydrogen peroxide (H2O2). This antioxidant
property is intensified after conjugation with quinic acid (9), also found in T. esculenta fruits. In addition,
p-coumaric acid (8) also has antimicrobial activity tested against three Gram-positive bacteria
(Streptococcus pneumonia, Staphylococcus aureus and Bacillus subtilis) and three Gram-negative bacteria
(Escherichia coli, Shigelladys enteriae and Salmonella typhimurium), by increasing the permeability of
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the bacterial membrane and binding to the phosphate anion of the DNA (deoxyribonucleic acid),
altering the processes of bacterial transcription and replication [65].
In a previous study, researchers analyzed the antioxidant properties of T. esculenta fruits using
two tests, the scavenging of DPPH radicals and the iron reduction capacity. Antioxidant activity
was detected in the seed extract, in which naringenin (7), luteolin (6) and rutin (10) flavonoids were
identified and also for pulp extracts, where phenolic compounds such as gallic acid (5), p-coumaric
acid (8), rutin (10), catechin (3), epicatechin (4) were also found, as well the cyclitol quinic acid (9),
to which antioxidant activity can be attributed [33].
Flavonoids mirecetin (1) and quercetin (2), also found in T. esculenta fruits, have significant
antiproliferative activity, suggesting a chemopreventive and anti-tumor potential that should be
investigated in the future [32]. [35] reported two other properties of T. esculenta phytochemicals,
diuretic and antihypertensive. Studies have shown that the hydroalcoholic extract obtained from
T. esculenta leaves and stem promotes significant increase in urinary volume, without changing urine
pH and density, indicating a diuretic effect, and significant increase in renal potassium elimination,
which are properties related to phenolic acids and flavonoids found in extracts.
Pinheiro et al. [66] analyzed the possible antifungal activity of lectin extracted from T. esculenta
seeds. This activity was tested on Microsporum canis, a filamentous keratinophilic fungus that causes
infections in skin, hair and nails in humans and animals. The results show the ability of lectin to inhibit
the growth of the fungus, which may be associated with the interaction of lectin with carbohydrates
on the surface of microorganism such as d-mannose and N-acetyl-glucosamine, since the addition
of these carbohydrates caused inhibition of the antifungal effect, probably due to competition for
the interaction of fungal carbohydrates with lectin. The ability of lectin to inhibit the adherence of
microorganisms and exert antimicrobial effects was analyzed in another study, which tested such
properties on bacteria Streptococcus mutans UA159, Streptococcus sobrinus 6715, Streptococcus sanguinis
ATCC10556, Streptococcus mitis ATCC903 and Streptococcus oralis PB182. The results indicate that lectin
was not able to inhibit the growth of bacteria at any of the applied concentrations and also did not
inhibit the adherence of microorganisms, that is, it does not present antimicrobial activity and does not
inhibit biofilm formation [67].
3.1.5. Toxicity Studies
So far, there are no records of human poisoning by T. esculenta, probably because seeds and leaves
are not consumed in the fresh form, only the pulp; however, there are records of intoxication in some
animals, such as sheep and cattle that ingest leaves and seeds without heat treatment, which may
indicate that the toxic compound is affected by high temperatures [68].
The Northeastern region of Brazil presented an outbreak of spontaneous poisoning in sheep and
cattle, which showed severe signs of nervous system damage, some irreversible. Thus, an experimental
reproduction of the poisoning was carried out with 5 sheep by administering 30–60 g of leaves per
kilogram of body weight, and two sheep with doses of 5–10 g of seeds per kilogram of body weight,
with samples from different regions of Brazil. All sheep showed clinical signs of intoxication 72 h
after exposure. The main signs and symptoms were mild to moderate tympanism, drowsiness, ataxia,
depressive behavior and humeral hypomotility. The chemical compound present in leaves and seeds
responsible for the toxic effect is still unknown. In addition, the minimum amount that exerted toxicity
was lower for seeds than for leaves, indicating greater potential for seed toxicity [69].
In the same region, cattle spontaneously intoxicated with the same clinical signs, were analyzed
72 h after exposure. In autopsy exams, partially digested seeds and leaves were found in the
rumen. Laboratory and histological exams showed no significant changes, either in spontaneous or
experimental poisoning. However, the presence of seeds in the rumen content associated with clinical
signs suggests that there is risk of human poisoning by both seeds and leaves [70]. Similar clinical
signs were observed in a dog after ingestion of T. esculenta seeds. Although the substance responsible
for the toxicity is unknown, the induction of inflammatory response by lectin found in seeds is the
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focus of a study that describes the recruitment of neutrophils and mononuclear cells caused by lectin.
The proposed mechanism is related to the specific properties of lectin binding to carbohydrates in the
cell membrane [71,72].
In contrast, Wistar rats treated with purified aqueous extract from T. esculenta leaves and stem at
oral doses of 5, 50, 300 and 2000 mg did not show any sign of acute toxicity, and regardless of dose,
there were no abnormal signs in comparison with control animals. Water intake and body weight did
not change during the experimental period and the biochemical and hematological parameters showed
no abnormalities. After euthanasia, heart, lung, spleen, kidney and liver samples were collected for
pathological evaluation and also showed no signs of abnormality, which may be related to the lectin
concentration, which is higher in seeds than in leaves and stem; therefore, the absence of toxicity may
be due to the fact that seeds were not used in this study [35].
4. Moraceae Family
The Moraceae family has 53 genera and about 1500 identified species, with tropical prevalence,
being more than 50% of the genera present in the Neotropical region, mainly in South America. Species
of the Moraceae family are found in humid forests or in their vicinities. Artocarpus, Brosimum, Ficus
and Morus are among the most widely known genera, which correspond to the widely known and
consumed fruit-producing plants of great nutritional and economic importance such as jackfruit,
walnut, fig, and blackberry. In addition, some species of this family provide wood and leaves, used as
food for silkworm [11,73,74].
Belonging to the Rosales order, this family has members that stand out for their ornamental
possibilities, such as the genus Ficus, Maclura and Dorstenia and medicinal possibilities such as
Brosimum gaudichaudii Trécul. This family was classified as the most important in terms of number of
species with phytotherapic potential, emphasizing the genus Brosimum [75,76].
Like other families characteristic of tropical climates, Moraceae members also present adaptations
to water scarcity and intense solar radiation. An example of these adaptations is the development of a
thick waxy layer, called cuticle, with significant photoprotective property, which due to its reflective
capacity, prevents the intense and harmful absorption of excessive solar radiation [77].
4.1. Genus Brosimum and Species Brosimum gaudichaudii
The genus Brosimum is composed of 13 species: Brosimuma cutifolium Huber, Brosimum alicastrum Sw.,
Brosimum gaudichaudii Trécul, Brosimum glaucum Taub., Brosimum glaziovii Taub., Brosimum guianense (Aubl.)
Huber, Brosimum lactescens (S. Moore) C.C. Berg, Brosimum longifolium Ducke, Brosimum melanopotamicum
C.C. Berg, Brosimum parinarioides Ducke, Brosimum potabile Ducke, Brosimum rubescens Taub.,
and Brosimu mutile (Kunth) Pittier, with B. gaudichaudii being the only representative of the genus
Brosimum found in the Cerrado vegetation [78,79].
There are several studies focused on the biological properties of Brosimum gaudichaudii Trécul,
which has great economic importance due to the production of latex, in addition to the use of roots,
stem bark and leaves in popular medicine, whose pharamacological activities are attributed to the
high content of coumarins, its main class of active metabolites, which may represent about 3% of the
dry root weight [80–82].
Popularly known as mama-cadela, mamica de cadela, conduru and inharé, this species has
properties of agribusiness interest, contributing to the economic development of the country. Its wood
is used in civil construction and paper-making industries, and although its fruit is edible, the use of
roots, stems and leaves in popular medicine prevails [73].
4.1.1. Geographical Distribution and Popular Use
B. gaudichaudii is not endemic to Brazil, despite being widespread in the country, as it occurs in
other countries, mainly in Paraguay, Bolivia, and Argentina. It is predominant in regions with typical
Cerrado, Cerradão and Amazon savanna vegetation. However, it is under threat of extinction due to its
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occurrence in regions with constant change, such as the Brazilian cerrado, whose native vegetation is
commonly subjected to burning and reduced by the expansion of the agricultural frontier, in addition
to being affected by the indiscriminate extraction of latex [83,84].
Ribeiro et al. [85] conducted a survey on the popular use of several species, among them
B. gaudichaudii, whose most used plant organs were roots, stem bark and latex, either in the fresh
form or prepared by decoction, infusion, or maceration. The therapeutic indications reported in
the research were: infections, venereal diseases, that is, those sexually transmitted, boils, superficial
skin mycoses, cancer, anemia, cardiac arrhythmia, pneumonia, vitiligo, joint pain, inflammation,
rheumatism, kidney disorders and wound healing.
For the treatment of vitiligo and other skin diseases, the extract, usually obtained by infusion or
decoction of roots or stem bark, is used topically. In addition, it has also been described as a depurative,
that is, it is used to eliminate toxins and improve blood circulation, and in this case, preparation is
carried out by decoction or maceration of branches and leaves in dry wine. Its use against flu, colds and
bronchitis occurs from the infusion of any plant part in wine or water [86].
Popularly known as bottleful, homemade preparations using dry wine as vehicle are produced by
macerating the chosen vegetable organ in wine and honey for a period of at least 8 days. After this
period, the liquid obtained is packed in capped bottles. Generally, extracts are orally administered
and although they do not have a health record, they can be found available for purchase at street
markets [87,88].
4.1.2. Botanical Aspects
B. gaudichaudii can be found as shrub, tree or bush, reaching up to 4 m in height. Roots are
terrestrial and gemiferous, that is, with the ability to sprout and generate new plants, a strategy of
survival to common fires that occur in the Cerrado region, they form a root system, composed of
a main root to which longitudinal roots that grow in different directions are anchored. The stem is
aerial, erect and of the trunk type, with sympodial growth; leaves are glabrous on the adaxial surface
and may present glandular trichomes on the abaxial epidermis, phyllotaxis is alternate, with simple
and petiolate leaves, with oblong, oblong-lanceolate or elliptical shape, obtuse to acuminate apex,
oblique base, entire margins of the limb, wavy or serrated, with camptodrome-like peninerval venation,
that is, secondary venation do not end at the margin [83].
It blooms between the months of June and October; inflorescences are monopodial, bisexual,
ear-like, globose, composed of 30 to 100 flowers, which are pedunculated, aclamidic, diclinic, monoic,
that is, they present unisexual female and male flowers in the same individual, and staminate flowers
are protected by bracteole. They have green to yellowish color, with gamocarpelar gynoecium and
unilocular ovary [89,90].
B. gaudichaudii fruits are edible, drupe type, fleshy, with about 2 to 4 cm in diameter, globose,
monospermic, and should be harvested between the months of September and November. Each fruit
contains an ellipsoid seed, whitish in color, considered recalcitrant, as it is not viable after drying.
The embryo has two fleshy cotyledons and fills the entire seed volume. Regarding shape and size,
these cotyledons have starch, protein, and lipid reserves. They have short and swollen hypocotyl
located below the point of insertion of cotyledons [82].
4.1.3. Phytochemical Aspects
The summary of phytochemical studies carried out with different B. gaudichaudii plant organs and
the structures of isolated substances are shown in Table 2.
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B. gaudichaudii is the target of some phytochemical screening studies, mainly qualitative,
which show significant concentrations of coumarins, especially furanocoumarin psoralen (25) and
bergaptene (26). The analysis of the proximate composition of the fresh ripe fruit with bark showed
for every 100 g on a wet basis: 77.63 g of moisture, 1.63 g of proteins, 0.60 g of lipids, 13.35 g of
carbohydrates, 5.11 g of dietary fiber, 0.82 g of ash content and 62.21 kcal of total energy value.
In addition, 46.47 mgGAE (gallic acid equivalents) of phenolic compounds and 14.92 g of vitamins C
were also quantified [95,96].
Lourenço, [91] identified and quantified the content of furanocoumarin psoralen (25) and bergaptene
(26) in the lyophilized methanolic and aqueous extracts of the root cortex of B. gaudichaudii. For each 1 g of
dry weight of the plant organ used, 27.6 mg of psoralen (25) and 32 mg of bergaptene (26) were found in the
methanolic extract, which correspond, respectively, to 2.8% and 3% of the sample. For the aqueous extract,
7.1 mg/g of psoralen (25) were quantified, that is, 0.7% and 2.6 mg/g of baptapene (26). This study analyzed
the composition of the methanolic extract of leaves, branches, latex, and heartwood of B. gaudichaudii
roots. In leaves, glycosylated flavonoids 5,7,3’, 4’-tetrahydroxy-6-C-glucopyranosylflavone (27) and
5,7,3’,4’-tetrahydroxy-3-O-ß-d-galactopyranosyl-flavonol were detected (28), also in the extract of
leaves, branches and heartwood in roots, psoralen (25) and bergaptene (26) were also isolated, but in
less amount compared to that found in the root cortex, while furanocoumarins were not detected in
the latex.
Other analyses using the hydroalcoholic extract of B. gaudichaudii roots also identified psoralen (25)
and bergaptene (26). Two extraction techniques were compared, percolation and ultrasound-assisted
extraction (UEA), and both showed satisfactory results, but UEA extraction technique was more
quick [92].
Spectral analysis was carried out on an extract from B. gaudichaudii root bark, which led to the
identification of a new coumarin called gaudichaudine (29), the coumarins psoralen (25), bergaptene
(26), luvangetin (30) and (+)−(2’S, 3’R)-3’-hydroxyrmesin (31) and the pyranocoumarin xanthyletin
(32). Subsequently, using the same type of extract and the same plant organ, the same researchers
found the following secondary metabolites: coumarins marmesin (33), 1’,2’-dehydromarmesin
(34), 8-methoxymarmesin (35) and 1’-hydroxy-3’-O-β-glucopyranosylmarmesin (36); the chalcone
2’,4’,4-trihydroxy-3’3-diprenylchalcone (37); and the triterpene β-amyrin (38) [93,94].
The determination of total tannins in the methanolic extract from B. gaudichaudii stem bark carried
out by [97] revealed that for each 1 g of sample, there are approximately 17.50 mg of total tannins,
which have not been isolated so far. Another study on the same species qualitatively identified in the
alcoholic extract of leaves and stem bark, alkaloids, anthraquinones, phenols and tannins [98].
The qualitative analysis of the ethanolic extract from B. gaudichaudii root bark pointed out the
presence of triterpenes, steroids, coumarins, alkaloids and anthraquinones, but tested negative for
saponins and tannins [99]. To investigate the presence of these and other compounds in the ethanolic
extract from B. gaudichaudii leaves, a previous study carried out a qualitative analysis of this extract,
which was positive for alkaloids, coumarins, flavonoids and cardiotonic glycosides, and negative for
anthraquinones, catechins and saponins [100].
4.1.4. Pharmacological Studies
The pharmacological use of B. gaudichaudii is widely explored due to its repigmentating property,
clinically used for the treatment of vitiligo, a skin pigmentation anomaly. This property is attributed to
the presence of furanocoumarins, molecules found mainly in the B. gaudichaudii root cortex, which have
photosensitizing action, and associated with ultraviolet (UV) radiation, is used to treat not only vitiligo,
but also other skin disorders such as psoriasis, systemic lupus erythematosus and mycoses [101]
(Figure 3).
The mechanism of action of furanocoumarins for the UV phototherapy technique is not yet
defined. However, previous studies have proposed that there is induction of apoptosis of cells that
participate in the generation of disorders, such as T cells, mast cells and keratinocytes, in addition to
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increased proliferation of melanocytes and reduced histamine release by mast cells and basophils [102].
Lang et al. [103] reported an increase in CD8 + T lymphocytes specific for the skin in a patient with
vitiligo and that this may be related to the etiology of the disease, since these cytotoxic T lymphocytes
may participate in the reduction in the number of melanocytes observed in the disease (Figure 3).
 
Figure 3. Use of furanocoumarins in the technique of extracorporeal photopheresis for the treatment of
systemic or multifocal diseases: Leukocytes obtained by apheresis are exposed to 8-metoxipsoraleno
(8-MOP), which is activated by UVA radiation and covalently binds to the DNA of these cells, causing
damage and inducing apoptosis within 48 h. Pre-apoptotic leukocytes are reintroduced into the
peripheral circulation, being recognized and phagocyted by antigen-presenting cells in phagolysosomes.
This recognition induces tolerogenic anti-inflammatory response, which reduces the production
of pro-inflammatory cytokines like IL-6, IL-12, IL-23, and TNF-α and increases the production
of anti-inflammatory cytokines like IL-10, TGF-β1, and PGE2 [104]. 8-MOP, 8-metoxipsoraleno;
IL-6, interleukin 6; IL-10, interleukin 10; IL-12, interleukin12; IL-23, interleukin 23; TGF-β1,
Transforming growth factor beta 1; TNF-α, Tumor Necrosis Factor-Alpha. Another technique that uses
furanocoumarins is extracorporeal photopheresis (ECP), which treats systemic or multifocal diseases
such as Crohn’s disease, type 1 diabetes mellitus, multiple sclerosis, and rheumatoid arthritis. In this
technique, the most used furanocoumarin is 8-methoxypsoralen (8-MOP), to which leukocytes, obtained
by apheresis, are exposed. 8-MOP is activated by radiation and covalently binds to leukocyte DNA,
leading to apoptosis within 48 h. These pre-apoptotic leukocytes are reintroduced into the peripheral
circulation, where are recognized and phagocyted by antigen-presenting cells in phagolysosomes.
This recognition induces a tolerogenic anti-inflammatory response that leads to a reduction in the
production of pro-inflammatory cytokines IL-6, interleukin-12 (IL-12), interleukin-23 (IL-23) and TNF-α
and induces the production of anti-inflammatory cytokines such as interleukin-10 (IL-10), transforming
growth factor beta 1 (TGF-β1) and prostaglandin E2 (PGE2) (Figure 3) [102,104].
Lourenço, [105] tested the possible antibacterial activity of the ethanolic extract of B. gaudichaudii
leaves and stem bark against S. aureus from clinical samples, beta-hemolytic streptococci, P. aeruginosa,
E. coli, Citrobacter sp. and Proteus sp. Both extracts showed antimicrobial activity against all bacterial
strains, including multi-resistant strains, with variable percentage of bacterial growth inhibition.
However, the bioactive compounds responsible for this activity have not yet been identified.
The ethanolic extract from B. gaudichaudii stem bark was analyzed for antifungal properties on
Candida albicans and Candida sp. This activity was observed for C. albicans at concentration of 200 mg/mL
and for C. non albicans at concentrations of 100 mg/mL and 200 mg/mL [96]. The hydroalcoholic extract
from B. gaudichaudii leaves was also tested for trypanocidal activity. Mice previously infected with the
blood form of Trypanosoma cruzi received the extract at different concentrations. The infection was
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assessed by counting parasites present in 10 μL of blood between the 5th and the 11th day after infection,
showing reduction in the number of trypomastigotes at concentration of 100 mg/kg. Although the
chemical compound responsible for this activity has not been identified, it is possible to associate it
with furanocoumarins, which are the main components of the extract that may have acted through the
production of oxide and superoxide radicals [106].
β-Amyrin (38), a triterpene found in B. gaudichaudii root bark promotes sleep modulation through
the activation of the GABAergic system. For the analysis, a pentabarbital-induced sleep model was used
in mice, and it was observed that, after the administration of 1, 3 or 10 mg/kg of β-amyrin (38), the time
for the beginning of sleep was reduced and the sleep duration increased significantly, which effects were
inhibited after administration of a type A gamma-aminobutyric acid antagonist receptor (GABAA),
demonstrating that this property is associated with the GABAergic system. In addition, the levels of
gamma-aminobutyric acid (GABA) in the brain were analyzed, which increased after the administration
of β-amyrin (38), which could be related to the blocking of GABA transaminase, inhibiting GABA
degradation and, consequently, increasing its available concentration [107].
A study was carried out on the role of β-amyrin (38) in attenuating the neurodegeneration of
Parkinson’s disease using Caenorhabditis elegans strain. The analysis describes a protective effect of
β-amyrin (38) against neurotoxicity induced by 6-hydroxydopamine (6-OHDA), which was related to
the possible antioxidant role of β-amyrin (38). This study also investigated its anti-apoptotic activity on
the expression of pro-apoptotic genes in C. elegans, which were not significantly altered after treatment
with β-amyrin (38). The aggregation of α-synuclein protein is one of the mechanisms associated with
Parkinson’s disease. The effects of β-amyrin (38) on this mechanism were compared to the effect of the
medicine clinically used to treat the disease, L-dopa and both substances significantly reduced the
α-synuclein aggregation [108].
Sunil et al. [109] analyzed the antioxidant activity of β-amyrin (38) in Wistar rats with oxidative
stress induced by carbon tetrachloride (CCl4). The effect was positive in the elimination of DPPH
radicals, hydroxyl, nitric oxide (NO), superoxide radicals and had strong reducing and suppressive
power of lipid peroxidation. The increase in free radical levels also leads to elevated levels of hepatic
enzymes serum glutamic oxalacetic transaminase (SGOT), serum glutamic pyruvic transaminase
(SGPT) and LDH, which after administration of β-amyrin (38), had their levels reduced. In addition,
the levels of the antioxidant enzymes SOD, CAT, GSH and GPx, were high.
A study analyzed the β-amyrin (38) activity on inflammation induced by lipopolysaccharide (LPS)
and IFN-γ in the microglial cells of rats. β-amyrin (38) reduced the expression of pro-inflammatory
factors such as TNF-α, IL-1β, IL-6, PGE-2 and cyclooxygenase-2 (COX-2) and increased the expression
of arginase-1. The reduction of factors was attributed to the activation of the cannabinoid receptor, since
antagonists of these receptors inhibit the anti-inflammatory effects of β-amyrin (38). Through another
not yet identified mechanism, β-amyrin (38) reduces the activity of COX-2 and, consequently,
the production of PGE-2, commonly inhibited by the action of non-steroidal anti-inflammatory
drugs. Enzymes arginase-1 and NO synthase compete for the same substrate, L-arginine, with the
overexpression of arginase-1, observed by the increase in its product, urea, NO production is
compromised, since the availability of substrate for NO synthase is reduced [110].
Marmesin (33), a coumarin found in B. gaudichaudii root bark, is the target of several studies
that investigate its medicinal properties, especially its anti-tumor properties. The in vitro and in vivo
activity of marmesin (33) was evaluated on cells with human leukemia and healthy human monocytes.
The results indicate that marmesin (33) exerts dose-dependent anti-tumor activity and that the cytotoxic
effect on healthy monocytes was lower, which is essential for the safety of a probable treatment,
since it predicts that the compound has action selectivity, reducing the possibility of adverse effects.
Marmesin (33) increased the expression of pro-apoptotic protein Bax and reduced the expression of
anti-apoptotic protein Bcl-2, increasing the Bax/Bcl-2 ratio, which promotes activation of caspase 3,
leading to apoptosis, with mechanism of action similar to other chemotherapeutic drugs. Marmesin
(33) also causes an increase in intracellular ROS and reduces the mitochondrial membrane potential
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(MMP), which was related to the reduced migration of cells with leukemia, important in inhibiting
metastases [111].
Another analysis of the same property associated with marmesin (33), but on lung cancer and
tumor angiogenesis, reports anti-tumor activities of marmesin (33) mediated by the inactivation of
mitogenic signaling pathways and negative regulation of proteins related to cell signaling, including
vascular endothelial growth factor-2 receptor (VEGFR-2), integrin β1, integrin-linked kinase (ILK) and
matrix metalloproteinases-2 (MMP-2), nullifying mitogen-stimulated proliferation and invasion in
cells expressing p53 or not [112].
4.1.5. Toxicity Studies
Furanocoumarins, the major constituents of B. gaudichaudii roots, are phototoxic substances that
the plant uses as a protection mechanism against phytopathogenic microorganisms and herbivores.
The mechanism of action is intercalation in the double helix of the DNA structure and in molecular
complexation, and when activated by light, they react with pyrimidine bases, mainly with thymine,
which can promote toxic, mutagenic and carcinogenic effects [113].
The genotoxic activity of B. gaudichaudii was evaluated using aqueous and methanolic extracts
on Salmonella typhimurium strains, which showed an increase in chromosomal aberrations in cultures
submitted to the methanolic extract in the G1/S and S phases of the cell cycle. For the aqueous extract,
results were not significant, which is due to the lower amount of furanocoumarins extracted by the
aqueous extract compared to the methanolic extract [114].
Lourenço, [91] performed toxicity tests for the aqueous and methanolic extract from B. gaudichaudii
root cortex and obtained through the MTT technique (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl
tetrazolium bromide), cytotoxicity indexes (IC50) of 4.65 mg/mL and 1.31 mg/mL, for each extract,
respectively. The mutagenicity assay was also performed with Salmonella typhimurium, which generated
the mutagenicity ratio (MR) through the observation of revertants, that is, the number of individuals
whose natural phenotype induced by mutation, was restored. The ratio is calculated using the average
number of revertants in the test plate, spontaneous or induced, divided by the average number of
revertants per negative control plate, that is, spontaneous, with the sample being considered positive
with ratio greater than or equal to 2. MR was higher for the aqueous and methanolic extracts in
the TA102 strain in the presence of microsomal fraction S9, which reveals whether the substance or
sample is mutagenic in its original form or whether it needs to be metabolized or activated to become
mutagenic, in this case, it has been metabolized.
A study determined the acute toxicity of the extract from B. gaudichaudii root bark orally and
intraperitoneally administered in mice. Oral administration led some animals to death, and the median
lethal oral dose (LD50) was 3517.54 mg/kg and intraperitoneally, LD50 was 2871.76 mg/kg. Up to
2000 mg/kg, 40% of animals had diarrhea, and increasing the dose, some of them presented, in addition
to diarrhea, dry eyes, eyelid occlusion, ocular hemorrhage, epistaxis, weight loss, tachypnea and death
at the lethal dose. Dead animals were analyzed and showed dilation and hemorrhage, in addition to
increase in the amount of hemosiderin in the spleen, indicating previous hemorrhage and destruction
of erythrocytes [80].
Using dry B. gaudichaudii extract, the acute and subacute toxicities of this species were analyzed,
with an estimated lethal dose (DLA) of 3800 mg/kg. In the acute study, 14 days after administration,
leukopenia and hemosiderin accumulation were observed in the spleen, and in the subacute,
after 30 days, changes in the levels of aspartate aminotransferase (AST), alanine aminotransferase
(ALT), creatinine and total proteins were observed, indicating hepatotoxicity and nephrotoxicity for
the dose of 100 mg/kg, in addition to leukopenia and renal hemorrhage [115].
These clinical signs of hemorrhage may be related to the anticoagulant property of some coumarins
found in large amounts in this species. To exert such activity, coumarins act as competitive inhibitors
of epoxide reductase, an enzyme that reduces vitamin K, oxidized by participating as co-factor
in the synthesis of coagulation factors II, VII, IX and X. With the inhibition of epoxide reductase,
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this regeneration does not occur, depleting the levels of active vitamin K and consequently inhibiting
the synthesis of coagulation factors (Figure 4) [116].
 
Figure 4. Proposed mechanism for inducing hemorrhage by coumarins: Coumarins act as competitive
epoxide reductase inhibitors. This enzyme reduces oxidized vitamin K during its participation as
co-factor in the synthesis of coagulation factors II, VII, IX, and X. With epoxide reductase inhibition,
the reduction that occurs to regenerate vitamin K is blocked, depleting its levels and, consequently,
inhibiting the synthesis of coagulation factors, causing hemorrhage.
5. Rubiaceae Family
The Rubiaceae family is the fourth largest family of angiosperms, composed of about 650 genera
and more than 13,000 species. Belonging to the order Gentianales, it is a cosmopolitan and pantropical
family distributed as herbs, shrubs, lianas, small and large trees. It has great biodiversity, being of
paramount importance in floristic formation, in addition to the conservation of tropical vegetation [117].
This family includes important species for the economy of several countries, being widely used
as food, such as Coffea arabica; in popular medicine such as Cinchona sp.; in civil construction such as
species of the genera Sarcomphalus, Mitragyna, Morindae Pausinystalia; and in ornamentation such as
Gardenia spp., Ixora spp. and Mussaenda spp. [118].
Most fruits produced by species of this family have high levels of iridoids, which act as plant
defenders against the attack of herbivores. These substances make up pigments found in extracts of
species of this family and which are used as cosmetics due to their pigmenting property for the dyeing
of keratin fibers [119].
5.1. Genus Genipa L. and Species Genipa americana L.
Genipa L. is a neotropical genus with species distributed in several countries, mainly on the
American continent. Genipa americana L. is a fruit species characterized by high survival rate against
drastic environmental changes, such as floods, which can cause reduction in the growth of shoots
and roots, reduction in biomass and changes in their partitioning, in addition to promoting plant
senescence, which promotes a mechanism of tolerance in some species frequently exposed to these
conditions [120,121].
This species has been used for the regeneration of reserve areas and environmental preservation.
Due to its adaptive characteristics, it can be domesticated and used in urban afforestation and
agriculture, since its wood and fruits have considerable commercial value. Although little consumed
49
Molecules 2020, 25, 3879
in the fresh form, fruits are used for the production of jams, candies, ice cream, soft drinks, wines and
liqueurs [122].
Its seeds are of easy propagation, which can be sown soon after being removed from fruits
and support up to 60 days of storage, which should be performed after drying or under freezing.
In addition, G. americana can be grown not only from seeds, but also by budding or grafting of plant
parts, which produces fruit about 6 years after planting [123,124].
5.1.1. Geographical Distribution and Popular Use
Genipa americana is widely distributed from South America to Central America. It has tropism
for coastal regions and river banks, being found in the Cerrado vegetation and popularly known as
jenipapo, janapabeiro, janipaba, janipapo, genipapeiro, jenipapinho, jenipá, jenipapeirol, genipapo,
genipapeiro [125].
All plant organs of this species are used in folk medicine. Leaves, stem bark, fruits and roots
are indicated for cough, anemia, bruises, dislocations, as depurative, cathartic, purgative, febrifuge,
aphrodisiac, diuretic, for spleen and liver diseases, jaundice, and injuries. The pulp of the fresh fruit is
indicated for diabetes and liver diseases, and the fruit juice is indicated for anemia [126–128].
For dermatitis, pulp and heated seeds are applied over the affected area. The use of tea from fruits
and leaves produced by decoction for 1 h is described for the treatment of anemia, and tea from roots
and stem bark is used as aphrodisiac. Tea from toasted stem bark obtained by decoction is applied in
the form of poultice on bruises, fractures and twists [129–131].
Other forms of fruit use are reported for the treatment of anemia such as juice, bottleful, and dye.
The juice is obtained after crushing the fresh vegetable organ and in its homemade preparation a
pestle or blender is used, the former being more used for less juicy parts. The dye is a concentrated
extract of medicinal plants and consists of an alcoholic or hydroalcoholic preparation in which the
macerated plant is immersed in the extraction liquid for 8 to 10 days, and after that period the mixture
is filtered, packed in a capped flask and used in the form of drops dissolved in water or used in
ointments [132–134].
5.1.2. Botanical Aspects
G. americana is a tree with terrestrial, adventitious roots, aerial and erect stem of trunk and circular
type and sympodial growth. Leaves are simple, petiolate, with opposite phyllotaxis with obovate,
elliptical-obovate or oblanceolate shape, acuminated limb apex, cuneiform base and smooth margin,
with gland trichomes on the abaxial epidermis and pinnate venation [120,135].
Flowering occurs between October and December; inflorescences are dichasium with about
16 flowers, which are hermaphroditic, white to yellowish in color, aromatic, pedunculated, pentamera,
with bilocular ovary. Fruits are subglobous, polyspermic, indehiscent berries, with brown color when
ripe and thin pericarp. Maturation usually occurs between the months of May and August [136,137].
Seeds have ovoid shape, flat, with rigid seed coat and dark brown in color and orthodox, that is,
unlike recalcitrant seeds, the degree of humidity does not imply loss of viability and are resistant to
low temperatures, so drying of seeds up to 10% does not compromise their germination [137,138].
5.1.3. Phytochemical Aspects
Table 3 presents a summary of phytochemical studies of G. americana extracts, as well as the
structures of their phytochemical constituents.
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The chemical characterization of G. americana fruits and leaves presents iridoids as major
constituents, belonging to the class of terpenes. Genipin (55) is the main iridoid found in G. americana
fruits and has considerable economic potential due to its pigmentation property. The extraction of
genipin (55) can occur by three different methods, enzymatic hydrolysis, extraction with solvents
and ultrasound. A study performed the extraction of genipin (55) from G. americana fruits using the
enzymatic method and quantified 7.85 mg/g of this phytochemical in the sample [119,145].
Pacheco et al. [146] carried out a study on the nutritional composition and energy value of the
pulp of G. americana fruits. After triplicate analysis, 70% of moisture, 0.5% of proteins, 0.0% of lipids,
1.1% of ash, 22.1% of carbohydrates, 6.3% of dietary fiber, 0.0 mg/100g of beta-carotene, 22.5 mg/100g
of vitamin C, 176 mg GAE/100g of phenolic compounds and 90.7 kcal/100g of total energy value
were found.
In the methanolic extract of G. americana fruits, the following iridoid glycosides were identified,
isolated and structurally elucidated: geniposidic acid (40), geniposide (48), gardenoside (54),
genipin-gentiobioside (49) and 4 new iridoids not previously identified: genameside A (50),
genameside B (51), genameside C (52) and genameside D (53) [140]. Also in G. americana fruits,
iridoids geniposidic acid (40), gardenoside (54), genipin-1-β-gentiobioside (49), geniposide (48),
6′′-O-p-coumaroyl-1-β-gentiobioside geniposidic acid (59), 6′′-O-p-coumaroylgenipin gentiobioside
(60), genipin (55), 6′-O-p-coumaroyl-geniposidic acid (61), 6′-O-feruloylgeniposidic acid (62) were
found in the methanolic extract from the endocarp and mesocarp. In addition, possible antioxidant
and antiproliferative properties have been attributed to the extract and, mainly, to genipin (55) [143].
After extraction by pressurized ethanol and analysis of the genipin (55) and geniposide (48)
content in the whole fruit and its parts separately at 50 ◦C and pressure of 2 bars, 20.7 mg/g of genipin
(55) and 59 mg/g of geniposide (48) were found in the mesocarp; 1.16 mg/g of genipin (55) and 0.06 mg/g
of geniposide (48) were found in seeds; 7.5 mg/g of genipin (55) and 39.9 mg/g of geniposide (48)
were found in fruit bark; 38.9 mg/g of genipin (55) and 0.01 mg/g of geniposide (48) were found in
the endocarp; 22.9 mg/g of genipin (55) and 0.1 mg/g of geniposide (48) were found in the endocarp
extract and seeds; and 37.2 mg/g of genipin (55) and 0.57 mg/g of geniposide (48) were found in the
whole fruit [144].
For fruits, the presence of other classes of secondary metabolites was investigated in the
hydroalcoholic extract. Mayer reagent was used to detect alkaloids; for tannins, reaction with
ferric chloride; for anthraquinones, reaction with ammonia; for flavonoids, Shinoda’s reaction;
for steroids and triterpenes, the Libermann-Burchard reagent was used; the saponins test was carried
out through agitation, observing the presence or absence of foam; and the coumarin test by fluorescence
under UV light. The results for this qualitative analysis point to the presence of alkaloids, tannins,
flavonoids, triterpenes, saponins and coumarins in the fruit pulp extract and absence of steroids and
anthraquinones [147].
Silva et al. [139] identified 13 compounds in a hydroalcoholic extract of G. americana
leaves. The following are among the isolated substances: (A) coniferin; (B) the
iridoids asystasioside D (39), geniposidic acid (40), tarenoside (41) and teneoside A
(42); (C) loganic, chlorogenic and 1,3-di-O-caffeoylquinic acids; and (D) flavonoids,
first identified in this genus, kaempferol-3-O-hexoside-deoxyhexoside-7-O- deoxyhexoside
(43), isorhamnetin-3-O-hexoside-deoxyhexoside-7-O-deoxy-hexoside (44), quercetin-
3-O-hexoside-deoxyhexoside (45), kaempferol-3-O-hexoside-deoxyhexoside (46) and isorhamnetin-
3-O-hexoside-deoxyhexoside (47). Other iridoids were also found in the hydroalcoholic extract
of G. americana leaves such as genipin derivative (55), 1-hydroxy-7-(hydroxymethyl)-1H,4aH,5H,
7aH-cyclopenta[c]pyran-4-carbaldehyde (56) and 7-(hydroxymethyl)-1-methoxy-1H,4aH,5H,7aH-
cyclopenta[c]pyran-4-carbaldehyde (57) [142].
There are few studies on phytochemical screening and characterization of compounds for
G. americana stem, roots, and seeds. A qualitative study that analyzed the ethanolic extract of leaves
and stem bark determined the presence of flavonoids, xanthones, saponins and triterpenes in the stem
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bark and saponins and triterpenes in leaves [148]. [149] isolated and characterized lectin present in
G. americana stem bark, which was named GaBL and tested for hemagglutinating properties.
Neri-numa et al. [143] evaluated the antioxidant and antiproliferative activity of the methanolic
extract from G. americana ripe and green fruits. The ability to eliminate DPPH radicals has been
reported to be like that of ascorbic acid, and the extract from green fruits has higher concentration
of iridoids and greater efficiency to eliminate radicals. The in vitro antiproliferative activity was also
observed with efficiency in all tested cell lines, with greater activity for the extract from green fruits,
which has high concentration of iridoid genipin (55), to which this property was attributed. In addition,
the anticholinesterase activity of the ethanol extract from G. americana fruit bark, pulp and seeds was
also observed and may be associated with the presence of chlorogenic acid, an acetylcholinesterase
(AChE) inhibitor [139,150].
Genipin (55), a triterpene found in G. americana fruits was tested in vitro and in vivo for
its anti-inflammatory property and its role on memory deficiencies induced by LPS. Microglia
stimulation by LPS of gram-negative bacteria induces the production of inflammatory mediators,
whose overproduction can cause neuronal damage. Genipin (55) inhibited the production of these
mediators in the BV2 microglial cell line through the dose-dependent suppression of LPSe-induced
NF-κB activation by activating the expression of erythroid nuclear factor 2 (Nrf2) and heme oxygenase-1
(HO-1). Active NF-κB induces the production of inflammatory mediators such as PGE2, TNF-α and
IL-1β, while Nrf2 encodes antioxidant enzymes such as HO-1, which promote the elimination of ROS
and, consequently, the inhibition of the NF-κB expression [151].
The anti-inflammatory role of genipin (55) is also associated to another mechanism, the inhibition
of the activation of NLRP3 and NLRC4 inflammasomes by suppressing macrophage autophagy.
Agonists of NLRP3 and NLRC4 inflammasomes promote the activation of autophagy in macrophages,
which enhances the secretion of IL-1β and ASC oligomerization, while suppression of autophagy
promoted by genipin (55) inhibits this effect [152].
The protective role of genipin (55) on LPS-induced acute lung injury has been investigated.
Genipin (55) positively regulated the signaling of the phosphoinositide 3-kinase/phosphorylated
protein kinase B (PI3K/p-AKT) pathway by increasing the levels of p-AKT. PI3K generates
phosphatidylinositol-3,4,5-triphosphate (PIP3), which acts as a second messenger and facilitates
the translocation of protein kinase B (AKT) to the plasma membrane, where it is activated by
phosphorylation and can later be transported to the nucleus. AKT promotes the phosphorylation of
some molecules, among them AMPc-responsive binding protein (CREB), whose activation is associated
with increased Bcl-2 activity, which inhibits pro-apoptotic caspase-9, promoting a protective effect of
cell survival [153,154].
In contrast, the action of genipin (55) on the PI3K/p-AKT pathway was also related to its inhibitory
activity on the growth of human bladder cancer cells [155] and squamous cell carcinoma [156]. It was
observed that genipin (55) induced the cell cycle to stop in G0/G1 phases, and promoted the apoptosis of
cancer cells, with increase in the expression of pro-apoptotic protein Bax. Such cell growth suppressive
effects have been associated with inactivation of the PI3K/p-AKT pathway, shown by the reduction of
phosphorylated PI3K and AKT levels [155].
Zhao et al. [157] analyzed the protective role of genipin (55) against ischemia-reperfusion
lesion associated with energy deficiency and oxidative stress, which are regulated by mitochondrial
uncoupling protein 2 (UCP2) and NAD-dependent deacetylase sirtuin-3 (SIRT3), respectively. In this
lesion, damage increases due to the increase in the ischemia duration, as well as the degree of energy
deficiency and oxidative stress, with increase in UCP2 expression and SIRT3 activity. Genipin (55) acts
as a specific inhibitor of UCP2. Therefore, in mice submitted to treatment with genipin (55), reduction
in UCP2 expression and SIRT3 activity was observed, as well as a lower NAD +/NADH ratio and
increased levels of adenosine triphosphate (ATP), reducing oxidative stress and energy deficiency and,
consequently, mitigating damage.
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The effects of genipin (55) on energy metabolism are also related to its anti-tumor property, capable
of inhibiting the proliferation of several cancer cells in breast [158], colon [159], hepatocellular [160]
cholangiocarcinoma [161] and gioblastoma [162]. UCP2 overexpression is observed in tumor cells,
which gives genipin (55), a UCP2 inhibitor, a potential anti-tumor activity mechanism. UCP2 promotes
the decoupling of the electron transport chain to oxidative phosphorylation, reducing energy availability
and the production of O2−, a ROS.
Cancer cells are under oxidative stress and to protect themselves, they increase the UCP2 expression
to reduce the formation of ROS. UCP2 inhibition by genipin (55) promotes an increase in ROS, triggers
the nuclear translocation of glycolytic enzyme glyceraldehyde 3-phosphate dehydrogenase (GAPDH),
formation of autophagosomes and expression of LC3-II autophagy marker, leading to cell death or
growth inhibition, invasion and migration of tumor cells. In addition, genipin (55) enhances autophagic
cell death induced by gemcitabine, a clinically used chemotherapeutic agent (Figure 5) [163,164].
 
Figure 5. Effects of genipin on energy metabolism: anti-tumor property: Transport mechanisms of
geniposide and genipin, which are abundantly present in extracts from plants such as Genipa americana,
involve converting geniposide into genipin in the intestinal lumen through bacterial enzymes
β-glucosidases. Uncoupling protein 2 (UCP2) is a genipin target in the treatment of cancer.
In mitochondria, the respiratory chain, formed by complexes I to IV, transfers electrons from NADH
through oxidation-reduction reactions. Complexes I, II, and III contribute to the production of H+ ion
gradient. The electrochemical gradient generated is coupled to the ADP phosphorylation process via
ATP synthase. Oxygen is the final electron acceptor and is reduced to water by the electron transfer
of complex IV. However, its early reduction into complexes I and III leads to the formation of O2•–.
UCP2 is a protein widely expressed in tumor cells. Its function is to reduce ROS production and increase
the survival of tumor cells by uncoupling the electrochemical gradient generated by the respiratory
chain. For this purpose, UCP2 increases H+ output from the intermembrane space to the mitochondrial
matrix and reduces the mitochondrial membrane potential. This mechanism, present in tumor cells as
a survival factor by reducing ROS generation, is the genipin target [165]. A, adenosine; CoQ, coenzyme
Q; Cyt C, cytochrome C; FAD, flavin adenine dinucleotide; NAD, Nicotinamide adenine dinucleotide;
ROS, reactive oxygen species; UCP2, uncoupling protein 2.
Another anti-tumor mechanism associated with genipin (55) occurs through negative regulation
of the signal transducer and transcription activator (Stat)/cell differentiation protein of induced
myeloid cell leukemia 1 (Mcl-1). Mcl-1 is a member of the Bcl-2 family and has anti-apoptotic
activity, being associated with cell survival and is overexpressed in gastric cancer cells. The apoptotic
mechanism of cancer cells promoted by genipin (55) is related to the negative regulation of Mcl-1,
which can occur through the activation of the SHP-1 phosphatase and the suppressor of cytokine
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signaling 3 (SOCS3). In addition, this phytoconstituent inhibits the activity of JAK2 enzymes of
the Janus kinase family (JAK), responsible for the activation of the Stat3 transcription factor, which
regulates the expression of genes related to cell survival. Thus, inactivating JAK2 enzymes, there is no
activation of Stat3 and expression of the MCL1 gene, which encodes the anti-apoptotic protein Mcl-1
(Figure 6a,b) [166].
Figure 6. Apoptosis mediated by genipin through interference with myeloid cell leukemia-1 (Mcl-1)
synthesis in gastric cancer cell lines: (a) Cytokine receptors without intrinsic protein kinase domain
amplify extracellular signals through signal transduction via Janus Kinase (JAK) family (JAK1 to
JAK3 and tyrosine kinase 2). After receptor activation, JAK2 phosphorylates the tyrosine residue
of transcription factor Signal Transducer and Activator of Transcription 3 (STAT3), which enables
its binding to the promoter of target genes related to survival and apoptosis. Subsequently, Mcl-1 is
synthesized; (b) Genipin absorption by tumor cells induces mitochondrial dysfunction due to decreased
Mcl-1 expression through the JAK2/STAT3 pathway. Δψm, mitochondrial membrane potential; JAK2,
Janus Kinase 2; Mcl-1, myeloid cell leukemia-1; STA3, Signal transducer and activator of transcription
3 [166].
Inhibition of Sonic Hedgehog, one of three proteins in the signal family called hedgehog found in
mammals by genipin (55), was also associated with its anti-tumor property. Genipin (55) binds to the
protein of the Hedgehog Smoothened (SMO) signaling pathway through the drug-affinity-responsive
target stability (DARTS), increasing the expression of p53 and NOXA, a protein of the Bcl-2 family
that contributes to apoptosis promoted by p53. This mechanism occurs by inhibiting the expression
of the GLI1 gene, a transcriptional activator of the Hedgehog pathway that reduces p53 expression.
Thus, the binding of genipin (55) to SMO promoter induces a reduction in GLI1 activity and an increase
in p53 expression [167].
Genipin (55) was used in cattle to increase corneal stiffness and induce corneal collagen cross-linking
(CXL), which reduces the progression of ectasia, that is, corneal distention. Through a mechanism
still unknown, genipin (55) induces CXL by up to 7%, a result superior to that induced by treatment
with riboflavin and UV light applied in the control group, which presented only 5.6% cross-linking.
To achieve 7% cross-linking, 140 μL of 0.5% genipin (55) was administered every 1 h for 2 h [168].
The role of genipin (55) investigated in cattle suggests further studies in humans. Furthermore,
this cross-linking property of genipin (55) has also been used in the biotechnological production of
hydrogels, gelatin biofilms and transdermal patches for the controlled release of drugs [169].
Also, for ophthalmic treatment, genipin (55) was used in posterior scleral contraction/reinforcement
surgery (PSCR), which delays axial stretching of the eyeball, common in human myopia. However,
despite the significant effect of the procedure, it was not sustained in the long term, which was related
to the loss of sclera resistance to traction. The sclera is a layer of fibrous, opaque and dense tissue that
lines the eye, on which the cross-linking capacity of genipin was tested (55), which doubled the sclera
resistance and increased by 30 % resistance to enzymatic degradation, which could promote sclera
weakening. The study points out the efficacy and safety of PSCR with sclera cross-linked with genipin
(55) to restrict axial elongation of the eyeball [168].
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Genipin (55) was tested for possible antiviral activity on Kaposi’s sarcoma herpes virus (KSHV).
Genipin (55) played a double and dose-dependent role. At lower concentration and administered for
48 h, the phytochemical significantly reduced the production of the nuclear antigen associated with
KSHV latency (LANA) and increased the number of copies of the virus intracellular genome, favoring
lytic replication of KSHV. Treatment with higher genipin (55) doses induced the activation of caspases
3 and 7 by reducing the expression of Bcl-2, promoting apoptosis, which is impaired, since the virus
produces viral Bcl-2, approximately 60% identical to cellular Bcl-2, which makes the infected cell more
resistant. New studies have been proposed to investigate the role of genipin (55) in modulating the
KSHV life cycle and possibly prevent disorders associated with the virus [170].
Nonato et al. [171] evaluated the GABA-mediated anticonvulsant effect of the methanolic extract
from G. americana leaves rich in polysaccharides. A heteropolysaccharide (PRE) with inhibitory and
anticonvulsant effect on the central nervous system (CNS) was identified, which was reversed after the
administration of the GABAergic flumazenil antagonist, indicating the participation of this receptor in
the effect performed by PRE, which also reduced oxidative stress in the pre-frontal cortex, hippocampus
and striated nucleus of animals that had induced seizures, observed by the increase of GSH levels and
reduction of lipid peroxidation levels.
In G. americana leaves, a glycoconjugate rich in arabinogalactane and uronic acid was found, with
anticoagulant, antiplatelet, and antithrombotic properties. Anticoagulant activity was observed in
fraction containing uronic acid and occurs through the intrinsic and/or the common pathway of the
coagulation cascade by a still unknown mechanism. Glycoconjugate inhibits platelet aggregation
induced by adenosine diphosphate (ADP), but not collagen-induced aggregation. Antithrombotic
action was observed in a model of rats with venous thrombosis and, similar to the antiplatelet activity,
it was found in fraction rich in arabinogalactane [172].
The hydroalcoholic extract from G. americana stem bark was evaluated for its possible antimicrobial
properties. Minimum Inhibitory Concentration (MIC) tests were carried out with E. coli, S. aureus and
P. aeruginosa and MIC was≥ 1024 μg/mL in all strains. Efficiency was not considered satisfactory, but the
association of the extract with aminoglycoside drugs amikacin and gentamicin and the lincosamide
clindamycin, increased the antimicrobial potential of these drugs. This property was attributed to
tannins present in the extract with antimicrobial activity. The result of this association induced greater
susceptibility of P. aeruginosa and E. coli to death by gentamicin and S. aureus by Amikacin in all strains
submitted to this treatment [173].
The polysaccharide extract from G. americana leaves was tested against Trypanosoma cruzi
epimastigotes, trypomastigotes and amastigotes. The results showed antiparasitic effect against
the three forms of the protozoan with low toxicity to mammalian cells. In addition, it demonstrated
potent activity even on amastigote forms, which are intracellular, suggesting that the compound
responsible for this activity has access to the intracellular medium. After extract administration,
ROS generation was observed, which causes damage to trypanothione reductase, an enzyme important
for the oxidative balance of the protozoan. Morphological changes indicate cell death due to necrosis
with rounding and shortening of the parasite, cytoplasmic leakage and membrane degradation [174].
5.1.4. Toxicity Studies
Studies focusing on the possible toxicological effects of G. americana extract and its chemical
constituents are still scarce. A study carried out on the acute toxicological analysis of the hydroalcoholic
extract from G. americana fruits reported that animals receiving the extract did not present any apparent
behavioral or clinical changes; the microscopic study of organs also did not present any changes, there
were no deaths by the end of the study, although it was estimated that the LD50 would be greater
than 2000 mg/kg. In the analysis of the subchronic toxicity, macroscopic changes in kidneys were
described, such as increased size, which may be related to renal hyperplasia or thrombosis at dose of
100 mg/kg [175].
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The toxicological evaluation of the aqueous extract from G. americana leaves induced mortality
in Danio rerio fish species at concentrations above 100 mg/L. No genetic mutations were observed;
however, some nuclear abnormalities such as blebbed, lobed and notched nucleus and binucleated
cells were rather observed [176].
6. Bromeliaceae Family
The Bromeliaceae family is composed of approximately 56 genera and 3086 species. Due to the great
economic potential, extraction from natural environments and, mainly, due to the ornamental value among
landscapers and gardeners, some species are threatened with extinction. Species are predominantly
neotropical and can be found on the American and African continents. They present great ecological
diversity, with terrestrial and epiphytic species, which are arboreal, shrub or cactaceae [175,177].
One species that stands out for its economic potential is Ananas comosus (L) Merr, known as
pineapple which, in addition to its potential for fresh consumption, is also used as a raw material to
produce numerous by-products. Many plants in this family are utilized in the automotive and textile
industry, such as Ananas lucidus Miller and Neoglaziovia variegata Mez due to their important properties
for the production of fibers [178].
In addition, some members of the Bromeliaceae family stand out for producing large amounts of
proteins and enzymes that cleave peptide bonds between amino acids in proteins. The effect of these
proteins on plant physiology is not yet known, but one hypothesis is that these enzymes play the role
of protecting plants against pathogens and herbivores [179].
6.1. Genus Bromelia and Species Bromelia antiacantha
The genus Bromelia comprises about 46 species distributed throughout Americas and used in
folk medicine against parasitic diseases, edema, respiratory and kidney problems, intestinal disorders,
and diabetes. B. antiacantha Bertol. is popularly known as caraguatá, gravatá, carauatá or croatá and
has properties that contribute on a large scale for the economic development of the region where it
occurs or is cultivated [180–182].
The species adapts to different climatic conditions, being found in humid and flooded soils and
even in the post-beach forest, which indicates tolerance to high salinity and soaked soils. In addition,
it can also be found in xerophytic environments, in which there is scarcity of water and nutrients such
as Cerrado soils submitted to drought periods, in these cases, the plant adapts with the presence of a
structure for storing water and nutrients, the rhizome [183].
This species has great diversity of applications, and fruits are not only used as food in the
production of jellies and ice cream, but the plant is also used for ornamental purposes. Proteolytic
enzymes were detected in the crude extract from B. antiacantha fruits and the new protease Antiacanthain
A, a molecule with interesting characteristics for biotechnological use, was recently isolated [179,184].
These enzymes are used in the chemical, pharmaceutical, food and textile industries and in the
production of detergent for cleaning clothes due to their stain-removing property [185].
6.1.1. Geographical Distribution and Popular Use
Occurrences of B. antiacantha are recorded in several American countries, among them, Venezuela,
Brazil, Mexico, Peru, Uruguay, and the Caribbean islands. The species has perennial germination cycle,
its leaves are prickly and, due to the beauty of its flowers, attracts pollinators like hummingbirds,
increasing the natural dispersion of the species [186,187].
In folk medicine, the fruits of this species are used for respiratory problems such as flu, asthma,
and bronchitis through the administration of homemade syrup produced by decoction. For the
production of this syrup, the pulp of 1 B. antiacantha fruit is submitted to heating together with one cup
of solvent, which in this case is water, for about 5 min; then the mixture is filtered and sugar is added
in the proportion of two cups of sugar for one cup of the mixture. Sugar must be mixed under heating
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until complete homogenization and acts not only as sweetener, but also as a preservative, which is
used according to the dose of one tablespoon three times a day [188,189].
In some cases, vegetable organs of other species are added in the syrup preparation to enhance the
expectorant action. The most added species are Achillea millefolium, Mentha sativa and Zingiber officinale.
Other indications for the use of the fruit are purgative, diuretic, vermifuge and abortion. Leaves are
used in the form of tea prepared by infusion or decoction, with drops of propolis, used in mouthwash
for the treatment of thrush and other disorders of the oral mucosa and the extract produced by
maceration is indicated as antipyretic and anthelmintic [182,190,191].
6.1.2. Botanical Aspects
B. antiacantha has stem with rhizomes about 1 m in length from which adventitious roots emerge.
Rhizomes are covered by leaves and are responsible for the survival of the species under different
climatic conditions. Leaves exhibit alternate and spiral phyllotaxis with 80 to 185 cm in length, arranged
in non petiolated rosette without the cistern formation, with lanceolate and caniculate limb shape and
aculeate limb margin [183,188].
Flowering is annual and occurs between the months of December and February. From the
center of leaves, monopodial inflorescence emerges, which is composed of 150 to 350 meliophilous,
ornithophilous and pedunculated flowers with oval sepals, entire margin of the sepal, oblong petal
purple in color. During the flowering period, central leaves and bracts show intense red color. Fruits are
polyspermic, fleshy, gaba type, yellow when ripe, with approximately 2 cm in diameter, pleasant
odor, and edible pulp. Seeds are photoblastic, that is, they need sunlight to germinate, present 26% of
moisture, with high germination rate at temperatures between 25 ◦C and 35 ◦C [78,183,191,192].
6.1.3. Phytochemical Aspects
Table 4 presents a summary of classes of secondary metabolites found in the respective extracts
and plant organs of B. antiacantha species.
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There are few studies on the chemical composition of B. antiacantha, and most of them only
perform qualitative screening, without quantifying or isolating substances. The analysis of the
proximate composition of ripe fruits showed 82.63% of moisture, 0.62% of protein, 2% of fiber, 8.75% of
carbohydrates and 0.93% of ash. In addition, other compounds were quantified, which are associated
with the antioxidant activity of fruits and are composed of 70.73 mg/100 g of phenolic compounds,
162.67 mg/100 g of total carotenoids and 60.01 mg/100 g of vitamin C [197].
A qualitative phytochemical analysis performed with the methanolic extract from B. antiacantha
leaves and fruits detected, in the methanolic extract of fruits, the following groups of secondary
metabolites: alkaloids, phenols, flavonoids, tannins, triterpenes, steroids, anthraquinones and
coumarins. In the methanolic extract of leaves, the following groups of secondary metabolites
were identified: alkaloids, phenols, flavonoids, tannins, triterpenes, steroids and coumarins [193].
The presence of flavonoids, tannins and saponins was confirmed by analyses from another study, which
also used the methanolic extract from B. antiacantha leaves and [182]. With regard to B. antiacantha
fruits, the presence of hydroxycinnamic acids and flavone derivative was detected in the aqueous
extract, which was not structurally identified [194]. The characterization of secondary metabolites
of B. antiacantha species using the ethanolic extract to quantify flavonoids and the hydromethanolic
extract to quantify anthocyanins showed: (1) in leaf extracts, 1.68 mg/mL of flavonoids and 0.0 mg/mL
of anthocyanins and; (2) in bract extracts, 0.43 mg/mL of flavonoids and 10.83 mg/mL of anthocyanins.
The greater production of anthocyanins in bracts may indicate the effort in the allocation of energy by
plants to attract pollinators, since the amount of flavonoids found in leaves, although larger than in
bracts, is still insignificant compared to other species that are sources of flavonoids [195]. Analyzing
B. antiacantha leaves, [196] detected the presence of saponins in the methanolic extract and isolated
saponin daucosterol (63), which was attributed the hemolytic property of the extract.
6.1.4. Pharmacological Studies
The alcoholic extract from B. antiacantha fruits, and methanolic, hexanic, ethyl acetate and raw
alcoholic extract from leaves were tested for antimicrobial, molluscicidal and antioxidant properties.
All extracts were tested against clinically isolated C. albicans and C. glabrata strains and C. albicans
(ATCC 90028), E. coli (ATCC 8739), P. aeruginosa (ATCC 9027) and S. aureus (ATCC 6538) reference
strains. All strains tested were not affected by extracts, that is, none of the extracts showed antimicrobial
or antifungal activity. The evaluated extracts were considered inactive in relation to the molluscicidal
activity, since no significant effects were found at concentration of 400 μg/mL, a value above the
maximum for this activity. To test the antioxidant activity, the performance of extracts against the
DPPH radical was observed, showing unsatisfactory results, since only the extract from leaves with
ethyl acetate obtained moderate performance, with 35% inhibition of radicals [182].
The methanolic (BAM), hexanic (BAH), dichloromethane (BAD), ethyl acetate (BAA) and
hydromethanolic (BAHa) extracts from B. antiacantha leaves and fruits were submitted to antibacterial
activity tests. Only BAM and BAD extracts from leaves and BAA extract from fruits inhibited the
growth of P. aeruginosa, and the BAM extract from leaves showed activity on E. coli [193].
Daucosterol (63) is a saponin found in the methanolic extract from B. antiacantha leaves.
This substance was the focus of a study that investigates its possible anti-inflammatory role on
colitis induced by dextran sulfate sodium (DSS) in mice. Colitis is an inflammatory reaction in the
large intestine, which source may be infectious or autoimmune. Pre or post-treatment with daucosterol
(63) provided relief from the clinical symptoms of colitis, with reduction in the number of regulatory
T cells, in the activity of Natural Killer (NK) cells and in the production of Immunoglobulin A (IgA),
whose increase is characteristic of the disease. In addition, ROS inhibition and reduction in the
expression of inflammatory cytokines such as TNF-α, IL-6, IL-1β and IFN-γ were observed, as well as
increase in the anti-inflammatory cytokine IL-10 [198].
Induction of autophagic apoptosis in prostate cancer by daucosterol (63) was also analyzed,
indicating anti-tumor activity. The action of this phytoconstituent on cancer cells promoted the
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interruption of the cell cycle by activating the mitochondrial-dependent apoptotic signaling pathway
that leads to increased expression of the pro-apoptotic proteins caspase 3 and 9 and Bax, in addition
to reducing the expression of Bcl-2. The administration of the 3-methyladenine (3-MA) autophagy
inhibitor attenuated the apoptotic effect triggered by daucosterol (63), indicating that its mechanism of
action is the induction of autophagic apoptosis. This mechanism may also be related to the action of
JNK protein kinases, known for the regulatory role of cell proliferation, survival and death. Daucosterol
(63) increased the level of JNK proteins active in cancer cells, while the specific JNK inhibitor (SP600125)
inhibited its action, which indicates that this phytoconstituent has tumor suppressive effect through
the induction of autophagic apoptosis dependent on the activation of the JNK signaling [199].
The apoptotic action promoted by daucosterol (63) has been investigated by several studies that
correlate it with the anti-tumor action on breast [200] and prostate [201] cancers. Esmaeili et al. [202]
investigated the anti-tumor mechanism of daucosterol (63) on human breast adenocarcinoma cells and
concluded that the apoptotic mechanism is associated with the mitochondrial pathway, with loss of
the mitochondria membrane potential and release of cytochrome C being observed after reduction of
the Bcl-2/Bax ratio through the increase in the levels of intracellular ROS and decrease in the levels of
antioxidant protein GSH and MMP. In addition, the PI3K/AKT pathway is inhibited by daucosterol (63)
by reducing the AKT expression, whose levels are increased in some types of tumor. This reduction
occurs by increasing the expression of the phosphatase and tensin homolog (PTEN), a negative
regulator of the PI3K/AKT pathway. Thus, the inhibition of the PI3K/AKT pathway, the increase in
Bax expression and the reduction of Bcl-2 levels, promote apoptosis mediated by the mitochondrial
pathway and activation of caspases 3 and 9 (Figure 7) [202].
 
Figure 7. Daucosterol mechanism on human breast adenocarcinoma cells: After treatment of tumor cells
(MCF-7) with daucusterol, a phytosterol abundantly present in Bromelia antiacantha extracts, the positive
regulation of Phosphatase and Tensin Homologue (PTEN) blocks Protein Kinase B (Akt) activation
through PI3K. Daucusterol induces reactive oxygen species (ROS) synthesis that leads to mitochondrial
oxidative stress and, subsequently, release of cytochrome C. Subsequently, the activation of caspases
causes cell apoptosis [202]. Δψm, mitochondrial membrane potential; Akt, Protein Kinase B; Bax, BCL2
Associated X; Bcl2, B-cell lymphoma 2; Cyt C, cytochrome C; PI3K, phosphatidylinositol-3-kinase;
PTEN, phosphatase and tensin homologue; ROS, reactive oxygen species.
Another study also investigated the anti-tumor property of daucosterol (63), which inhibits the
migration and invasion of hepatocellular carcinoma cells using another mechanism, the Wnt/β-catenin
signaling pathway, which regulates various physiological processes such as cell proliferation, apoptosis,
differentiation, transcription and translation. Daucosterol (63) acts by significantly inhibiting the
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expression of β-catenin, reducing the possibilities of cell proliferation, migration and invasion,
which would occur through the Wnt/β-catenin pathway [203].
The neuroprotective effect of daucosterol (63) was also investigated in a study that reported the
action of this compound as a modulator of the growth factor expression similar to insulin type 1 (IGF-1),
which plays a neuroprotective role. Daucosterol (63) increased the level of AKT phosphorylation,
resulting in more AKT in the active form and indicating that the AKT pathway was activated, resulting
in protective effect on treated neurons, since the activation of the PI3K/AKT pathway favors cell
survival, as it promotes the inactivation of GSK-3b, a pro-apoptotic protein, whose inhibition causes an
increase in Mcl-1, which has the opposite effect, reducing the activity of caspase 3 [204].
6.1.5. Toxicity Studies
Regarding the toxic effects of extracts obtained from B. antiacantha, a cytotoxicity test was carried
out using Artemia salina nauplii, on which the alcoholic extracts from fruits and methanolic and alcoholic
extracts from leaves of this plant showed toxicity, with LD50 values of 618.3 μg/mL, 275.9 μg/mL and
362.1 μg/mL, respectively [182]. In another study, hexane extracts in dichloromethane and ethyl acetate
from B. antiacantha leaves showed toxicity against Artemia salina, with LD50 values of 53.9 μg/mL,
112.4 μg/mL and 241.6 μg/mL, respectively. For fruits, extract in dichloromethane was the only one
with cytototoxic activity, with an LD50 of 29.8 μg/mL [193].
The hemolysis index promoted by the aqueous extract from B. antiacantha leaves and fruits was
stipulated after analyzing lamb blood, observing total hemolysis in 0.85% and 1.00% dilutions for
fruits, and 0.90% and 1.00% for leaves, while partial hemolysis occurred at 0.70% dilution for fruits
and leaves. This hemolytic action was associated with the presence of saponin compounds in extracts,
such as daucosterol (63), which were isolated from this species [196].
Saponins have cytotoxic activity, and this activity can occur through the promotion of autophagic
cell death or cytoskeleton disintegration. In the case of hemolysis promoted by saponins, this may occur
due to their ability to complex with cholesterol of the erythrocyte cell membrane, which results in the
formation of pores in the membrane, increasing its permeability. In addition, some saponins, such as
daucosterol (63) can act through signaling pathways such as PI3K/AKT, Wnt/β-catenin, promoting
apoptosis. Autophagy induction can also occur by increasing the levels of light chain protein 3 (LC3)
induced by some saponins. LC3 is associated with microtubules and is a marker for autophagy, being
related to the formation of autophagic vacuoles [205,206].
7. Clinical Trials
Finally, it is essential to note that medicinal plants are used to prevent and treat diseases by humans,
being used by about 80% of the population for primary health care. The rich biodiversity of the Brazilian
cerrado offers a unique and incomparable potential for discovering and developing bioactive agents.
Therefore, clinical trials with metabolites isolated from these species are of fundamental importance.
Once the pharmacological effect and the absence of side and toxic effects are proven, the test
substance goes on to the clinical trial phase. Clinical trials involve research conducted on
humans to discover or confirm the clinical and pharmacological effects observed during preclinical
research. Besides, they identify adverse events and study the process of absorption, distribution,
biotransformation, and secretion of the test substance. In the present study, we list the phytochemicals
from the four reviewed plants that stood out during pre-clinical research and reviewed the clinical
studies involving these compounds in the current literature. Table 5 summarizes these clinical studies.
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All the species reviewed in the present study showed promising therapeutic potential due to
the presence of phytochemicals. The species with the highest number of clinical trials found in the
literature was Talisia esculenta. In general, clinical trials involving medicinal plants or their isolated
secondary metabolites are scarce. However, studies like these are necessary for the development
of more efficient pharmaceutical products for the treatment of various disorders that affect humans,
in addition to being crucial for the health professional to be safe in prescribing these drugs.
8. Conclusions
The species under study reveal great economic importance not only in the consumption and
marketing of fruits, but also as sources for the extraction of molecules with significant bioactive
potential, which can be used as phytotherapeutic agents or as raw materials for the development of
new drugs. T. esculenta has high concentration of phenolic acids, flavonoids, and terpenes, justifying
its antioxidant, anti-tumor, anti-inflammatory and antimicrobial action reported by several studies,
lacking studies that investigate toxicity associated with the ingestion of its seeds.
Future studies should perform quantitative analyses and isolation of substances from
B. gaudichaudii, G. americana and B. antiacantha, favoring the understanding of the antiproliferative,
antimicrobial, anti-inflammatory, neuroprotective, and photosensitizing effects associated with their
extracts. Therefore, fruits of the Brazilian Cerrado offer an immeasurable richness of molecules with
biological activity of great interest to the pharmaceutical and cosmetic industries, in addition to the
possibility of marketing of fruits and their by-products. The knowledge of the mechanism of action of
substances isolated in these extracts enables correlating concentration, effectiveness, desirable and side
effects, which is fundamental for the establishment of a therapeutic planning and interventions in case
of intoxication.
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Abstract: Epigallocatechin gallate (EGCG) is the main bioactive component of catechins predominantly
present in various types of tea. EGCG is well known for a wide spectrum of biological activities
as an anti-oxidative, anti-inflammatory, and anti-tumor agent. The effect of EGCG on cell death
mechanisms via the induction of apoptosis, necrosis, and autophagy has been documented. Moreover,
its anti-proliferative action has been demonstrated in many cancer cell lines. It was also involved in
the modulation of cyclooxygenase-2, oxidative stress and inflammation of different cellular processes.
EGCG has been reported as a promising agent target for plasma membrane proteins, such as epidermal
growth factor receptor. In addition, it has been demonstrated a mechanism of action relying on
the inhibition of ERK1/2, p38 MAPK, NF-κB, and vascular endothelial growth factor. Furthermore,
EGCG and its derivatives were used in proteasome inhibition and they were involved in epigenetic
mechanisms. In summary, EGCG is the most predominant and bioactive constituent of tea and may
play a role in cancer prevention.
Keywords: epigallocatechin-3-gallate; EGCG; catechin; green tea; cancer preventive; pharmacological
activities
1. Introduction
Tea has been known to be the world most renowned non-alcoholic beverage since ancient times
and it is currently being utilized by two-thirds population of the world, owing to its taste, stimulating
effects, unique aroma, and associated health perspectives [1,2]. Various types of tea like green, black
and oolong tea are derived from the Camellia sinensis (L.) plant containing variety of components among
Molecules 2020, 25, 467; doi:10.3390/molecules25030467 www.mdpi.com/journal/molecules87
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which polyphenols are most significant ones. Basic differences among all of these teas depends upon the
stage of fermentation processes from which they are produced. Purposely, green tea is not fermented
while black tea and oolong tea are completely and partially fermented, respectively. Amongst all of the
investigated teas around the globe, green tea is well studied, owing to its health promoting benefits. In
general, tea based phenolics possess protective action against numerous metabolic syndromes.
Several nutraceutical aspects of green tea extracts depends upon the concentration of phenolics
and their associated derivatives. The major biologically active moiety present in leaves of green tea
are classified as catechins that nearly account for 25–35% on dry weight basis. This catechin group
comprises eight phenolic flavonoid constituents, specifically, catechin, epicatechin, gallocatechin,
epigallocatechin, catechin gallate, epicatechin gallate, gallocatechin gallate, and epigallocatechin gallate
(EGCG) [3,4]. Among above mentioned polyphenols, EGCG is the most vital tea based catechin which
is considered to be the main reason for bioactivity of green tea [5–8].
Catechins are plant secondary metabolites [9,10]. They possess numerous functions in plant
survival, growth, and metabolism, but they can also interact with other living organisms if
ingested or came into direct contact. Catechins or flavanols probably constitute the most abundant
subclass of flavonoids and they are essentially represented by (–)-epigallocatechin-3-gallate (EGCG),
(–)-epigallocatechin (EGC), (–)-epicatechin-3-gallate (ECG), and (–)-epicatechin (EC) [11]. These
last four bioactive compounds are found in large amount in green tea (leaves of Camellia sinensis)
and cocoa/chocolate, but they are also present in many fruits or seeds, such apples, blueberries
(Vaccinium myrtillus) and grapes (red wine and beer) and peanuts [12]. This review focuses on catechins
that are derived from green tea and in particular on EGCG, which represents 50% to 80% of all Camellia
sinensis catechins (200–300 mg/brewed cup of green tea) [13]. Moreover, we analyzed preclinical works
examining its pharmacological and biomolecular mechanism of action.
Epigallocatechin gallate is the most bioactive catechin that is predominantly present in tea.
Among all of the tea types, it is found at maximum comncentration in green tea leaves. EGCG
molecule (Figure 1) comprises two aromatic structures that are co-joined by three carbon bridge
structure (C6-C3-C6) along with hydroxyl group (OH) at simultaneous carbons i.e., 3’, 4’, 5’ of ring-B.
Carbon-3 of ring-C is esterified with a gallate molecule (features of catechins originated from tea are
responsible for bioactivity due to position and number of OH-group on the rings. They regulate
their capability to interact with biological matter via hydrogen bonding, a hydrogen and electron
transferring process contained by their antioxidative potentials. The presence and absence of a galloyl
molecule differentiates EGCG from remaining three catechins [14].
Figure 1. Chemical structure of epigallocatechin gallate.
Pure epigallocatechin gallate is classified as an odourless crystal and/or powder available in
white, pink, or cream colour. It is considered to be soluble in water as a colorless and clear solution
(5 mg mL−1). It is also soluble in methanol, tetrahydrofuran, acetone, pyridine, and ethanol. EGCG
have a melting point at 218 ◦C [15].
Even though EGCG is found to be the most predominant and bioactive constituent present in tea,
it is considered to be poorly stable in aqueous solutions and poorly soluble in oils and fats [16–19]. This
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poor stability and solubility restricts its direct addition in food products. Numerous delivery systems
are, in practice, to preserve its structural integrity and shield EGCG from degradation [18,20–24].
Additionally, structural modification in EGCG has also aided in elevating its lipophilicity [25,26].
Numerous physical aspects like pH, light, oxidants contents, oxygen, temperature, and
concentration of EGCG, influence the stability of epigallocatechin gallate [17,26–29]. Epimerization
and auto-oxidation are two most important reactions that result in instability of EGCG and loss of its
health promoting properties [30]. EGCG is oxidized at low concentration and temperature i.e., 20 to
100 μM & < 44 ◦C, respectively. On the other hand, it is epimerized to gallocatechin gallate at elevated
temperature (greater than 44 ◦C) and acidic conditions (pH 2 to 5.5) [30–33]. EGCG at a concentration
of 300 mg per litre has been found to be stable at 25 ◦C (24 h) in a pH range of 3 to 6, nonetheless if
kept at 4 ◦C & 25 ◦C for 24 h (pH 7), a loss of 25 & 83%, respectively, was observed [29].
EGCG is an abundant source of phenolic OH-groups that leads to its health escalating properties.
Various scientific studies (in vivo and in vitro) have been carried out to authenticate the potential of
EGCG as an anti-oxidative, antiinflammatory, and anti-cancerous agent [34,35].
Wei and co-authors have reported that EGCG exerts an anti-tumor effect through the inhibition of
key enzymes that participate in the glycolytic pathway and the suppression of glucose metabolism [36].
Shang and coworkers proposed that tea catechins in combination with anticancer drugs are being
evaluated as a new cancer treatment strategy [37]. It has a potential role as adjuvant in cancer therapy
and it could enhance the effect of conventional cancer therapies through additive or synergistic effects,
as well as through the amelioration of deleterious side effects [38]. EGCG interacts with catalase and
highlighted as an anticancer drug [39]. Green tea polyphenols are reported as a translational perspective
of chemoprevention and treatment for cancer with concrete influence on signaling pathways [2]. EGCG
as a powerful antioxidant, antiangiogenic, and antitumor agent, and as a modulator of tumor cell has
the potential to impact in variety of human diseases [40].
This review was prepared systematically searching for articles, papers, books from different
sources, such as Embase-Elsevier, Google Scholar, Ovid, PubMed, Science Direct, Scopus, and Web
of Science. The search strategy was based on the combination of different keywords, such as EGCG,
cancer, tumor, mechanism of action, preclinical, and clinical data, while considering any time of
publication. Only sources written in English were included.
2. Occurrence of Epigallocatechin-3-Gallate in Different Foods
The close relationship between food and disease is well known [41], thus EGCG consumed in
food could be a natural potential source of health benefits, even in complex and intricated disorder
as cancer.
Principal catechin in tea is EGCG, which is also known to be responsible for various health
modulating perspectives tht are related to utilization of tea. According to Wu et al., (2012), a cup of
green tea prepared by adding 2500 mg leaves in 0.2 L of water contains 90 mg of EGCG [42]. The
content of EGCG in black tea is less when compared to green tea, mainly due to polymerization of
catechins [43]. EGCG that are derived from tea possess various bioactive properties and, therefore,
have attained attention as potent functional and nutraceutical ingredient in food and pharmaceutical
industry. Table 1 lists EGCG contents in some selected foods.
89
Molecules 2020, 25, 467
Table 1. Occurrence of epigallocatechin-3-gallate in different food.
Description Content Reference
Japanese green tea 18.1–23.1 mg/g
[44]
Long-jing tea 32.9–35.5 mg/g
Jasmine tea 29.8–31.0 mg/g
Pu-erh tea 16.9–19.19.1 mg/g
Iron Buddha tea 0.12–0.30 mg/g
Oolong tea 11.8–12.2 mg/g
Ceylon tea 7.4–8.9 mg/g
Green tea 4.62 mg/100 mL [45]
Black tea 1.35 mg/100 mL
Ban-cha (tea leaves) 12.2–27.3 mg/g DM
[46]
Fukamushi-cha (tea leaves) 13.8–18.6 mg/g DM
Yame-cha (tea leaves) 19.7–32.9 mg/g DM
Uji-cha tea leaves) 22.2–35.9 mg/g DM
Sayama-cha (tea leaves) 21.5–37.2 mg/g DM
Uji-matt-cha (Powder tea) 20.1–29.6 mg/g DM
Gyokuro-cha (Powder tea) 29.9–37.2 mg/g DM
Sen-cha (tea bags) 12.9–23.6 mg/g DM
Green tea (Bagged leave form) 54.3–153.0 mg/g dry tea
[47]Green tea (Loose leave form) 56.5–205.0 mg/g dry tea
White tea (Bagged leave form) 46.0–154.0 mg/g dry tea
White tea (Loose leave form) 38.9–144.0 mg/g dry tea
Green tea (Infusions) 117 to 442 mg/l [48]
Typhoo, 7.9 mg/230 mL (mg/serving)
[49]
Tesco standard blend, 4.7 mg/230 mL (mg/serving)
Tesco premium blend, 5.6 mg/230 mL (mg/serving)
Sainsbury red blend, 8.5 mg/230 mL (mg/serving)
Sainsbury gold blend, 11.8 mg/230 mL (mg/serving)
PG Tips, 7.1 mg/230 mL (mg/serving)
Tetley 5.7 mg/230 mL (mg/serving)
Apples, Fuji, raw, with skin 1.93 mg/100 g edible portion
[50]
Apples, Golden Delicious, raw, with skin 0.19 mg/100 g edible portion
Apples, Granny Smith, raw, with skin 0.24 mg/100 g edible portion
Apples, Red Delicious, raw, without skin 0.46 mg/100 g edible portion
Apples, Red Delicious, raw. with skin 0.13 mg/100 g edible portion
Avocados, raw, 0.15 mg/100 g edible portion
Blackberries, raw (Rubus spp.) 0.68 mg/100 g edible portion
Cranberries, raw 0.97 mg/100 g edible portion
Peaches, raw 0.30 mg/100 g edible portion
Pears, raw 0.17 mg/100 g edible portion
Plums, black diamond, with peel, raw 0.48 mg/100 g edible portion
Raspberries, raw 0.54 mg/100 g edible portion
Nuts, hazelnuts or filberts 1.06 mg/100 g edible portion
Nuts, pecans 2.30 mg/100 g edible portion
Nuts, pistachio nuts, raw 0.40 mg/100 g edible portion
Tea, black, brewed, prepared with tap water 9.36 mg/100 g edible portion
Tea, black, brewed, prepared with tap water, decaffeinated 1.01 mg/100 g edible portion
Tea, fruit, dry 415.0 mg/100 g edible portion
Tea, green, brewed 64.0 mg/100 g edible portion
Tea, green, brewed, decaffeinated 26.0 mg/100 g edible portion
Tea, green, large leaf, Quingmao, dry leaves 7380 mg/100 g edible portion
Tea, oolong, brewed 34.48 mg/100 g edible portion
Tea, white, brewed 46.0 mg/100 g edible portion
Tea, white, dry leaves 4245 mg/100 g edible portion
Carob flour 109.46 mg/100 g edibleportion
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3. Signaling Pathways Involving EGCG: Proliferation, Differentiation, Apoptosis, Inflammation,
Angiogenesis and Metastasis
A plethora of biomolecular mechanisms has been demonstrated and proposed to be involved in
the use of this catechin in preclinical models. These can include, but are not limited to, the induction
of apoptosis, cell cycle changes, antioxidant activity, modulation of drug metabolism enzymes, etc.
EGCG possesses multiple pharmacological activities, depending on cancer cell type, thus reflecting
different protein expression and epigenetic mechanisms. Every cell model can express and modulate at
convenience its genetic background, and this is at the basis of the diverse biomolecular targets triggered
by EGCG. More consistently, EGCG has been analyzed in different tumor cell lines and less frequently in
animal models: this paragraph investigates the association of EGCG with proliferation, differentiation,
apoptosis, inflammation, angiogenesis, and metastasis, i.e., the main signaling pathways and processes
of living cells (Figure 2).
Figure 2. Epigallocatechin gallate (EGCG) involved in the signaling pathways in cancer.
3.1. Cell Death Induction (Apoptosis, Necrosis, Autophagy)
The effects of EGCG on cell death induction, including apoptosis and autophagy, have been
investigated in several preclinical studies. Jian and colleagues demonstrated that EGCG induced
apoptosis of human liver hepatocellular carcinoma HepG2 cells and rat pheochromocytoma PC12
cells by decreasing the Bcl-2 protein and up-regulating Bax, when used at >20 μM [51]. The proposed
mechanism of action of EGCG was related to Human antigen R (HuR, also known as ELAVL1), which
can control amyloid protein precursor (APP) via HuR-Erk1/2-APP pathway. APP is implicated in
Alzheimer’s disease and cancer, blocking ATP with EGCG might be useful in the treatment.
A combination of clofarabine (640 nM and 50 nM in MCF7 and MDA-MB-231 cells, respectively)
and EGCG (10 μM) also induced apoptosis in human breast cancer cells, followed by hypomethylation
of the tumor suppressor gene RARβ (retinoic acid receptor β) and the upregulation of RARβ, PTEN,
and CDKN1A genes [52]. Clofarfabine can inhibit DNA methylation reaction and, thus, its combination
with EGCG can have a role in blocking breast cancer development.
The effects of EGCG (>80 μM) on tongue squamous cell carcinoma were recently investigated,
showing that it reduced proliferation while promoting apoptosis in CAL27 and SCC 15 cells via the
Hippo-TAZ signaling pathway [53]. Similar to other tumor cell models, EGCG (10–200 μM) induced
apoptosis in a dose-dependent manner in human thyroid carcinoma cell lines by increasing the
Bax/Bcl-2 ratio, thus pointing to an increase of mitochondrial-mediated apoptosis and the involvement
of EGFR/RAS/RAF/MEK/ERK signaling pathway [54]. In addition to apoptosis, cell treated with
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EGCG has been associated with autophagy regulation. The treatment of human embryonic kidney
cell line (HEK293T cells) with EGCG increased cell viability by promoting autophagy through mTOR
pathway [55]. In hepatocellular carcinoma cells, EGCG induced autophagy via direct interaction
with LC3-I protein and, consequently, led to the degradation of α-fetal protein (AFP); an effect that
suggests a potential therapeutic application for the treatment of this type of tumor [56]. EGCG-induced
autophagy is also involved in the regulation of ectopic lipid accumulation in vascular endothelial cells,
which indicates a potential beneficial effect in preventing cardiovascular diseases [57]. Thus, EGCG is
involved in autophagy, even in different tumor cell lines, but with concentration dependent on cell
tissue origin. The effect of EGCG on cell death mechanisms is well documented. EGCG has been
also proposed as protective agent against necrosis induction because of its demonstrated action on
reduction of oxidative stress and inflammatory responses [58].
3.2. Cell Cycle Arrest (Cyclin, CDK)
The effect of EGCG on cell proliferation and cycle has been investigated in various cancers.
EGCG in a early work has been demonstrated to play an effective role as an anti-proliferative and
chemopreventive agent breast cancer, colon cancer, and skin cancers, such as melanoma in experiments
while using MCF-7, HT-29, and UACC-375 cell lines [59]. Specific effects on cell cycle modulation were
also investigated in a liver cancer model in which EGCG inhibited the proliferation of liver cancer cells
in G2 phase and induced apoptosis after the blocking of the cell cycle progression in the G1 phase [60].
Similar effects were supported in a study on skin cancer, in which the benefits of using polyphenols,
such as EGCG, in the treatment and prevention of skin cancer were extensively presented [61]. The
effect of EGCG treatment has been also investigated on different cancer types in which cell cycle
modulation was demonstrated through the alteration of the pattern of cell cycle proteins with specific
reference to CDKs. EGCG increased the expression of CDK1 proteins and inhibited the expression
of Cyclin D1 and the phosphorylation of retinoblastoma proteins. Moreover, EGCG treatment has
been associated to cell cycle arrest affecting upregulation/downregulation balance in which p1/p21,
Kip1/p27, p16/INK4A, cyclin D1, cyclin E, CDK2, and CDK4 proteins are involved. This effect was
demonstrated to be the first step of the apoptosis cascade induction via ROS and subsequent caspase-3
and caspase-9 action [62]. These conclusions were then supported by additional in vitro and in vivo
experiments in melanoma cancer cells. EGCG treatment of melanoma cells results in the modulation
of cyclin-dependent kinases inhibitor network and Bcl2 family proteins with a consequent inhibition
of viability and growth, cell cycle blocking, and apoptosis induction [63]. Nevertheless, it was also
demonstrated that EGCG can enhance the therapeutic effect if used in synergy with IFN in both
in vitro and in vivo models of melanoma, which could be an important advantage in reducing the
concentration of IFN and the toxicity of the treatment [64]. The reliability of the treatment or the
synergic use of EGCG is additionally supported by a large number of in vitro and in vivo scientific
reports on the effects of EGCG on cell cycle modulation and apoptosis induction without affecting
normal cells [65]. The studies that are presented in this paragraph point to the usefulness of EGCG in
treatment against malignancies by cell cycle modulation and cell death induction, both as therapeutic
agent and synergic adjuvant [13,66].
3.3. COX-2
Cyclooxygenase-2 (COX-2) is involved in the modulation of different cell processes, such as
oxidative stress and inflammation. COX-2 interaction was considered to be part of the mechanism since
EGCG was associated with cell cycle modulation and cell death induction in different cancer models.
Dysregulated activity of COX-2 were described in many cancers and pathologic conditions. EGCG
was demonstrated to inhibit COX-2 both in terms of transcription and translation in human prostate
carcinoma cells (androgen-sensitive LNCaP and androgen-insensitive PC-3), without interfering with
COX-1 regulation, and this is an important issue in cancer research. These findings point to the use of
EGCG >10 μM in the treatment or prevention of prostate cancer [67]. Furthermore, the EGCG inhibition
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of COX-2 was investigated on a colon cancer model, in which a significant decrease of COX-2 activity
in the cells of the colon of rats treated with green tea extract pointing to a prevention in the formation of
preneoplastic foci [68]. The authors fed the animals with freshly prepared an aqueous solution of green
tea extract, reconstituted from the lyophilisate, at a concentration of 0.02% (wt/vol) in which EGCG
was at 14% dry weight. COX-2 inhibition was also studied on the potential antitumor activity of EGCG
in skin cancer [69]. EGCG was administred to mice by gavage at a dose of either 20 or 50 mg/kg body
weight 1 h before topical application of the tumor promoter 12-O-tetradecanoylphorbol-13-acetate
to the shaved back. In this paper, the inhibitor mechanism of COX-2 by EGCG was described as the
cascade effect of EGCG inhibition of the catalytic activity of ERK and p38 MAPK that are the upstream
enzymes that regulate COX-2 expression [69]. From another point of view, the interaction between
EGCG and COX-2 were investigated in arthritis. A solution of 0.2% green tea polyphenols in the water
was prepared and given ad libitum (the sole source of drinking water for mice). Treatment with this
preparation in a collagen II-induced arthritis mouse model demonstrated to reduce the pathological
picture of arthritis, with decrease of TNF-α, IFN-γ, and Cox-2 especially in mice arthritic joints [70].
Thus, it was demonstrated that the treatment of human chondrocytes with EGCG at concentration
>100 μM was related to the inhibition of COX-2 and iNOS activity indicating a possible involvement of
this treatment in the inhibition of cartilage resorption in arthritis [71].
3.4. EGFR Pathway
EGFR (epidermal growth factor receptor) is a plasma membrane protein that is characterized by an
intracellular region acting as tyrosine kinase and an extracellular receptor domain. The dysregulation
of EGFR expression has been associated with cellular neoplastic transformation. EGCG interaction with
EGFR was demonstrated and described in its mechanism. EGCG binds to a specific laminin receptor
whose expression is reported in a variety of tumor cells: this connection can interfere with the activity
of the kinase-phosphatase cascades [72]. The laminin receptor has been recently related to MAPK
signaling in human melanoma metastasis mechanism [73]. EGCG inhibition of EGFR and HER2 was
demonstrated in colon cancer cells line (HT29), in which these proteins are overexpressed in comparison
with normal tissue. EGCG at 20 μg/mL resulted in cell growth reduction, cell cycle arrest in G1 phase,
and apotosis induction by the activation of caspase-3 and -9, with critical impact on EGFR/ERK
and EGFR/Akt signaling pathways [74]. The adjuvant effect of EGFR in breast cancer treatment
was demonstrated in different cell lines (MCF-7, MCF-7TAM, and MDA-MB-231). The combined
treatment of EGCG with IIF (6-OH-11-O-hydroxyphenanthrene) reduced the invasive phenotype and
up-regulated the expression of molecules that are involved in the invasion process, again acting on
EGFR/Akt pathway and their regulated targets, such as CD44, extracellular matrix metalloproteinases
inducer (EMMPRIN), matrix metalloproteinases, and tissue inhibitor of metalloproteinases (TIMPs) [75].
Similarly EGCG activity was also investigated in MCF-7tam (a breast carcinoma cell line resistant to
the chemoagent tamoxifen), where EGCG was demonstrated to reduce the resistance to Tamoxifen and
block cell growth and invasion [76]. In this last work, the EGFR/ERK pathway was downregulated,
with effects on matrix metalloproteinase-2 and -9, EMMPRIN. It emerges as the effects EGCG on EGFR
pathway depend on cancer cell type and suggest as EGCG can have an adjuvant role in EGFR targeted
therapy approach.
3.5. MAPK Pathway
The MAPK pathway (or extensively “Ras-Raf-MEK-ERK pathway”) is a key signaling pathway
frequently dysregulated in human cancer and can control multiple cell functions, such as proliferation
and growth [77]. For these reasons, different chemotherapeutic drugs have been already clinically
evaluated or are currently undergoing to specific clinical trials, for example, most promising are the
MEK1/2 and Raf inhibitors [78]. In mammalian cells, three major types of MAP kinases are present;
ERK, p38 MAP kinase, and JNK, and they can activate c-JNK and ELK [79]. These were the main
actors studied and they were associated with EGCG interaction in the MAPK pathway. A recent
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work studied EGCG and candesartan (anti-hypertensive drug) in a rat model of gentamicin-induced
nephrotoxicity [80]. EGCG was administred at 25 mg/kg, intraperitoneally, alone or combined with the
above drugs for 21 days. While renal disease revealed increased levels of NF-κB, p38-MAPK, caspase 3,
TNF-α, and interleukin-1 β, the pre-treatments with EGCG and candesartan (co-treatment had the best
results if compared to compounds alone) reduced such key factors, which impacted the MAPK pathway.
On the same line, a work with mice of Wang et al. showed that, in animals with artificial unilateral
ureteral obstruction, the intraperitoneally administration of EGCG (5 mg/kg) for 14 days inhibited
phosphorylation of ERK, JNK and p38 MAPK [81]. The effect of EGCG on mastitis in rats were evaluated
by injecting lipopolysaccharide (LPS) into the duct of mammary gland. EGCG was orally given at 25 or
100 mg/kg/day in the morning for 14 days. MAPKs, NFκB-p65 and hypoxia-inducible factor-1α (HIF-1α)
were decreased after the treatment with EGCG at both concentrations. The results showed that EGCG
suppressed MAPK related oxidative stress and inflammatory responses [82]. In another rat disease
model, EGCG exhibited cardioprotective effects in myocardial ischemia/reperfusion (I/R) injuries [83].
The authors showed that EGCG 10mg/kg intravenously administered alone or with wortmannin
(PI3K inhibitor) 5 min. before the onset of reperfusion reduced p38 and JNK phosphorylation while
enhancing AKT and GSK-3β, but not ERK1/2. Additionally, in artificial induced hypertensive rats,
ERK, p38, and JNK phosphorylation were decreased, when the rats were treated with 50 mg/kg
EGCG per day, intraperitoneally for 21 days [84]. Previously in human umbilical vein endothelial
cell (HUVEC) model, EGCG induced cell proliferation inhibition during ischemia/reperfusion, but,
in contrast with previous work, JNK1/2 (and c-Jun) phosphorylation was increased [85]. These data
could be imputable to the different model and time of incubation proposed. Also, EGCG >50 μM
inhibited angiotensin II- induced phosphorylation of ERK and p38 in HUVEC cells, influencing vascular
cell adhesion molecules (VCAMs) and intercellular adhesion molecules (ICAMs) expression [86,87].
In addition, EGCG impacted AKT phosphorylation and its downstream substrates Foxo1, Foxo3a,
and ERK1/2. In a prostate cancer mouse model (TRAMP mice: Transgenic Adenocarcinoma Mouse
Prostate), Harper and collaborators demonstrated that EGCG given ad libitum as 0.06% in water
reduced ERK phosphorylation, together with androgen receptor (AR), insulin-like growth factor-1
(IGF-1), IGF-1 receptor (IGF-1R), COX-2, and inducible nitric oxide synthase (iNOS) [88]. The authors
claimed that the EGCG dose should mimic a human consumption of six cups of green tea and that the
catechin, through the decrease of MAPK signaling, could modulate inflammation biomarkers, reduce
cell proliferation, and induce apoptosis. In the same mouse TRAMP model, another work showed a
key role for IGF-I/IGFBP-3 signaling pathway, with the modulation of ERK [89]. However, the authors
used a solution of 0.1% green tea polyphenols (in which EGCG represented 62%) to experimental
animals [89]. The two works are very similar in EGCG dose, but analyzed and demonstrated the
implaction of different key factors: they are probably the two sides of the same coin, but more research
is needed to confirm this hyphothesis. Moreover, in a NOD mouse, a model for Sjogren’s syndrome,
oral administration of 0.2% green tea extract in ad libitum water for 21 days (in which EGCG represented
40%) reduced the total autoantibody levels in the serum and lymphocytic infiltration of submandibular
glands (a key point of Sjogren’s syndrome) [90]. The research was also expanded in normal human
keratinocytes and immortalized normal human salivary acinar cells, where EGCG was able to protect
the cells by specific phosphorylation of p38 MAPK [90–93], contrary to most of works in which there is
a de-phosphorylation/deactivation of MAPK pathway. Again, these apparently inconsistent results
should be ascribed to different models used and the different human-derived tissue.
In SKH-1 hairless mouse model, the topical application of green tea polyphenols (in which EGCG
represented 18.8%) showed a decrease in UVB-induced thickness, skin edem, a and infiltration of
leukocytes, processes mediated by inhibition of ERK, c-JUN, and p38, as well as NF-kB [94]. Before the
animal model, the authors demonstrated the same results in cell models in which EGCG was used at
10–40 μM [92,95]. In addition, EGCG diminished the negative effects of ultraviolet irradiation in human
dermal fibroblasts, reducing the phosphorylation of MAPK, JNK, p38 MAPK, and ERK1/2 [95,96].
Collagen destruction was reduced by inhibiting matrix metalloproteinases (MMP-1, MMP-8, and
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MMP-13). In human AC16 cardiomyocytes, EGCG was examined for alleviating cigarette smoke
medium (CSM)-induced inflammation: EGCG protected from oxidative stress, inflammation, and
apoptosis, modifying interleukin (IL)-8 productions via the inhibition of ERK1/2, p38 MAPK, and
NF-κB pathways [97]. In the human retinal endothelial cell (HREC) line, a preclinical model for
diabetic retinopathy, EGCG was able to decrease phosphorylated p38, ERK, VEGF, and the expression
of inflammatory markers, such as TNF-α, IL-6, and ICAM-1 [98]. In addition, EGCG amended
the negative effect of high glucose concentrations acting on the MAPK pathway. Furthermore,
EGCG in chronic myeloid leukaemia cells inhibited cell growth and induced apoptosis through
the inhibition of Bcr/Abl oncoprotein and regulation of its downstream signals, such as p38-MAPK
and JNK (in addition to involvement of JAK2/STAT3/AKT pathway) [99]. In a different cellular
context, JB6 mouse epidermal cell line, it has been shown that EGCG could inhibit AP-1(activating
protein-1)-dependent transcriptional activity through the inhibition of a c-JUN, but not ERK [100].
AP-1 is a transcription factor involved that can be stimulated by cytokines, growth factors, stress, and,
consequently, implicated in proliferation and apoptosis, with overlapping role to MAPK pathway.
Successively, another work remarked the importance of AP-1 (and MAPK), with the inhibition of
c-JUN, and also ERK by EGCG, differently from previous research [101]. Of note that a different cell
line was used (human gastric AGS cells). EGCG also impacted endothelial cell activation, where
the catechin could downregulate endothelial inflammation by acting on MAPK signaling through a
caveolae-regulated cell mechanism [102]. Endothelial cells are fundamental in atherosclerosis: EGCG
demonstrated antiatherogenic effect in reducing oxidized LDL upregulated by c-Jun phosphorylation
and blocking oxidized LDL-induced endothelial apoptosis [103]. In the pancreatic alpha TC1-6 (αTC1-6)
cell line, EGCG confirmed its anti-hyperglycemia and antioxidant potential [104]. Indeed, EGCG
re-established glucagon secretion and reduced ROS, while inhibiting JNK and p38 and activating AKT
signaling. It is of note that a higher concentration of EGCG (100 μM) was used, if compared to previous
studies, and this can potentially reduce EGCG efficacy when moved to clinical trials. Moreover, in a
cell model of insulin-stimulated mitogenesis (3T3-L1 preadipocytes), it has been shown that EGCG
inhibited the insulin effects, switching off signaling through both insulin receptor-β, insulin receptor
substrates 1 and 2 (IRS1 and IRS2) and RAF1, MEK1/2, and ERK1/2, but not JNK [105].
Interestingly, EGCG was associated with sunitinib, which is a multi-target receptor tyrosine kinase
inhibitor approved for renal carcinoma and gastrointestinal stromal tumor, in MCF-7 (breast cancer)
and H460 (lung cancer) mouse xenograft tumors [106]. The authors found that synergize with sunitinib
due to its ability to suppress both insulin receptor substrate-1 pathway and MAPK signaling induced by
sunitinib. In another breast cancer cell line T47D, EGCG induced the phosphorylation of JNK/SAPK and
p38 and modulated cyclin A, cyclin B1, and cdk proteins, triggering G2 arrest [107]. In a human colon
cancer cell line (HT-29), it was found that EGCG activated phospho-AKT, phospho-ERK, phospho-JNK,
and phospho-p38α/γ/δ and, consequently, induced cell death, a potential mechanism for anti-cancer
effect of EGCG [108]. Previously with same cell line, Chen et al. showed the activation of caspase-3
and -9, cytochrome c, mitochondria, c-Jun, and MAPK pathway after treatment with EGCG, with the
end result of apoptosis induction [109]. In another colon cancer cell line (SW480), EGCG induced the
phosphorylation of p38, which mediated the phosphorylation of EGFR at Ser1046/1047, leading to a
downregulation of the EGFR/MAPK pathway [110]. The author claimed that this phosphorylation
could play a pivotal role in EGFR downregulation that is induced by EGCG. Furthermore, in HCT116
colorectal carcinoma cells, EGCG triggered the phosphorylation of ERK, JNK, and p38, which, in
turn, conducted to apoptosis [111]. In human lung cancer cell line PC-9, EGCG was associated with
celecoxib (a cyclooxygenase-2 selective inhibitor) provoking an activation of ERK1/2 and p38 regulated
by GADD153 (DNA damage-inducible 153) expression [112]. EGCG induced apoptosis and the authors
suggested that GADD153 could be a new molecular target for cancer prevention in combination
with EGCG. Similarly, EGCG was found to suppress cell proliferation by upregulating BTG2 (B-cell
translocation gene 2) expression via MAPK pathway in oral squamous cell carcinoma (OSCC), in
particular with the phosphorylation of p38, JNK, and ERK [113].
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Moreover, in anaplastic thyroid cell carcinoma (ARO cells), EGCG 50 μM showed anti-proliferative
and pro-apoptotic effects, being mediated by the suppression of phosphorylated EGFR, ERK1/2, JNK,
and p38 and p21, caspase-3, and cleaved PARP increase and cyclin B1/CDK1 expression decline [114].
In a previous work, human hepatoma HepG2-C8 cells and human cervical squamous carcinoma
HeLa cells were used to evaluate EGCG [115]. The results indicated that catechin induced the
activation of ERK, JNK, and p38 in a dose- and time-dependent manner, with stimulation of apoptosis
(mediated by caspase-3) and antioxidant response element (ARE). In DU-145 prostate cancer cells,
EGCG associated with ibuprofen reduced >90% tumor cell growth through the activation of both
MAPK and caspases [116]. Similarly, human prostate cancer androgen-unresponsive and responsive
cells (DU145 and LNCaP, respectively) that were treated with EGCG showed an increase of ERK1/2 with
concomitant decrease of phosphorylated AKT and the level of PI3K, again underlining the anticancer
effect of the catechin [117].
3.6. NF-kB Pathway
NF-κB (Nuclear factor-κB) is involved in a variety of cellular mechanisms, such as death, growth,
inflammation, and immune response. NF-κB mainly acts as a regulator of gene transcription in
response to oxidative stress. The interaction with EGCG was described in a variety of cell models,
both in vivo and in vitro [64]. NF-κB is one of the most investigated targets in cancer research and the
interaction with this pathway should be considered to be a relevant topic in cancer treatment design.
The inhibitory activity of EGCG on NF-κB has been demonstrated in a large number of independent
studies. Studies that were performed in normal human epidermal keratinocytes in which EGCG was
used at different concentration to modulate NF-κB activity, leading to a protective effect towards the
negative cascade that was induced by UV radiation. This is considered the proof of the mechanism
of action of green tea as a photoprotective agent [92]. Moreover EGCG has been shown to reduce
significantly the gut mucosa inflammation in response to injury, thus inhibiting the production of
inflammatory factors via the modulation of NF-κB expression and other involved genes [118]. The
authors showed that, in ulcerative colitis (a refractory inflammatory disease of the large intestine) rat
model, EGCG intraperitoneally administered at 50 mg/kg/d could reduce the severity of the disease,
through the TLR4/MyD88/NF-κB signaling pathway. Moving on cancer research, EGCG was able to
activate caspases in epidermoid carcinoma cells, and this has been demonstrated to play a relevant
role in the inhibition of NF-κB and induction of apoptosis [119]. Nevertheless, EGCG has been
demonstrated to play a potential role in human colon cancer prevention inhibiting AP-1, c-fos, cyclin
D1 promoters, and NF-κB activity in four different human colon cancer cell lines, with an IC50 value of
about 20 μg/mL [74].
3.7. PI3k/AKT Pathway
Numerous studies on diseases that involve PI3K/AKT signaling investigated the possible effect
of green tea administration [120]. Since green tea role in asthma treatment or occurrence need to
be better clarified [121,122], the effect on molecular pathways at the basis of pathological processes
has been explored. Recently, a possible mechanism of action has been proposed in brochial asthma.
EGCG, being administered in drinking water 0.5 mg/mL, was demonstrated to reduce inflammation
and the subsequent cellular infiltration in lung tissue of ovalbumin-challenged asthmatic mouse,
inhibiting EMT via PI3/AKT pathway modulation in vivo and in vitro models [123]. On the other hand,
EGCG modulation on the PI3K/AKT signaling pathway was associated to lung cancer prevention
and suppression. EGCG activation/inhibition of PI3K/AKT was found to be a key switch in H1299
cells growth inhibition ad apoptosis induction [124]. Another interesting research has been carried on
the neuroprotective action of EGCG in a middle cerebral artery occlusion model (MCAO), acting as
a modulating agent PI3K/AKT/eNOS signaling pathway [125]. The rats were treated with 20 mg/kg
EGCG, injecting it with an arterial pump and the expressions of PI3K, p-AKT, and eNOS were detected
by both immunohistochemistry and Western blot. Similarly, in unilateral chronic constriction injury to
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the sciatic nerve, EGCG role as neuroprotective agent was confirmed in rats [126]. 50 mg/kg EGCG
was intraperitoneally administered daily for three days after nerve crush injury.
3.8. VEGF Pathway
Angiogenesis is known to play a major role in the pathogenesis of many cancer types [127]. Given
its involvement in metastasis and growth of tumor cells, angiogenesis possesses a key player in vascular
endothelial growth factor (VEGF, also known as VEGF-A) and it has been intensively studied as a
therapeutic target [128]. Consequently, EGCG has been investigated in the VEGF pathway, discovering
its capacity to modulate angiogenesis, with stimutating effects in nervous tissue and inhibiting effects in
tumor tissue. For example, in a mouse model of transient middle cerebral artery occlusion (MCAO), the
authors showed that EGCG injected intraperitoneally daily for seven days could stimulate angiogenesis.
EGCG had a neuroprotective effect, indeed treated mice had better neurologic outcome, a decreased
infarct volume, greater vascular density, with the modulation of VEGF signaling pathway and increased
Nrf2 expression (fundamental role in against ischemic stroke) [129]. Similarly, hepatic tissue from mice
that were treated with EGCG showed increased heme oxygenase-1 (HO-1) and decreased vascular cell
adhesion molecule (VCAM)-1 expression, with an increased expression of Nrf-2 (mediated by p38) that
drives the expression of HO-1, as also demonstrated in human aortic endothelial cells (HAEC) [130].
Another group used the same mouse model (MCAO) and demonstrated the involvement of the
PI3K/AKT/eNOS signaling pathway with a concomitant reduction of apoptotic rate and caspase-3 in
neurons, while Bcl-2 increased in the ECGC treated set (EGCG intraperitoneally injected at 20 mg/kg
for 24 h) [125]. Similarly, it was studied on the effects of EGCG on murine dendritic cells (DC), with a
reduction of ERK1/2, p38, JNK, and blockade of NF-κB p65 translocation [131]. EGCG was given to
cells at different doses, but 100 μM was the most effective with suppression of the phenotypic and
functional maturation of DC. Differently in tumor tissue EGCG acted in a opposite way. For example,
in human gastric cancer SGC7901 cells (in hypoxic state) EGCG (5, 10, 20, 40 μM), reduced expressions
of HIF-1α (a subunit of a heterodimeric transcription factor hypoxia-inducible factor 1-HIF1) and VEGF
with a concentration-dependent effect. In addition, in SGC-7901 mouse xenografts, 1.5 mg/day EGCG
intraperitoneally injected reduced VEGF, tumor microvessel density, endothelial cell proliferation,
migration, and tube formation, substantially blocking tumor growth [132]. Similarly, in gastric cancer
5-fluorouracil (5-FU) resistant cells (MGC803/FU treated with 100 μg/mL and SGC7901/FU treated
with 20 μM), EGCG inhibited VEGF and HIF-1 expression, reversing 5-FU resistance that is mediated
by VEGF pathway [133,134]. HIF-1 is a master regulator of cell homeostatic response to hypoxia by
activating the transcription of numerous genes that are implicated in growth, apoptosis, angiogenesis,
and metabolism [135]. HIF-1 is strictly connected with VEGF (it is a primary target of HIF-1) and, thus,
understanding the regulation of HIF-1 will offer new insight into VEGF pathway and new potential
therapeutic targets. In human gastric cancer cells (AGS) EGCG >10 μM reduce dose-dependently
VEGF expression and secretion mediated by signal transducer and activator of transcription 3 (Stat3)
activity [136]. In colon cancer cells (Caco2, HCT116, HT29, SW480, and SW837 lines) and SW837 mouse
xenograft, EGCG impacted on VEGF/VEGFR axis suppressing VEGFR2 (a primary responder to VEGF
signal), together with HIF-1α, ERK, and AKT [137]. Moreover in a different human colon cancer cell
line (HT29) and derived mouse xenografts, EGCG lessened VEGF expression and its promoter activity,
while decreasing the tumour growth and microvessel density in mice (treated daily intraperitoneally
with 1.5 mg EGCG), and modulating cell proliferation and apoptosis in HT29 cells [138]. In breast
cancer cells (MCF-7), HIF-1α and VEGF was decreased by EGCG in a dose-dependent manner (25, 50,
100 mg/L) [139], similarly to non-small lung cancer cells (A549), in which the catechin (25, 50, 100 μM)
was able both to inhibit HIF-1α protein expression (stimulated by IGF-I, insulin growth factor-1,
a growth hormone mediating cell growth) and the formation of capillary tube-like structures on a
model of extracellular matrix [140]. In head and neck squamous cell carcinoma (YCU-H891) and
breast carcinoma cell lines (MDA-MB-231), EGCG blocked VEGF activity, thanks to the inhibition of
constitutive activation of Stat3 and NF-κB [141]. The results showed that EGCG could modulate a
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plethora a key factors, such as TNF-α, Rantes, monocyte chemotactic protein-1 (MCP-1), intercellular
adhesion molecule-1 (ICAM-1), nitric oxide (NO), VEGF, and MMP-2, through the inhibition of NF-κB
and MAPK signaling pathways (downregulation of p-IκBα, p65, p-p65, p-p38, p-ERK1/2, and p-AKT).
EGCG repressed hypoxia- and serum-induced HIF-1α and VEGF, through MAPK and PI3K/AKT
pathways, in another hepatoma cell line (HepG2) and in human cervical carcinoma cell line (HeLa) [142].
In a group of acute myeloid leukemia (AML) cell lines harboring FLT3 mutation (FLT3 is a commonly
mutated gene in AML), EGCG 60 μM (and (−)-epigallocatechin (EGC), (−)-epicatechin-3-gallate (ECG),
and (+)-Catechin (C)) showed reduced levels of FLT3 and the suppression of phosphorylated MAPK,
AKT, and STAT5 [143]. Moreover, in B-cell chronic lymphocytic leukemia (B-CLL), EGCG 3–25 μM
reduced VEGF-R1 and VEGF-R2 phosphorylation (fundamental in B-CLL survival and growth) and
induced apoptosis by caspase-3 activation, poly-adenosine diphosphate ribose polymerase (PARP)
cleavage, and B-cell leukemia/lymphoma-2 protein (Bcl-2) [144,145].
Additionally, in non-tumoral cell lines, EGCG demonstrated a concrete role. In human
microvascular endothelial cells (HMVEC) used as a model of angiogenesis, EGCG inhibited
VEGF-induced tube formation through the suppression of vascular endothelial-cadherin
phosphorylation and AKT activation [146]. In normal human keratinocytes (NHK) that were
stimulated by TNFα, EGCG at different concentrations (0.1 to 10 μM) decreased VEGF and interleukin-8
(proinflammatory cytokine involved in skin inflammation) [147]. Similarly, in human umbilical vein
endothelial cells (HUVEC), EGCG inhibited VEGF in a concentration dependent manner and reduced
cell proliferation [148]. On the same line, two works from the same research group used HUVEC
cells (and MDA-MB231 breast cancer cell) and found that EGCG decreased VEGF production in a
concentration-dependent manner (6.25, 25, 100 μM) [149,150]. They also demonstrated that, in HUVEC
and MDA-MB231 mouse xenografts, in addition to cell line, green tea extract reduced the proliferation,
tumor size, and tumor vessel density [150]. Mice fed with green tea extract in water ad libitum with a
concentration of 0.62, 1.25, and 2.5 g/L (in which EGCG represented 46.8% weight). The effects were
both time and concetration dependent. In human vascular smooth muscle cells (hVSMCs), EGCG
was investigated after cell stimulation with platelet-derived growth factor (PDGF), which is known
to induce VEGF expression [151]. EGCG blocked dose-dependently VEGF expression and PDGF
receptor activation, in addition to ERK1/2 and AP-1. Additionally, in livestock ovarian cell model
(swine granulosa cells), EGCG was evaluated as a food supplement. The catechin reduced VEGF
production independently of oxygen condition and decreased cell growth, which suggested a role in
angiogenic process, fundamental for follicle development [152].
3.9. Proteasome
The proteasome is a protein complex that is dedicated to degrade damaged or useless proteins
that are unusable to cell [153]. It is strictly dependent on ubiquitins, molecules that tag unwanted
proteins and continues with the degradation process mediated by proteases [154]. The proteasome
has been investigated as a key target for multiple diseases, given its importance in cell physiology.
Effectively, three approved drugs are available, bortezomib (for multiple myeloma and mantle cell
lymphoma), carfilzomib and ixazomib (for relapsed or refractory multiple myeloma), and many others
are in development [155]. Different cell types were tested with EGCG: human Jurkat T, prostate cancer
(LNCaP, PC-3), breast cancer (MCF-7), normal (WI-38), and SV40-transformed (VA-13) human fibroblast
cells [156,157]. The works showed that EGCG specifically blocked proteasome activity in LNCaP, PC-3,
and MCF-7 cell extracts with a range of IC50 from 86 to 194 nm. In addition, in cell models, EGCG 1–10
μM induced the accumulation of two natural proteasome substrates, p27(Kip1) and IkappaB-alpha,
an inhibitor of transcription factor NF-κB, together with G1 cell cycle phase arrest. Moreover, EGCG
derivatives were studied both to understand the biochemical role of such molecules in proteasome
inhibition and to find novel potent or stabilized alternatives to EGCG [158]. For example, a work of Kazi
and collaborators revealed that the A-ring and gallate ester/amide bond are necessary for the blockade
of proteasome [159]. Similarly, EGCG modified with peracetate presented higher proteasome-inhibitory
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activity if compared to EGCG, with increased cell death mechanism in Jurkat T cells [160]. Again, other
EGCG analogs were tested and showed that B-ring/D-ring peracetate-protected EGCG derivatives
could induce cell death [161,162]. Additionally, peracetate-protected EGCG in breast carcinoma cell
line (MDA-MB-231) and in MDA-MB-231 mouse xenografts (daily sub cute injection with 50 mg/kg)
was tested, showing tumor growth decrement, with concomitant proteasome inhibition and apoptosis
activation [163]. Later, different fluoro-substituted EGCG analogs were generated and, among these,
Pro-F-EGCG4 ((-)-(2R,3R)-5,7-Diacetoxy-2-(3,4,5-triacetoxyphenyl)chroman-3-yl3,4-difluorobenzoate)
had potent effects than peracetate EGCG inducing apoptosis and decreasing cell proliferation
(concentration-dependent effects from 10 to 50 μM) in the Jurkat and MDA-MB-231 cell lines,
in addition to reducing tumor size in MDA-MB-231 mouse xenografts (daily subcutaneous
injection with 50 mg/kg) [164,165]. In the same cell line (MDA-MB-231), EGCG was tested with
catechol-σ-methyltransferase (COMT), an human enzyme that degrades catecholamines [166]. COMT
can methylate EGCG, reducing its biological activity. The work reported that decreasing COMT
activity could augment EGCG efficacy through apoptosis induction and proteasome inhibition. In
YT (human natural killer) and Jurkat cell lines, EGCG (and other proteasome inhibitors) produced
cell cycle modulation (subG0/G1 phase increase in Jurkat cells and G2/M phase arrest in YT cells),
apoptosis with caspase-3 activation, and with mitochondrial membrane potential decrement [167].
Moreover, in Caco-2 cells, EGCG inhibited 20S proteasomes activity with antioxidant and proteasome
blocking properties in cell lysates [168]. In the human neuroblastoma cell line (SH-SY5Y), EGCG
at low concentration (1 μM) impacted on BCL2 associated agonist of cell death (Bad) levels, while
the protein kinase C (PKC) inhibitor GF109203X impeded Bad degradation [169]. The authors
claimed that EGCG promoted neuronal survival through the rapid removal of Bad (PKC-mediated) by
proteasome, while using low doses, whereas most of works showed general EGCG inhibitory effects
at 50 μM. This difference could probably reside in the specific cell model used. In a mouse model
of experimental autoimmune encephalomyelitis (EAE), EGCG administered by gavage 300 μL per
mouse twice daily was able to decrease clinical severity, as suggested by reduced brain inflammation
and neuronal damage [170]. In addition, in the same work with human myelin-specific CD4+ T
cells, EGCG impacted cyclin-dependent kinase 4 expression (with cell cycle arrest) and on 20S/26S
proteasome complex activity (with subsequent NF-κB inhibition), demonstrating anti-inflammatory
and neuronal protective capacities. In skin cancer cells (SCC-13 and A431), EGCG alone or associated to
3-deazaneplanocin A (a potent inhibitor of S-adenosylhomocysteine hydrolase, enzyme that is involved
in homocysteine metabolism) suppressed cell cycle progression and increased apoptosis, through
proteasome-dependent degradation of the polycomb group proteins, molecules that are involved in
development, differentiation, and survival [171]. A study investigated the effects of extremely low
frequency electromagnetic fields (ELFEF) on 20S proteasome while using EGCG in Caco-2 cells [172].
It is known that ELFEF can modulate intracellular ROS levels and the cell cycle progression, indeed
EGCG was able to reduce the pro-oxidant effects, regulate cell cycle, and proteasome functionality.
However, EGCG did not alter cell viability as measured by MTT assay.
Though numerous works demonstrated a positive interaction of EGCG in proteasome function,
others showed a deleterious activity of EGCG. For example, in HepG2 cells, EGCG 50 μM
exerted anti-cholesterolemic activity, reducing apolipoprotein B-100 (apoB) production and lipid
assembly, thorough a proteasome-independent pathway, as demonstrated by a lack of response to
N-acetyl-leucyl-leucyl-norleucinal, a proteasome inhibitor [173]. Moreover, the association of EGCG
and bortezomib (proteasome inhibitor for multiple myeloma) should not be suggested, as their
experimentation in human multiple myeloma cells (RPMI/8226 and U266) showed strong antagonism,
with EGCG blocking proteasome inhibition being produced by bortezomib and, thus, stopping tumor
cell death [174,175]. Similarly, in prostate cancer cells (PC3), bortezomib anti-tumor effects was
counteracted by EGCG which induced autophagy while decreasing endoplasmic reticulum stress [176].
These data underline in a different cell model, as EGCG can antagonize bortezomib, blocking prostate
cancer cells death, and thus negatively supporting tumor pro-survival.
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3.10. Senescence
Senescence is defined the condition or process of deterioration with age [177]. Senescence plays
a role in multiple biological events, such as embryogenesis, tissue regeneration and repair, ageing,
cardiovascular, renal, liver diseases, and cancer [178,179]. EGCG has been implicated in senescence in
different works. For example human mesenchymal stem cells (hMSCs) show the peculiar behavior of
producing abundant ROS during culturing and this issue has been exploited with a natural anti-oxidant
as EGCG [180]. The work explored the anti-senescent effect of EGCG in H2O2-exposed hMSCs and
proved that EGCG reversed oxidative stress by downregulating the p53–p21 signaling pathway and
upregulating Nrf2 expression. Similarly, in primary cells, including rat vascular smooth muscle cells
(RVSMCs), human dermal fibroblasts (HDFs) and human articular chondrocytes (HACs), the same
concentrations of EGCG (50 or 100 μM) could prevent senescence and recover cell cycle progression,
again impacting on the p53 pathway at least in HDFs cells [181]. Furthermore, in 3T3-L1 preadipocytes,
EGCG could inhibit stress-induced senescence (H2O2-induced) by countering DNA damage and cell
cycle arrest [182]. In this work, EGCG (same concentrations as above, 50 or 100 μM) modulated
PI3K/Akt/mTOR and AMPK pathways by blocking ROS, iNOS, Cox-2, NF-kB, and p53, and increasing
apoptosis by suppressing antiapoptotic protein Bcl-2. Moreover, in WI-38 fibroblasts at late-stage
(population doubling > 25) used as model of oxidative stress and inflammation, EGCG (25, 50, 100 μM)
reduced TNF-α, IL-6, ROS, again acting on p53 [183]. ECGC also decreased retinoblastoma expressions,
while enhancing E2F2 expressions and superoxide dismutase (SOD) 1 and 2, all being implicated
in oxidation processes. EGCG has been shown to affect the development and severity of cellular
senescence, but from a therapeutic perspective more work is needed. Senolytic attributes of EGCG
are interesting, especially for attenuating age-associated disorders, though clinical trails and health
consequence still need to be proposed and discovered.
3.11. Epigenetics and Mirnas
Epigenetics refers to heritable phenotype changes, in which DNA sequence alteration are
not included. The most known epigenetic mechanisms involve DNA methylation and histone
modification [184]. Extensively, epigenetics concerns all events “outside” DNA sequence modification;
indeed, this paragraph wants to describe those mechanisms characteristic of DNA methylation
and histone modification involving EGCG. Numerous works have been reported the significant
impact of EGCG in epigenetic mechanism. For example, in 2003, EGCG was first studied as an
inhibitor of DNA hypermethylation of CpG islands by acting on 5-cytosine DNA methyltransferase
(DNMT). EGCG was used at 20 and 50 μM with concentration-dependent effects in human esophageal
cancer cells (KYSE 510), colon cancer HT-29, and prostate cancer PC3 cells [185]. The authors
showed that EGCG could block DMNT and reactivate methylated-silenced genes, as p16(INK4a),
retinoic acid receptor β (RARβ), O-(6)-methylguanine methyltransferase (MGMT), and human mutL
homologue 1 (hMLH1). Similar results were obtained in human breast cancer cell lines (MCF-7 and
MDA-MB-231), whereas EGCG was able to block prokaryotic SssI DNA methyltransferase (DNMT)
and human DNMT1 [186]. A recent work used the same cell lines (MCF-7 and MDA-MB-231)
investigating RARβ expression and methylation, as mentioned in the first paragraph [52]. EGCG
combined with 2-chloro-2’-fluoro-2’-deoxyarabinosyladenine (a deoxyadenosine analogue) reduced
RARβ methylation with consequent increase of its expression, together with PTEN and CDKN1A,
and with apoptosis induction and cell proliferation inhibition. EGCG acted on inhibitor of matrix
metalloproteinases (TIMPs) and MMPs, being highly involved in tumorigenesis, in human prostate
cancer cells (DUPRO and LNCaP) [187]. The authors showed that EGCG restored TIMP-3 expression
and concomitantly increased histone H3K9/18 acetylation and decreased class I histone deacetylase,
impacting on cell invasion and migration. Interestingly in serum of patients undergoing prostatectomy
consuming 800 mg EGCG up to 6 weeks (participating to clinical trial NCT01340599), TIMP-3 levels
were increased, suggesting a potential mechanism of action of EGCG in prostate cancer [187]. However,
the trial failed to show a significant benefit of EGCG-treated prostate cancer patients [188].
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Moreover, in a SKH-1 hairless mouse model, EGCG added to a hydrophilic cream and applied to
approximately 1 mg/cm2 skin area could protect against photocarcinogenesis through the reduction of
tumor incidence, tumor multiplicity, and tumor size [189]. Mechanisms at the basis of these results are
related to the inhibition of DNA hypomethylation induced by ultraviolet B treatment. Likewise, in
human skin cancer cells (A431) and squamous cell carcinoma (SCC 13) cells, EGCG could reactivate
p16INK4a and Cip1/p21, impacting not only on DNA methylation and DNMT activity, but also
on histone deacetylase (HDAC) activity and acetylated histones [190]. Again, in CD4+ Jurkat T
cells, EGCG 50 μM could inhibit DNMT and induce a concomitant Foxp3 (a factor regulating the
development and function of regulatory T cells) and IL-10 expression. Moreover, in mice that were
treated with EGCG (injected intraperitoneally daily per mouse 50 mg/kg), there was an increase of
regulatory T cells frequencies and numbers [191]. In human malignant lymphoma cells (CA46), EGCG
alone (6 μg/mL) or combined with trichostatin A (inhibitor of HDACs) diminished p16INK4a gene
methylation (thus increasing its expression) and provoked a cell proliferation decrement [192]. The
effects were more evident with the combination of the compounds, rather than EGCG alone, being
suggestive an additive or synergist effect. In human breast tumor tissues, expression of DNMTs was
found increased by Mirza et al., consequently MCF-7 and MDA MB 231 cells were used as models
for testing EGCG and other compounds [193]. The authors showed that EGCG decreased DNMT1,
HDAC1, and methyl-CpG binding protein 2 (MeCP2 essential for nerve function), with a reversal of
epigenetic changes present in cancer cells. On the same line, another work investigated a co-treatment
of 5-aza-2’-deoxycytidine and EGCG in breast cancer cells (MCF-10A) and confirmed the effects on
DNA methylation and histone modifications [194]. In a mouse lung tumor model that was induced
by the tobacco-specific carcinogen 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), EGCG
(0.5% in diet ad libitum) was implicated in DMNT1 reduction with simultaneous decrease of p-AKT,
phospho-histone H2AX and tumor growth, again emphasizing the epigenetic effects of the catechin,
potentially due the antioxidant activity of EGCG, as suggested by the authors. [195]. Furthermore
EGCG was studied in the methylation status of the reversion-inducing cysteine-rich protein with
Kazal motifs (RECK) gene, a tumour suppressor gene downregulating matrix metalloproteinases and
blocking metastatic potential [196]. It has been shown in a salivary adenoid cystic carcinoma cells
(SACC83) that the catechin was able to demethylate RACK gene and thus impact on invasion, migration,
and metastasis. EGCG has been also implicated in autophagic process, as seen in Paragraph 3.1. It
is known that in macrophages from aged mice Atg5 and LC3B genes are normally hypermethylated
(genes regulating autophagy). The use of EGCG (probably a high dose, even if the authors did
not report any cell viability change) in macrophages restored these genes expressions both in vivo
and in vitro [197]. Similarly, in macrophages cells of cystic fibrosis (CF) mice, EGCG (administered
intratracheally for three days with 25 mg/kg) restored Atg12 gene expression, improving autophagy
in such a disease, where autophagic process highly impaired [198]. EGCG (10 μM given diabetic
pregnant mice at embryonic day 5.5 in drinking water) inhibited DNA hypermethylation in maternal
diabetes-induced neural tube defects, decreasing the congenital defects and opposing the high glucose
levels in embryo [199]. In another animal models, C57BL/6J male mice thatwere fed with high-fat diet
(HFD) or control diet (CD), EGCG administered ad libitum at 25 mg/kg body weight per day in water
modulated DNMT1 and MutL homologue 1 genes methylation, ameliorating inflammatory status in
HFD mice [200]. In addition, EGCG enhanced gut microbiota, as evidenced by DNA damage in the
Firmicutes/Bacteroidetes ratio and the total number of bacteria in the same work. In HeLa cells, EGCG
abrogated DNMT3B and HDAC1 activity, while only the expression of DNMT3B was reduced, also
affecting expression of retinoic acid receptor-β, cadherin 1, and death-associated protein kinase-1 [201].
A genome-wide study of DNA methylation reported the effects of EGCG in oral squamous cell
carcinoma (CAL-27) [202]. The results showed that the main differentially expressed genes that were
derived from MAPK, Wnt, and cell cycle signaling pathways, cell processes that are strongly associated
cancer proliferation.
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MicroRNA (miRNA) is a small non-coding RNA molecule that contains about 22 nucleotides
that can post-transcriptionally regulate gene expression [203]. miRNAs are involved in numerous
cell processes, including growth, proliferation, apoptosis, autophagy, metabolism, etc., and play
a fundamental part in cancer. In prostate cancer cells (PC3) and PC3 mouse xenografts, EGCG
blocked nuclear translocation and protein expression of androgen receptor (implicated in prostate
cancer etiology), and these effects were associated with the down-regulation of androgen-regulated
miRNA-21 and up-regulation of miRNA-330, a tumor suppressor [204]. Another target of EGCG was
miRNA-210, being upregulated by the catechin in lung cancer cell lines (CL13, H1299, H460, A549), with
induced accumulation of HIF-1α, which is a known miRNA-210 activator [205]. Moreover, in tobacco
carcinogen-induced lung tumors in A/J mice, miRNAs profile was analysed after EGCG treatment
(mice fed with purified diet containing 0.4% EGCG) [206]. It has been revealed that these miRNAs were
strictly connected with MAPK, AKT, NF-κB pathways, and cell cycle regulation. Rat hepatoma cell
line (FAO) were used to test different extracts and polyphenols, including EGCG [207]. The catechin
reduced miR-33a and miR-122 levels (both being involved in dyslipidemia, cholesterol homeostasis,
insulin resistance), with direct binding to miRNAs, as demonstrated by 1H NMR spectroscopy and,
thus, could potentially impact cell metabolism. In non-small cell lung cancer cells (A549) mouse
xenografts, EGCG that was associated with cisplatin was able to reduce tumor size, while in NCI-H460
cells (another non-small cell lung cancer cell line) was not [208]. This difference was imputable to
different expression of miRNA-98-5p and miRNA-125a-3p after EGCG treatment, consequently, the
authors suggested that EGCG and cisplatin could have a therapeutic role in some subtype of non-small
cell lung cancer and could conveniently be associated. In nasopharyngeal carcinoma cell line (CNE2)
differential miRNAs expression was observed, in particular 16 miRNAs with 20 μM EGCG-treated
and 32 miRNAs with 40 μM EGCG-treated were modulated (>2-fold expression changes when
compared with the control) [209]. Furthermore, while using an in vitro subarachnoid hemorrhage
model (oxyhemoglobin added to PC12 cells), EGCG at 1 and 50 μM altered miRNAs expression
and mainly impacted on the MAPK pathway (p38, Ca2+, autophagic activation), suggesting that
the differential expression of miRNAs could be at the basis of the therapeutic efficacy of different
concentrations of EGCG [210]. EGCG in a dose- and time-dependent manner inhibited the proliferation
and regulated miRNAs expression of miR-210, miR-29a, miR-203, and miR-125b in different cervical
carcinoma cells in multiple human cervical cancer cell lines (HeLa (HPV16/18+), SiHa (HPV16+),
CaSki (HPV16+), and C33A (HPV-)) [211]. In osteosarcoma cell lines (MG-63 and U-2OS), EGCG
induced miRNA-1 upregulation and inhibited c-MET expression, while its combination with c-MET
inhibitor enhanced inhibitory effects on tumor cell growth, heading to cell proliferation reduction,
cell cycle arrest, and apoptosis induction [212]. EGCG downregulated Ca2+ (CRAC) channel (Orai1),
its regulator stromal cell-interaction molecule 2 (STIM2), and store operated Ca2+ entry (SOCE), all
being implicated in Ca2+ regulation, in murine CD4+ T cells and human Jurkat T cells. The work
showed that EGCG repressed Ca2+ entry by up-regulation of miR-15b, which ruled STIM2, Orai1,
SOCE, and acted on AKT/PTEN pathway [213]. In anaplastic thyroid carcinoma cells (SW1736 and
8505C), EGCG and other natural compounds had heterogeneous effects, with curcumin being the most
effective [214]. Nonetheless, EGCG provoked a significant reduction of miRNA-221 only, even if five
important miRNAs that were implicated in thyroid cancer progression were studied (miRNA-221,
miRNA-222, miRNA-21, miRNA-146b, and miRNA-204). In multiple myeloma cells (MM1.s), EGCG
(1 and 5 μM) was shown to inhibit miRNA-25, miRNA-92, miRNA-141, and miRNA-200a, all being
implicated in p53 targeting reduction, a hallmark of multiple myeloma [215]. The suppression of
these miRNAs could have a potential effect in the treatment of such disease, as the authors claimed
that the EGCG doses were physiologically relevant and within the range of human consumption.
In pancreatic ductal adenocarcinoma cell lines (BxPc-3, MIA-PaCa2, and CRL-1097), EGCG and other
catechins (also associated with quercetin and sulforaphane) were used and showed to reduce apoptosis,
migration, and the matrix metalloproteinases MMP-9 and MMP-2, with the activation of miR-let-7
leading to the inhibition of its target gene K-Ras [216]. Of note that EGCG was not among the most
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effective compounds, whereas the combination of sulforaphane, quercetin, and catechins extract
seemed to have a strong therapeutic action.
3.12. Other Mechanisms
The effects of EGCG have been also reported in many other signaling pathways and other diseases
other than cancer could be involved in the benefit of the catechin. For example, EGCG treatment
inhibited VEGF signaling, leading to a reduction in mitogenesis of human umbelical arterial cells [217].
Mitogenesis is key process for cell energy and its modulation can impact the survival, growth, and
replication. As already reported in paragraphs 3.8 and 3.10, the inhibition of some components of
MMP family by EGCG could reduce tumor invasion and metastasis. For instance, MMP-2 and MMP-9
are both inhibited by EGCG in the prostate of transgenic adenocarcinoma of mouse prostate (TRAMP)
model, as mentioned before [89], as well in endothelial cells [218]. In addition, the anticancer properties
of EGCG may be dependent on the inhibition of the protease urokinase-plasminogen activator (uPA),
which is often overexpressed in human tumors and whose activity is involved in the regulation of
apoptosis, cell replication, migration, and adhesion [219]. EGCG was also studied in the amyloid
aggregation and neurotoxicity model. The catechin effects were examined in relation to misfolded or
misassembled proteins in human islet amyloid polypeptide (hIAPP) transgenic mice, an animal model
for investigating the formation of amyloid fibrils and, thus, pancreas dysfunction and diabetes [220].
EGCG was administered at 60 mg/kg in drinking water for three weeks and revealed potential benefit
in reducing amyloid fibril formation. Another work explored the effect of EGCG on the aggregation
process and toxicity of the expanded ataxin-3 (AT3), the polyglutamine (polyQ)-containing protein
responsible for spinocerebellar ataxia type 3 (SCA3) [221]. EGCG interfered with fibril aggregation
and blocked mature fibrils formation of both the cell and animal model. Indeed, in fibroblast-like
cells (COS-7), co-incubation of EGCG and AT3 diminished the toxicity of protein aggregates, as also
demonstrated in in vivo model (Caenorhabditis elegans simplified SCA3), whereas EGCG increased
motility of affected worms. In Alzheimer disease, amyloid β (Aβ) accumulates in the brain, leading
to neuronal cell death. EGCG reduced the inflammation and neurotoxicity in EOC 13.31 mouse cell
line, with a mechanism suppressing TNFα, IL-1β, IL-6, iNOS, NF-κB, JNK, p38, ERK, and restoring
Nrf2/HO-1 antioxidant signaling in neuroinflammatory responses of Aβ -stimulated microglia [222].
Moreover, the effect of EGCG on cAMP activated protein kinase (PKA) is currently under investigation:
pioneeristic studies were considering a possible role of EGCG in the regulation of glucose homeostasis
via PKA inhibition downregulation of FoxO1. The proposed model needs further confirmation, but
opens a new door for EGCG [223].
4. Conclusions
EGCG is responsible for a wide variety of biological activities, including cancer prevention.
The preclinical activities of EGCG are associated with proliferation, differentiation, apoptosis,
inflammation, angiogenesis, and metastasis. More efforts are needed to translate the plethora
of preclinical data in effective human therapeutic options.
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Abbreviations
EGCG: (−)-epigallocatechin-3-gallate
ELK: Eph-related tyrosine kinase
ERK: extracellular signal–regulated kinase
JNK: c-Jun N-terminal kinase
MAPK: mitogen-activated protein kinase
MEK: mitogen-activated protein kinase kinase
PIK3: phosphoinositide 3-kinases
PTEN: phosphatase and tensin homolog
SAPK: stress-activated protein kinase
VEGF: vascular endothelial growth factor
VEGFR: vascular endothelial growth factor receptor
Wnt: Wingless-related integration site
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Abstract: Depression is a health problem that compromises the quality of life of the world′s population.
It has different levels of severity and a symptomatic profile that affects social life and performance
in work activities, as well as a high number of deaths in certain age groups. In the search for new
therapeutic options for the treatment of this behavioral disorder, the present review describes studies
on antidepressant activity of cinnamic acids, which are natural products found in medicinal plants and
foods. The description of the animal models used and the mechanisms of action of these compounds
are discussed.
Keywords: natural products; phenylpropanoids; phenolic acids; plants; depression; behavioral
disorders; forced swim test; tail suspension test
1. Introduction
Depression is a widespread chronic psychiatric disease, characterized by low mood, lack of energy,
sadness, insomnia, and high morbidity, that affects more than 300 million people worldwide [1,2].
This illness can affect anyone, regardless of age, sex, social status, education, nationality or ethnic
origin [3,4]. It is the leading cause of disability and is directly associated with a remarkable number of
suicides cases around the world [5,6].
Despite the physiopathological mechanism of depression remaining not widely elucidated and
unclear, numerous studies have shown a multifactorial origin, involving genetics, environmental,
psychological, and social factors, as well as dysfunction in multiple brain areas such as the hippocampus,
prefrontal cortex, nucleus accumbens, and amygdale [7–10]. Recent findings of the presence of
inflammatory process and oxidative stress in the pathophysiology of depression provide new pathways
and treatment targets for improvement of pharmacological approach in depression [11]. Recently,
Réus et al. (2019) have reported a microglial activation with formation of intracellular multiprotein
complexes, the inflammasomes, which in turn activate interleukin-1β (IL-1β) that leads to a significant
increase in the production and expression of tumor necrosis factor-α (TNF-α), IL-1β, reactive species
of oxygen (ROS), and nitric oxide (NO) [12]. This finding is in accordance with a previous study
performed by Oglodek (2017), in which it was identified that major depressive disorders, associated
or not to posttraumatic stress disorder, present changes in the cytokines and increased oxidative
stress [13].
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Although efforts to increase knowledge and skills for healthcare providers have been made,
depression remains both underdiagnosed and undertreated [14]. Actually, the therapeutics tools
used in the treatment of depression have not produced satisfactory outcomes as necessary novel
strategies to improve treatment outcomes [15,16]. Figure 1 summarizes the main mechanisms of action
of antidepressant drugs.
Figure 1. Mechanisms of action of antidepressant drugs.
Natural products have been important sources of new drugs against various pathologies. Reports
of antidepressant activity on these compounds indicate that they may be an alternative treatment option
for depression [17]. Cinnamic acids are a group of aromatic carboxylic acids with carbonic skeleton
C6–C3 (Figure 2) found in a variety of plants and foods, for which the biosynthetic route can generate
several secondary metabolites such as coumarins, lignans, isoflavonoids, flavonoids, and others natural
products [18].Cinnamic acids and their derivatives have attracted the attention of researchers due to
their wide distribution in nature, low toxicity, structural diversity, and pharmacological actions [19],
as anti-inflammatory [20], antioxidant [21], antitumor [22], hypoglycemic [23], antidepressant [24],
and cytoprotective actions of neuroinflammation in neurodegenerative diseases [25]. Considering
the importance of cinnamic acids as bioactive substances and their presence in various foods and
medicinal plants, this review discusses the antidepressant action mechanisms of these compounds,
demonstrating their therapeutic potential for depressive disorders.
Figure 2. Chemical structure of cinnamic acid.
2. Materials and Methods
The present study was carried out based on the literature review of cinnamic acids with
antidepressant activity. The survey, conducted in the Pubmed database, for studies published
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from January 2002 to October 2019, used the following keywords: Cinnamic acid, coumaric acid,
para-coumaric acid, meta-coumaric acid, ortho-coumaric acid, ferulic acid, caffeic acid, sinapic acid,
trimethoxycinnamic acid, methylenedioxycinnamic acid, methoxycinnamic acid, dimethoxycinnamic
acid, antidepressant, and depression. The scientific publications were selected from studies published
in English language.
3. Antidepressant Activity of Cinnamic Acids
Based on increasing evidence of the contributions of neuronal pro-inflammatory mediators and
oxidative stress in the pathogenesis and development of depression, new therapeutic tools have been
experimentally tested in order to improve the current treatment of depressive disorders. In this context,
hydroxylated and/or methoxylated aromatic acids have shown promising results as neuroprotective
agents [25]. Among these acids, there are phenolic acids, which are divided into hydroxybenzoic
acids and hydroxycinnamic acids, based on C6–C1 and C6–C3 skeletons, respectively [26]. According
to the literature, phenolic acids have potentially antioxidant properties due to the presence of a
phenolic ring that promotes the electron donation and hydrogen atom transfer to free radicals, acting as
free-radical scavengers, reducing agents, and quenchers of single oxygen formation [27,28]. It has been
reported that phenolic compounds produce a significant reduction of pro-inflammatory cytokines,
including TNF-α and IL-1β, and stimulate a concomitant increase of anti-inflammatory cytokines
as interleukin-8 (IL-8) in different in vitro and in vivo models of inflammation [29–32]. Here, the
antidepressant effect of cinnamic acids was investigated, specifically the trimethoxycinnamic acids,
p-coumaric acid, caffeic acid, and ferulic acid on animal models and their relevance to the treatment of
depression. The last three compounds are classified as phenolic acids.
Fifteen studies were found on cinnamic acids in experimental models of depression; the chemical
structures of these acids are shown in Figure 3. Basically, the experimental model used in almost all
studies for assessing antidepressant-like activity of cinnamic acids were the forced swim test (FST) and
the tail suspension test (TST). Both tests are validated animal models fundamental for understanding
the pathogenesis and treatment of mood and anxiety disorders, such as depression. The FST is based
on the immersion of rodents in a beaker of water without a possible escape—a compound qualifies
as a potential antidepressant if it reverts or delays the initial attempts to escape (active behavior)
and promotes a progressive increase in the frequency and duration of episodes of immobile floating
(passive behavior). The TST is based on the fact that animals subjected to the short-term, inescapable
stress of being suspended by their tail, will develop an immobile posture [33,34]. Other important
tests used to evaluate the effect of cinnamic acids on anxiety behaviors were the elevated plus maze
(EPM) test, sucrose preference test, and open field test (OFT). In the EPM, the measure for anxiety is
calculated by percentage of the total number of arm entries and the period of time spent on the open
arms. Open-arm entries indicate security and low anxiety, while closed-arm entries, a sign of need for
security. Decreased sucrose preference indicates the loss of the ability to feel pleasure (anhedonia),
a common symptom of depression [34,35]. The OFT measures locomotor activity, including ambulation,
exploration, latency, escape attempts, exploration, and the aversions of rodents to novel, brightly lit,
open environments. In the OFT, reduced locomotor activity suggests anxiety-like behaviors associated
with depression [34].
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Figure 3. Chemical structures of antidepressant cinnamic acids.
In the literature, two studies have reported the effects of trimethoxycinnamic acid (TMCA) on depressive
behaviors, showing divergences in results. In Nakazawa et al. (2003), 2,4,5-trimethoxycinnamic acid failed
to alter the duration of immobility in FST for Male ddY mice intraperitoneally treated with TMCA, at a
dose ranging from 25–200 mg/kg. Differently, Leem and Oh (2015) have shown that Male C57BL/6J
mice, orally treated with 3,4,5-trimethoxycinnamicacid (50 mg/kg) for 15 days, showed reduced
immobility in the FST and higher time and frequency of visits in the open arms than the control group
in the EPM. The data suggest an antidepressant effect of 3,4,5-trimethoxycinnamic acid, which the
authors have attributed to increased expression of the ΔFosB protein on the nucleus accumbens
observed in TMCA-treated animals. There were differences in some methodological aspects between
the two investigative approaches. Thus, it is difficult to conclude about the presence or absence of
antidepressant effect of TMCA based on only two experimental studies that used different routes
of administration, species of mice, and experimental protocols. In addition, antidepressant activity
may be related to the position of the methoxyl group in the aromatic ring, since animals treated with
3,4,5-trimethoxycinnamic acid had antidepressant effects, which did not occur in those treated with
2,4,5-trimethoxycinnamic acid [36,37].
Some studies performed by Takeda and his group have shown that male ICR mice subjected to
intraperitoneal treatment with caffeic acid, at a dose of 4 mg/kg, exhibit decreased immobility time in
the FST, as well as a reduction in the duration of freezing of mice in the conditioned fear stress test.
According to authors, the caffeic acid’s ability to reduce depressive behavior might be attributed to,
at least in part, an indirect modulation of the α1A-adrenoceptor and α1-adrenoceptor system and
regulation of brain-derived neurotrophic factor (BDNF) expression in the frontal cortex caused by
caffeic acid [38–40]. These data corroborate a study by Dzitoyeva and colleagues in which caffeic acid
demonstrated antidepressant activity, attenuating BDNF mRNA decrease, by forced swimming test,
using wild type mice and a 5-lipoxygenase (5-LOX) deficient group—previous studies have shown
that caffeic acid inhibits 5-LOX. However, in this study it was observed that attenuation occurred
only in wild rats, indicating that this acid can be used as a tool to study the regulation of the 5-LOX
pathway of BDNF expression [41]. Therefore, antidepressant activity of caffeic acid may be related to
its ability to regulate inflammation, as observed in the study by Huang et al. (2018), in which this acid
inhibited dose-dependent increase in inflammatory and inducing cytokines affecting 5-HT, DA, and
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NE metabolism, such as tyrosine (Tyr), 3-methoxy-4-hydroxyphenylglycol (MHPG), Tryptophan (Trp),
and 5-hydroxyindoleacetic acid (5-HIAA), improving the behavior of depressed rats [42].
The antidepressant activity of ferulic acid is the most investigated among hydroxycinnamic
acids [32,43]. According to Zeni and colleagues, ferulic acid exhibits major effects on free radical
and inflammatory messengers and has the ability to counteract the reduction in reward-seeking
behavior that tends to occur with depression. Animals also exhibit decreased immobility time in
the FST and TST, using ferulic acid oral treatment ranging from 0.001–80 mg/kg/day. Moreover,
several studies show that ferulic acid has no effect on locomotor activity in the OFT, indicating its
specificity, while others show a reversal of decreased locomotor activity, suggesting ferulic acid’s
ability to reduce anxiety-like behaviors associated with depression. The antidepressant effect of ferulic
acid has been attributed to diverse mechanisms, including modulation of serotonergic system by
signaling pathway of protein kinase A (PKA), Ca2+/calmodulin-dependent protein kinase II (CaMKII),
protein kinase C (PKC), mitogen-activated protein kinases/extracellular signal-regulated kinases
(MAPK/ERK), and phosphoinositide 3-kinases (PI3K) [44,45].
Ferulic acid acts as some of the antidepressant drugs from the pharmaceutical market, as shown
by the study by Chen et al. (2015), in which there is an increase on the concentrations of monoamines
serotonin and norepinephrine in the hippocampus and frontal cortex through the inhibition of
monoamine oxidase A (MAO-A) activity in male ICR mice treated with ferulic acid [46]. However, unlike
commercially available selective serotonin reuptake inhibitor (SSRI) drugs, which may cause bowel
movement inhibition, ferulic acid exhibited both antidepressant and prokinetic activity. The Zhang et al.
study performed the TST on rats, noting a reduction in immobility time, and increased locomotor
activity, associated with an increase in gastric emptying speed [47].
In addition, it was noted that oral administration of ferulic acid at a dose of 5 mg/kg in male ICR
mice for 7 days decreased TST immobility due to up-regulation of gene expression associated with cell
survival and proliferation, energy metabolism, and synthesis of dopamine in the limbic system of the
brain of mice [48].
Lenziet al. (2015) have related ferulic acid’s antioxidant activity and its effects on the central
nervous system, evidenced by increasing superoxide dismutase (SOD), catalase (CAT) activities,
and low thiobarbituric acid reactive substances (TBARS) levels found in hippocampus of ferulic
acid-treated male swiss mice [49]. Furthermore, Li et al. attributed the ferulic acid’s ability to reduce
depressive-like behaviors, suggested by reducing immobility time in the FST and TST, observed in
ferulic acid-treated male ICR mice to anti-inflammatory mechanisms [50]. In addition, a study of
Liu et al. (2017) reported that ferulic acid increased the levels of BDNF and synaptic proteins (synapsin
I and PSD-95) in the prefrontal cortex and hippocampus, as well as inhibited microglia activation,
pro-inflammatory cytokines expression, nuclear factor kappa B (NF-κB) signaling, and decreased PYD
domains-containing protein 3 NLRP3 [51].
A similar study by Zheng and colleagues demonstrated the relationship between the antidepressant
effect and the anti-inflammatory activity of ferulic acid in prenatally-stressed offspring rats. In this
work, it was noted that the administration of ferulic acid decreased the time of immobility and total
number of crossing, rearing, grooming, and increased sucrose intake in the animals. Furthermore,
it was able to reduce the concentration of inflammatory cytokines such as IL-6, IL-1, and TNF-α,
and increase IL-10. As such, it was concluded that the antidepressant activity of ferulic acid occurs in
part due to its anti-inflammatory activity and regulation on hypothalamic-pituitary-adrenal (HPA)
axis [52].
In the study of Lee et al., it was observed that the antidepressant effects of p-coumaric acid may be
related to its anti-inflammatory activity, as has also been shown in studies with caffeic acid. In this
study, p-coumaric acid reduced lipopolysaccharide-induced tumor necrosis factor-α (LPS)-induced
despair-related behavioral symptoms in the FST, TST, and sucrose splash test (SST), preventing the
increase of inflammatory cytokines such as cyclooxygenase-2 and lipopolysaccharide-induced tumor
necrosis factor-α (LPS), as well as inhibiting BDNF reduction [53].
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Medicinal plants used to treat behavioral disorders that contain these psychoactive acids may
have antidepressant action such as Eugenia catharinensis D. Legrand. Ethyl acetate extract of this
species had antioxidant and antidepressant-like action in mice treated with corticosterone. Analysis
of the extract using HPLC-ESI-MS/MS demonstrated the presence of several phenolic compounds,
mainly phenolic acids, such as p-coumaric acid, ferulic acid, and caffeic acid. The authors suggest
that chemical constituents are the active principles of antidepressant action [54]. Antidepressant
action also was demonstrated for butanol fraction of Olax subscorpioidea Oliv. and was involved in
the monoaminergic mechanism. Analysis of the chemical composition by HPLC indicated caffeic
acid as one of the active ingredients of the plant [55]. In another study, ethyl acetate fraction from
Tabernaemontana catharinensis A. DC. leaves showed antidepressant activity in animal models. Analysis
of the chemical composition of this fraction proposes that the pharmacological action may be dependent
on the presence of p-coumaric acid in the plant [56]. Therefore, the collection of studies discussed in
this review (Table 1) show the pharmacological effect of cinnamic acids against the name Table 1 was
added in text.
Depressive disorders. Figure 4 summarizes the main effects of cinnamic acids as antidepressants.
 
Figure 4. Antidepressant action of cinnamic acids.
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4. Conclusions
Despite the few studies with cinnamic acids in animal depression models, the results indicate their
potential applicability as candidates for antidepressant drugs. The studies discussed show that the
antidepressant action of these natural products occurs via important neurotransmitters such as serotonin,
as well as via the participation of inflammation-related metabolites such as AA-COX-2/5-LOX and
BDNF. In some reports, there is a similarity in the mechanism of action with commercial antidepressant
drugs. This data confirms the therapeutic potential of these compounds against behavioral disorders,
such as depression. The availability of these compounds via commercial companies or laboratory
synthesis, and the low cost of some acids, such as ferulic acid, make them interesting prototypes to
advance the development of new antidepressant agents.
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BDNF Brain-derived neurotrophic factor
CaMKII Ca2+/calmodulin-dependent protein kinase II
CAT Catalase
COX-2 Cyclooxygenase-2
EPM Elevated plus maze test














OFT Open field test
PI3K Phosphoinositide 3-kinases
PKA Protein kinase A
PKC Protein kinase C
ROS Reactive species of oxygen
SERT Serotonin transporter
SNRI Serotonin norepinephrine reuptake inhibitors
SOD Superoxide dismutase
SSRI Selective serotonin reuptake inhibitor
SST Sucrose splash test
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TNF-α Tumor necrosis factor-α
TRP Tryptophan
TST Tail suspension test
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Abstract: Mahonia aquifolium and its secondary metabolites have been shown to have anticancer
potential. We performed MTT, scratch, and colony formation assays; analyzed cell cycle phase
distribution and doxorubicin uptake and retention with flow cytometry; and detected alterations
in the expression of genes involved in the formation of cell–cell interactions and migration using
quantitative real-time PCR following treatment of lung adenocarcinoma cells with doxorubicin,
M. aquifolium extracts, or their combination. MTT assay results suggested strong synergistic effects of
the combined treatments, and their application led to an increase in cell numbers in the subG1 phase of
the cell cycle. Both extracts were shown to prolong doxorubicin retention time in cancer cells, while the
application of doxorubicin/extract combination led to a decrease in MMP9 expression. Furthermore,
cells treated with doxorubicin/extract combinations were shown to have lower migratory and colony
formation potentials than untreated cells or cells treated with doxorubicin alone. The obtained results
suggest that nontoxic M. aquifolium extracts can enhance the activity of doxorubicin, thus potentially
allowing the application of lower doxorubicin doses in vivo, which may decrease its toxic effects in
normal tissues.
Keywords: doxorubicin; Mahonia aquifolium; matrix metalloproteinases; cytotoxicity; human
lung adenocarcinoma
1. Introduction
Doxorubicin (DOX) is a first-line anticancer agent that is highly effective against a wide spectrum
of malignancies, including breast, lung, gastric, ovarian, and thyroid ones, as well as lymphoma,
myeloma, sarcoma, and some forms of pediatric neoplasms. Despite good clinical effectiveness,
DOX induces cumulative, dose-dependent toxicity and adverse effects, such as cardiotoxicity, and
affects the brain, kidney, and liver [1]. Currently, both cancer treatments and in vivo studies are
usually based on combined therapies that include various antineoplastic agents, possibly resulting in
drug–drug interactions and even an increase in toxicity [2]. Studies investigating the management
of DOX-induced toxicity have focused on the administration of antioxidant and/or antiapoptotic
compounds in combination with DOX, the development of effective delivery systems, and the synthesis
of DOX analogs [1]. One potential approach to the minimization of adverse effects is reducing
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the therapeutic dose of DOX by combining its application with that of other anticancer and/or
organ-protective agents [3]. However, although some of these strategies fail to decrease DOX toxicity,
recent investigations have demonstrated that certain phytocompounds in combination with DOX can
ultimately be more successful [4,5].
The genus Mahonia includes approximately 60 species, which are widely distributed throughout
Asia, North America, and Europe. Species belonging to the genus Mahonia, including the Mahonia
aquifolium plant, have been shown to have antibacterial, antifungal, anti-inflammatory, and antioxidant
effects and have been used in traditional Chinese and North American medicine [6]. Some research
has shown that several representatives of this genus, such as Mahonia oiwakensis and Mahonia bealei,
which are native to China, demonstrate antiproliferative activity against human cancer cells as well [7,8].
Berberine and similar alkaloids represent a major class of secondary metabolites of the Mahonia genus
with a wide spectrum of different properties. These alkaloids have been reported to significantly
inhibit growth of cancer cells and exhibit other anticancer effects [9–12]. Although M. aquifolium has
been used in traditional medicine solely for treatment of inflammatory skin disorders [13], its chemical
composition, as well as previously obtained results demonstrating the activity of different plants
belonging to this genus, suggest that this plant possesses anticancer properties as well, as we have
previously confirmed and reported [14].
Previous studies have demonstrated that the phytocompound berberine in combination with DOX
can effectively limit the toxicity and adverse effects of DOX [4] and that M. aquifolium, whose main
constituents are berberine and protoberberine alkaloids, has anticancer properties [14,15]. Therefore,
we investigated the anticancer efficacy of the combination of DOX and water or ethanol extracts of
M. aquifolium (MAW and MAE, respectively) in vitro.
The objective of our study was to elucidate the effects of DOX and MAW or MAE combinations
on proliferation, migratory potential, and invasiveness of malignant cells. Furthermore, we examined
the influence of these extracts on cellular uptake and retention of DOX. In order to understand the
mechanisms underlying the effects of these extracts on migration and invasiveness, we analyzed gene
expression changes of matrix metalloproteinases 2 and 9 (MMP2 and MMP9), occludin (OCLN), catenin
beta-1 (CTNNB1), and excision repair cross-complementation group 1 (ERCC1) in the treated human
malignant cells.
2. Results
2.1. Cytotoxic Activity In Vitro
2.1.1. Cytotoxic Activity of Extracts and DOX
MAW and MAE showed moderate cytotoxic activities against A549 cells. After 72 h of
treatment with extracts, MAW IC50 value was shown to be 56.36 ± 0.30 μg/mL, while MAE IC50 was
51.97 ± 3.27 μg/mL. The IC50 of DOX was 0.44 ± 0.02 μg/mL.
2.1.2. Cytotoxic Activity of DOX in Combination with Extracts
The combined extracts and DOX effects were evaluated using an isobolographic analysis method.
After incubating cells with subtoxic concentrations of extracts in combination with DOX, there was an
increase in cytotoxicity compared to the controls (Table 1). The CI values ranged from 0.14 to 0.38 for
DOX/MAW and from 0.12 to 0.4 for DOX/MAE treatment, suggesting strong synergism (Table 2).
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Table 1. Concentrations of doxorubicin alone or in combination with extracts that induced 50% decrease
in cell survival after 72 h of treatment.
IC50 (μg/mL)
A549
DOX 0.4457 ± 0.0154
DOX + 5 μg/mL MAW 0.0234 ± 0.0022
DOX + 10 μg/mL MAW 0.0141 ± 0.0046
DOX + 20 μg/mL MAW 0.0067 ± 0.0018
DOX + 5 μg/mL MAE 0.0113 ± 0.0006
DOX + 10 μg/mL MAE 0.0103 ± 0.0016
DOX + 20 μg/mL MAE 0.0036 ± 0.0012
IC50 values are presented as the mean ± standard deviation (SD) from three independent experiments; DOX:
doxorubicin; MAW: water extract of M. aquifolium; MAE: ethanol extract of M. aquifolium.
Table 2. Isobolographic analysis.
CI
Treatment A549
DOX + 5 μg/mL MAW 0.14
DOX + 10 μg/mL MAW 0.21
DOX + 20 μg/mL MAW 0.38
DOX + 5 μg/mL MAE 0.12
DOX + 10 μg/mL MAE 0.22
DOX + 20 μg/mL MAE 0.40
CI: combination index.
2.2. Cell Cycle Analysis
A549 cells treated with subtoxic concentrations of both MAE and MAW extracts for 24 h showed a
slight increase in the percentage of cells in the G2/M phase of the cell cycle, but the changes induced by
this treatment did not significantly differ from those in the controls. However, treatment of cells with
IC20 and IC50 DOX led to a significant increase in the percentage of cells in the G2/M phase (Figure 1A),
while cells treated with combination of DOX (IC20 or IC50) and MAW or MAE (20 μg/mL) were shown
to accumulate in the G1 phase compared to those treated with DOX alone (Figure 1B). Samples treated
with combinations of DOX (IC20 or IC50) and extracts showed an increase in the subG1 phase as well,
compared to samples treated with DOX alone, and this increase in the number of subG1 cells was
shown to be statistically significant for cells treated with combination of DOX and MAE (Figure 1B).
2.3. Cellular Uptake and DOX Retention
No significant changes in DOX uptake were observed following treatment with extracts (Table 3).
However, the effects of extract treatment on DOX retention were more pronounced. Cells treated with
extracts after DOX treatment retained considerably more DOX (up to 22% more) than cells treated with
DOX and medium only (Table 3).
Table 3. Effects of M. aquifolium water and ethanol extracts on the uptake and retention of doxorubicin
in A549 cells.
Treatment Uptake Retention
DOX IC50 100 100
DOX IC50 +MAW (40 μg/mL) 92.34 ± 6.64 112.97 ± 0.25
DOX IC50 +MAE (40 μg/mL) 96.58 ± 2.77 122.23 ± 1.60
The results are presented as the mean ± standard deviation (SD) from three independent experiments.
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Figure 1. Changes in the cell cycle phase distribution of A549 cells after 24 h of treatment induced
by (A) MAW (20 μg/mL), MAE (20 μg/mL), DOX IC20, or DOX IC50 compared to the control and (B)
combination DOX/extract treatment compared to DOX treatment alone.
2.4. Cell Migration
Both extracts demonstrated an improved ability to reduce cell migration compared to the control or
DOX (Figure 2). After 48 h, this decrease was shown to be statistically significant in both extract-treated
samples. Cells treated with DOX alone did not show any significant variation, while the migratory
ability of cells treated with DOX and MAE or MAW was shown to be considerably lower after 48 h
(Figure 2B).
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Figure 2. Effects of M. aquifolium extracts and DOX on migration of A549 cells. The cells were treated
with DOX IC20, MAW (20 μg/mL), MAE (20 μg/mL), or their combinations. (A) Representative images
of one of three independent experiments. (B) Quantitative analysis of results presented in (A).
2.5. Colony Formation
As shown in Figure 3, DOX considerably affected the ability of cells to form colonies even when
applied in subtoxic concentrations, unlike MAW and MAE extracts, which caused only a slight decrease
in the colony-forming ability. However, combinations of DOX and MAE/MAW extracts were shown to
lead to an even more pronounced decrease in the colony-forming ability of the treated cells compared
to DOX treatment alone.
Figure 3. Effects of M. aquifolium extracts and DOX on A549 colony forming ability. (A) Representative
images of colonies stained with Coomassie Brilliant Blue following treatment with DOX IC20, MAW
(20 μg/mL), MAE (20 μg/mL), or their combinations. Experiments were performed at least three times.
(B) Quantitative analysis of results presented in (A).
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2.6. Gene Expression Analyses
We investigated the gene expression involved in the formation of cell junctions, in cell migration,
and in DNA repair, as well as whether this gene expression is associated with the metastatic potential
of cells (MMP2, MMP9, OCLN, CTNNB1, and ERCC1). Gene expression levels in the treated A549
cells were compared with those measured in the untreated, control cells grown only in the nutrient
medium (Figure 4).
Figure 4. Effects of DOX IC20, MAE (20 μg/mL), MAW (20 μg/mL), or their combinations on
gene expression.
DOX treatment was shown to decrease MMP2 expression, while both the applied extracts and
DOX/extract combinations slightly increased the expression of this gene (Figure 4). In contrast to this,
MMP9 expression was considerably lower after treatment with combination of the cytostatic and the
investigated plant extracts (Figure 4), but it increased after treatment with DOX alone, in contrast to
the control. Furthermore, DOX treatment was shown to inhibit the expression of OCLN and induce
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CTNNB1 expression. Both the investigated extracts alone and the DOX/MAE combination treatment
induced expression of OCLN (Figure 4) as opposed to the control cells, while its expression in cells
treated with the DOX/MAW combination was higher than in cells treated with DOX alone. There were
no alterations in CTNNB1 expression after treatment with the DOX/MAW combination, while its
expression was shown to be slightly lower after treatment of cells with the DOX/MAE combination
than in the untreated cells (Figure 4).
Cells treated with MAE alone showed a slight increase in ERCC1 expression levels, while inhibition
of this gene expression was observed in samples treated with DOX, in those treated with MAW, as well
as in those treated with the DOX/plant extract combination (Figure 4).
3. Discussion
Despite decades of good results in the clinical application of DOX in cancer therapy, this drug
induces cumulative, dose-dependent adverse effects. Our previous studies have demonstrated that
ethanol and water extracts obtained from M. aquifolium show good anticancer potential and that
berberine and berberine-type alkaloids can be detected in both extracts [14]. Higher content of berberine
was detected in MAE extract (2.44%) compared to MAW extract (1.34%) (LC-MC analyses).
Furthermore, after identifying cytotoxic metabolites from M. aquifolium using 1H NMR-based
metabolomic approach, we concluded that alkaloids with the highest cytotoxicity in our extracts are
berberine, palmatine, and the bisbenzylisoquinoline alkaloid berbamine [15]. It has previously been
reported that berberine and similar alkaloids can inhibit the growth of cancer cells [9], effectively
limiting the toxicity of DOX [4].
Our initial screenings demonstrated that, of the tested cell lines, A549 cells were the least sensitive
to the cytotoxic activity of MAE and MAW [14]. Nonsmall cell lung cancer patients often show
resistance to therapy [16], and several mechanisms underlying the development of multidrug resistance
in lung cancer have been identified, such as overexpression of drug efflux proteins and ATP-binding
cassette (ABC) transporters [17]. Many studies have confirmed the presence of ABC transporters, breast
cancer-resistant protein (BCRP), and lung resistance-related protein (LRP) in A549 cells, which have
been shown to be related to anticancer drug resistance [18–20]; therefore, we selected the A549 cell
line for all further experiments. The results obtained here demonstrate that the IC50 concentration of
DOX can be multiply reduced (19 to 123 times) when DOX is combined with M. aquifolium extracts,
suggesting that the same antiproliferative effects can be achieved using much lower concentrations
of this drug. Furthermore, DOX and the plant extracts showed strong synergistic effects, clearly
demonstrating that the individual anticancer activities of both constituents were preserved. It has
been reported that cardiomyophaty, the most important adverse effect of DOX, primarily depends
on the applied dose [21]. Doses below 450 mg/m2 reduce the frequency of on-treatment events,
but the cumulative effects lead to the development of late-onset adverse events [22,23]. Based on
this, we hereby propose that coadministration of DOX with an additional agent with a synergistic
effect may decrease the toxicity of this treatment without affecting the anticancer activity of DOX.
Our previous studies have shown that M. aquifolium extracts are several times less cytotoxic to normal,
healthy cells than to cancer cells in vitro [14], indicating good selectivity and potential for their use in
anticancer therapy.
We conducted the experiments on A549 cells, which are the most invasive but also the least
sensitive to DOX, which is part of medical therapy in the treatment of lung cancer. Previous research
has shown that both berberine and berbamine can inhibit the growth of lung cancer cells in in vivo
systems [24,25], and based on these results, we can conclude that the active principles of our extracts
have potential to reach this target in the body.
A549 cell cycle analysis has demonstrated that DOX induces a strong G2/M transition block [26]
as well as a considerable increase in the percentage of cells in the subG1 phase in contrast to that in the
control sample, indicating that treated cells cannot pass through mitosis, which ultimately leads to
apoptosis [27,28]. We demonstrated that the percentage of cells in the subG1 phase was similar when
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cells were treated with IC50 DOX alone or with plant extracts and IC20 DOX combined, confirming
that the extracts allowed maintenance of the anticancer activity of DOX even when applying lower
drug doses. Furthermore, we observed an increase in the number of cells in the G1 phase following
treatment of cells with DOX/plant extract combinations in contrast to the number of cells in the G1
phase treated with DOX alone. As one of the goals of drug discovery efforts today is identifying the
agents that target cell cycle checkpoints responsible for the control of progression through the cell
cycle [29], we believe that the results obtained may be very important. Cell percentage increase in the
G1 and subG1 phases observed in samples treated with DOX/plant extract combinations may suggest
that this G1 block is irreversible and that treatment induces apoptosis, which leads to an increase in
the number of cells in the subG1 phase. This significantly higher percentage in samples treated with
the DOX/MAE combination than in the control sample, as well as the existing DOX-induced G2/M
arrest observed after the treatment of cells with both MAE/MAW and DOX combinations, additionally
confirms their synergistic effects.
Although extracts did not affect DOX uptake, we have demonstrated that they induce the retention
of DOX up to 20% more than in untreated samples. Increasing drug dose to overcome drug resistance
in cancer therapy is not feasible due to numerous potential side effects [30], and alternative approaches
include improving accumulation, prolonging retention of drugs in cancer cells [31], and reducing
drug exposure time [32]. The inhibition of drug efflux transporters p-glycoprotein (Pgp) and BCRP
restores the intracellular levels of drug in DOX-resistant osteosarcoma cells and leads to the retention
of DOX [33]. Our research suggests that the investigated extracts inhibit one or more of these proteins
and induce the retention of DOX. Furthermore, this may be a mechanism underlying the activation
of apoptosis and increase in the subG1 phase cell numbers after the DOX/extract treatment [33].
Our further studies should clarify the mechanisms of DOX retention.
The inhibitors of matrix metalloproteinases are considered potential novel agents able to inhibit
tumor growth and metastases, but they were shown to be unsuccessful in several clinical trials,
which may result from the dual role of matrix metalloproteinases during cancer cell invasion and
metastases [34]. These enzymes can degrade extracellular matrix as well as promote cancer cell
invasion, migration, and neovascularization [35], but, on the other hand, they are able to reduce cancer
growth and vascularization by inducing the generation of angiogenesis inhibitors (angiostatin and
tumstatin) [35–38]. Scientists [39] concluded that MMP-2 and MMP-9 drive metastatic pathways,
migration, viability, and secretion of angiogenic factors in two cell lines representing the metastatic
and nonmetastatic forms of retinoblastoma cells. The observed inhibition of MMP9 expression in
cells treated with the extracts was maintained even after combining these extracts with DOX. Chen et
al. [34] showed that the increase in plasma levels of MMP9 promotes tumorigenicity in vivo, and these
tumors are smaller and less vascularized compared with those grown in mice with lower MMP9 levels,
which is explained by MMP9-induced angiostatin synthesis. MMP9 inhibitors lead to a decrease in the
number of tumor colonies, but tumors in vivo are larger and more vascularized, which may provide a
rationale for the coadministration of MMP inhibitors and antiangiogenic agents [34]. Our previous
study [14] showed good antiangiogenic potential of M. aquifolium extracts, especially MAE, and this
effect may indicate that these agents are suitable for overcoming the aforementioned issue of tumor
vascularization and growth at lower MMP9 levels, while lower MMP9 expression in cells treated with
extracts may reduce the metastatic potential of cancer cells. However, further experiments with a
broader range of extract doses must be carried out to establish the proapoptotic activity of M. aquifolium.
Berberine, the main plant alkaloid of the genus Mahonia and the constituent of both M. aquifolium
extracts involved [14], exhibits antimetastatic potential as well by blocking Wnt/β-catenin signaling
pathway [40–42]. Furthermore, berberine can activate ZO-1 (Zonula Occludance-1), which participates
in the formation of cell-tight junctions and indirectly reduces cell mobility [43]. We have investigated
the influence of DOX, extracts, and their combinations on the expression of genes that participate in
cell adherence and tight junction formation. CTNNB1 encodes β-catenin, while OCLN encodes the
occludin protein, one of the main components of tight junctions. Taken together, the results obtained
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here suggest that a decrease in MMP9 and an increase in OCLN expression levels following treatment
with a combination of DOX and the investigated extracts may lead to inhibition of cell migration and
reduction of the metastatic potential of the treated cells. We have also examined the effects of plant
extracts on cell migration, showing that both extracts, alone or in combination with DOX, inhibit cell
migration, unlike DOX alone. Colony formation analysis results support our observations that the
investigated plant extracts work together with DOX, enhancing its anticancer effects.
4. Materials and Methods
4.1. Plant Extracts/LC-MC Analyses
The stem bark of cultivated Mahonia aquifolium (Pursh) Nutt. was collected in the National Garden
park in Pančevo, Serbia, in October 2014. The voucher specimen is deposited at the herbarium of the
Institute for Medicinal Plants Research “Dr Josif Pančić “, Belgrade (No. 046/14).
Both dry extracts were obtained from air-dried and finely powdered stem bark of cultivated
M. aquifolium. MAE was extracted with 70% EtOH at room temperature for 24 h (1:5, w/v), while MAW
was prepared by ultrasound-assisted extraction with water (1:10, w/v) for 30 min. Dry extracts were
analyzed by the LC/MS method on Agilent 1200 Series, Agilent Technologies, with a DAD detector
on the column Zorbax Eclipse XDB-C18 (RRHT, 50 × 4.6 mm i.d.; 1.8 μm) in combination with 6210
time-of-flight LC/MS system (Agilent Technologies) [14].
4.2. Reagents
High-capacity cDNA reverse transcription kit was obtained from Thermo Fisher Scientific
(Waltham, MA, USA). All other reagents were purchased from Sigma-Aldrich (St. Louis, MO, USA),
unless otherwise specified.
4.3. Cell Lines
Human lung adenocarcinoma (A549) cells (ATCC, Manassas, VA, USA) were maintained in
RPMI-1640 medium at 37 ◦C in humidified atmosphere with 5% CO2 [44].
4.4. MTT Assay
Stock solutions of MAW, MAE, and DOX were dissolved in dimethyl sulfoxide (DMSO) at the
concentration of 50 mg/mL (extracts) or 1 mM (DOX). Cells were seeded into 96-well microtiter plates
at a density of 5000 cells/well. After 24 h, they were treated with five different extract concentrations
(12.5, 25, 50, 100, and 200 μg/mL) or DOX (0.31, 0.62, 1.25, 2.5, and 5 μM). To determine the combined
effect of DOX and extracts, cells were treated with various concentrations of DOX in the presence of
subtoxic concentrations of MAW or MAE (5, 10, or 20 μg/mL). The control cells were grown in culture
medium only. After an additional 72 h of incubation, cell survival was determined by MTT test, as
described elsewhere [44–46]. The absorbance was measured at 570 nm using Multiskan EX reader
(Thermo Labsystems Beverly, MA, USA). The experiments were performed in triplicate, and the data are
presented as mean ± standard deviation (SD) of the results obtained in three independent experiments.
Combination index (CI) was used to determine the degree of interaction between DOX and
M. aquifolium, and its formula is the sum of the ratio of the dose of each drug in the compound to the
dose when used alone when the combination and compound produce 50% efficacy [47].
The CI values represent the mean of three experiments with the following values: CI 1.3:
antagonism; CI 1.1–1.3: moderate antagonism; CI 0.9–1.1: additive effect; CI 0.8–0.9: slight synergism;
CI 0.6–0.8: moderate synergism; CI 0.4–0.6: synergism; and CI 0.2–0.4: strong synergism [48,49].
4.5. Cell Cycle Analysis
A549 cells were seeded into six-well plates (2 × 105 cells/well). After 24 h, the cells were treated
with concentrations corresponding to IC20 or IC50 values of DOX with 20 μg/mL of extracts or with
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combination of IC20 or IC50 DOX with 20 μg/mL of extracts. The cells were incubated, collected,
and fixed. Afterward, the cells were washed, treated with RNase A, stained with propidium iodide,
and analyzed using FACSCalibur flow cytometer (BD Biosciences Franklin Lakes, NJ, USA) and
CELLQuest software (BD Biosciences) [44]. The obtained results are presented as mean ± SD of the
results obtained in three independent experiments.
4.6. Cellular Uptake and Retention of Doxorubicin
A549 cells were seeded in six-well plates (2 × 105 cells/well). For DOX uptake experiments,
the cells were treated with IC50 DOX alone or in combination with 40 μg/mL of extracts. After 24 h,
the cells were washed with the medium and analyzed using FACSCalibur. For DOX retention, the
cells were treated with IC50 of DOX for 24 h, and afterward, the samples were washed and treated
with 40 μg/mL of extracts or with the nutrient medium only. After 24 h, the treated cells were washed
again and analyzed. Fluorescence intensity measured in cells treated with DOX alone was used
as a mark of 100% DOX retention/uptake. All data are presented as mean ± SD obtained in three
independent experiments.
4.7. Scratch Assay
A549 cells were seeded in 24-well plates (7 × 104 cells/well), where they formed confluent
monolayers after 24 h. The monolayers were scraped with a 200 μL pipette tip, and straight, cell-free
gaps in the middle of cell monolayers were created. The cells were subsequently washed with nutrient
medium and treated with IC20 concentration of DOX in the presence or absence of the subtoxic extract
concentration (20 μg/mL) or with 20 μg/mL extracts only. The control cells were maintained in nutrient
medium only. Images were obtained immediately after making the scratches and after 24 and 48 h
of incubation. Three independent experiments were performed. Three representative points were
selected in each image; the widths of the gap were measured and averaged. The average gap width at
0 h was considered 100%, and other average gap widths (%) were calculated relative to this value.
4.8. Colony Formation Assay
A549 cells (5× 104 cells/well) were seeded into six-well plates and incubated for 24 h. Subsequently,
they were treated with 0.11 μg/mL (IC20) of DOX alone, subtoxic concentrations of MAE or MAW
(20 μg/mL), or their combination. After an additional 24 h of treatment, the medium was removed
from the wells, cells were harvested by trypsinization and replated at different densities, and they were
left to grow for 1 week. Afterward, the colonies were stained, and the total number of colonies per
well was counted. The experiments were performed in triplicate and repeated three times. For each
treatment, the obtained number of colonies/well was divided by the cell-seeding density, and these
results were averaged.
4.9. Gene Expression Analyses
A549 cells were seeded in 75 cm2 cell culture flasks (3 × 106 cells/flasks) and grown for 24 h.
Afterward, the cells were treated with subtoxic IC20 concentrations of DOX, 20 μg/mL extracts, or
combination of IC20 DOX and 20 μg/mL extracts for 24 h. The control cells were grown in the culture
medium. Following incubation, cells were collected by trypsinization, washed using PBS, and the
collected cell pellet was stored at −80 ◦C until further experiments.
Total RNA was extracted from cells using TRI Reagent BD kit in line with the manufacturer’s
recommendations. RNA bands were visualized on a UV transilluminator, and RNA concentration
was determined spectrophotometrically (BioSpec Nano, Shimadzu, Kyoto, Japan). Primary cDNA
was prepared with RT-PCR using random primers, and 2 μg of total RNA was used as a template for
MultiScribe reverse transcriptase in a high-capacity cDNA reverse transcription kit in line with the
manufacturer’s instructions.
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4.10. Real-Time PCR Amplification
All target transcripts were detected using quantitative real-time PCR (qPCR) and TaqMan
assays. TaqMan gene expression assays (OCLN: Hs00170162_m1, CTNNB1: Hs00355049_m1, MMP2:
Hs01548727_m1, MMP9: Hs00234579_m1, and ERCC1: Hs01012158_m1) contained 20× mix of
unlabeled PCR primers and TaqMan (Minor groove blinder (MGB)) probes (FAM dye-labeled).
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) levels obtained using TaqMan control reagents
(Hs02758991_g1) were used as an endogenous control. PCR reactions were performed using an ABI
Prism 7500 sequence detection system (Applied Biosystems) under previously described conditions [50].
4.11. Statistical Analysis
One-way ANOVA with Tukey’s multiple comparison test was used for multiple data comparisons
and p value < 0.05 was considered statistically significant.
5. Conclusions
Taken together, our results show that M. aquifolium extracts and their active principles should be
investigated further, either on their own or in combination with other anticancer drugs similar to DOX.
It remains to be determined whether changes in MMP9 expression and DOX retention underlie these
effects and which alkaloids are responsible for the anticancer activities against A549 cells. In addition,
the synergistic effects of extracts with DOX in other systems remain to be confirmed.
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Abstract: Kirsten rat sarcoma viral oncogene homolog (KRAS)-driven colorectal cancer (CRC) is
notorious to target with drugs and has shown ineffective treatment response. The seeds of Pharbitis
nil, also known as morning glory, have been used as traditional medicine in East Asia. We focused
on whether Pharbitis nil seeds have a suppressive effect on mutated KRAS-driven CRC as well as
reserving muscle cell functions during CRC progression. Seeds of Pharbitis nil (Pharbitis semen) were
separated by chromatography and the active compound of Pharbitis semen (PN) was purified by
HPLC. The compound PN efficiently suppressed the proliferation of mutated KRAS-driven CRC cells
and their clonogenic potentials in a concentration-dependent manner. It also induced apoptosis of
SW480 human colon cancer cells and cell cycle arrest at the G2/M phase. The CRC related pathways,
including RAS/ERK and AKT/mTOR, were assessed and PN reduced the phosphorylation of AKT
and mTOR. Furthermore, PN preserved muscle cell proliferation and myotube formation in cancer
conditioned media. In summary, PN significantly suppressed mutated KRAS-driven cell growth and
reserved muscle cell function. Based on the current study, PN could be considered as a promising
starting point for the development of a nature-derived drug against KRAS-mutated CRC progression.
Keywords: Pharbitis nil; colorectal cancer; KRAS; muscle function
1. Introduction
Colorectal cancer (CRC) is the third most diagnosed cancer worldwide. Recent statistics showed
CRC caused 832,000 deaths and nearly 1.6 million new cases were diagnosed [1]. Among the various
CRCs, Kirsten rat sarcoma viral oncogene homolog (KRAS) genetic mutation driven-CRC are known
to be difficult to target, and prone to drug-induced side effects [2,3]. Mutated KRAS proteins cause
persistent activation of GTP, which endlessly send signals to the RAS/extracellular signal–regulated
kinases (RAS/ERK) or protein kinase B/mammalian target of rapamycin (AKT/mTOR) cell regulation
pathways [2]. ERK or mTOR proteins activate transcription factors involved in cell death, cell cycle
progression, and transcription [2,4]. To inhibit RAS activation, antibody therapy was developed to
target EGFR, such as Cetuximab, but various drug-resistance issues were documented [5–7]. Therefore,
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novel medicinal substances with effective anti-cancer properties are needed and plant-derived foods or
medicinal plants can offer potential means.
Several natural products have exhibited anti-CRC activity. For example, Danshen (Salvia miltiorrhiza)
improved the survival rate of patients with colorectal cancer [8]. Triterpenoids from Rhus chinensis
Mill [9], protopine from Nandina domestica [10], Paris saponin VII from Trillium tschonoskii [11] and
protein hydrolysates from Fenugreek (Trigonella foenum graecum) [12] suppressed the proliferation and
induced apoptosis of CRC cells. Additionally, rosemary (Rosmarinus officinalis) inhibited CRC growth
by inducing necrosis [13]. However, limited studies have examined the effects of natural extracts
targeting mutated KRAS-driven CRC and none of these studies tested the efficacy of these extracts on
muscle function. In our previous study, Cordyceps militaris germinated soybeans suppressed mutated
KRAS-driven CRC via the RAS/ERK pathway [14]. Phellinus linteus grown on germinated brown rice
increased the sensitivity of Cetuximab to inhibit KRAS-CRC progression both in vitro and in vivo [15].
Although the two natural compounds have anti-CRC activities, more medicinal substances are needed
to target the notorious and drug-resistant nature of mutated KRAS-driven CRC.
Morning glory (Pharbitis nil) is a well-known ornamental plant, and its seeds have been used in
traditional medicine to treat various cancers and inflammatory diseases in Korea, China, and Japan [16].
Recent studies have demonstrated its suppressive effects on breast cancer [17], lung cancer [18] and
gastric cancer cells [19]. In addition, the seed of Pharbitis nil is the main constitute of the approved
drug, DA-9701 (Motilitone) [20]. DA-9701 is a botanical drug for treating functional dyspepsia and
composed of the seed of Pharbitis nil and Corydalis tuber. Therefore, we anticipated its safety on human
and can be adapted for therapies in a relatively short timeframe if proven its efficiency. In view of
its anticancer effects, we considered the active compound of Pharbitis semen (PN) may inhibit the
proliferation and progression of mutated KRAS-driven CRC without inducing serious side effects.
In addition to the suppressive effect of PN on CRCs, we evaluated the effect of compound PN on
muscle cell function. During the course of CRC, cachexia, a complex syndrome showing severe muscle
weight loss, is often accompanied with CRC progression and worsened treatment therapies [21–23].
Therefore, treating cachexia becomes an important combinational therapy in the treatment of CRCs.
We mimicked cancer-associated environment with conditioned media and evaluated the effect of PN
on muscle cells.
In the present study, the anticancer activity of PN was investigated by examining its
anti-proliferation and clonogenic features in five different CRC cell models. Cell cycle and apoptotic
analyses were performed, and the changes in RAS/ERK and AKT/mTOR pathways were investigated.
Finally, we assessed the effect of the compound PN on muscle cell proliferation and function.
2. Results and Discussion
2.1. PN Suppressed Colorectal Cancer Cell Progress
To investigate the anti-proliferative effects of PN on mutated KRAS-driven CRC, KRAS mutated
SW480 and HCT116 cells as well as KRAS-wild type (WT) HT29 and WiDr were evaluated. Cells were
treated with PN at 0, 0.1, 0.5, 1, 2, or 4 μg/mL and incubated for 48 or 72 h in triplicate. Cetuximab
which has been used to treat mutated KRAS-driven CRCs was used as a control. Figure 1A summarized
the proliferation profiles. PN inhibited cell growth in a concentration dependent manner in mutated
KRAS-driven cell lines at 48 and 72 h. At 72 h, SW480 viability was decreased to 41.6 ± 1.0% when
treated with PN at 2 μg/mL and to 26.0 ± 4.5% when treated with 4 μg/mL PN. When compared to
control drug of Cetuximab, PN showed higher suppressive effect from 2 μg/mL concentration. Data also
indicated that KRAS mutated cell lines responded more sensitively on PN treatment compared to KRAS
wild type cells of HT-29 and WiDr. In KRAS wild type cells, PN treatment did not show statistical
decrease on proliferation at 48 h. The IC50 values of KRAS mutated cells at 72 h are 1.74 and 2.78 μg/mL
on SW480 and HCT116 cells, whereas they are 4.14 and 4.46 μg/mL on KRAS WT cells of HT29 and
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WiDr cells. IC50 values of KRAS mutated cells are relatively low compared to other natural extract
such as pogostone (HCT116: 18.7 ± 1.93 μg/mL) [24].
Figure 1. (A) PN suppressive effect on KRAS-mutated colorectal cancer cells of SW480 (KRASG12V)
and HCT116 (KRASG13D), and KRAS-wild types CRCs of HCT116 and WiDr. Cells were treated
for 48 and 72 h under PN treatment (0, 0.1, 0.5, 1, 2 and 4 μg/mL) and Cetuximab (30 μg/mL). IC50
values are calculated. Results are presented as means ± S.D. of three independent experiments.
* p < 0.05, ** p < 0.01, *** p < 0.001. (B) Representative colorectal cancer cell images under PN treatment
(0, 0.5, 1 and 4 μg/mL). Blue represents the DAPI-stained cell nuclei, and the propidium iodide-stained
dead cells are red. Scale bar = 500 μm. DAPI, 4′,6-diamidino-2-phenylindole; PI, propidium iodide.
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Cells were stained with DAPI and PI for live and dead cell detection. Cell nuclei were stained
with DAPI (blue) which represent all cells, and dead cells were stained with PI (red). Most cells in
control group were stained with DAPI and little PI staining after 48 h of cultivation indicating most
cells are alive (Figure 1B). In contrast, cells treated with PN began to appear dead PI stained cells from
0.5 μg/mL.
By assessing clonogenic potentials, we evaluated if PN inhibited tumorogeneity. As shown in
Figure 2, PN dose-dependently suppressed colony formation by the KRAS mutated cell lines SW480,
and HCT116. For example, PN treatment at 1 μg/mL suppressed SW480 cell colony formation to
26%. Surprisingly, almost no colony formation was observed by KRAS mutated CRCs treated with
4 μg/mL of PN. In contrast, HT29 and WiDr colonies are still visible even at the highest concentration.
These findings show that PN sensitively suppress proliferation rate and tumor forming abilities in
the long-term aspects of mutated KRAS-driven CRC cells. Further mechanistic and molecular studies
were performed with SW480 cells at PN concentrations ranging from 0.1 to 4 μg/mL.
 
Figure 2. (A) Clonogenic potential after the PN treatment (0, 1 and 4 μg/mL) on KRAS-mutated
colorectal cell lines of SW480 (KRASG12V) and HCT116 (KRASG13D) and KRAS-WT cells of HT29
and WiDr. (B) Relative colony numbers upon the PN treatment were calculated compared to the
control. Results are presented as means ± S.D. of three independent experiments. * p < 0.05, ** p < 0.01,
*** p < 0.001.
Seeds of Pharbitis nil contains several bioactive compounds such as polysaccharides [16], pharbitin
(resin glycosides) [25], anthocyanins, diterpenoids [26], triterpene saponins [27], pharbilignan C [17],
neolignane, and monoterpene glycosides [28]. Pharbilignan C has been reported to induce human
breast cancer cell apoptosis via the mitochondria-medicated intrinsic pathway [17], and lignans
exhibited anti-inflammatory and anti-cancer activities [29]. Thus, the observed suppressive effects of
PN on CRC cell-lines may have been due to the presence of these functional compounds.
2.2. PN Induced Apoptosis and Cell Cycle Arrest in the G2/M Phase
To investigate the mechanism of cell death in mutated KRAS-driven human colorectal cell lines
induced by PN, we analyzed apoptosis and cell cycles. For detecting apoptotic cells, Annexin V-FITC
and PI staining was used. Annexin V binds specifically to a phosphatidylserine residue that is
externalized by cells undergoing apoptosis. As seen in Figure 3, PN substantially increased the
percentage of apoptotic cells in a concentration-dependent manner. Early (Annexin V FITC+/PI−) and
late (Annexin V FITC+/PI+) apoptosis counts were increased up to 28.6 ± 1.4 % and 40.2 ± 2.7 % at 2 or
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4 μg/mL PN treatment for 48 h, respectively. These observations suggest PN inhibits CRC proliferation
by inducing apoptosis.
Figure 3. (A) Flow cytometric apoptosis images PN treatment using Annexin V-FITC/PI staining.
SW480 cells were stained with Annexin V-FITC/PI upon PN treatment (0, 0.1, 0.5, 1, 2, and 4 μg/mL).
(B) The percentage of apoptotic cells upon the PN treatment were compared. Asterisks (*) indicate
statistical differences compared to untreated control (n = 3). * p < 0.05, ** p < 0.01, *** p < 0.001; Student’s
t test. Statistical differences among the experimental groups were confirmed via one-way ANOVA test.
FITC, fluorescein isothiocyanate; PI, propidium iodide.
Cell cycle is progressed into four phases: gap1 (G1), DNA synthesis (S), gap2 (G2) and mitosis (M).
Arresting cancer cells at a certain stage are often viewed as therapeutic targets [30]. The cell cycle after
exposing SW480 cells at concentrations of 0.5–4 μg/mL of PN was investigated. As seen in Figure 4A,
cell cycle analysis showed PN concentration-dependently induced accumulation in the G2/M phase
and a concomitant reduction in the G0/G1 phase. For example, the proportions of cells in the G2/M
phase after treatment with 1 or 4 μg/mL of PN were 28.5 ± 0.3% and 41.2 ± 6.7%, respectively, which
demonstrated PN inhibited cell growth by arresting cells in the G2/M phase. Then, we investigated
expression levels of the cdc2 and cyclin B1, which are proteins for cell cycle progression from G2/M to
G0/G1. Indeed, western blot images revealed that PN concentration-dependently reduced the levels of
both proteins (Figure 4B).
PN was found to arrest cells in the G2/M phase to reduce the number of cells in the G0/G1 phase
(Figure 4), therefore less cells enter into mitosis. This is interesting in that most of the cell cycle arrests
caused by natural extracts reported to date have occurred in the G0/G1 or G2/M stages. [21,31,32].
For example, pogostone induced G0/G1 arrest in a KRAS mutated HCT116 cell-line [24].
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Figure 4. (A) Cell cycle analysis upon PN treatment (0, 0.5, 1, 2, and 4 μg/mL). Images represent the
SW480 cell response under PN treatment. Percentages in each cell cycle phase (G0/G1, S, G2/M) are
calculated and G2/M phase are increased as concentration dependent manner. Asterisks indicates
statistical differences compared to untreated control through Student’s t-test (* p < 0.05, ** p < 0.01,
*** p < 0.001). (B) Expression of G2/M phase related proteins of cdc2 and cyclin B1 upon PN treatment.
HSP90 was used as a loading control and the protein intensity was analyzed in triplicate. The ratios of
cdc2/HSP90 and cyclin B1/HSP90 were calculated and analyzed by Student t-test * p < 0.05, ** p < 0.01,
*** p < 0.001.
2.3. Inhibition of the AKT/mTOR Pathway Enhanced PN-Induced Cell Death
Mutated KRAS-driven CRC signals are through the ERK/MEK or AKT/mTOR pathways [3,4].
During mutated KRAS-driven CRC progression, mutant RAS constitutively activates ERK/MEK or
AKT/mTOR phosphorylation, and as a result promotes cancer cell proliferation. To determine whether
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SW480 growth inhibition by PN is regulated by RAS/ERK or AKT/mTOR pathways, cells are treated
with PN for 48 h and protein levels of KRAS, p-ERK, p-AKT, and p-mTOR were assessed by western
blot. As shown in Figure 5, PN significantly and concentration-dependently suppressed p-AKT
and p-mTOR phosphorylation. For example, the expression of p-AKT was reduced to 0.31 in PN
4 μg/mL treated cells as compared with 1.0 in the non-treated control. The level of KRAS and ERK
phosphorylation was similar in all groups as observed in Figure 5. These results demonstrated that
PN suppressed CRC progression predominantly via the AKT/mTOR pathway. The AKT/mTOR and
ERK/MEK pathways are known to be major regulatory signaling pathways that relate to CRC cell
proliferation, metabolism, and survival [2,4,33]. Our observations suggest that the antitumor effect of
PN is caused by reductions in the phosphorylations of AKT and mTOR.
 
Figure 5. (A) Representative western blot images of KRAS, HSP90, phospho-p42/44 MAPK
(phospho-ERK1/2), phospho-AKT, phospho-mTOR protein expression in SW480 cells treated with
the compound PN (0, 0.5, 1, 2 and 4 μg/mL). (B) The ratios of KRAS/HSP90, phospho-ERK1/2/HSP90,
and phospho-AKT/GAPDH, phospho-mTOR/GAPDH were calculated and compared to the control.
(N = 3; mean SEM, * p < 0.05, ** p < 0.01, *** p < 0.001; Student’s t test).
2.4. PN Restores Muscle Cell Function during Cancer Progression
During cancer progression, skeletal muscles are weakened which causes progressive functional
impairment, called cachexia [21–23]. Accordingly, it is important aspects that agents targeting cancers
do not adversely affect muscle cells. Thus, we examined the proliferation and function of muscle
cells of myoblast, treated with different concentrations of PN (0, 0.1, 0.5, 1, 2, or 4 μg/mL) for 48 or
72 h. In Figure 6A, PN did not inhibit cell proliferation up to 2 μg/mL concentrations. After 72 h of
treatment with 2 or 4 μg/mL of PN, cell viabilities remained at 97% and 61% of non-treated control
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levels. Next, we examined if PN affected muscle functions of myotube formation by inducing myogenic
differentiation. Phenotypes were detected by myosin heavy chain (MyHC) immunostaining and
fusion indices were calculated. Surprisingly, PN treatment did not inhibit myogenic differentiation as
determined by MyHC staining and fusion indices (Figure 6B,C). In fact, fusion indices even improved
at all PN treated groups. Our data suggest that PN has a beneficial effect on muscle cell function.
Figure 6. (A) C2C12 cells were treated with different PN concentrations (0, 0.1, 0.5, 1, 2 and 4 μg/mL) for
48 and 72 h. Results are presented as means ± S.D. of 3 independent experiments, * p < 0.05, ** p < 0.01,
*** p < 0.001. (B) Immunofluorescence microscopy for the expression of the myogenic markers Myosin
heavy Chain (MyHC) and DAPI. Myogenesis was induced in differentiation media and treated for 5 days
with different PN concentration (0, 0.5 and 1 μg/mL). (C) Fusion indexes were calculated as the % of the
nuclei inside myotubes compared to the total number of nuclei. (N= 3 independent experiments; mean
SEM, * p< 0.05, ** p< 0.01, *** p< 0.001; Student’s t test). Between experimental groups, statistical difference
was found via one-way ANOVA (### p < 0.001). (D) Representative images of myotube formation on
cancer conditioned media upon PN treatment (0, 0.1, 0.5 and 1 μg /mL). Myotube was detected with MyHC
(green) immunostaining and nuclear counterstained DAPI (blue). Scale bar = 200 μm. (E) Fusion index
were calculated as the % of the nuclei inside myotubes compared to the total number of nuclei. (Data were
from three independent experiments; mean SEM, * p < 0.05; Student’s t test).
Because PN did not impair and rather supported C2C12 myogenic differentiation into myotube
formation, we further investigated if PN could attenuate conditioned media (CM)-mediated muscle
function impairment. In Figure 6D,E, reduced myotube numbers and MyHC expression were observed
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on PN-untreated control, which indicated cancer environment significantly impaired muscle cell
function. However, PN-treatment rescued C2C12 muscle cell dysfunctions. In detail, increased
myotube formation and MyHC expression compared to the SW480 control CM were observed
(Figure 6D,E).
During cancer progression, cancer-associated cachexia is common [21], and one of the problems
posed by anti-cancer drugs is that they impair normal cell proliferation and function. Therefore,
the maintenance of muscle cell proliferation and myogenic differentiation are important aspects at the
cancer therapeutic development. Interestingly, we found PN did not impair muscle cell proliferation,
but actually restored muscle cell function.
3. Materials and Methods
3.1. Preparation of PN from the Seeds of Pharbitis nil
PN was prepared as previously reported [34]. In brief, dried seeds of Pharbitis nil (1 kg) were
ground. Then, ground Pharbitis nil was immersed in methanol (MeOH) at room temperature for 48 h
and extracted. The MeOH extract was filtered with 5 μm filter paper and concentrated using a rotary
evaporator (Tokyo Rikakikai, Tokyo, Japan). To purify compound PN, the MeOH extract (5 g) was
dissolved in 50% MeOH and chromatographed on a Diaion HP-20 column by the gradient MEOH (50%,
80%, 100%, each fraction 500 mL). The 100% MeOH fraction (800 mg) was further chromatographed on
reversed-phase C-18 and Sephadex LH-20 column using 100% MeOH as mobile phase, simultaneously.
The 250 mg of purified compound PN was confirmed by high performance liquid chromatography
(HPLC) in our previous study.
3.2. Cell Culture and Treatment
The human CRC cell-lines, SW480, HCT116, HT29 and WiDR were purchased from the American
Type Culture Collection (Rockville, MD, USA). G12V KRAS mutated SW480 (KRASG12V), G13D KRAS
mutated HCT116 (KRASG13D), KRAS wild types of HT29 and WiDR were cultured in RPMI-1640
supplemented with 10% fetal bovine serum (FBS; Invitrogen), and 1% penicillin-streptomycin (P/S; Sigma,
St. Louis, MO, USA). C2C12 cells were purchased from ATCC and cultured in DMEM (Dulbecco’s
modified Eagle’s medium) containing 10% FBS and 1% P/S in a 5% CO2 atmosphere at 37 ◦C.
3.3. Cell Proliferation by MTS Assay
An MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium)
assay (Promega, Fitchburg, WA, USA) was used to determine the anti-proliferative effect of PN on
CRC cell lines and its toxic effect on C2C12 muscle cells. For each cell line tested, 2 × 104 cells per
well were seeded onto 96-well plates and allowed to attach. Cells were treated with PN at 0.1, 0.5, 1,
2, or 4 μg/mL and incubated for 48 and 72 h. Cetuximab of 30 μg/mL was added as a control. MTS
solution (20 μL) was then added and cells were incubated at 37 ◦C for 1 h. Absorbance were measured
at 490 nm (Model 550, Bio-Rad, Hercules, CA, USA). The experiments were performed in triplicate.
IC50 values (concentrations that inhibited cell growth by 50%) were compared.
3.4. DAPI/PI Staining
Cells were treated with PN for 48 h, fixed with 4% paraformaldehyde (Sigma), washed with
PBS, and stained with DAPI (4′,6-diamidino-2-phenylindole, Sigma) to detect cell nuclei and with PI
(propidium iodide, Sigma) to detect dead cells in the dark. Stained cells were then observed under a
fluorescence microscope (EVOS®, Thermo Scientific, Waltham, MA, USA).
3.5. Clonogenic Assay
Human CRC cell lines were seeded at 1 × 103 cell/well onto six-well plates. After cells had
completely attached, they were treated with 1 or 4 μg/mL of PN, and 10 days later, fixed with
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4% paraformaldehyde for 10 min, dried, and stained with 0.05% crystal violet (Sigma) for 15 min.
The experiments were performed in triplicate.
3.6. Cell Apoptosis Analysis
Human CRC cells were treated with PN at 0.1, 0.5, 1, 2, or 4 μg/mL for 48 h, harvested, stained
with Annexin V-FITC and PI for 15 min in the dark, according to the manufacturer’s instructions
(BD Biosciences, San Jose, CA, USA). Apoptotic cells were analyzed by flow cytometry (FC 500,
Beckman Coulter, Indianapolis, IN, USA). The experiments were performed in triplicate.
3.7. Cell Cycle Analysis
Cell cycles were analyzed by flow cytometry in triplicate. Cells were seeded, treated with PN at
0.5, 1, 2, or 4 μg/mL for 24 h, detached, fixed in ice-cold 70% ethanol, and stained with PI solution
containing RNase for 10 min in the dark. Cell cycle distributions were analyzed by flow cytometry
(FC 500).
3.8. Western Blotting
Western blot analysis was performed in triplicate as previously described [14]. Cells were treated
with compound PN (0.5–4μg/mL) for 48 h and detached with trypsin-EDTA. Proteins were isolated with
RIPA buffer containing protease inhibitors (Sigma) and quantified using a bicinchoninic acid (BCA) assay
(Thermo Scientific). Proteins were separated in precast SDS-PAGE gels (10%, Invitrogen) and transferred
to membranes using the iBlot system (Thermo Scientific). Membranes were blocked with 5% skimmed
milk in Tris buffered saline (TBS) and incubated with the following primary antibodies overnight at 4
◦C; cdc2, cyclin B1, HSP90, phospho-mTOR, GAPDH, KRAS, phospho-ERK1/2, and phospho-AKT.
Membranes were then washed and incubated with HRP-conjugated goat anti-rabbit or anti-mouse
antibodies (Pierce, Rockford, IL, USA). Densitometric analysis was performed using ImageJ software
(NIH, Bethesda, MD, USA) and ratios of proteins versus the loading control were calculated.
3.9. Myogenic Differentiation
C2C12 myoblasts were seeded onto six-well plates (4 × 104 cells/well) in triplicate and cultured for
2 days in DMEM. Myogenesis was induced by culturing cells in differentiation medium (DMEM, 2%
Horse serum, 1% P/S) containing PN at 0.5, 1 μg/mL for 5 days [35]. Differentiated muscle cells were
immunostained for fast myosin heavy chain (f-MyHC, a marker of terminal myogenic differentiation),
fixed with 4% paraformaldehyde, blocked with 5% goat serum, and incubated at room temperature
with myosin 4 monoclonal antibody (MF20)-Alexa Fluor 488 (Thermo Scientific) overnight at 4 ◦C.
The nuclei were visualized by staining with DAPI (Sigma) for 10 min. Total cell nuclei and nuclei
within f-MyHC-positive myofibers in at least 15 fields of three replicate platings were counted by using
ImageJ. Myotube fusion indices were calculated by expressing the number of cells expressing f-MyHC
(green) as a percentage of total nuclei (DAPI, blue) [35,36].
3.10. Preparation of SW480-Conditioned Media
To prepare conditioned media, SW480 cells were cultured on the 100 mm cell culture dish with
the concentration of 5 × 104 cells/seeding. After 24 h, cells were washed with 1× PBS and changed to
serum-free DMEM. Upon one day of incubation, media were collected and supernatant parts were
filtered through 0.2 μm syringe filter for conditioned media (CM).
3.11. C2C12 Myogenic Differentiation in Cancer Conditioned Media
To investigate the effect of PN on C2C12 myogenic differentiation under during cancer progression,
conditioned media (CM) were applied as follows. First of all, C2C12 myoblasts were seeded onto
six-well plates (4 × 104 cells/well) and cultured for 2 days in regular DMEM. After cells are attached,
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the mixture of CM and differentiation media (2% horse serum in DMEM) with the ratio of 1:3 were
added and PN with the concentrations of 0.1, 0.5 and 1 μg/mL were treated.
3.12. Statistical Analysis
Results were reported as means ± standard errors of means (SEM) of experiments performed in
triplicate. Comparisons among experimental groups were performed by one-way ANOVA using SPSS
ver. 12.0 (SPSS, IBM, USA). p-values of <0.05 were deemed significant.
4. Conclusions
The results of the present study showed two beneficial effect of PN on KRAS-mutated CRC. Firstly,
it significantly suppressed KRAS-mutated CRC progression. Cell proliferation and clonogenic potential
were decreased at relatively low concentrations via apoptosis and G2/M phase arrest. The mechanism
responsible for the effects of PN may be associated with the AKT/mTOR signaling pathway. Secondly,
PN rescued muscle cells dysfunction under cancer progression. Collectively, our results provide
support for the incorporation of PN into therapeutic regimens targeting mutated KRAS-driven CRC.
For future research, the toxicity and efficacy of PN needs to be performed in animal studies.
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Abstract: Multifloroside (4), together with 10-hydroxyoleoside 11-methyl ester (1), 10-hydroxyoleoside
dimethyl ester (2), and 10-hydroxyligustroside (3), are all secoiridoids, which are naturally occurring
compounds that possess a wide range of biological and pharmacological activities. However, the
anti-cancer activity of 1–4 has not been evaluated yet. The objective of this work was to study the
anti-cancer activities of 1–4 in the human epidermoid carcinoma cell lines A431 and the human
non-small cell lung cancer (NSCLC) cell lines A549. The results indicate that 1–4 differ in potency in
their ability to inhibit the proliferation of human A431 and A549 cells, and multifloroside (4) display
the highest inhibitory activity against A431 cells. The structure-activity relationships suggest that the
o-hydroxy-p-hydroxy-phenylethyl group may contribute to the anti-cancer activity against A431 cells.
Multifloroside treatment can also inhibit cell colony formation, arrest the cell cycle in the S-phase,
increase the levels of reactive-oxygen-species (ROS), and mitochondrial membrane potential (MMP),
but it did not significantly induce cell apoptosis at low concentrations. The findings indicated that
multifloroside (4) has the tendency to show selective anti-cancer effects in A431 cells, along with
suppressing the colony formation, inducing S cell cycle arrest, ROS production, and increasing MMP.
Keywords: anti-cancer activities; multifloroside; 10-oxyderivatives of oleoside secoiridoids;
structure-activity relationship; flow cytometry
1. Introduction
Cancer is currently the second leading cause of death globally [1–3]. While great strides have
been made in the treatment of cancer in recent decades, we still face many open challenges to existing
cancer therapies, such as adaptive resistance [4]. Throughout the development of human society, the
importance of natural products [4–9] and their derivatives [10–12] in cancer treatment or prevention is
supported by abundant evidence from cancer research [3,13,14], and give hopes to cancer patients.
The Oleaceae is a botanical family of woody dicotyledonous plants that are important in daily
lives of many people due to their broad economic, food, and medicinal values. As previously
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reported, a total of 232 secoiridoids (glycosides, aglycones, derivatives, and dimers) have been isolated
from species in the Oleaceae. Multifloroside (4), together with 10-hydroxyoleoside 11-methyl ester
(1), 10-hydroxyoleoside dimethyl ester (2), and 10-hydroxyligustroside (3), are 10-oxyderivatives of
oleoside secoiridoid (Figure 1), and have been isolated from many Oleaceae plants, such as Osmanthus
asiaticus Nakai [15], Jasminum lanceolarium Roxb [16,17], Jasminum multiflorum extract [18], and Jasminum
elongatum (Bergius) Willd [19] (Figure 1). These four 10-oxyderivatives of oleoside secoiridoids (1–4)
are similar in structure, with a hydroxyl substituent at 10 position, one of substituents, such as
hydroxyl, methyl, p-hydroxy-phenylethyl, or o-hydroxy-p-hydroxy-phenylethyl, at 7 position, and one
of substituents, such as methyl or o-hydroxy-p-hydroxy-phenylethyl, at 11 position.
Figure 1. Chemical structures of four 10-oxyderivative of oleoside secoiridoids (1–4) isolated from
plants in the Oleaceae family. The images of the Oleaceae plants were downloaded from the Chinese
Field Herbarium website (http://www.cfh.ac.cn/default.html).
No previous anti-cancer studies on 1–4 have been reported. Therefore, the study was basically
aimed at helping us understand in vitro anti-cancer effect of 1–4 against the human epidermoid
carcinoma cell lines A431 and the non-small cell lung cancer (NSCLC) cell lines A549. The
structure-activity relationships (SAR) and their effect on cell colony formation, apoptosis, cell-cycle
distribution, intracellular reactive-oxygen-species (ROS) generation, and the mitochondrial membrane
potential (MMP) were also demonstrated in the present study.
2. Results
2.1. Anti-Proliferative Activity of 1–4 In Vitro
The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay [20,21] was used
to evaluated the anti-proliferative activities of 1–4 against the human epidermoid carcinoma cell
lines A431 and human NSCLC cell lines A549. Cells were cultured with indicated concentrations
(250, 200, 100, and 25 μM) of 1–4 or the reference compound gefitinib (an epidermal growth factor
receptor inhibitor) for 72 h, and living cells were detected by MTT assay. The results are shown in
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Figure 2. When against A549 cells, compared with the control cells, significant growth inhibitor effect
could be observed when cells were treated with 200 μM of 1, 200, 100, and 50 μM of 3, 250 μM of
4, and 250, 200, 100, and 50 μM of gefitinib (Figure 2A). When against A431 cells, compared with
the control cells, significant growth inhibitor effect could be observed when cells were treated by
250 μM of 1, 200 μM of 2, and 250, 200, 100, and 50 μM of 4 and gefitinib (Figure 2B). The results are
further shown in Figure 2C and D, when A549 cells were treated with 250 μM of 4 (multifloroside)
or 25 μM of gefitinib, cell viabilities decreased markedly to 30.30% and 70.85% compared with the
control group, respectively (p < 0.001), when A431 cells were treated with 250, 200, 100, 50, and 25
μM of 4 (multifloroside) or 25 μM of gefitinib, cell viabilities decreased markedly to 7.21%, 12.44%,
70.29%, 75.87%, 84.62%, and 34.02% compared with the control group, respectively (p < 0.001), and the
inhibitory effect was concentration-dependent. The above results suggest that 1–4 possess different
anti-proliferative activities against A549 and A431 cells, and 4 (multifloroside) is the most potent agent
against A431 cells.
Figure 2. Anti-proliferative activity of compounds in two human cancer cell lines (A549 and A431) as
determined by the MTT assay. (A) 1–4 against A549 cells, (B) 1–4 against A431 cells, (C) Multifloroside
(4) against A549 cells, (D) Multifloroside (4) against A431 cells. All results are shown as the mean ±
SEM (n = 3). * p < 0.05, ** p < 0.01, and *** p < 0.001 indicate significant differences compared with
the control.
2.2. The Structure-Activity Relationships (SAR)
The structure-activity relationships were analyzed basing on the MTT results, and we found that,
in the core structure of 10-oxyderivatives of oleoside secoiridoids, 1–4 all had a hydroxyl substituent
at the 10 position and only differed at the 7 and 11 positions. 1 had a hydroxyl group at the 7
position and a methyl group at the 11 position, 2 had methyl groups at the 7 and 11 positions, and
3 had a p-hydroxy-phenylethyl group at the 7 position and a methyl group at the 11 position, while
4 (multifloroside) had an o-hydroxy-p-hydroxy-phenylethyl group at both the 7 and 11 positions
(Figure 1), which indicated that the o-hydroxy-p-hydroxy-phenylethyl group may contribute to the
anti-proliferative activity of multifloroside against A431 cells.
2.3. Multifloroside Inhibits Tumor Cell Colony Formation
Encouraged by the above results, we further investigated the bioactivity of multifloroside. First,
the inhibitory effect of multifloroside on the proliferative ability of A431 cells was determined via
colony formation assay. Herein, A431 cells were seeded into a 6-well cell culture plate at a density
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of 400 cells/well and treated with multifloroside at several concentrations (200, 100, 50, and 25 μM),
gefitinib (25 μM) or 0.5% DMSO for 12 days, and then stained with crystal violet. As shown in Figure 3,
multifloroside resulted in a significant suppression of cell colony formation. When the cells were
incubated with multifloroside (200 and 100 μM) or gefitinib (25 μM), colony formation were completely
suppressed. In addition, the cells incubated with multifloroside (50 and 25 μM) formed fewer and
smaller colonies in a concentration-dependent manner compared to the control group. There were
337 viable colonies when A431 cells were treated with 0.5% DMSO, but only 183 and 76 colonies were
observed when the cells were exposed to multifloroside at concentrations of 50 and 25 μM, respectively.
Therefore, the plating efficiency (PE) showed a significant decrease compared to the control (p < 0.001).
The PEs were 84%, 46%, and 24% for the control, and the 25 μM and 50 μM multifloroside treatments,
respectively, and were 0 for the other groups. These results demonstrate that multifloroside inhibits
the growth of A431 cells and that the inhibitory effect of multifloroside persists for a significant period
of time.
Figure 3. Colony formation of A431 cells inhibited by multifloroside. (A) A431 cells were incubated
with the indicated concentrations of multifloroside or gefitinib and fixed with 4% paraformaldehyde
and stained with 0.2% crystal violet 12 days after cell treatment. (B) Bar chart showing the decrease
in the number of colonies after incubation with multifloroside. (C) Micrographs showing differences
between the cell colonies. Images were taken of stained single colonies observed under a microscope.
A single colony was defined to be an aggregate of >50 cells. Data are shown as mean ± SEM (n = 3), ***
p < 0.001 indicates a significant difference compared with the control.
2.4. Effect of Multifloroside on Cell Apoptosis in A431 Cells
After treatment with multifloroside for 48 h, apoptosis of A431 cells was measured by flow
cytometry using annexin V-FITC and PI labeling. As shown in Figure 4, 96.30% of A431 cells were in
their normal state in the untreated control groups. When cells were treated with multifloroside (200
μM) or gefitinib (25 μM), the numbers of early apoptotic cells were significantly higher than in the
control groups (p < 0.001). However, there were no significant differences in the numbers of early
apoptotic cells when cells exposed to lower concentrations of multifloroside (25, 50 and 100 μM). In
addition, there were no significant differences in the numbers of late apoptotic cells and necrotic cells
when cells were treated with multifloroside at 25, 50, 100, and 200 μM and gefitinib at 25 μM. These
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results indicate not only that early apoptosis of A431 cells was not significantly influenced by treatment
with low concentrations of multifloroside but also that late apoptosis was not significantly affected by
multifloroside at the tested concentrations (25–200 μM).
Figure 4. Effect of multifloroside on cell apoptosis in A431 cells. (A) Representative histograms of
apoptosis in the cells treated with multifloroside for 48 h, (B) Percentages of apoptotic cells in each
group from (A). All values are expressed as mean ± SEM (n = 3). *** p < 0.001 indicates a significant
differences compared with the control at the same group.
2.5. S-Phase Cell Cycle Arrest Induced by Multifloroside
In order to study the relationship between the anti-proliferative activity of multifloroside and cell
cycle arrest, A431 cells were treated with multifloroside or gefitinib for 48 h, after which the cells were
stained with PI and examined using flow cytometry. As shown in Figure 5, when cells were treated with
multifloroside at four different concentrations (25, 50, 100 and 200 μM), the number of A431 cells in S
phase were significantly increased (p < 0.001), from 28.55% to 31.78%, 49.29%, and 55.30%, respectively,
accompanied by a decrease in the number of cells in G0/G1 and G2/M. In the gefitinib (25 μM) treated
cells, the percentage of cells in G0/G1, S, and G2/M were 77.54%, 16.17%, and 6.29%, respectively. These
results indicate, unlike gefitinib which arrests the A431 cells in the G0/G1-phase, multifloroside can
arrest the cell cycle of A431 cells in the S-phase and showed concentration-dependent activity.
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Figure 5. Effect of multifloroside on the cell cycle phase distribution in A431 cells. (A) Representative
histograms of DNA content in the cells treated with multifloroside for 48 h, and (B) percentages of cell
populations in the G0/G1, S and G2/M phases from (A). All values are expressed as mean ± SEM (n =
3). * p < 0.05, ** p < 0.01, and *** p < 0.001 indicate significant differences compared with the control at
the same phase.
2.6. Intracellular ROS Production Induced by Multifloroside
Intracellular ROS generation was evaluated via MitoSox red reagent staining and flow cytometry
analysis. As shown in Figure 6, treatment with gefitinib (25 μM) significantly increased the fluorescence
intensity (p < 0.001), and treatment with multifloroside at high concentrations (50 and 100 μM) also
significantly increased the fluorescence intensity (p < 0.001) in a dose-dependent manner. Treatment
with multifloroside at a low concentration (25 μM) also increased the fluorescence intensity, but the
difference was not statistically significant (p > 0.05). These results indicate that ROS production can be
induced by multifloroside at the tested concentrations.
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Figure 6. Effect of multifloroside on ROS production. A431 cells were treated with different
concentrations of multifloroside for 48 h, then MitoSox red reagent (5 μM) was loaded and the
cells were analyzed by flow cytometry for the quantification of multifloroside-induced oxidative stress
in A431 cells. The fluorescence intensity of MitoSox Red reagent in cells was obtained by FACS (A) and
the data was analyzed using GraphPad Prism 5 (B). The values are presented as mean ± SEM (n = 3).
*** p < 0.001 indicates a significant differences compared with the control.
2.7. Effect of Multifloroside on the MMP
MMP of A431 cells stained with JC-10 was assayed by flow cytometry. As shown in Figure 7, the
JC-10 fluorescence ratio (% of J-aggregates with Red Fluorescence divided by the % of J-monomers with
Green Fluorescence) decreased but was not significantly different (p > 0.05) when cells were treated
with gefitinib (25 μM), while the ratios increased when cells were treated with multifloroside (25, 50,
and 100 μM). Moreover, the differences in the JC-10 fluorescence ratios were not significant when cells
were treated with multifloroside at 25 and 100 μM, and they were significant when cells were treated
with 50 μM multifloroside (p < 0.01). The above results indicate the MMP did not decrease, but rather
increased, with multifloroside treatment
Figure 7. Effect of multifloroside on the MMP of A431 cells. A431 cells were treated with different
concentrations of multifloroside for 48 h and analyzed by flow cytometry after JC-10 staining. The
fluorescent intensity of JC-10 in cells was obtained by FACS (A) and the data was analyzed by GraphPad
Prism 5 (B). The percentage of cells with JC-10 red fluorescence is indicated. JC-10 fluorescence ratio
(%) equals the red/green fluorescence intensity ratio. The values are presented as mean ± SEM (n = 3).
** p < 0.01 indicates a significant differences compared with the control.
3. Discussion
Cancer incidence and mortality are rising rapidly worldwide. Throughout the development
of human society, nature has catered to the basic needs of humans, not the least of which is the
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provision of medicines for the treatment of a wide spectrum of diseases [22,23]. There is growing
evidence that specific bioactive compounds present in plants used as spices, fruits, vegetables, and
nuts can be effective against some cancers. Secoiridoids, isolated from Oleaceae family, which are now
widely used in the fields of food and medicine, have been extensively investigated in recent years and
have been shown to possess a variety of pharmacological effects [24–29], such as anti-diabetic [30,31],
anti-oxidant [32,33], anti-inflammatory [34–36], immunosuppressive [37], neuroprotective [36,38,39],
and anti-cancer [1,40–42]. Multifloroside (4), together with 10-hydroxyoleoside 11-methyl ester (1),
10-hydroxyoleoside dimethyl ester (2), and 10-hydroxyligustroside (3), are all 10-oxyderivatives of
oleoside secoiridoids.
1–3, together with other eight secoiridoid glycosides, were isolated from the bark of Osmanthus
asiaticus Nakai in 1993 [15]; 2 was isolated from Jasminum lanceolarium Roxb in 1997 and 2007 [16,17];
1 was also isolated from Jasminum lanceolarium Roxb in 2007 [16]; 1, 3, and 4 were isolated from
the water soluble fraction of Jasminum multiflorum extract [18]; 1 and 4, with the other 11 types of
iridoid glycosides and 15 other compounds, were identified by UPLC-MS in extracts of Jasminum
elongatum (Bergius) Willd in 2016 [19]. However, by now, only 1 and 4 have been found to possess
coronary dilating and cardiotropic activities [18]. Therefore, we aimed to investigate the in vitro
anti-cancer activities of 1–4 in this study. Cancer is characterized by uncontrolled cell growth,
invasiveness, and formation of metastasis, and the cells of most of malignant tumors are proliferate
intensively [14]. Thus, we first evaluated the anti-proliferative activities of 1–4 against A431 human
epidermoid carcinoma cells and A549 human NSCLC cells. The results showed that 1–4 possess
different anti-proliferative activities against A549 and A431 cells, and that 4 (multifloroside) had the
most potent inhibitory activity against A431 cells (Figure 2). As reported, it appears that the best
way to prevent cancer is through rational dietary habits and behaviors, and consumption of sufficient
amounts of antioxidants and bioactive plant-derived compounds that demonstrate protective effects
against carcinogenesis in pre-clinical and clinical studies [43], 4 (multifloroside) and its derivatives
may be the way to prevent epidermoid carcinoma cancer. The SAR were analyzed, and we found
that the o-hydroxy-p-hydroxy-phenylethyl group may contribute to the anti-proliferative activity of
multifloroside against A431 cells. In a future study, it may be advantageous to study other oleoside
secoiridoids with o-hydroxy-p-hydroxy-phenylethyl substituents in order to identify the most potent
compounds in the Oleaceae that can protect against the epidermoid carcinomas.
Second, a colony formation assay was performed to detect the inhibitory effect of multifloroside
on the proliferative ability of A431 cells. The assay is now widely used to examine the effect of agents
with potential clinical applications [44], and it shows the ability of a cancer cell to produce a viable
colony after drug treatment; thus, the results obtained may help to predict the efficacy of agents
in vivo [45]. Similarly to other reported plant anti-cancer molecules and their derivatives, such as
panaxatriol [46], cycloartenol [47], and oridonin derivatives [48], the number and the size of tumor
cell colonies were significantly decreased when A431 cell were treated by 200, 100, 50, and 25 μM
multifloroside (Figure 3). These results all illustrate that multifloroside can significantly inhibit the
growth of A431 cells, which is consistent with the results of MTT assay.
As reported, most of malignant tumors whose cells proliferate intensively, represent very dynamic
structures that create numerous mutations resulting in new tumor cell lines with different genotypes
and phenotypes within the tumor mass. In such malignancies, a highly variable sensitivity to
therapeutics can be observed, and some of cell lines develop resistance to the treatment [14,49].
Therefore, the biological effects of combining various plant molecules (phytochemicals) with proven
cytotoxic effects administered together with conventional therapy to target a markedly wider range
of signaling pathways in cancer cells should be superior compared to single compound in cancer
treatment and thus may delay the development of drug resistance in cancer [43]. So, further urgent
research is needed for the identification of new molecules (including plant-derived compounds) with
well-validated anticancer properties within combinational clinical approach in oncology. Further
studies were then done to elucidate the mechanism of action of multifloroside on A431 cells. In
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general, drug-induced apoptosis is one major mechanism of action for the treatment of cancer, and
various signaling pathways are involved in the process [50]. However, the apoptotic assay suggested
multifloroside at high concentration (200 μM) induced cell apoptosis but that at lower concentrations
(100, 50, and 25 μM) could not (Figure 4). Cell cycle regulating is a key method in controlling tumor
propagation [50]. As reported, most antitumor compounds inhibit cell proliferation by inducing cell
cycle arrest [48]. Cell-cycle analyses indicated the cell-cycle distribution was significantly changed, and
was also different from that resulting from gefitinib, where the cells were arrested in the G0/G1-phase,
multifloroside-treated cells were arrested cells in the S-phase (Figure 5). Mitochondria are the main
source of cellular ROS, which have a double-edged sword role in cytotoxicity in cancer cells [51,52].
Herein, ROS levels were significantly increased after cells were treated with multifloroside at 50 and 100
μM for 48 h (Figure 6). Similarly, the MMP was increased when cells were treated with multifloroside
at the tested concentrations compared with the control group (Figure 7). JC-10 forms “J-aggregates”
displaying red fluorescence in healthy cells, in contrast, as the membrane potential decreases, JC-10
monomers are generated, resulting in a shift to green fluorescence [52]. These results all suggest that
multifloroside may exert its anti-cancer effect through cell-cycle arrest and an increase in the ROS and
MMP in A431 cells. The above gives a well-validated anticancer properties for multifloroside and
suggests multifloroside may be the potential one in applying to anti-epidermoid carcinoma cancer.
4. Methods
4.1. Chemicals and Other Reagents
10-hydroxyoleoside 11-methyl ester (1, C17H24O12, CAS No. 131836-11-8, MW 420.37, purity
98%), 10-hydroxyoleoside dimethyl ester (2, C18H26O12, CAS No. 91679-27-5, MW 434.39, purity
98%), 10-hydroxyligustroside (3, C25H32O13, CAS No. 35897-94-0, MW 540.51, purity 97%) and
multifloroside (4, C32H38O16, CAS No. 131836-10-7, MW 678.64, purity 98%) (Figure 1) were purchased
from BioBioPha Co., Ltd. (Kunming, China). MTT was from Merck Millipore. The Annexin V-FITC/PI
double staining apoptosis assay kit and Cell Cycle Detection Kit were from KeyGEN Bio Tech (Nanjing,
China). MitoSox Red mitochondrial superoxide indicator was obtained from Thermo Fisher (Shanghai,
China). The JC-10 Mitochondrial Membrane Potential Assay Kit was from Mybiotech, (Xi’an, China).
Dulbecco’s Modified Eagle’s Medium (DMEM) and fetal bovine serum (FBS) were purchased from
Gibco (Carlsbad, California, USA). Trypsin, penicillin, streptomycin and l-glutamate were purchased
from MP Biomedicals, LLC (Santa Ana, CA, USA). All other chemicals used in this work were analytical
grade and were purchased from local commercial suppliers and used without further purification
unless otherwise noted.
4.2. Chemicals and Other Reagents
Human epidermoid carcinoma cell lines A431 and human NSCLC cell lines A549 were purchased
from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China). Cells were maintained
in 60 mm cell culture dishes and cultured using DMEM supplemented with 10% FBS, 100 units/mL
penicillin, 100 μg/mL streptomycin, and 2 mM l-glutamate at 37 ◦C in a 5% CO2 atmosphere with
95% humidity.
4.3. MTT Assay for In Vitro Anti-Proliferative Activity
The effect of compounds on cell proliferation was determined using the MTT assay, which is one
of the most versatile and popular assays to assess the rate of cell proliferation caused by drugs and
cytotoxic agents [53]. The assays were performed as previously described [52,54,55].
4.4. Colony Formation Assay
Cell colony formation assay was performed according to the reference methods [45,48]. Firstly,
cells were digested, harvested, and suspended using DMEM medium, and 400 cells/well were seeded
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into 6-well cell culture plates and incubated with multifloroside (25-200 μM) or gefitinib (25 μM) for 12
days, until the cells in the control dishes had formed visible colonies. Then the colonies were washed
three times with PBS and fixed with 4% paraformaldehyde for 20 min. All cells were stained with 0.2%
crystal violet for 20 min. The stained colonies were counted and compared with the control samples.
The medium was changed every three days.
4.5. Cell Apoptosis Analysis
Following treatment with different concentrations of multifloroside for 48 h, the apoptosis of
A431 cells was measured using the Annexin V-FITC/PI apoptosis detection kit according to the
manufacturer’s instructions. Apoptosis of the treated cells was then detected by flow cytometry (ACEA
NovoCyte™, ACEA Biosciences, San Diego, CA, USA).
4.6. Cell Cycle Analysis
Following treatment with different concentrations of multifloroside for 48 h, the distribution of
cell cycle was measured using the cell cycle detection kit according to the manufacturer’s instructions.
The cell cycle of the treated cells was then detected by flow cytometry to quantify the amount of DNA
in each cell (ACEA NovoCyte™, ACEA Biosciences, San Diego, CA, USA).
4.7. Detection of Intracellular ROS
Intracellular ROS production was examined using MitoSox Red mitochondrial superoxide indicator
according to the manufacturer’s protocol and following our previously described method [52]. In brief,
24 h after plating the cells, the culture medium was replaced with fresh medium containing various
concentrations of multifloroside (25-100 μM) or gefitinib (25 μM). After incubation for 48 h, cells were
trypsinized, washed, and stained with MitoSox. Next, cells were washed, centrifuged to remove
the supernatant, and resuspended in HBSS. Finally, ROS production in the cells was immediately
monitored by flow cytometry (ACEA NovoCyte™, ACEA Biosciences, San Diego, CA, USA).
4.8. Mitochondrial Membrane Potential (MMP) Assay
MMP was analyzed using the JC-10 Mitochondrial Membrane Potential Assay Kit according to
the manufacturer’s instructions and following our previously described protocol [52]. In brief, 24
h after plating the cells, the culture medium was replaced with fresh medium containing various
concentrations of multifloroside (25-100 μM) or gefitinib (25 μM). After incubation for 48 h, cells were
trypsinized, washed, and stained with JC-10 dye. Next, cells were washed, centrifuged to remove
the supernatant, and resuspended in PBS. Finally, the red/green fluorescence was detected by flow
cytometry (ACEA NovoCyte™, ACEA Biosciences, San Diego, CA, USA).
4.9. Statistical Analysis
All measurements were made in triplicate, and all data are expressed as means ± SEM of three
independent experiments. The significant differences from the respective control for each experimental
group were examined by one-way analysis of variance (ANOVA) using GraphPad Prism 5 software.
A value of p < 0.05 was considered to be statistically significant, and values of p < 0.01 or p < 0.001
indicated extremely significant differences.
5. Conclusions
In summary, multifloroside (4), together with other three 10-oxyderivatives of oleoside secoiridoids
(1–3), were evaluated for their anti-cancer activities in vitro. These four compounds differ in their
inhibition potency against human cancer cell lines A431 and A549, and interestingly, only multifloroside
exhibited the most potent inhibitory activity against A431 cells. Further studies on multifloroside
suggest that it can inhibit cell colony formation, arrest the cell cycle in the S-phase, and increase the
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level of ROS and MMP but cannot exert significant changes in cell apoptosis. These findings can help
us understand the structure-activity relationships behind the tumor-inhibitory effect of 1–4 against
the two tumor cell lines and have important implications for the potential use of multifloroside in the
treatment of human epidermoid carcinoma. In a subsequent study, we will identify and design novel
derivatives of multifloroside, investigate their activities in vitro and in vivo, and provide additional
information on the ability of these compounds to protect against epidermoid carcinoma cancer.
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Abstract: Hibiscus species are rich in phenolic compounds and have been traditionally used for
improving human health through their bioactive activities. The present study investigated the
phenolic compounds of leaf extracts from 18 different H. acetosella accessions and evaluated their
biofunctional properties, focusing on antioxidant and antibacterial activity. The most abundant
phenolic compound in H. acetosella was caffeic acid, with levels ranging from 14.95 to 42.93 mg/100 g.
The antioxidant activity measured by the ABTS assay allowed the accessions to be classified into two
groups: a high activity group with red leaf varieties (74.71–84.02%) and a relatively low activity group
with green leaf varieties (57.47–65.94%). The antioxidant activity was significantly correlated with TAC
(0.933), Dp3-Sam (0.932), Dp3-Glu (0.924), and Cy3-Sam (0.913) contents (p < 0.001). The H. acetosella
phenolic extracts exhibited antibacterial activity against two bacteria, with zones of inhibition between
12.00 and 13.67 mm (Staphylococcus aureus), and 10.67 and 13.33 mm (Pseudomonas aeruginosa). All
accessions exhibited a basal antibacterial activity level (12 mm) against the Gram-positive S. aureus,
with PI500758 and PI500764 exhibiting increased antibacterial activity (13.67 mm), but they exhibited
a more dynamic antibacterial activity level against the Gram-negative P. aeruginosa.
Keywords: Hibiscus acetosella; phenolic compound; antioxidant; antibacterial; UPLC
1. Introduction
Hibiscus acetosella, a member of the Malvaceae family, is an amphidiploid plant native to Africa
and is usually consumed as a green vegetable. In the traditional medicine of western and central Africa,
decoction drinks have been prepared from extracts of the leaves and shoots because of their anti-anemic
and antipyretic properties [1]. The presence of a wide variety of biochemical compounds, such as
polyphenols, flavonoids, and anthocyanins have been reported in Hibiscus species [2,3]. Two examples,
H. cannabinus and H. sabdariffa, have been studied most regarding the relationship between their
Molecules 2020, 25, 4190; doi:10.3390/molecules25184190 www.mdpi.com/journal/molecules171
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biochemical compounds in the plant leaves and their biofunctional activity [4–7], while H. acetosella
has been much less studied.
Phenolic compounds found in Hibiscus plants consist of phenolic acids such as hibiscus,
protocatechuic, gallic, chlorogenic and caffeic acids, and the organic acid, citric acid. Flavonoids
such as kaempferitrin, gallocatechin, quercetin, and luteolin are also present in these plants.
Anthocyanins, detected mostly in flowers with calyces and some of the red-colored leaves, include
cyanidin-3-glucoside, delphinidin-3-galactoside, delphinidin-3-glucoside, cyanidin-3-sambubioside,
and delphinidin-3-sambubioside [8–10]. These compounds possess antioxidant properties shown
by their effective scavenging activity on reactive oxygen species (ROS) and free radicals. Generally,
to investigate the antioxidant activity of Hibiscus plants based on phenolic compound levels, the
2,2′-azino-bis (3-ethylbenzthiazoline-6-sulfonic acid) (ABTS) hydroxyl radical scavenging assay and
2,2-diphenyl-1-picryl-hydrazyl-hydrate (DPPH) free radical assay have been widely used [4,7,11].
Kapepula et al. [12] investigated the ability of H. cannabinus, H. sabdariffa, and H. acetosella to scavenge
free radicals and reported IC50 values ranging from 43 to 186 μg/mL from ABTS and DPPH assays,
although the three species differed in the composition of their phenolic compounds.
In terms of pharmacological effects, Hibiscus plants have also attracted interest because of their
biological activities, which include antibacterial, anti-inflammatory, antigenotoxic, hepatoprotective,
and antimutagenic activities [13–16]. In particular, the antibacterial activity of H. sabdariffa has been
well-studied as well as other biological activities of extracts of its leaves and flowers [4,17,18], while
H. acetosella has been reported as having anti-inflammatory [12] and antimutagenic activity [16], but no
antibacterial activity.
The present study therefore aimed to determine the composition of phenolic compounds in the
extracts of leaves from 18 H. acetosella accessions using UPLC analysis and to assess their bioactive
properties, antioxidant and antibacterial activities, using the ABTS assay and agar-well diffusion test,
respectively. The relationship between phenolic extracts and their biofunctional properties will also be
evaluated using statistical analysis.
2. Results and Discussion
2.1. Phenolic Composition of H. acetosella Leaf Extracts
First, before measuring the content of phenolic compounds, the color characteristics of the
H. acetosella leaves were investigated (Figure 1). The leaf color is usually green, but three accessions
appeared red (PI500777, PI500801, and PI500805). The petiole colors could be divided into four types:
7 accessions were green, 5 accessions green-red, 2 accessions light-red, and 4 accessions red (Table 1).
The phenolic compounds of the H. acetosella accessions were detected by UV-spectrophotometry and
UPLC (Table 2). The total phenolic content (TPC) and total flavonoid content (TFC) levels ranged from
193.14 to 434.67, and 199.10 to 262.19 mg/100 g, respectively, with the highest level in PI500707. A
previous study on H. acetosella, investigating a different variety using a different extraction method,
reported TPC and TFC levels of 1730 and 775 mg/100 g, respectively, values more than three times those
found in the present study [19]. Phenolic compounds play an important role in the adaptation of plants
to the environment, and their content is determined by the origin, harvesting time, and cultivation
conditions [3,20]. Previous data has shown that the TPC and TFC contents can vary by approximately
three times according to the region where the plants are collected [21,22]. In the present study, the
major polyphenols in H. acetosella were identified as caffeic acid (CA) and chlorogenic acid (CGA),
while gallocatechin (GC) and gallic acid (GAL) were present in relatively small amounts (Table 2). In
particular, CA is present in three Hibiscus plants, H. cannabinus, H. sabdariffa, and H. acetosella, with the
highest amounts in H. acetosella [12]. CGA is also a major phenolic compound in H. sabdariffa aqueous
extract [23]. The PI500707 accession also exhibited significantly higher levels of polyphenols such
as GC (1.57 mg/100 g), GAL (1.97 mg/100 g), CGA (41.56 mg/100 g), and CA (42.93 mg/100 g) in the
collected accessions. As expected, the TAC level was associated with the coloration of the leaf, as
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well as with the anthocyanins content. In green leaves, the TAC content was less than 1 mg/100 g,
but in three accessions with red leaves, the contents ranged from 17.25 to 19.98 mg/100 g (Table 2).
Three anthocyanins, delphinidin-3-sambubioside (Dp3-Sam), delphinidin-3-glucoside (Dp3-Glu),
and cyanidin-3-sambubioside (Cy3-Sam), were only detected in red leaves but also seen in UPLC
3D profiling (Figure S1). Similar findings have also been reported in a previous study of phenolic
compounds in Hibiscus plants [4,6,24].
Figure 1. Leaf color of the 18 different H. acetosella accessions used in this study.
Table 1. Leaf and petiole color of the 18 different H. acetosella accessions used in this study.
Number ID Leaf Color Petiole Color
1 PI 500707 Green Green-red
2 PI 500730 Green Green-red
3 PI 500744 Green Green-red
4 PI 500749 Green Green
5 PI 500755 Green Green
6 PI 500756 Green Green
7 PI 500758 Green Green
8 PI 500761 Green Red
9 PI 500764 Green Light-red
10 PI 500765 Green Light-red
11 PI 500766 Green Green-red
12 PI 500777 Red Red
13 PI 500778 Green Green
14 PI 500794 Green Green
15 PI 500801 Red Red
16 PI 500804 Green Green
17 PI 500805 Red Red
18 PI 591552 Green Green-red
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2.2. Effects of Phenolic Extracts on the Radical Cation Scavenging Activity
To compare the antioxidant properties of the 18 H. acetosella accessions, the radical cation scavenging
activity of their phenolic extracts (10 times diluted) was determined using the ABTS assay (Table 3).
The ABTS assay mainly depends on hydrogen peroxide in the presence of ABTS to produce the radical
cation and has been previously used for measuring the total antioxidant activity in a wide variety
of plants rich in polyphenols [25]. The antioxidant activity varied from the highest value of 84.02%
(PI500805) to the lowest value of 57.47% (PI500756) in the H. acetosella extracts, with that of the control
ascorbic acid (500 μM) at 99.83%. These values of antioxidant activity were higher than those previously
reported for H. acetosella [26]. The activity of the phenolic compounds from the ABTS assay increased
with the contents of the related anthocyanins, TAC, Dp3-Sam, Dp3-Glu, and Cy3-Sam (Table 3).
For example, PI500801 (74.71%), PI500777 (82.34%) and PI500805 (84.02%) exhibited the highest
antioxidant activity, as well as abundant TAC and anthocyanins contents. In contrast, 15 H. acetosella
accessions with no detectable anthocyanins contents, showed a slightly decreased antioxidant activity
from 57.47% (PI500756) to 65.94% (PI500707). The antioxidant effect of the extracts was probably
caused by flavonoids and anthocyanins, especially anthocyanins, which have been reported to exhibit
excellent antioxidant activity in Hibiscus plants [27,28]. Interestingly, Maciel et al. [29] have purified
anthocyanins such as Dp3-Sam, Dp3-Glu, Cy3-Sam, and cyanidin-3-glucoside (Cy3-Glu) from a crude
extract of the H. sabdariffa calyx, which exhibited a higher antioxidant activity from the DPPH assay than
that of the crude extract. The present study attempted to make use of the DPPH radical activity assay,
but an unknown precipitate was produced in the reaction mixture, which affected the measurements
in the extracts from some of the accessions. This might have been caused by the reaction of unknown
compounds with the organic solvent (Table S1). Nonetheless, all accessions, except for the four aberrant
accessions, tended to exhibit a higher antioxidant activity measured by the DPPH assay than that
measured by the ABTS activity assay. The antioxidant and bioactive properties of anthocyanins
have also been linked to health benefits such as anti-cancer, anti-inflammatory, and anti-diabetic
activities [30–34]. Consequently, these results are consistent with previous studies, indicating that
anthocyanin compounds were the main contributors to the antioxidant activity of H. acetosella.
Table 3. Antioxidant and antibacterial activities of 18 different H. acetosella accessions.
ID
Antioxidant Activity Antibacterial Activities (mm) (2)
ABTS (%) S. aureus P. aeruginosa
Control (1) 99.83 ± 0.18 12.80 ± 0.34 13.10 ± 0.42
PI 500707 65.94 ± 0.18 h 12.00 ± 1.00 a 11.33 ± 0.58 ab
PI 500730 59.36 ± 0.13 bc 12.33 ± 0.58 ab 13.00 ± 0.00 de
PI 500744 64.47 ± 0.18 fg 13.33 ± 0.58 bc 12.33 ± 0.58 cd
PI 500749 62.25 ± 0.22 de 12.00 ± 0.00 a 12.00 ± 0.00 bc
PI 500755 59.44 ± 0.99 bc 12.00 ± 0.00 a 12.00 ± 0.00 bc
PI 500756 57.47 ± 0.15 a 13.00 ± 0.00 abc 12.00 ± 0.00 bc
PI 500758 62.46 ± 0.15 de 13.67 ± 0.58 c 11.33 ± 0.58 ab
PI 500761 65.10 ± 0.15 gh 13.33 ± 0.58 bc 13.33 ± 0.58 e
PI 500764 61.91 ± 0.23 d 13.67 ± 0.58 c 12.00 ± 0.00 bc
PI 500765 64.05 ± 0.36 f 12.67 ± 0.58 abc 12.00 ± 0.00 bc
PI 500766 60.11 ± 0.51 c 12.00 ± 0.00 a 11.67 ± 0.58 bc
PI 500777 82.34 ± 0.23 j 12.67 ± 0.58 abc 11.33 ± 0.58 ab
PI 500778 61.75 ± 0.40 d 12.33 ± 0.58 ab 12.00 ± 0.00 bc
PI 500794 63.00 ± 0.38 e 12.67 ± 0.58 abc 11.67 ± 0.58 bc
PI 500801 74.71 ± 0.07 i 12.67 ± 0.58 abc 11.67 ± 0.58 bc
PI 500804 58.56 ± 0.08 b 13.33 ± 0.58 bc 12.00 ± 0.00 bc
PI 500805 84.02 ± 0.15 k 13.33 ± 0.58 bc 11.33 ± 0.58 ab
PI 591552 65.61 ± 0.08 h 12.67 ± 0.58 abc 10.67 ± 0.58 a
(1) Control used were: ascorbic acid (500 μM) in antioxidant assay and gentamicin (5 μg) (antibacterial assay).
(2) Inhibition zone of H. acetosella leaf extract against Staphylococcus aureus (Gram-positive) and Pseudomonas aeruginosa
(Gram-negative). The results are shown as the mean ± standard error of three replicates. Mean with the same letter
are not significantly different at the 5% probability level (Duncan’s multiple range test). nd; not detectable.
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2.3. Inhibitory Effects of Phenolic Extracts against Gram-Positive and Gram-Negative Bacteria
The inhibitory effects of the phenolic extracts of H. acetosella leaves on the Gram-positive
(Staphylococcus aureus ATCC 6538) and Gram-negative (Pseudomonas aeruginosa ATCC 9027) bacteria are
shown in Table 3. Distilled water, used as the negative control, exhibited no inhibitory effect against the
two bacteria (Figure S2), but gentamicin (5 μg), used as the positive control, exhibited inhibition zones
against the two bacteria of 12.80 ± 0.34 mm (S. aureus) and 13.10 ± 0.42 mm (P. aeruginosa). The phenolic
extracts of the 18 H. acetosella accessions showed antibacterial activity against two bacteria, the zones
of inhibition ranging from 12.00 to 13.67 mm (S. aureus) and from 10.67 to 13.33 mm (P. aeruginosa). For
the S. aureus bacteria, all accessions exhibited a basal antibacterial activity level (12 mm), with PI500758
and PI500764 exhibiting an increased level of antibacterial activity (13.67 mm), but the Gram-negative
(P. aeruginosa) bacteria exhibited a wider range of levels of antibacterial activity (Table 3). These
antibacterial activities were exhibited similar levels against both Gram-positive and Gram-negative
bacteria in H. sabdariffa [4,31,35]. The present study first confirmed the presence of antibacterial activity
against two bacteria among the phenolic extracts of the 18 different H. acetosella accessions as a basis
for optimization in future research using a formal antibacterial measuring method.
2.4. Relationship between Phenolic Extracts and Biofunctional Properties
The Pearson correlation coefficient and hierarchical clustering were used to assess the relationship
between the contents of phenolic compounds in the extracts and the biofunctional properties
(antioxidant and antibacterial activities) in the 18 H. acetosella accessions (Table 4, Figure 2). The
antioxidant activity (ABST) was significantly correlated with TAC (0.933), Dp3-Sam (0.932), Dp3-Glu
(0.924), and Cy3-Sam (0.913) contents (p < 0.001). The TPC, TFC, and GC contents also exhibited
significant correlation coefficients ranging between 0.526 and 0.567 (p < 0.05). Consequently, the
antioxidant activity in H. acetosella was strongly correlated with its contents of phenolic compounds,
with the related anthocyanin contents also being involved in the antioxidant activity. In contrast, the
antibacterial activity against Gram-positive bacteria was not significantly correlated with the content
of phenolic compounds but antibacterial activity against Gram-negative bacteria was negatively
correlated with the GAL content (−0.433, p < 0.05). However, the content of GAL is too low in
H. acetosella to produce an antibacterial response. Overall, the antibacterial activity varied between the
accessions, suggesting the involvement of other specific phenolic compounds present in their extracts.
Borrás-Linares et al. [4] have also reported that the antimicrobial assay revealed no significant or a
negative correlation between phenolic contents and antibacterial activity in H. sabdariffa, suggesting
a similar response. Hierarchical clustering classified the accessions and measurements according
to their chemical and biofunctional similarities. The accessions divided into two clusters: the first
cluster contained high contents of anthocyanins and the second cluster according to the status of
the phenolic compounds and biofunctional properties. The measurements were classified into three
clusters: cluster I contained antibacterial activities, cluster II contained phenolic compounds without
anthocyanins, and cluster III contained antioxidant activity with anthocyanins (Figure 2). These results,
as mentioned earlier, indicated that the antioxidant activity was strongly associated with the levels of
anthocyanins such as TAC, Dp3-Sam, Dp3-Glu, and Cy3-Sam.
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Figure 2. Hierarchical cluster analysis of the 18 different H. acetosella accessions according to their
phenolic compound contents and biofunctional properties.
3. Materials and Methods
3.1. Plant Materials
The 18 accessions studied (Table 1, Figure 1) were collected from the USDA and originated in
Zambia. The leaves of the genotypes were harvested in August for each accession for the analysis of
the functional compounds. The leaves were picked by hand from plants grown in three separate plots
on the same plantation. The seeds were planted 20 cm apart in rows 60 cm apart in plots (3 × 4.2 m).
Fertilizer (N:P:K 4:2:2 w/w/w) was applied at 550 kg/ha shortly after seeding. The experiment was
conducted at the Korea Atomic Energy Research Institute (35◦30′33.9” N, 126◦50′02.3” E, Jeongeup,
Korea). The plants’ cultivation conditions between May and August 2017 were as follows: mean
temperature 17.8–24.4 ◦C, relative humidity 66.0–80.9%, mean sunlight 10.4–7.0 h. All of these climate
data were accessed through the Korea Meteorological Administration web portal (http://weather.go.kr/).
3.2. Phenolic Compounds Extraction
All samples were ground to achieve a particle sizeable to pass through a 500-mesh sieve. The
ground samples (1 g) were extracted in 5 mL of distilled water for 16 h then filtered through a
0.45-μm membrane filter. The antioxidant and antibacterial activities were measured using these
aqueous extracts.
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3.3. Total Phenolic Content
The total phenolic content (TPC) was determined by the Folin–Ciocalteu colorimetric method [7].
A small quantity (0.2 mL) of each extract and 1.5 mL of Folin–Ciocalteu reagent (20% v/v) were mixed
thoroughly. Four mL of Na2CO3 (7%) were added, then made up to 10 mL with water. The mixture was
kept in the dark at room temperature for 90 min. The absorbance was then measured at 760 nm using
a UV-spectrophotometer (UV-1800, Shimadzu, Kyoto, Japan). TPC was calculated using a calibration
curve of gallic acid.
3.4. Total Flavonoid Content
The total flavonoid content (TFC) of the H. acetosella extracts was determined as described by
Ryu et al. [7]. Each extract sample (0.2 mL) was added to 4 mL double-distilled water and 0.3 mL of 5%
NaNO2 in a flask. The samples were left for 5 min, then 0.3 mL of 10% AlCl3 was added. After 6 min,
2 mL NaOH were added then made up to 10 mL with double-distilled water. The absorbance was then
measured at 510 nm. TFC was calculated using a calibration curve of quercetin equivalents.
3.5. Total Anthocyanin Content
The total anthocyanin contents (TAC) of the H. acetosella extracts were determined as described
by Sutharut et al. [36]. The pH differential method, consisting of a KCl buffer (0.025 M, pH 1.0) and
a CH3COONa buffer (0.4 M, pH 4.5), was used to determine the total anthocyanin content of the
methanol extract prepared from each sample. A 1-mL aliquot of the extract was mixed with 4 mL
of each of the buffers then incubated at 28 ◦C for 15 min so that the solution could equilibrate. The
absorbance was measured at 510 nm and 700 nm using deionized water as a blank. The final result was
converted to milligrams of cyanidin-3-glucoside equivalents (CGE) per gram dry weight (mg CGE/g
dry weight).
3.6. UPLC Analysis
The phenolic compounds were analyzed using a ultra-high performance liquid chromatography
(UPLC) system (CBM-20A, Shimadzu) with two gradient pump systems (LC-30AD, Shimadzu), a
UV-detector (SPD-M30A, Shimadzu), an auto sample injector (SIL-30AC, Shimadzu), and a column
oven (CTO-30A, Shimadzu). Separation was achieved on an XR-ODS column (3.0 × 100 mm, 1.8 μm,
Shimadzu) using a linear gradient elution program with a mobile phase containing solvent A (0.1%,
v/v, trifluoroacetic acid in distilled deionized water) and solvent B (0.1%, v/v, trifluoroacetic acid in
acetonitrile). The phenolic compounds were separated using the following gradient: 0–5 min, 10–15%
B; 5–10 min, 15–20% B; 10–15 min, 20–30% B; 15–25 min, 30–50% B; 25–30 min, 50–75% B; 30–35 min,
75–100% B; 35–40 min, 100–5% B; and 40–45 min, 5–0% B. The phenolic compounds and anthocyanins
were detected at 280 nm and 520 nm, respectively. The chlorogenic acid (CGA), caffeic acid (CA),
delphinidin-3-sambubioside (Dp3-Sam), delphinidin-3-glucoside (Dp3-Glu), cyanidin-3-sambubioside
(Cy3-Sam), all obtained from Sigma-Aldrich Co. (St. Louis, MO, USA) were identified based on the
retention times of commercial standards (UV spectrum). Gallocatechin (GC) and gallic acid (GAL)
were identified as described in a previous study [16] and by their UV-visible spectral characteristics.
3.7. ABTS Radical Cation Scavenging Activity
Each extract sample was diluted 10-fold with water, then the ABTS value was evaluated as
described by Re et al. [25]. In brief, ABTS was measured using pre-formed radical monocations. The
mixtures, along with 7.4 mM ABTS solution and 2.6 mM potassium persulfate, were incubated at
room temperature in the dark for 24 h. The ABTS solution was diluted with phosphate-buffered saline
(pH 7.4) to achieve an absorbance of 0.7 ± 0.02 at 734 nm. Each sample (10 μL) was then reacted with
190 μL of the ABTS solution. The absorbance at 734 nm was measured 6 min after the reaction using
the Benchmark Plus ELISA reader (Bio-Rad, Hercules, CA, USA).
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3.8. Antibacterial Activity Assays
The antibacterial activities of the extracts were tested against two pathogenic species, a
Gram-positive bacterium (Staphylococcus aureus ATCC 6538) and a Gram-negative bacterium
(Pseudomonas aeruginosa ATCC 9027), using the agar-well diffusion method [4] with some modification.
The two bacterial cultures were grown in Difco Nutrient Agar (BD Difco, Franklin Lakes, NJ, USA) for
24 h at 32 ◦C then diluted with sterile distilled water to obtain an inoculum concentration of 106 cfu/mL
before the suspensions were spread on the nutrient agar medium. Aliquots of each phenolic extract
(70 μL) were added to an 8-mm diameter paper disc placed on the plates then incubated at 32 ◦C for
24 h. The positive and negative controls used gentamicin (5 μg) (Merck, Kenilworth, NJ, USA) and
sterile distilled water, respectively. The antibacterial activity was determined as the diameter of the
inhibition zones (mm) around the discs from each extract.
3.9. Statistical Analysis
The chemical analysis and biofunctional assay data were assessed using multiple variance analysis
(ANOVA) with Duncan’s multiple range post-hoc test in the SPSS version 20 statistical software package
(IBM Corp., Armonk, NY, USA). Differences between mean values were considered to be significant
at p < 0.05. The hierarchical clustering analysis was performed using the complete linkage method
based on the phenolic compound contents and biofunctional data from the 18 different H. acetosella
accessions. The phenolic compounds were visualized as z-values on a heatmap.
4. Conclusions
In this study, the composition of phenolic compounds in the leaf extracts of 18 different H. acetosella
accessions was determined and how it contributed to their antioxidant and antibacterial activities. The
antioxidant activity was significantly associated with the level of anthocyanins in the phenolic extracts.
This study is the first to report the antibacterial activity of H. acetosella against both Gram-positive and
Gram-negative bacteria. These results could be useful for exploring the potential of medicinal crops as
a valuable resource for discovering new pharmaceutical drugs.
Supplementary Materials: The Supplementary Materials are available online. Figure S1: Ultra-high performance
liquid chromatography (UPLC) 3D profiles of the 18 H. acetosella accessions. The numbers in the boxes correspond
to the numbers in column 1 of Table 1. Figure S2: Agar-well diffusion test demonstrating inhibition zones against
S. aureus and P. aeruginosa bacteria. All test were performed three replicates. Table S1: DPPH radical activity of 18
different H. acetosella accessions.
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Abstract: The objective of this study was to examine the effect of inulin and maltodextrin
applied during vacuum drying of Saskatoon berry fruit, juice, and pomace on the retention of
bioactive compounds and antioxidant capacity (radical scavenging capacity (ABTS), ferric reducing
antioxidant potential (FRAP)) of powders obtained. Ultra-high performance liquid chromatography
(UPLC-PDA-ESI-MS/MS) was used to identify major groups of polyphenolic compounds, such as:
flavan-3-ols (35% of all polyphenols for fruit powder, 33% for juice powder, and 39% for pomace
powders of all polyphenols), anthocyanins (26% for fruit powder, 5% for juice powder, and 34% for
pomace), phenolic acids (33% for fruit powder, 55% for juice powder, and 20% for pomace powder),
and flavanols (6% for fruit powder, 6% for juice powder, and 7% for pomace powder). In general,
the content of polyphenols was more dependent on the content than on the type of carrier used
for drying, regardless of the matrix tested. The average sum of polyphenols and the antioxidant
activity (for ABTS and FRAP assay) of the powders with 30% of carrier addition were 5054.2 mg/100 g
dry matter (d.m.) as well as 5.3 and 3.6 mmol Trolox/100 g d.m. in the ABTS and FRAP tests,
respectively. The increase in carrier concentration by 20% caused a decrease of 1.5-fold in the content
of polyphenols and a 1.6-fold and 1.5-fold in the antioxidant potential, regardless of the matrix tested.
The principal component analysis (PCA) analysis indicated that the freeze-drying process led to the
lowest degradation of the identified compounds, regardless of the matrix tested, with the exception of
juice and pomace powders dried by vacuum drying at 60 ◦C. In this case, the release of (−)-epicatechin
was observed, causing an increase in the flavanol contents. Thus, this work demonstrated the effect of
processing and matrix composition on the preservation of antioxidant bioactives in Saskatoon berry
powders. Properly designed high-quality Saskatoon berry powders with the mentioned carriers may
be used as nutraceutical additives to fortify food products and to improve their functional properties.
Keywords: Amelanchier alnifolia Nutt.; carriers; powders; bioactive compounds; functional food
1. Introduction
Saskatoon berry (Amelanchier alnifolia Nutt.) belongs to the Rosaceae family and is commonly
found in the North America [1,2], and also in Poland. In folk medicine, it was used to combat many
ailments [3]. Its fruits contain polyphenolic compounds, like e.g., anthocyanins, phenolic acids (mainly
hydroxycinnamic acids), polymers of procyanidins, (+)-catechins, (−)-epicatechins, and quercetin
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derivatives [3,4]. These compounds have a wide spectrum of biological functions and biochemical
activities, e.g., anti-diabetic, anti-inflammatory, antioxidant, and anti-cancer properties [1,3,5,6].
In order to preserve of bioactive constituents from fruits during processing, the powdering process
has recently been proposed as one of the possible ways to obtain products with natural health-promoting
constituents. The processing of fruits, including thermal treatment, causes significant changes in the
composition of processed products compared to the raw materials [7]. The transformation of fruit
material into powdered is made easier when the addition of a carrier agent is applied. Such an approach
may lead to stability improvement of natural bioactive compounds during further processing. This may
allow entrapping polyphenolic compounds in the carrier shell or matrix so that the thermolabile active
substance gains protection against degradation and their stability [8–10]. The most commonly used
carriers include maltodextrin, gums, proteins, and starches [11,12]. Recently, carriers with functional
properties have been used during food the powdering process. In this study, we used two carriers:
maltodextrin—because it is the most commonly used carrier, and inulin—due to its proven prebiotic
effects and pro-health potential. What is more, the addition of maltodextrin and inulin improve the
drying yield [13,14].
The selection of carriers, their concentration, and drying technique are all important factors
that affect the profile and concentration of antioxidant compounds. Although the impact of carriers
and their concentration on the profile of bioactive compounds in fruit powders has been evaluated
in some previous studies [15,16], there is lack of information on the impact of these factors on the
phytochemicals of Amelanchier alnifolia Nutt. Thus, the objective of the present study was to investigate
the influence of maltodextrin and inulin used as a carrier and of their concentration on the quantitative
and qualitative composition of polyphenolic profile of Amelanchier alnifolia Nutt. fruit, juice, and
pomace powders obtained by freeze-drying and vacuum-drying at 50 and 60 ◦C. Polyphenol profile
was determined by ultra-high performance liquid chromatography (UPLC-PDA-ESI-MS/MS) and
their antioxidant properties determined by radical scavenging capacity (ABTS), and ferric reducing
antioxidant potential (FRAP).
2. Results and Discussion
2.1. Polyphenolic Content and Chemical Profile
In the present study, polyphenolic compounds were determined using UPLC-PDA-ESI-MS/MS in
Saskatoon berry powders with carriers considering the type of the material subjected to drying (whole
fruit, juice, pomace), the drying method, and the type of carrier and its concentration (Table 1 and
Tables S1–S4). Detailed analyses allowed identifying 42 compounds classified to four main groups as
anthocyanins, phenolic acids, flavonols, and flavan-3-ols. Their presence in powders obtained from
Saskatoon berry fruits was also confirmed in earlier works [1,2,4,6,17,18].
The most abundant group belonging to polyphenolic compounds was represented in the analyzed
powders by flavan-3-ols (monomers, oligomers, and polymeric procyanidins). These compounds
were previously identified in fruits by Lachowicz et al. [6,17]. This group accounted for 35% of total
polyphenolic compounds in fruit powder, for 33% in juice powder, and for 39% in pomace powder.
Among the monomers and oligomers, the presence of 14 compounds was identified; they accounted
for 36% of total flavan-3-ols in fruit powder, for 67% in juice powder, and for 20% in pomace powder.
In addition, the presence of polymeric procyanidins was determined by phloroglucinolysis (they
accounted for 64% of total flavan-3-ols in fruit powder, for 33% in juice powder, and for 80% in pomace
powder) (Table S1). In this research two monomers (main ion at m/z 289), two dimers (main ion at m/z
577), five trimers (main ion at m/z 863), and five tetramers (main ion at m/z 1153) were identified based
on MS data and available literature [1,17].
Anthocyanins were the second abundant group determined in the powders [1] and constituted
26% of total polyphenolic compounds in fruit powder, 5% in juice powder, and 34% in pomace
powder. Furthermore, six cyanidins were identified including four glycosides of cyanidins
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(cyanidin-3-O-galactoside: m/z 449, -3-O-glucoside: m/z 499, -3-O-xyloside: m/z 419, -3-O-arabinoside:
m/z 419) and two cyanidin aglycons (m/z 287). Among the 6 identified compounds, the major compound
belonging to anthocyanins was cyanidin-3-O-galactoside (it accounted for 69.9% of all anthocyanins).
This was confirmed in earlier reports [2].
Phenolic acids were the next group of polyphenols that accounted for 33% of total polyphenolic
compounds in fruit powder, for 55% in juice powder, and for 20% in pomace powder. According to the
MS spectra, standards, and literature, eight hydroxycinnamic acids were determined, including: three
isomers of caffeoylquinic acid (m/z 353), two coumaroylquinic acids (m/z 353), and three isomers of caffeic
acids (m/z 341), as well as one hydroxybenzoic acid identified as protocatechuic acid (m/z 153). The
major phenolic acids were 5-O-caffeoylquinic acid (56% of all phenolic acids), and 4-O-caffeoylquinic
acid (19%). The mass noted on the negative mode was m/z 353 with similar MS spectra to those reported
in literature [1,2].
The last and the smallest group of phenolic compounds was constituted by flavonols [17]. This
group accounted for 6% of total flavonols in fruit powder, for 6% in juice powder, and for 7% in pomace
powder; and the major compound was quercetin-3-O-galactoside [1,2] which represented 46% of all
flavonols. In this work, thirteen flavonols were identified including ten glycosides of kaempferol and
quercetin (based on ion at m/z 285 and 301, respectively), two acetylated compounds (m/z 507), and one
quercetin aglycon (m/z 301) [1,2].
The average total content of identified polyphenols was 6535 mg/100 g d.m. in pomace powders.
Their content was lower by 38% and 70% in fruit and juice powders, respectively (Table 1 and
Tables S1–S4). This is due to the accumulation location of these constituents in the outer layer of
the fruit that remains in the pomace during pressing [19,20]. In addition, the highest antioxidant
capacity was found in pomace powders and was 3.4-fold (ABTS assay) and 3-fold (FRAP assay)
higher when compared to the fruit powders as well as 7-fold (ABTS assay) and 6-fold (FRAP assay)
compared to juice powders (Table 2). These relationships were also confirmed during the drying of
chokeberry [21] and cranberry fruits [22] and can be explained by distribution of phenols, because
they are not equally distributed in the plant material [22]. Anthocyanins and flavonols are mostly
presented in the peel of berry, also polymeric procyanidins, monomers, and oligomers of flavan-3-ols
are essentially located in the peel, but some content of these compounds occur in the pulp thus
in the juice [21,22]. In addition, conditions of juice processing, mash maceration, and the type of
enzymatic preparation may significantly impact the content of polyphenols in the juice and pomace
of product [21,22]. This fact is widely known in the literature, but there is little information on the
impact of carriers and their quantity and drying methods on the individual matrix, especially of
Saskatoon berry. What is more, according to literature [1–3,17,23,24], the Saskatoon berry fruits are an
excellent source of polyphenolic compounds and antioxidant properties responsible for their proved
anti-inflammatory, antidiabetic, and chemo-protective effects. They have more bioactive compounds
than e.g., blueberry, blackberry, bilberry, raspberry, and strawberry [25,26]. However, little is known
about the use of this raw material as a functional additive. Available data relate only to Saskatoon berry
supplements and used the accumulation of plasma levels of anthocyanins [27]. Amelanchier alnifolia
Nutt. (90 g) were administered immediately after every low antioxidant meal. The authors noted
plasma concentrations of cyanidin-3-O-xyloside and cyanidin-3-O-galactoside were significantly
increased following 3 consecutive supplements 4 h apart. Therefore, they recommend that anthocyanin
supplements with every meal would higher their plasma concentrations [27]. Another work concerned
the prevention of diabetes in obese mice by consuming Saskatoon berry [28]. Male mice were served a
control diet, high fat and high sucrose diet, and high fat and high sucrose with 5% of Saskatoon berry
powder (weight/weight) diet for 15 weeks. The results showed that Saskatoon berry powder suppressed
high fat, high sucrose diet-induced hyperglycemia, hyperlipidemia, insulin resistance, and vascular
inflammation [28]. Therefore, research was undertaken to obtain new functional additives (powders)
from various Saskatoon berry matrices with the highest possible content of antioxidant compounds.
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2.2. Influence Type of Carriers on Polyphenolic Compounds and Antioxidant Capacity in Dependence on
the Matrix
The principal component analysis (PCA) was used to study the impact of the type of carriers on
the protection of polyphenolic compounds and their antioxidant activity depending on the matrix
tested (Figure 1). It showed that in the case of fruit powders, drying in the presence of inulin was
associated with a higher concentration and protection of flavan-3-ols group and their individual
compounds ((+)-catechin, B-type procyanidin: dimer, and tetramer, and A-type procyanidin dimer), 3
and 4-O-caffeoylquinic acids, di-caffeoylquinic acid, and cyanidin-3-O-arabinoside. While maltodextrin
caused the higher retention and ensured protection of polymeric procyanidins, total phenolic acids
and their derivatives, total flavonols and their derivatives, total anthocyanins and their derivatives,
and total phenolic acids and their antioxidant activity (strong correlation with the ferric reducing
antioxidant potential (FRAP)) and positive correlation with the radical scavenging capacity (ABTS)).
Bakowska-Barczak and Kołodziejczyk [29] also reported that the use of maltodextrin resulted in the
highest contents of anthocyanins and polyphenols in black currant powders. The higher retention
of polyphenolic compounds was also noted in cactus pear with maltodextrin when compared to
inulin [30]. In turn, PCA analysis showed that in the case of juice powders, inulin had a stronger impact
on total flavonols and their main derivatives, (+)-catechin, (−)-epicatechin, B-type procyanidin dimer,
polymeric procyanidins, cyanidin-3-O-arabinoside, and 3-O-caffeoylquinic acid; while, maltodextrin
led to the higher retention of total phenolic acid, total anthocyanins, total flavan-3-ols. What is
more, the ability to scavenge the ABTS radicals was higher in the case of the juice powders with
maltodextrin addition, whereas higher FRAP values were noted for the powders prepared with inulin.
The addition of maltodextrin into juice powders affected the release of free cyanidin and quercetin
aglycons. Whereas, in black currant juice powder, the use of inulin resulted in a 9% higher anthocyanin
retention compared to the use of maltodextrin [16]. Furthermore, the PCA analysis of pomace powders
showed that the product with inulin had higher contents of total of polyphenolic compounds, A and
B-type procyanidin dimer, polymeric procyanidin, and quercetin-3-O-robinobioside, and also a higher
degree of polymerization. This product had higher antioxidant potency, while maltodextrin was
responsible for the protection of total anthocyanins and their derivatives, total flavan-3-ols and their
derivatives, total phenolic acids and their derivatives, and total flavonols and their derivatives. Thus,
the type of carrier and its impact on antioxidant compounds depended mainly on the analyzed matrix.
The high antioxidant power of the juice and pomace powders with inulin and also of the fruit powders
with maltodextrin can be affected by polymerized compounds. This can also be confirmed by a strong
correlation between the polymerized compounds and antioxidant activity i.e., r = 0.997 for FRAP and
0.430 for ABTS (for fruit powders), r = 0.995 and 0.998 for FRAP and ABTS assay (juice powders), and
r = 0.997 and 0.998 for FRAP and ABTS assay (pomace powders). Therefore, the choice of a carrier will
largely depend on the desired composition of bioactive compounds with antioxidant activity for the
functional additive regardless of the Saskatoon berry matrix tested.
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Figure 1. Principal component analysis (PCA) of the impact of type of carrier to
phytochemical parameter in fruit (A), juice (B), pomace (C) powders. Abbreviations: ANT—sum
of anthocyanins; FL—sum of flavonols; PA—sum of phenolic acid; PP—polymeric procyanidins;
F3O—sum of flavan-3-ols (monomers and oligomers); DP—degree of polymerization;
PC—sum of polyphenolic compounds; 1—cyanidin-3-O-galactoside; 2—cyanidin-3-O-glucoside;
3—cyanidin-3-O-arabinoside; 4—cyanidin-3-O-xyloside; 5—cyanidin; 6—protocatechuic
acid; 7—caffeic acid glucoside; 8—caffeoylhexose; 9—acid isomers; 10—3-O-caffeoylquinic
acid; 11—5-O-caffeoylquinic acid; 12—4-O-caffeoylquinic acid; 13—3-O-p-coumaroylquinic
acid; 14—di-caffeoylquinic acid; 15—di-caffeoylquinic acid; 16—kaempferol-3-O-galactoside;
17—quercetin-3-O-arabinobioside; 18—kampferol-3-O-glucoside; 19—quercetin; 20—quercetin-3-O-
rutinoside; 21—quercetin-3-O-robinobioside; 22—quercetin-3-O-galactoside; 23—quercetin-3-O-glucoside;
24—quercetin-3-O-arabinoside; 25—quercetin-3-O-xyloside; 26—quercetin-3-O-(6”-acetyl)glucoside;
27—quercetin-3-O-(6”-acetyl)galactoside; 28—quercetin-deoxyhexo-hexoside; 29—sum of B-type
procyanidin tetramer; 30—sum of B-type procyanidin trimer; 31—sum of B-type procyanidin dimer;
32—A-type procyanidin dimer; 33—(-)-epicatechin; 34—(+)-catechin.
2.3. Impact of the Amount of Added Carriers’ on Polyphenols Content and Antioxidant Capacity in Dependence
on the Matrix
The concentration of carriers had a stronger impact on the retention of polyphenolic compounds
than the type of carrier or drying method. A similar observation was made for black currant powders
with the use of the mentioned-above carriers for drying [16]. In turn, addition of maltodextrin at
the level of 15% was found to protect the bioactive compounds from thermal degradation [31]. The
principal component analysis (PCA) was used to evaluate the influence of the concentration of carriers
on the protection of antioxidant compounds depending on the matrix tested (Figure 2). PCA graph
for powders with 30% of carriers showed by 20% and 37% higher content of total polyphenols, and
by 29% and 47% higher antioxidant potential determined with ABTS and FRAP assays compared
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to the powders obtained with 40% and 50% of carriers, respectively, regardless of the matrix tested.
Probably, the content of phenolics was affected by the dilution effect with the carrier; the higher the
carrier concentration, the lower the content of bioactive compounds. A similar observation was made
in the case of Eugenia dysenterica DC. powders pointing to a concentration of a carrier on the content
of polyphenols. Samples obtained using 10% of carriers showed the highest content of polyphenols,
while the powders with 30% of carrier presenting the lowest amount of phenols [32]. This can also be
confirmed by a strong positive correlation between individual polyphenolic compounds (anthocyanins,
phenolic acids, flavonols, flavan-3-ols) and antioxidant activity (ABTS assay) of r = 0.979, 0.999, 0.998,
0.992 (for fruit powders), r = 0.993, 0.974, 0.998, 0.999 (juice powders), and r = 0.958, 0.993, 0.994, 0.998
(pomace powders). Depending on the matrix, the lowest loss of polyphenolic compounds was noted in
juice powders and it was 17% and 21% with 40% and 50% of carriers compared to the powders with 30%
of carriers. While in fruit and pomace powders losses were 11% and 18% higher. Greater degradation of
flavan-3-ols (monomers and oligomer) and polymeric procyanidin was found in the fruit and pomace
powders than in the juice powders; it reached ca. 24% and 30%. As for the anthocyanins, the greatest
degradation was found in fruit powder (ca. 43% in product with 50% of carrier) > pomace powder
(around 40%) > juice powders (38%). While, the smallest degradation of phenolic acids and flavonols
was found in the pomace powders—around 15% and 26% and 12% and 28% in products with 40% and
50% of carriers, respectively, compared to the final product with 30% of carrier. Probably high stability
can be due to presence of cell wall polysaccharide compounds e.g., pectins, whether lower water
activity [21,22]. Additionally, it might be due to the better encapsulation process of these samples,
which is confirmed by Daza et al. [32] who followed the highest retentions of bioactive compounds in
cagaita powders with 20%–30% of carriers. However, the higher carrier concentration affected the
protection of individual compounds, e.g., in the case of fruit powders—40% of carrier influenced higher
protection of cyanidin-3-O-arabinose and a higher degree of polymerization, but 50% of carrier affected
the B-type procyanidin tetramer. Whereas in the case of juice powders—40% of carrier caused high
retention of quercetin-3-O-robinobioside, -3-O-arabinoside, -3-O-glucoside, and protocatechuic acid,
but 50% of carrier caused a high degree of polymerization. Finally, in the case of pomace powders—40%
of carrier caused a high degree of polarization just like in the fruit powders. Indicating that might
have led to a release of the compounds from more polymerized structures. Similarly as with pulp and
juice powders made from cagaita and plum, the concentration of carriers had a strong influence on
the decrease of total polyphenolic compounds [32,33]. Thus, the higher carrier concentration led to
a lower polyphenol content and lower antioxidant activity, indicating the strong effect of the initial
composition of the matrix tested. Moreover, dried products with carriers showed a 1.6 and 1.9, and
1.5 times higher protection of the antioxidant capacity and phenolic compounds, than the products
without carriers [17]. Which is also confirmed by other authors who confirmed that the use of carriers
affects the protection of bioactive compounds [32,33]. Different interactions between the powders
compounds and the carrier might also occur compared to the powders without a carrier [32].
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Figure 2. Principal component analysis (PCA) of the impact of carriers’ concentration on
phytochemicals in fruit (A), juice (B), pomace (C) powders. Abbreviations: 30%, 40%, 50%, concentration;
ANT—sum of anthocyanins; FL—sum of flavonols; PA—sum of phenolic acid; PP—polymeric
procyanidins; F3O—sum of flavan-3-ols (monomers and oligomers); DP—degree of polymerization;
PC—sum of polyphenolic compounds; 1—cyanidin-3-O-galactoside; 2—cyanidin-3-O-glucoside;
3—cyanidin-3-O-arabinoside; 4—cyanidin-3-O-xyloside; 5—cyanidin; 6—protocatechuic acid; 7—caffeic
acid glucoside; 8—caffeoylhexose; 9—trihydroxycinnamoylquinic acid isomers; 10—3-O-caffeoylquinic
acid; 11—5-O-caffeoylquinic acid; 12—4-O-caffeoylquinic acid; 13—3-O-p-coumaroylquinic
acid; 14—di-caffeoylquinic acid; 15—di-caffeoylquinic acid; 16—kaempferol-3-O-galactoside;
17—quercetin-3-O-arabinobioside; 18—kaempferol-3-O-glucoside; 19—quercetin; 20—quercetin-3-O-
rutinoside; 21—quercetin-3-O-robinobioside; 22—quercetin-3-O-galactoside; 23—quercetin-3-O-glucoside;
24—quercetin-3-O-arabinoside; 25—quercetin-3-O-xyloside; 26—quercetin-3-O-(6”-acetyl)glucoside;
27—quercetin-3-O-(6”-acetyl)galactoside; 28—quercetin-deoxyhexo-hexoside; 29—sum of B-type
procyanidin tetramer; 30—sum of B-type procyanidin trimer; 31—sum of B-type procyanidin dimer;
32—A-type procyanidin dimer; 33—(-)-epicatechin; 34—(+)-catechin.
2.4. Impact of the Type of Drying Method on Polyphenolic Compounds and Antioxidant Capacity in
Dependence on the Matrix
The PCA analyses showed that the powders produced after the freeze-drying process had the
highest content of almost all polyphenolic compounds and antioxidant activity, regardless of the matrix
tested (Figure 3). Similar observations were made during drying Averrhoa carambola pomace. The
freeze-drying with carriers was more effective in ensuring the retention of polyphenolic compounds
when compared to spray drying [12]. Moreover, after freeze-drying Averrhoa carambola pomace, it
was noted that the higher the drying process temperature, the lower the antioxidant activity, while
opposite observation was made for the juice powder. The higher the vacuum drying temperature,
the stronger the degradation of anthocyanins in juice powders made from black currant. However,
vacuum drying at 50 ◦C affected high retained phenolic acids and flavonols [16]. The best effect of
drying cranberry products was obtained after spray-drying and freeze-drying, while an increase in
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aglycon of quercetin after vacuum-drying at 60 ◦C was observed [31]. Therefore, it can be concluded
that the antioxidant activity of the tested material was dependent on the content of polyphenolic
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Figure 3. Principal component analysis (PCA) of the impact of drying method on
phytochemicals in fruit (A), juice (B), pomace (C) powders. Abbreviations: FD, freeze-drying;
VD/50, vacuum-drying in 50 ◦C; VD/60, vacuum-drying in 60 ◦C; ANT—sum of anthocyanins;
FL—sum of flavonols; PA—sum of phenolic acid; PP—polymeric procyanidins; F3O—sum of
flavan-3-ols (monomers and oligomers); DP—degree of polymerization; PC—sum of polyphenolic
compounds; 1—cyanidin-3-O-galactoside; 2—cyanidin-3-O-glucoside; 3—cyanidin-3-O-arabinoside;
4—cyanidin-3-O-xyloside; 5—cyanidin; 6—protocatechuic acid; 7—caffeic acid glucoside;
8—caffeoylhexose; 9—trihydroxycinnamoylquinic acid isomers; 10—3-O-caffeoylquinic
acid; 11—5-O-caffeoylquinic acid; 12—4-O-caffeoylquinic acid; 13—3-O-p-coumaroylquinic
acid; 14—di-caffeoylquinic acid; 15—di-caffeoylquinic acid; 16—kaempferol-3-O-galactoside;
17—quercetin-3-O-arabinobioside; 18—kampferol-3-O-glucoside; 19—quercetin; 20—quercetin-3-O-
xrutinoside; 21—quercetin-3-O-robinobioside; 22—quercetin-3-O-galactoside; 23—quercetin-3-O-glucoside;
24—quercetin-3-O-arabinoside; 25—quercetin-3-O-xyloside; 26—quercetin-3-O-(6”-acetyl)glucoside;
27—quercetin-3-O-(6”-acetyl)galactoside; 28—quercetin-deoxyhexo-hexoside; 29—sum of B-type
procyanidin tetramer; 30—sum of B-type procyanidin trimer; 31—sum of B-type procyanidin dimer;
32—A-type procyanidin dimer; 33—(-)-epicatechin; 34—(+)-catechin.
Vacuum drying method affected the retention of individual compounds: for fruit powders,
vacuum drying at 50 ◦C resulted in a higher retention of hydroxybenzoic acid (protocatechuic acid),
and hydroxycinnamic acid (caffeic acid) in powders whereas drying at 60 ◦C had an impact on B-type
procyanidin dimer, and tetramer, 4, 3-O-caffeoylquinic acids, di-caffeoylquinic acid, free cyanidin,
and quercetin aglycon. In the case of juice powders, application of the temperature of 50 ◦C during
vacuum drying resulted in a higher retention of quercetin-3-O-robinobioside, -3-O-arabinoside, and
quercetin aglycon. Drying at 60 ◦C influenced a higher content of total flavonols and their derivatives,
flavan-3-ols and their monomers and oligomers, and free cyanidin aglycon. However, in blackcurrant
juice powders, the vacuum drying at 50 ◦C and 70 ◦C caused a higher retention of anthocyanins, and
according to the authors, this could be due to the inactivation of polyphenol oxidase [16]. In the
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present study, the higher temperature contributed only to the release of free aglycon of anthocyanins.
As far as the pomace powders are concerned, the vacuum drying at 50 ◦C had a strong impact
on the content of free aglycon, and quercetin-3-O-rutinoside. The drying at 60 ◦C influenced the
retention of monomers ((−)-epicatechin) and oligomers of flavan-3-ols, and total flavonols and their
derivatives. On the other hand, among all compounds identified in flavan-3-ols group, (−)-epicatechin
content in juice powders was 2.8 times higher after vacuum drying at 60 ◦C when compared to the
freeze-drying. This suggests the temperature-depended release of this compound from polymerized
structures. A similar observation was made for blackcurrant juice the vacuum drying of which at 90 ◦C
resulted in 130 times higher (+)-catechin content compared to vacuum drying at 50 ◦C. The authors
concluded that the controlled release of compounds from polymerized structures during drying may
be helpful in obtaining the desired content of polyphenolic compounds in the powders [16]. In turn, a
similar increase of flavonols aglycon content under the influence of high temperature as a result of
the deglycosylation of flavonol glycosides was observed in cranberry products [31,34]. In addition,
similarly to cranberry juice powders [31], the temperature influenced the retention of total flavonols
in juice and pomace powders made from Saskatoon berry. This can also be confirmed by negative
correlation between flavonols and antioxidant activity of r = −0.265 for ABTS assay, and r = −0.253 for
FRAP assay (for juice powders), and r = −0.925 for ABTS assay, and r = −0.890 for FRAP assay (pomace
powders). Moreover, the increased content of flavonols and their derivatives was also observed upon
vacuum drying of juice and pomace powders made of black currant at 50 ◦C and 70 ◦C [16,35]; however,
the authors observed that an increase of temperature above 80 ◦C and 90 ◦C decreased flavonols
content. Among all of the compounds tested, anthocyanins were the most unstable constituents when
the higher temperature of drying was applied. Their average amount after vacuum drying at 50 ◦C
was 42% lower when compared to the freeze-drying. Moreover, the increase of the temperature during
vacuum drying by 10 ◦C caused their 13% loss. Bakowska-Barczak and Kołodziejczyk [29] reported
that the higher the temperature during drying black current powder, the stronger the degradation of
anthocyanins. Cai and Corke [36] also noted that a higher drying temperature had a stronger effect on
amaranthus betacyanins degradation. On the other hand, depending on the matrix tested, the smallest
degradation of anthocyanins was noted in the pomace powder after freeze-drying and it was 1.4 and
1.7 times lower when compared to vacuum drying at 50 and 60 ◦C, respectively. While, degradation of
anthocyanins in the fruit and juice powder after vacuum drying at 50 and 60 ◦C was 56% and 65%.
Probably the highest retention of compounds from pomace can be due to lower water activity, and
also with location of compounds because most of them are distributed in berry skin which does not
lead to their complete degradation during heat conditions [21,22]. Thus, the research confirmed that
mild conditions of freeze-drying ensured the protection of anthocyanins, and this was in line with the
previous reports showing that the temperature strongly affected their degradation [37–39]. Moreover,
the higher the drying temperature is, the greater the degradation of the polyphenolic compounds
and their antioxidant activity. The temperature of 50 ◦C influenced the release of quercetin aglycon.
Regardless of the matrix tested, the temperature of 60 ◦C used for vacuum drying resulted in greater
retention of phenolic acid derivatives as well as flavan-3-ols monomers ((−)-epicatechin) and oligomers.
It could be due to the partial inactivation of polyphenol oxidase, because Siddiq et al. [40] noted
that PPO lost about partial inactivation during thermal treatment of blueberry at 55 and 65 ◦C [40].
Therefore, the selection of drying technique for the preparation of Saskatoon berry powders is highly
important when the retention of bioactive compounds is concerned.
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Table 2. Antioxidant activity [mmol Trolox/100 g d.m.] of the fruit, juice, and pomace powders made
from Saskatoon berry.
Drying Method Type of Carriers Con. [%]





30 5.2 ± 0.4 1 3.4 ± 0.1
40 3.9 ± 0.1 2.5 ± 0.1
50 3.8 ± 0.2 2.1 ± 0.2
Maltodextrin
30 5.4 ± 0.1 4.0 ± 0.1
40 4.4 ± 0.1 3.1 ± 0.3
50 2.4 ± 0.1 1.9 ± 0.2
VD/50
Inulin
30 4.9 ± 0.1 3.0 ± 0.1
40 4.2 ± 0.3 2.7 ± 0.1
50 3.1 ± 0.1 2.0 ± 0.2
Maltodextrin
30 4.9 ± 0.1 3.4 ± 0.1
40 3.2 ± 0.1 2.2 ± 0.1
50 1.9 ± 0.1 1.5 ± 0.1
VD/60
Inulin
30 5.8 ± 0.5 3.9 ± 0.1
40 3.4 ± 0.1 2.4 ± 0.2
50 2.7 ± 0.3 2.1 ± 0.2
Maltodextrin
30 4.9 ± 0.6 3.3 ± 0.3
40 2.9 ± 0.5 2.3 ± 0.2




30 10.0 ± 0.9 7.3 ± 0.1
40 9.0 ± 0.2 6.7 ± 0.5
50 7.9 ± 0.3 4.9 ± 0.2
Maltodextrin
30 11.6 ± 0.5 7.9 ± 0.2
40 9.7 ± 0.4 6.9 ± 0.1
50 6.9 ± 0.2 5.3 ± 0.5
VD/50
Inulin
30 9.6 ± 0.4 6.0 ± 0.4
40 7.7 ± 0.3 4.8 ± 0.1
50 5.7 ± 0.1 4.1 ± 0.5
Maltodextrin
30 8.6 ± 0.1 5.4 ± 0.1
40 7.7 ± 0.5 4.8 ± 0.2
50 6.1 ± 0.3 3.8 ± 0.4
VD/60
Inulin
30 7.9 ± 0.2 4.8 ± 0.3
40 6.3 ± 0.5 4.0 ± 0.1
50 5.7 ± 0.5 3.7 ± 0.1
Maltodextrin
30 7.7 ± 0.1 4.7 ± 0.6
40 6.6 ± 0.2 4.0 ± 0.3




30 1.7 ± 0.1 1.2 ± 0.1
40 1.1 ± 0.1 0.8 ± 0.1
50 0.8 ± 0.1 0.6 ± 0.1
Maltodextrin
30 1.5 ± 0.1 1.1 ± 0.1
40 0.9 ± 0.2 0.8 ± 0.1
50 0.7 ± 0.1 0.5 ± 0.1
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Table 2. Cont.
Drying Method Type of Carriers Con. [%]




30 1.5 ± 0.1 1.2 ± 0.1
40 1.2 ± 0.1 0.9 ± 0.1
50 1.0 ± 0.1 0.7 ± 0.1
Maltodextrin
30 1.4 ± 0.3 1.3 ± 0.1
40 1.2 ± 0.1 0.8 ± 0.1
50 0.7 ± 0.1 0.5 ± 0.1
VD/60
Inulin
30 1.6 ± 0.1 1.2 ± 0.1
40 1.2 ± 0.1 0.7 ± 0.1
50 0.9 ± 0.1 0.9 ± 0.1
Maltodextrin
30 1.4 ± 0.2 1.1 ± 0.2
40 1.1 ± 0.3 0.9 ± 0.1
50 0.7 ± 0.2 0.5 ± 0.1
1 Values are expressed as the mean (n = 3) ± standard deviation. ND, not detected; FD, freeze-drying; VD/50,
vacuum-drying at 50 ◦C; VD/60, vacuum-drying at 60 ◦C.
3. Materials and Methods
3.1. Reagents
Acetonitrile, formic acid, methanol, ABTS (2,2′-azinobis(3-ethylbenzothiazoline-6-sulfonic
acid), 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid (Trolox, Sigma-Aldrich, Steinheim,
Germany), 2,4,6-tri(2-pyridyl)-s-triazine (TPTZ), acetic acid, and phloroglucinol were purchased
from Sigma-Aldrich (Steinheim, Germany). (−)-Epicatechin, (+)-catechin, chlorogenic acid,
di-caffeic quinic acid, procyanidin B2, procyanidin A2, p-coumaric acid, keampferol-3-O-galactoside,
quercetin-3-O-galactoside, caffeic acid, cyanidin-3-O-galactoside, and cyanidin-3-O-glucoside standards
were purchased from Extrasynthese (Lyon, France). Acetonitrile for ultra-phase liquid chromatography
(UPLC; gradient grade) and ascorbic acid were from Merck (Darmstadt, Germany).
3.2. Material
The raw material used in the study included Saskatoon berries (A. alnifolia L.) cv. ‘Smoky’ that were
purchased from the horticultural farm in Wojciechów near Lublin, Poland (51◦14′08”N 22◦14′41”E).
This cultivar was chosen on the basis of the previous research (Lachowicz et al., 2019). The resulting
fruit was ground in Thermomix (Wuppertal, Vorkwek, Germany) at 40 ◦C for 10 min. Then, the juice
was extracted on a hydraulic press and centrifuged. Solutions with carrier concentrations of 30%,
40%, and 50% (w/w) were prepared. The carriers applied to produce powders were maltodextrin DE




Freeze-drying (FD, control) (ca. 100 g) was carried out in a freeze dryer (Christ Alpha 1–4 LSC;
Osterode am Harz, Germany) for 24 h. The temperature within the drying chamber was −60 ◦C, while
the heating plates had the temperature of 25 ◦C.
Vacuum drying (VD) was made in VACUCELL 111 ECO LINE vacuum dryer (MMM Medcenter
Einrichtungen GmbH, Planegg, Germany) at 50 and 60 ◦C under pressure of 0.1 mbar for 24, and
16 h, respectively.
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All drying experiment were performed in duplicate. The samples obtained were milled by
laboratory mill (IKA A.11, Wilmington, NC, US), and vacuum sealed. The powders were kept in a
freezer (−20 ◦C) until extracts’ preparation.
3.3.2. Identification and Quantification of Polyphenols
Polyphenols were extracted from the fruit, juice, and pomace powders in triplicate (n= 3) according
to Lachowicz et al. [17]. For polyphenolic compounds: wheat bread (1 g) were extracted with 10 mL of
mixture containing UPLC-grade methanol (30 mL/100 mL), and acetic acid (1 mL/100 mL of reagent).
The extraction was performed twice by incubation for 20 min under sonication (Sonic 6D, Polsonic,
Warsaw, Poland) and with occasional shaking. Next, the slurry was centrifuged at 19,000× g for 10 min,
and the supernatant was filtered through a hydrophilic PTFE 0.20 μm membrane (Millex Samplicity
Filter, Merck, Darmstadt, Germany) and used for analysis.
Qualitative (LC-QTOF-MS) and quantitative (UPLC-PDA-FL) analysis of polyphenols
(anthocyanins, flavan-3-ols, flavonols, and phenolic acids) was performed as previously described by
Lachowicz et al. (2017). Separations of individual polyphenols were carried out using a UPLC BEH
C18 column (1.7 μm, 2.1 × 100 mm, Waters Corporation, Milford, MA, USA) at 30 ◦C. The samples
(10 μL) were injected, and the elution was completed in 15 min with a sequence of linear gradients
and isocratic flow rates of 0.45 mL/min. The mobile phase consisted of solvent A (2% formic acid;
v/v) and solvent B (100% acetonitrile). The program began with isocratic elution with 99% solvent A
(0–1 min), and then a linear gradient was used until 12 min, lowering solvent A to 0%; from 12.5 to
13.5 min, the gradient returned to the initial composition (99% A), and then it was held constant to
re-equilibrate the column. Characterization of the single components was carried out via the retention
time and the accurate molecular masses. Each compound was optimized to its estimated molecular
mass [M − H]−/[M + H]+ in the negative and positive mode before and after fragmentation. The data
obtained from UPLC-MS were subsequently entered into the MassLynx 4.0 ChromaLynx Application
software (Waters Corporation, Milford, MA, USA). On the basis of these data, the software is able to
scan different samples for the characterized substances. The runs were monitored at the wavelength
of 360 nm for flavonol glycosides. The PDA spectra were measured over the wavelength range of
200–800 nm in steps of 2 nm. The retention times and spectra were compared to those of the pure
standard. The calibration curves were run at 360 nm for the standard keampferol-3-O-galactoside,
quercetin-3-O-galactoside, at 320 nm for the standard of chlorogenic, caffeic, di-caffeic quinic, and
p-coumaric acids, at 520 nm for the standard cyanidin-3-O-galactoside and cyanidin-3-O-glucoside
and at 280 nm for the standard (−) epicatechin, (+)-catechin, procyanidins B2 and A2, at concentrations
ranging from 0.05–5 mg/mL (R2 = 0.9999). The measurements were performed in triplicates. The
results were expressed as mg per 100 g dry matter (d.m.).
3.3.3. Analysis of Proanthocyanidins by Phloroglucinolysis
Direct phloroglucinolysis of samples was performed as described by Lachowicz et al. [17]. Samples
were weighed in an amount of 5 mg, then 0.8 mL of the methanolic solution of phloroglucinol (75 g/L)
and ascorbic acid (15 g/L) were added. After addition of 0.4 mL of methanolic HCl (0.3 mol/L), the
vials were incubated for 30 min at 50 ◦C with continuous vortexing in a thermo shaker (TS-100, BioSan,
Riga, Latvia). The reaction was stopped by placing the vials in an ice bath with the addition of
0.6 mL of the sodium acetate 0.2 mol/L. Next the vials were centrifuged immediately at 20,000× g
for 10 min at 4 ◦C. Samples were stored at 4 ◦C before reverse phase HPLC (RP-HPLC) analysis.
All incubations were done in triplicate. Phloroglucinolysis products were separated on a Cadenza
CD C18 (75 mm × 4.6 mm, 3 μm) column (Imtakt, Kyoto, Japan). The liquid chromatograph was a
Waters (Milford, MA, USA) system equipped with diode array and scanning fluorescence detectors
(Waters 474) and autosampler (Waters 717 plus). Solvent A (25 mL acetic acid and 975 mL water) and
solvent B (acetonitrile) were used in the following gradients: initial, 5 mL/100 mL B; 0–15 min, to
10 mL/100 mL B linear; 15–25 min to 60 mL/100 mL B linear; followed by washing and reconditioning
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of the column. A flow rate of 1 mL/min and an oven temperature of 15 ◦C with the injection of the
filtrate (20 μL) on the HPLC system. The fluorescence detection was recorded at excitation wavelength
of 278 nm and emission wavelength of 360 nm. The calibration curves, which were based on peak area,
were established using (+)-catechin, (−)-epicatechin, (+)-catechins, and (−)-epicatechin-phloroglucinol
adduct standards. The average degree of polymerization was measured by calculating the molar
ratio of all the flavan-3-ol units (phloroglucinol adducts + terminal units) to (−)-epicatechin and
(+)-catechin, which correspond to terminal units. Quantification of the (+)-catechin, (−)-epicatechin,
(+)-catechin, and (−)-epicatechin-phloroglucinol adducts was achieved by using the calibration curves
of the corresponding standards (Extrasynthese). All data were obtained in triplicate. The results were
expressed as mg per 100 g d.m.
3.3.4. Antioxidant Capacity
For antioxidant activity: the samples (1 g) were mixed with 10 mL of MeOH/water (80:20%,
v/v) and with 1% of HCl, sonicated at 20 ◦C for 15 min and left for 24 h at 4 ◦C. Then the extract
was again sonicated for 15 min, and centrifuged at 15,000g for 10 min. The ABTS and the FRAP
assays were determined according to Re et al. [41] and Benzie and Strain [42], respectively, by Synergy
H1 spectrophotometer (BioTek Instruments Inc., Winnoski, VT, USA). The antioxidant capacity was
expressed as mmol of Trolox per 100 g d.m.
3.3.5. Statistical Analysis
Statistical analysis, one-way ANOVA and principal component analysis (PCA) were conducted
using Statistica version 12.5 (StatSoft, Kraków, Poland). Significant differences (p ≤ 0.05) between
average values were evaluated by one-way ANOVA and HSD Tukey multiple range test.
4. Conclusions
The concentration of carriers had a stronger impact on the content of polyphenolic compounds
and antioxidant capacity than the type of carrier or drying method. The choice of a carrier should
be done in dependence of the matrix and of the desired composition of bioactive compounds and
antioxidant activity. Therefore, maltodextrin can be recommended for powders obtained from the fruit
and juice of Saskatoon berry, whereas inulin can be applied in order to produce pomace powders with
better functional composition of bioactive compounds. In addition, PCA showed that the freeze-drying
process led to the highest content of almost all polyphenolic compounds and their high antioxidant
activity, regardless of the matrix tested.
Thus, in future research, properly prepared Saskatoon berry powders with the mentioned carriers
will be used as functional additives to design functional food especially foodstuff for enhancing health
benefit properties.
Supplementary Materials: The following are available online, Table S1. Identification and quantification of
flavan-3-ols [mg/100 g d.m.] in fruit, juice, and pomace powders made form Saskatoon berry, Table S2. Identification
and quantification of anthocyanins [mg/100 g d.m.] in the fruit, juice, and pomace powders made form Saskatoon
berry, Table S3. Identification and quantification of phenolic acids [mg/100 g d.m.] in the fruit, juice, and pomace
powders made form Saskatoon berry, Table S4. Identification and quantification of flavonols [mg/100 g d.m.] in
the fruit, juice, and pomace powders made form Saskatoon berry.
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Abstract: Ageratina havanensis (Kunth) R. M. King & H. Robinson is a species of flowering shrub in
the family Asteraceae, native to the Caribbean and Texas. The aim of this work was to compare the
quantitative chemical composition of extracts obtained from Ageratina havanensis in its flowering and
vegetative stages with the antioxidant potential and to determine the effects on P-glycoprotein (P-gp)
function. The quantitative chemical composition of the extracts was determined quantifying their
major flavonoids by UPLC-ESI-MS/MS and by PCA analysis. The effects of the extracts on P-gp activity
was evaluated by Rhodamine 123 assay; antioxidant properties were determined by DPPH, FRAP
and inhibition of lipid peroxidation methods. The obtained results show that major flavonoids were
present in higher concentrations in vegetative stage than flowering stage. In particular, the extracts
obtained in the flowering season showed a significantly higher ability to sequester free radicals
compared to those of the vegetative season, meanwhile, the extracts obtained during the vegetative
stage showed a significant inhibitory effect against brain lipid peroxidation and a strong reductive
capacity. This study also showed the inhibitory effects of all ethanolic extracts on P-gp function in
4T1 cell line; these effects were unrelated to the phenological stage. This work shows, therefore,
the first evidence on: the inhibition of P-gp function, the antioxidant effects and the content of major
flavonoids of Ageratina havanensis. According to the obtained results, the species Ageratina havanensis
(Kunth) R. M. King & H. Robinson could be a source of new potential inhibitors of drug efflux
mediated by P-gp. A special focus on all these aspects must be taking into account for future studies.
Keywords: Ageratina havanensis; flavonoids; UPLC-ESI-MS/MS; P-glycoprotein; antioxidant potential
1. Introduction
Polyphenols, particularly flavonoids, have been widely studied for their bioactive properties and
their strong antioxidant effects are well noted [1–3]. In addition, some plant antioxidant polyphenols
exhibit anti-neoplastic activity by multiple pathways, including their potential to intensify the action
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of cytostatic drugs, through the attenuating the multidrug resistance (MDR) phenomenon [4]. The best
recognized and the most frequent cause of the MDR involves an increased activity of ATP-binding
cassette family transporters (ABC) [5]. A large number of compounds have been identified as MDR
suppressors by interfering with the P-gp-mediated export of chemotherapeutic agents [6–9]. However,
in many cases the high toxicity of these substances has limited their use [10]. Thus, natural antioxidants
have been identified as novel potential candidates [11–16].
Different studies show that plants of the genus Ageratina contain a variety of flavonoids. Particularly,
in our previous research studying the extracts obtained from the leaves of Ageratina havanensis (Kunth)
R. M. King & H. Robinson, growing in Cuba, by chromatographic, spectroscopic and spectrometric
methods, we identified a significant presence of flavonoids and their glucosides [17,18]. We also
determined that the qualitative composition of the flavonoids in the plant is similar in two different
phenological stages, that is flowering and vegetative state [18].
Taking into account the abundance of flavonoids in the extracts prepared from Ageratina havanensis,
it is expected that these extracts have antioxidant properties [19–21]. As qualitative composition of
flavonoids is similar in both phenological stages, it could be hypothesized that the biological activity
in both stages is similar, too. Based on these considerations, in this paper we studied the Ageratina
havanensis (Kunth) R. M. King & H. Robinson extracts to prove their ability to inhibit P-gp function
under no cytotoxicity conditions, their antioxidant potential and the influence of their quantitative
composition on the biological properties of the plant.
2. Results
2.1. P-gp Modulation by Extracts Obtained from Ageratina havanensis
The first step of this study was to investigate if the extracts obtained from Ageratina havanensis
could inhibit P-gp activity under no cytotoxicity conditions. In order to mimic the chemo-resistance in
humans, the cells chosen for this research were the well-characterized mouse mammary carcinoma 4T1
cells that express multi-resistance phenotype after exposure to different anticancer drugs mediated
by P-gp.
Firstly, to determine the cytotoxic effects of the eleven extracts obtained from Ageratina havanensis
on 4T1 cells, the MTT assay was employed. Table 1 reports the IC50 values calculated after exposure of
the cells to the Ageratina havanensis extracts for 24 h. As shown, the treatments reduced cell viability
showing only slight differences between the products. In all the cases, significant differences were
observed in comparison with control cells for values above 250 μg/mL. Thus, a range of concentrations
under IC50 values was selected for evaluating effects of the extracts on P-gp function.
Rho-123 is a fluorescent compound, which enters the cells passively and concentrates in
mitochondria. As P-gp substrate, the intracellular loading of this probe is inversely proportional to
P-gp activity. Intracellular fluorescence increased in a dose-dependent fashion in 4T1 cells exposed
to Lf-EtOH until F-EtOH extract for 1 h, but important differences between the extracts were found.
The percentage of the inhibitory effect on the activity of the transporter produced at the highest
concentration tested (200 μg/mL) are showed in Table 1. As reported, all ethanolic extracts (Lf-EtOH,
Lv-EtOH, Sf-EtOH and F-EtOH) showed promissory inhibitory effects. More in details, the inhibitory
activity was above 50% for both Sf-EtOH and Sv-EtOH, the two extracts obtained from the stem bark,
compared to controls. On the contrary, the F-EtOAc and F-n-BuOH extracts were not able to inhibit the
function of the transporter under the same experimental conditions.
204
Molecules 2020, 25, 2134
Table 1. Cytotoxicity and inhibitory effects on P-gp function of Ageratina havanensis (Kunth) R. M. King
& H. Robinson extracts on breast cancer 4T1 cells.
Harvesting Stage Plant Organs Extracts IC50 (μg/mL) Inhibition P-gp Function (%)
Flowering
Leaves
Lf-EtOH 381.6 ± 7.5 35
Lf-EtOAc 252.5 ± 10.1 23
Lf-n-BuOH 302.0 ± 8.0 19
Vegetative stage
Lv-EtOH 392.8 ± 6.7 58
Lv-EtOAc 313.0 ± 12.1 45
Lv-n-BuOH 496.5 ± 6.7 27
Flowering
Stems
Sf-EtOH 228.2 ± 8.7 84
Vegetative stage Sv-EtOH 355.7 ± 7.6 65
Flowering Flowers
F-EtOH 263.5 ± 8.2 85
F-EtOAc 259.5 ± 10.6 -
F-n-BuOH 315.5 ± 9.9 -
IC50 is defined, as the concentration required achieving 50% inhibition over control cells, values are shown as mean
± SEM. %: represents the percentage of inhibition P-gp activity at the higher concentration tested (200 μg/mL)
respect to control cells (untreated cells) after 1 h of exposure. Verapamil used as control positive was included,
showing values of inhibition in the order of 300% to the activity exhibit by control cells. Values showed are from
two independent experiments with three replicas.
2.2. Antioxidant Effects of Extracts Obtained from Ageratina havanensis
The screening of the antioxidant activity of the substances may require a combination of different
methods to describe the background about the antioxidant properties of the samples. Here, the
antioxidant potential of the Ageratina havanensis extracts was determined by using three in vitro
methods, which previously have been used to predict the antioxidant capacity of several substances
(DPPH free radical scavenging assay, FRAP assay and the determination of lipid peroxidation in brain
rat homogenates) [22–24].
The model of scavenging the stable DPPH radical has been used method to evaluate the free
radical scavenging ability of substances [23,24]. In this case, the antioxidant effect of the analyzed
sample on DPPH radical scavenging may be due to their hydrogen donating ability and it reduce the
stable violet DPPH radical to the yellow DPPH-H. Substances which are able to perform this reaction
can be considered as antioxidants and therefore radical scavengers [25]. On the other hands, FRAP
assay is based on the ability of antioxidant to reduce Fe3+ to Fe2+ in the presence of tripyridyltriazine
(TPTZ), forming the intense blue Fe2+–TPTZ complex with an absorption maximum at 593 nm; the
absorbance increase is proportional to the antioxidant content [22]. As shown in Table 2, the radical
scavenging activity of the eleven Ageratina havanensis extracts evaluated was significantly (p < 0.05)
higher in the flowering compared to the vegetative season, meanwhile, the reductive capacity was
significantly (p < 0.05) higher in vegetative state.
During the last years, lipid peroxidation has received renewed attention from the viewpoints of
nutrition and medicine. Lipid peroxidation is implicated in the underlying mechanisms of several
disorders and diseases such as cardiovascular diseases, cancer, neurodegenerative diseases, and even
aging [26]. It is the accumulated result of reactive oxygen species and a chain reaction that causes the
dysfunction of biological systems [27]. Furthermore, the extracts from the flowering season showed a
significant (p < 0.05) inhibition of lipid peroxidation against brain phospholipid peroxidation compared
with the extracts from the vegetative stage (Table 2).
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Table 2. In vitro antioxidant capacity of Ageratina havanensis (Kunth) R. M. King & H. Robinson extracts.
Harvesting Stage Plant Organs Extracts








Lf-EtOH 88.21 ± 3.77 a 22.65 ± 1.73 a 16.52 ± 2.19 a
Lf-EtOAc 90.52 ± 3.61 a 39.27 ± 2.04 a 21.63 ± 1.78 a
Lf-n-BuOH 63.51 ± 2.62 a 53.12 ± 0.92 a 38.91 ± 3.52 a
Vegetative stage
Lv-EtOH 279.42 ± 8.48 b 151.90 ± 3.71 b 41.66 ± 2.87 b
Lv-EtOAc 234.70 ± 7.93 b 138.11 ± 2.67 b 46.23 ± 3.12 b
Lv-n-BuOH 231.56 ± 10.14 b 84.24 ± 3.81 b 51.60 ± 2.04 b
Flowering
Stems
Sf-EtOH 88.43 ± 3.96 a 39.23 ± 1.92 a 37.21 ± 2.55 a
Vegetative stage Sv-EtOH 197.21 ± 3.30 b 32.72 ± 7.23 a 48.32 ± 3.87 b
Flowering Flowers
F-EtOH 169.91 ± 7.63 a 29.45 ± 1.99 a 21.35 ± 2.66 a
F-EtOAc 167.21 ± 5.34 a 38.77 ± 2.64 b 32.34 ± 2.01 b
F-n-BuOH 91.66 ± 3.21 b 54.13 ± 2.88 c 30.27 ± 3.81 b
Sakuranetin 319.38 ± 6.65 - -
7-methoxyaromadendrin 238.45 ± 2.11 - -
Ascorbic acid - 21.97 ± 0.84 -
Trolox-C 10.64 ± 1.02
Values represent the mean ± SEM of the antioxidant activity of A. havanensis extracts. IC50 values were calculated as
the extract concentration required to scavenge 50% of DPPH•, Ascorbic acid was employed as standard for DPPH•
assay and Trolox-C for lipid peroxidation assay. Different letters in the same column represent statistical differences
(ANOVA, Dunnet post-hoc test; p < 0.05). Comparisons were carried out between extracts according to the
seasonal stage (leaves, stems or flowers) or according to the solvent (EtOH, EtOAc or n-BuOH). Three independent
experiments were done and samples were analyzed by triplicate.
2.3. Quantification of Sakuranetin and 7-Methoxyromadendrin in the Extracts of Ageratina havanensis
The major flavonoids sakuranetin and 7-methoxyaromadendrin only differ for a hydroxyl group
(Figure 1) and thus elute with very close retention times. Because of this, it was necessary to develop a
rapid, sensitive and accurate method that would allow for their quantification in Ageratina havanensis
extracts. UPLC-ESI-MS/MS system provides high separation capacity, high analytical speed and high
analytical sensitivity. The addition of 0.1% formic acid to the mobile phase helped achieve satisfactory
peak symmetry, good resolution, and significantly enhanced sensitivity. In this case, this method was
useful for quantifying sakuranetin and 7-methoxyaromadendrin in the extracts of Ageratina havanensis
collected in both seasons.
Figure 1. Chemical structures of: (a) sakuranetin; (b) 7-methoxyromadendrin.
2.3.1. Method Validation
Linearity, LDQ and LOQ
Calibration curves of the standard sakuranetin and 7-methoxyaromadendrin were established
with negative UPLC-ESI-MS/MS on SRM mode. The validation data of the method showed good
correlation coefficients, 0.9909 and 0.9928, respectively, in the mass concentration range of 1–50 ppm,
Table S1.
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Matrix Effect and Recovery
The recoveries after SPE were 93.2% and 97.4% for sakuranetin and 7-methoxyaromadendrin
respectively, which means that 6.8 and 2.6% were lost in the solid phase extraction process. The ratios
(A/B × 100)% were 88.3% for sakuranetin and 94.7% for 7-methoxyaromadendrin, so the presence
of the matrix decreases the recovery of sakuranetin and 7-methoxyaromadendrin by 4.9% and 2.7%
respectively. These results showed that all values were within acceptable ranges.
Precision and Accuracy of the System
In this method, injection errors, dilution, adduct formation etc. can occur. Therefore, precision
and accuracy of the system were evaluated. The results suggest that both parameters were acceptable
for the quantification method developed. In the case of precision, very similar % RSD were observed.
The results of sakuranetin were less than 2.5% in the experiments intra-day and inter-day whereas for
7-methoxyaromadendrine were less than 3.5%. Accuracy showed results above 98% intra-day and
inter-day in both standards for the concentrations tested, Table S2.
2.3.2. Concentration of Standards in the Extracts
The linear calibration curves were used for quantitative analyses of the standards in the
extracts, Table 3. In general, the ethyl acetate extracts showed higher concentration of the analyzed
patterns. The concentration of sakuranetin is approximately three times the concentration of
7-methoxyarycomadendrine. Extracts from the leaves of the vegetative season present a higher
concentration of analyzed flavonoids than those from the flowering season.
Table 3. Concentration of sakuranetin and 7-methoxyaromadendrin in the extracts by UPLC/ESI/TQD/MSn.




Lf-EtOH Below LOQ 1.27
Lf-EtOAc 46.70 16.8




Lv-n-BuOH Below LOQ Below LOQ
Flowering
Stems
Sf-EtOH Below LOQ Below LOQ
Vegetative stage Sv-EtOH Below LOQ Below LOQ
Flowering Flowers
F-EtOH Below LOQ Below LOQ
F-EtOAc 29.90 6.30
F-n-BuOH Below LOQ Below LOQ
2.3.3. Principal Component Analysis of Extracts
Principal component analysis (PCA) allowed comparing extracts of Ageratina havanensis according
their chemical composition. The original variables were reduced to the two principal components
PC1 (77.9%) and PC2 (5.6%) representing an 83.6% of the total data variance (Table S3). According
to eigenvalues, peaks with m/z 447 gave principal contribution to PC1. Also, sakuranetin (m/z 285,
[M − H]−), 7-methoxyaromadendrin (m/z 301, [M − H]−) and peaks with m/z 463 had great influence
on the variability of the data in this component. From the extracts of Ageratina havanensis, were
isolated and identified in previous studies three glycosides with m/z 447 and the same fragmentation
([286+ 162−H]−) in its MS2 spectrum [17,18]. Because of that, it was concluded that the most influential
variables in PC1 were the concentration of sakuranetin and 7-methoxy-aromadendrin. On the other
hand, the glycosides (m/z 447 and m/z 463) were the variables that most influenced on PC2, Table S4.
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Figure 2 shows that the ethyl acetate extract from the leaves collected in vegetative state (Lv-EtOAc)
differs from the rest of the extracts with respect to PC1 followed by the ethyl acetate extract from
the leaves collected in flowering state (Lf-EtOAc). The rest of the extracts showed similarity in
PC1. According to this behavior, it was concluded that sakuranetin, 7-methoxyaromadendrin and
the glycosides (the original variables that most influence CP1) were higher in the vegetative stage,
mainly in the ethyl acetate extract of leaves. With respect to PC2, the n-butanol extract of the leaves
collected in flowering state (Lf-n-BuOH) is different from the rest of the extracts. Sakuranetin and
7-methoxyaromadendrin in this case do not influence the total variability of the data but the glycosides
have a significant influence. These results were expected since in the quantification, the concentration
of both sakuranetin and 7-methoxyaromadendrin resulted higher in the extracts of ethyl acetate of the
leaves, being greater in the vegetative state, whereas in the ethanolic and n-butanolic extracts, these
flavonoids were below the limit of quantification.
Figure 2. Scatter plot of PCA of the extracts on the first two principle components.
3. Discussion
Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer-related death
among women worldwide [28]. Despite the long list of drugs that have been used in the treatment
of breast tumors, marked drug multi-resistance during treatment remains one of the main problems
facing the clinic today when applying a therapy against breast cancer. Among various mechanisms of
chemo-resistance, resistance due to the increased expression of P-gp is the best characterized and it
is considered the most important in cancer therapy. The significance of the above mentioned is also
supported by the fact that more than 50% of existing anticancer drugs are going to P-gp mediated
efflux [29]. Since the results of clinical trials using P-gp inhibitors have not been very promising,
the search for new modulators which selectively inhibit P-gp activity without significant negative
side effects is currently under high interest and hopes are pinned on the application of some plant
polyphenols [11].
P-gp may affect the pharmacokinetic parameters of drugs or other compounds, possibly leading
to modifications of their bioavailability as well as of their distribution, metabolism, elimination and
toxicity (ADMET) [30]. Together with several CYP450 isoenzymes, P-gp is involved in drug-drug,
food-drug and, finally, herb-drug interactions [31]. Herbal medicines may interact with drugs at the
intestine, liver, kidneys, and targets of action. Importantly, many of these drugs have very narrow
therapeutic indices. Most of them are substrates for P-gp. The underlying mechanisms for most
described herb-drug interactions are not entirely understood, and several pharmacokinetic and/or
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pharmacodynamic interferences are often implicated in these interactions. In particular, enzyme
induction and inhibition may play an important role in the occurrence of some herb-drug interactions.
Because herb-drug interactions can significantly affect circulating levels of drug and, hence, alter
the clinical outcome, the identification of herb-drug interactions has important implications [32].
As present results suggest the species Ageratina havanensis (Kunth) R. M. King & H. Robinson could be
a source of new potential inhibitors of drug efflux mediated by P-gp; focus on these aspects must be
taking into account for future studies.
Today it is known that P-gp function and its regulation can be mediated via reactive oxidative
species (ROS) [33–37]. Therefore, the transport of P-gp substrates may be altered by modulation of
P-gp expression/activity under conditions of oxidative stress [38]. In this sense, natural antioxidants,
such as polyphenols, could influence the function of this membrane transporter. It was reported
that polyphenolic compounds, mainly flavonoids or their derivatives, can modulate the main ABC
transporters responsible for cancer drug resistance, including P-gp [16,39–41].
The interest in health benefits of polyphenols has increased due to their powerful antioxidant
and free radical scavenging activities observed in vitro [42]. Current evidence strongly supports a
contribution of polyphenols, in particular flavonoids, to the prevention and therapy of cancer and other
chronic diseases [1,43]. Literature data have shown that plant phenolic content and antioxidant activity
depend on several factors, mainly environmental conditions [3]. Previous studies show that summer
plants (reproductive stage) are richer in phenolic compounds than spring ones (vegetative stage), and
consequently exhibit higher antioxidant activities [2,3]. Here, we evaluated the antioxidant potential
of the Ageratina havanensis extracts by using three in vitro methods of well-established use to strongly
predict the antioxidant capacity of several substances [22–24]. But surprisingly, the results of the
performed studies showed the opposite, the concentration of flavonoids is higher in the vegetative state.
In fact, we observed that Ageratina havanensis extracts possess higher reductive capacity in the vegetative
period. This finding might be related to the content of sakuranetin and 7-methoxyaromadendrin,
which is greater in the vegetative stage. The antioxidant capacity of sakuranetin has been previously
demonstrated [44]. Indeed, here we observed that sakuranetin possesses the greatest reductive capacity
of the analyzed samples. In order to evaluate the antioxidant capacity in a biological system, we used
the lipid peroxidation model in brain homogenates. Rat brain homogenates exposed to oxygen
spontaneously exhibit lipid peroxidation by a mechanism which is independent of superoxide and free
hydroxyl radical production and whose initiation step may involve and iron-mediated cleavage of
lipid hydroperoxides to yield peroxide or alkoxy radicals [45,46]. In this system, the extracts obtained
from the flowering stage effectively inhibited TBARS generation with estimated values (see Table 1).
This result could be explained in term of several mechanisms comprising among others, iron chelation,
(at the initiation step) or a synergistic antioxidant activity (at the propagation step). In addition,
previous studies demonstrated the metal chelation properties of polyphenols [47,48]. The present
results suggest that Ageratina havanensis could be represent a source of antioxidants with potential
neuroprotective actions. In summary, these results show for first time the antioxidant potential of the
extracts obtained from the species Ageratina havanensis.
4. Materials and Methods
4.1. General
Analytical-grade n-hexane, ethyl acetate (EtOAc), n-butanol (n-BuOH), ethanol (EtOH) and
UPLC/MS-grade methanol (Sigma Aldrich, St. Luis, MO, USA) were used. HPLC-grade water
was prepared using a Milli-Q purification system (Millipore, Burlington, MA, USA). The RP18
cartridge was a Phenomenex Strata C18-E. Sakuranetin and 7-methoxyaromadendrin (standards) were
previously isolated from the leaves of Ageratina havanensis (Kunth) R. M. King & H. Robinson [17].
They were identified and standardized by spectroscopic techniques (1H-NMR, 13C-NMR, 2D NMR,
MS). The stability was evaluated by NMR.
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4.2. Plant Material and Extraction
Ageratina havanensis (Kunth) R. M. King & H. Robinson (Asteraceae) as authenticated by Prof.
Iralys Ventosa, Instituto de Ecología y Sistemática, Havana, Cuba (voucher herbarium specimen number
HAC-42498) was collected in Havana (East Havana, Alamar neighbourhood) during 2012 in flowering
and vegetative stage. The secondary metabolites were extracted as previously reported [17,18].
4.3. Cytotoxicity and P-glycoprotein Activity Assays
The study was conducted using 4T1 cells (ATCC, Manasssas, VA, USA) cultured in RPMI-1640
medium containing 10% fetal bovine serum, 1% penicillin-streptomycin and glutamine (2 mmol/L) at
37 ◦C in 5% CO2 humidified incubator.
Cytotoxicity was measured using the MTT reduction assay [49]. After extracts exposure, cells
were washed and a 100 μL/well of MTT reagent (5 mg/mL) was added. After a 4 h incubation period
at 37 ◦C, supernatants were discarded. The dye was extracted with dimethyl sulfoxide and optical
density was read at 540 nm. The inhibition of reduction of MTT was expressed as the percentage of
viable cells referred to control cells, those incubated in presence of the vehicle only (100% viability
value). IC50 values were calculated.
P-glycoprotein (P-gp) activity was evaluated by the Rhodamine-123 (Rho-123) accumulation
assay [13]. Cells (4 × 104/well) were treated for 24 h with sub-toxic concentrations of the extracts
(10–200 μg/mL) or verapamil (20 μM), an inhibitor of P-gp activity (positive control). Cells were
washed and incubated with 5 μg/mL Rho-123 for 2 h. Afterwards, the cells were lysed with 0.1%
Triton X-100. In cell lysates fluorescence intensity was measured at the 485 nm excitation and 535 nm
emission wavelengths. Data were expressed as percentage of fluorescence relative to control cells.
4.4. Antioxidant Capacity Assays
The free radicals scavenging capacity of the extracts was determined [50]. For it, an ethanolic
solution of 130 mM 2,2-diphenyl-1-picrylhydrazyl (DPPH•, Sigma Aldrich, St. Luis, MO, USA) was
mixed with the extracts (2–1000 μg/mL). Ascorbic acid (Sigma) 50 μg/mL was employed as standard.
The reaction mixtures were incubated in the dark at room temperature for 30 min and the absorbance
was measured at 515 nm. The inhibition percent of DPPH• radical was calculated by:
Inhibition (%) = (D.O. control − D.O. sample)/D.O. control) × 100 (1)
The concentration required to scavenge 50% of DPPH (IC50) was determined.
The reducing capacity of the plant extracts was measured according to the method of Benzie and
Strain (1996) [51]. Briefly, acetate buffer (300 mM, pH = 3.6), TPTZ (2, 4, 6-tripyridyl-s-triazine; Sigma)
10 mM in 40 mM HCl and FeCl3 × 6H2O (20 mM) were mixed in the ratio of 10:1:1 to obtain FRAP
reagent. The extracts (20 μL) were mixed with 900 μL of FRAP reagent. The mixtures were incubated
at room temperature for 4 min and absorbances were measured at 593 nm. Ascorbic acid (100 μM) was
used as standard.
To evaluate the inhibition of brain phospholipid peroxidation, rat brains were excised after
decapitation, weighed and washed with 0.9% NaCl ice cold solution. Tissue homogenates were
prepared in a ratio of 1 g of wet tissue to 9 mL of phosphate buffer (50 mM, pH 7.4), by using a
tissue homogenizer (Qiagen). The homogenates were centrifuged at 800× g in a Sigma centrifuge
at −4 ◦C during 15 min and the supernatants were kept at −70 ◦C until analysis. Thiobarbituric
reactive substances (TBARS) measurement assay was carried out as previously described [52]. Brain
homogenates (25 mL) were incubated with different extracts (5–125 μg/mL). Incubations were stopped
by the addition of 350 mL of cold acetic acid 20% pH 3.5. Malondialdehyde (MDA) levels were
determined by the addition of 600 mL of TBA 0.5% in acetic acid 20% pH 3.5. The mixtures were
incubated at 90 ◦C for 1 h. Then, 50 mL of sodium dodecyl sulfate (SDS) were added, and samples were
centrifuged at 500× g during 15 min at room temperature. The absorbance was measured at 532 nm.
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All the values are means of three determinations. Trolox-C (0.5–75 μg/mL), was used as standard. The
extract concentration which is needed to achieve the 50% of inhibition of lipid peroxidation (IC50)
was calculated.
4.5. Statistical Analysis
Values were expressed as mean± standard error of mean (SEM). Statistical analysis was performed
with SPSS 18.0 (SPSS Inc., Chicago, IL, USA). For multiple comparisons, one-way ANOVA was used
followed by Dunnett post-hoc test. Values of p < 0.05 were considered statistically significant.
4.6. Sample Preparation for UPLC-ESI-MS/MS Analysis
A solution of each extract (MeOH/H2O 8:2 v/v, 1 mg/mL) was submitted to the solid-phase
extraction using RP18 cartridge, eluted with MeOH/H2O 8:2 (v/v). After drying, 1 mg was dissolved
in 1 mL of MeOH/H2O 8:2 (v/v) solution (solution A) and an aliquot was diluted with MeOH/H2O
8:2 (v/v) to reach a final volume of 1 mL (150 μg/mL), and was filtered through a 0.22 μm nylon filter
membrane. The final solution was used for quantification analysis. For PCA, the solution A was
diluted with MeOH/H2O 8:2 (v/v) to reach a final concentration of 1 μg/mL. The sample preparations
were triplicated.
Standard Solutions Preparation for Quantification Analysis
Sakuranetin and 7-methoxyaromadendrin were dissolved in 1 mL of MeOH/H2O 8:2 (v/v) solution
(1 mg/mL) and filtered through a 0.22 μm nylon filter membrane. An aliquot was diluted with
MeOH/H2O 8:2 (v/v) up to a volume of 1 mL (100 ppm, solution A). The solution A was diluted to
obtain the solutions patterns between 1 and 50 μg/mL (three replicas for each concentration).
4.7. UPLC-ESI-MS Analysis of the Extracts
Analysis was performed on a Waters® Acquity UPLC system coupled with a XevoTqD® mass
spectrometer (Waters Corp., Milford, MA, USA). The analytical column used was an ACQUITYTM
UPLC X bridge C18 (2.1 × 50 mm, 2.5 μm). Analysis was carried out with water containing 0.1% formic
acid (A) and methanol (B) at a flow rate of 400 μL/min during 10 min. A gradient program was used for
quantification as follows: 0–8 min, 47% B isocratic; 8–10 min, 47–100% B linear and for PCA: 0–3.2 min,
40% B isocratic; 3.2–4 min, 40–60% B linear; 4–8.2 min, 60% B isocratic; 8.2–10 min, 60–100% B linear.
The injection volume was 5 μL in quantification analysis and 10 μL in PCA analysis. Mass spectrometric
detection was in negative mode. The MS conditions were as follows: capillary temperature 200 ◦C;
capillary voltage 3.5 kV; Cone voltage 39 kV; desolvation temperature 200 ◦C; Source gas flow:
desolvation 400 L/h. Selected reaction monitoring mode was used for quantification. The monitored
transitions included the following: sakuranetin (285 > 165) and 7-methoxyaromadendrin (301 > 165).
All data were acquired and processed using the MasslynxTM V4.1 software (Waters Corporation,
Milford, MA, USA).
4.7.1. Quantification Method Validation
Linearity, LDQ and LOQ
Calibration curves were generated by using 1/x-weighted least-square linear regression.
Concentrations of the flavonoids were calculated by linear interpolation from the calibration curves.
LDQ was determined by the following calculation: (Ybl + 3Sbl)/b, while LOQ was calculated multiplying
Sbl by 10 [53].
Matrix Effect and Recovery
Matrix effects were determined by comparing the peak area of standards in the extracts (A),
after evaluation of a sample target, with that of analyte standard solutions (B). The recoveries of the
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analytes were determined by comparing the peak area of analytes standard solution (8 ppm) after solid
phase extraction (SPE) with that of the analytes’ standard solution (8 ppm) before SPE. The ratio (after
SPE/before SPE) × 100 was determined.
Precision and Accuracy of the System
Precision and accuracy were assessed on three consecutive days by using mixtures containing
low, medium, or high concentrations of the analytes’ standard solution. Precision was expressed as the
RSD %, and accuracy (% RE) was calculated using the following equation:
[(mean measured concentration−concentration of standard solutions)/
(concentration of standard solutions)] × 100. (2)
4.7.2. PCA of Extracts
The software MarkerlynxXS (Waters Corporation, Milford, MA, USA) was used to generate a
matrix containing the m/z ratio of ions detected in each sample and the area under the curve of each peak
in the chromatogram. PCA calculation was performed using Past 2.14 software (Waters Corporation).
PC to be analyzed were selected according to the significance of the eigenvalues of each component.
The loads were considered to evaluate the impact of the original variables on the new components,
while percent of variance explained of the new PC selected were used to evaluate similarities and
differences between the extracts studied.
5. Conclusions
In this work, a rapid and sensitive method was developed to quantify the major flavonoids
present in eleven Ageratina havanensis extracts obtained from two phenological states of Ageratina
havanensis. The phenological state of the plant influences the concentration of sakuranetin,
7-methoxyaromadendrine and glycosides with m/z 447 in its extracts; in fact, the content of these
compounds is higher in the vegetative state. In addition, the antioxidant potential of Ageratina
havanensis (Kunth) R. M. King & H. Robinson extracts and its relationship with the concentration of
major flavonoids were demonstrated for the first time. The results obtained in this study also highlight
that this plant could be a source of new potential inhibitors of drug efflux mediated by P-gp. However,
other in vitro and in vivo studies must be conducted to confirm the potential pharmacological or
therapeutic relevance of these findings.
Supplementary Materials: The following are available online. Table S1: Equations for calibration curves, limit of
detection (LDQ) and limit of quantitation (LOQ) by UPLC/ESI/TQD/MSn. Table S2: Summary of precision and
accuracy results by UPLC/ESI/TQD/MSn, Table S3: Principal components selected for the PCA, Table S4: Most
influential variables in PC. Figure S1: Chromatogram of sakuranetin at 25 μg/mL, Figure S2: Chromatogram
of 7-methoxyaromadendrin at 25 μg/mL, Figure S3: MRM chromatogram of 7-methoxyaromadendrin and
sakuranetin in the ethyl acetate extract of Ageratina havanensis leaves.
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Abstract: The present investigation aimed to evaluate the protective effect of Zingerone (ZIN) against
lipopolysaccharide-induced oxidative stress, DNA damage, and cytokine storm in rats. For survival
study the rats were divided into four groups (n = 10). The control group was treated with normal saline;
Group II received an intraperitoneal (i.p) injection (10 mg/kg) of LPS as disease control. Rats in Group
III were treated with ZIN 150 mg/kg (p.o) 2 h before LPS challenge and rats in Group IV were given
ZIN only. Survival of the rats was monitored up to 96 h post LPS treatment. In another set, the animals
were divided into four groups of six rats. Animals in Group I served as normal control and were treated
with normal saline. Animals in Group II were treated with lipopolysaccharide (LPS) and served as
disease control. Group III animals were treated with ZIN 2 h before LPS challenge. Group IV served as
positive control and were treated with ZIN (150 mg/kg orally). The blood samples were collected and
used for the analysis of biochemical parameters like alanine transaminase (ALT), alkaline phosphatase
(ALP), aspartate transaminase (AST), blood urea nitrogen (BUN), Cr, Urea, lactate dehydrogenase
(LDH), albumin, bilirubin (BIL), and total protein. Oxidative stress markers malondialdehyde (MDA),
glutathione peroxidase (GSH), myeloperoxidase (MPO), and (DNA damage marker) 8-OHdG levels
were measured in different organs. Level of nitric oxide (NO) and inflammatory markers like TNF-α,
IL-1ß, IL-1α, IL-2, IL-6, and IL-10 were also quantified in plasma. Procalcitonin (PCT), a sepsis
biomarker, was also measured. ZIN treatment had shown significant (p < 0.5) restoration of plasma
enzymes, antioxidant markers and attenuated plasma proinflammatory cytokines and sepsis biomarker
(PCT), thereby preventing the multi-organ and tissue damage in LPS-induced rats also confirmed by
histopathological studies of different organs. The protective effect of ZIN may be due to its potent
antioxidant potential. Thus ZIN can prevent LPS-induced oxidative stress as well as inflammatory and
multi-organ damage in rats when administered to the LPS treated animals.
Keywords: zingerone; lipopolysaccharide; inflammation; anti-oxidant; cytokine storm;
procalcitonin; histopathology
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1. Introduction
Natural compounds have been used as treatments by ancient civilizations in drinks
and flavorings. One of the most popular herbs, ginger, is used as a traditional medicine
worldwide [1]. Ginger (Zingiber officinale) belongs to the family Zingiberaceae. Ginger is a perennial
herb used for medicinal and culinary purposes. Ginger is used to treat a variety of ailments around the
globe due to its varied phytochemical nature and health benefits [1]. Numerous phytoconstituents
are present in ginger which have been divided in to volatile and non-volatile compounds [2].
During drying of ginger, Zingerone is produced directly and by thermal degradation. Zingerone (ZIN)
[4-(3-methoxy-4-hydroxyphenyl)-butan-2-one] (Figure 1) is a vanillyl acetone which is a member
of phenolic alkanone group [3]. ZIN is present in a significant amount in ginger and it is
believed that the pharmacological activities of ginger is due to ZIN. It has a potent antioxidant,
anti-inflammatory, anticancer, antidiabetic, antihypertensive, antimicrobial, antithrombotic, anxiolytic,
anti-ulcer, and appetite stimulant properties [2].
Figure 1. Chemical structure of Zingerone [4-(3-methoxy-4-hydroxyphenyl)-butan-2-one].
Lipopolysaccharide (LPS) is a compound that forms part of Gram-negative bacteria, and is a
major pathogenic factor in systemic inflammation or sepsis [4]. Gram-negative bacteria are the only
species in existence that contain the endotoxic portion of LPS, and lipid. In septic conditions, LPS can
activate the innate immunity as a pathogen-associated molecular pattern (PAMP), which mediates an
inflammatory response locally or systemically. Also, LPS can activate non-immune cells and start the
inflammatory process which is typically detrimental [5,6]. LPS releases inflammatory cytokines in
numerous cell types, causing acute inflammatory response towards pathogens [7]. High doses of LPS
triggers the release of pro-inflammatory cytokines which causes a detrimental condition known as
oxidative stress [8]. Oxidative stress plays a major role in LPS-induced systemic inflammation and is
believed to promote the production of reactive oxygen species (ROS). ROS are believed to be involved
in the LPS toxicity mechanism [9,10]. The increased ROS level further encourages inflammatory
processes and elevate pro-inflammatory cytokines [11]. The first line of ROS mediated inflammation
defense mechanism includes multiple antioxidant enzymes, such as: Myeloperoxidase (MPO) and
glutathione peroxidase (GSH). Biological compounds (quercetin, resveratrol, curcumin, thymoquinone,
and lycopene) with antioxidant properties can help protect against LPS-induced ROS in the tissues and
organs [12]. ZIN is one the natural phytoconstituent considered to be reducing oxidative stress due
to its potent antioxidant potential [2,13]. Despite of its antioxidant capacity, ZIN can be used to treat
these diseases as an efficient medicine. This characteristic owes its potential to scavenge free oxidative
radicals. ZIN can therefore suppress ROS and preserve the antioxidant properties. Thus the aim of the
present investigation is to study the protective effect of zingerone against LPS-induced oxidative stress,
DNA damage, cytokine storm, and histopathological alterations of different organs in rats.
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2. Results
2.1. Effect of ZIN on Survival Rate of Animals
The survival rate of animals was monitored up to 96 h and is illustrated in Figure 2. Zingerone treatment
increases the animal survival rate (70%) in lipopolysaccharide (LPS)-challenged animals.
Figure 2. Kaplan–Meier survival plot (n = 10 rats per group). Effect of zingerone (ZIN) 150 mg/kg on
survival rate of LPS induce systemic inflammation in rats.
2.2. Effect of ZIN on Biochemical Markers
Zingerone treatment exhibit minor changes in the biochemical parameters in the rats as compared
with normal rats (Table 1). Animals in the endotoxemia (LPS) group showed significant abnormalities
in different organ function markers as apparent by enhanced biochemical marker levels. The hepatic
injury markers ALT (145.02 ± 3.84, U/L), ALP (186.54 ± 8.76, U/L) and AST (206.49 ± 11.45, U/L) levels
were significantly higher in LPS group as compared to the control group ALT (27.69 ± 3.20, U/L),
ALP (64.24 ± 4.32, U/L), and AST (57.65 ± 3.76, U/L), respectively. ZIN treatment decreases hepatic
marker levels significantly from ALT (145.02 ± 3.84 to 74.99 ± 6.69 U/L, p < 0.05), ALP (186.54 ± 8.76 to
91.29 ± 5.34 U/L, p < 0.05) and AST (206.49 ± 11.45 to 87.35 ± 8.29 U/L, p < 0.05). General tissue damage
of rats was confirmed from serum LDH levels in LPS group, a significantly increase in LDH levels were
observed (972.75 ± 20.74 U/L), and these levels were decreased with ZIN treatment (656.59 ± 7.46 U/L
p < 0.05). Similarly, a reduction in CK (553.83 ± 19.61 U/L p < 0.05), SCr (0.38 ± 0.05 mg/dL p < 0.05)
and, BUN (67.71 ± 2.27 mg/dL p < 0.05) were observed in ZIN treated groups as compared to the
animals in LPS group CK (855.47 ± 18.84 U/L), SCr (0.59 ± 0.09 mg/dL), and BUN (153.18 ± 7.34 mg/dL),
respectively. Also, albumin levels were also increased with the ZIN treatment (3.18 ± 0.013 g/dL
p < 0.05) as compared to the animals in the LPS group (2.36 ± 0.12 g/dL).
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Table 1. List of plasma biochemical levels of different groups.
S.No. Parameters Control LPS (10 mg/kg) ZIN (150 mg/kg) + LPS ZIN Only (150 mg/kg)
1 Creatinine Kinase (U/L) 68.32 ± 3.92 855.47 ± 18.84 * 553.83 ± 19.61 *# 66.67 ± 3.22
2 Serum Creatinine (mg/dL) 0.30 ± 0.03 0.59 ± 0.09 * 0.38 ± 0.05 *# 0.27 ± 0.01
3 BUN (mg/dL) 42.93 ± 1.92 153.18 ± 7.34 * 67.71 ± 2.27 *# 41.05 ± 0.59
4 LDH (U/L) 307.61 ± 12.27 972.75 ± 20.74 * 656.59 ± 7.46 *# 279.28 ± 7.50
5 ALT (U/L) 27.69 ± 3.20 145.02 ± 3.84 74.99 ± 6.69 *# 30.23 ± 1.43
6 ALP (U/L) 64.24 ± 4.32 186.54 ± 8.76 * 91.29 ± 5.34 *# 61.91 ± 2.65
7 AST (U/L) 57.65 ± 3.76 206.49 ± 11.45 * 87.35 ± 8.29 *# 52.24 ± 3.56
8 BIL (μmol/L) 1.69 ± 0.52 8.55 ± 1.07 * 4.56 ± 0.76*# 1.56 ± 0.75
9 GGT (U/L) 1.34 ± 0.24 3.89 ± 0.65 * 2.16 ± 0.66 *# 1.22 ± 0.34
10 Albumin (g/dL) 3.33 ± 0.12 2.36 ± 0.12 * 3.18 ± 0.013 *# 3.37 ± 0.05
Results are represented as mean ± SEM of six rats/group. * p < 0.05 vs. control; # p < 0.05 vs. LPS group.
BUN: Blood urea Nitrogen; LDH: Lactate dehydrogenase; ALT: Alanine transaminase; ALP: Alkaline phosphatase;
AST: Aspartate transaminase; BIL: Bilirubin; GGT: Gamma-glutamyl transferase.
2.3. Effect of ZIN on Oxidative Stress and Antioxidant Enzyme Markers
The LPS injection elicited levels of NO (97.08 ± 3.64 μM), which was significantly diminished
in ZIN treated animals (57.36 ± 3.50 μM p < 0.05). 8-OHdG an indicator of DNA damage, the levels
were significantly enhanced in the LPS treated groups (10.02 ± 0.84 ng/mL) and this was decreased
with ZIN treatment (5.26 ± 0.40 ng/mL p < 0.05), respectively (Figure 3). Oxidative stress markers
in different tissues e.g., brain, kidney, lung, and liver were measured in terms of glutathione (GSH),
malondialdehyde (MDA), and myeloperoxidase (MPO) levels (Figures 4–6). MPO an enzyme of
activated Polymorphonuclear (PMN) were used as an indication of tissue neutrophil accumulation.
ZIN treatment in all tissues showed a significant (p < 0.05) reduction of these oxidative markers which
was increased in LPS treated animals.
Figure 3. Effect of zingerone (ZIN) on LPS-induced DNA damage and oxidative stress marker.
(A) 8-OHdG levels (ng/mL), (B) Nitric Oxide (NO) levels (μM). Results are represented as mean ± SEM
of six rats/group. * p < 0.05 vs. control; # p < 0.05 vs. LPS group.
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(A) (B) 
(C) (D) 
Figure 4. Effect of zingerone (ZIN) on LPS-induced oxidative stress as malondialdehyde (MDA)
(nmol/kg). (A) Brain, (B) lung, (C) liver, and (D) kidney. Results are represented as mean ± SEM of six
rats/group. * p < 0.05 vs. control; # p < 0.05 vs. LPS group.
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(A) (B) 
(C) (D) 
Figure 5. Effect of zingerone (ZIN) on LPS-induced oxidative stress as GSH (μmol/kg). (A) Brain,
(B) Lung, (C) Liver and (D) Kidney. Results are represented as mean ± SEM of six rats/group.
* p < 0.05 vs. control; # p < 0.05 vs. LPS group.
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(A) (B) 
(C) (D) 
Figure 6. Effect of zingerone (ZIN) on LPS-induced oxidative stress as MPO (U/g). (A) Brain, (B) lung,
(C) liver, and (D) kidney. Results are represented as mean ± SEM of six rats/group. * p < 0.05 vs. control;
# p < 0.05 vs. LPS group.
2.4. Effect of ZIN on Cytokines and Inflammatory Markers
The inflammatory changes in the LPS-induced animals were determining as their cytokine
levels (Figure 7). LPS-induced rats demonstrated a significant increase in the plasma levels
of TNF-α (135.56 ± 4.17 pg/mL), IL-1α (509.12 ± 17.79 pg/mL), IL-1ß (1166.01 ± 27.54 pg/mL),
IL-2 (20.67 ± 1.70 pg/mL), IL-6 (106.56 ± 3.44 pg/mL) and IL-10 (1037.49 ± 31.65 pg/mL).
Zingerone treated animals showed reduced levels of these cytokines as compared to the disease
control animals TNF-α (60.16 ± 3.52 pg/mL p < 0.05), IL-1α (235.49 ± 10.07 pg/mL p < 0.05),
IL-1ß (739.78 ± 25.57 pg/mL p < 0.05), IL-2 (14.19 ± 1.77 pg/mL p < 0.05), IL-6 (61.60 ± 3.21 pg/mL
p < 0.05) and IL-10 (665.90 ± 14.17 pg/mL p < 0.05). PCT levels were determined in the plasma of rats
and were significantly increased in the LPS treated animals (2351.65 ± 39.75 pg/mL p < 0.05) compared
to the normal rats (1053.03 ± 49.49 pg/mL). ZIN treatment significantly diminish the plasma PCT levels
(1626.83 ± 86.70 pg/mL p < 0.05) Figure 7G.
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2.5. Effect of ZIN on Histoarchitecture of Different Organs
As depicted in Figure 8, the tissue sections from normal control group of different organs (brain,
lung, liver, and kidney) exhibit normal architecture. Brain, lung, liver, and kidney tissues from LPS
group exhibited the pathological alterations comprising widespread inflammation, portal inflammation,
and hepatic cell necrosis, infiltration of inflammatory cells, severe hemorrhage, and thickening of
alveolar septa, emphysema, and infiltration of leukocytes in walls alveoli and neuronal loss and
condensed nucleus. However, treatment with ZIN 150 mg/kg significantly prevented the LPS-induced
pathological changes and restored the histological architecture.
 
Figure 8. Light histograms of different rat organs (hematoxylin and eosin stains, magnification 40×
and scale bar of 100 μm). Effect of ZIN in LPS intoxicated rats. Brain (A) normal control group:
Showing normal histological structure with intact neurons, (B) LPS treated rats: Showing neuronal
loss with condensed nuclei, (C) Rats treated with (ZIN 150 mg/kg + LPS: Showing decrease in
neuronal loss with presence of intact neurons. Kidney (A) normal control group: Showing normal
histological structure of the glomeruli and tubules at the cortex with absence of histopathological
alterations, (B) LPS treated rats: Showing marked inflammatory cell aggregation in between the
tubules, marked degeneration in the lining epithelium of all the tubules, and blood vessel congestion,
(C) Rats treated with (ZIN 150 mg/kg + LPS: Showing absence of histopathological alterations.
Liver (A) Normal control group: Showing normal histological structure of the central vein and
intact hepatocytes, (B) LPS treated rats: Showing severe loss of hepatic architecture with multiple
focal necrosis, ballooning degeneration in the hepatocytes, (C) Rats treated with ZIN 150 mg/kg + LPS:
Showing absence of histopathological alterations. Lung (A) Normal control group showing normal
morphology, (B) LPS treated rats: Showing moderate to severe hemorrhage, thickening of alveolar septa,
emphysema, and infiltration of leukocytes in walls alveoli, (C) Rats treated with ZIN 150 mg/kg + LPS:
Showing absence of histopathological changes.
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3. Discussion
LPS is a significant component of Gram-negative bacteria’s outer membrane and can induce
inflammatory reactions by penetrating into the bloodstream that can trigger pain and eventually to
death [14]. In the current investigation LPS caused impairment of kidney and liver function markers
used for the determination of respective organ injuries. This increase in biochemical markers by
LPS has been previously reported [15]. LPS has been suggested to generate NO and other ROS
which causes peroxidation and cell alterations which further leads to the disruption of cell membrane
and subsequent release of cytosolic contents [16]. Moreover, albumin levels were decreased in
the in the present investigation which are corroborated with the reports of Amin et al., 2020 [12].
Bilirubin levels in LPS-induced animals were increase 4 fold compared to the normal control animals.
ZIN treatment markedly mitigated the alterations induced by LPS by diminishing the levels of CK, Scr,
alanine transaminase (ALT), alkaline phosphatase (ALP), aspartate transaminase (AST), blood urea
nitrogen (BUN), and bilirubin (BIL) and increasing levels of albumin which is supported by the
previous results of Amin et al., 2020 [15].
LPS treatment causes increase in the circulating nitrite levels in LPS intoxicated rats as compare to
normal control animals. It is well known that LPS causes’ significant increase in the nitrite levels because
of over expression of inducible nitric oxide (iNOS) [17]. The endothelial cells are responsible for the
increasing circulating levels of NO at the site of infection in response to pathogen [18]. NO is producing
a potent oxidant peroxynitrite (ONOO−) by reacting with superoxide anion (O2−) which increases
the lipid peroxidation and causes oxidative damages in different tissues [19]. The ZIN treatment
was found to have protective effect against LPS-induced inflammation as evident by the significant
decrease in circulating NO levels. These results were in agreement with the results of Alkharfy and
colleagues in 2015, reported that thymoquinone significantly decrease the plasma levels of nitric oxide
and the survival in animal model of sepsis [20]. Oxidative stress is characterized as an imbalance
between free radical development and antioxidant defense. Superoxide (02−), hydroxyl (OH−) and
nitric oxide (NO−) are among the most common reactive oxygen species. Antioxidants immediately
reverse oxidative stress by enzymes, such as GSH, and MPO as well as by plant derived flavonoids [21],
GSH (tripeptide thiol), found in cells is the most important anti-oxidant molecule and serves as a
protecting agent against pathogen induced ROS and RNS [22] and regulates the cell proliferation,
and apoptosis [23]. GSH depletion is an important pathological event in many tissues [24]. MPO is an
enzyme located predominantly in the primary neutrophil granules and its key function is to destroy
the pathogens, although in some circumstances it yields high amount of oxidants which further leads
to tissue damage [25]. ROS destroys the cell membrane, DNA damage to cells, causing oxidation of
lipid bilayer releasing MDA as the end product [26,27]. MDA, a lipid peroxidation marker used to
evaluate the lipid peroxidation due to oxidative stress [28]. ZIN has an exceptional ability of scavenging
reactive oxygen species (ROS), free radicals and other damaging oxidants by inhibiting the enzyme
xanthine oxidase [13]. Zingerone has also know to exert beneficial effect and protects DNA damage
against stannous chloride induced oxidative damage [13]. Zingerone administration has been shown to
suppress the mitochondrial injury and lipid peroxidation and mitigates proapoptotic proteins like BAX,
and caspases [29]. These findings suggest that zingerone is a potent antioxidant, which was further
supported by the fact that ZIN had shown high antioxidant potential as compared to the ascorbic
acid [13]. ZIN has shown antioxidant activity against superoxide and NO generated peroxynitrite
causing damage to the cells [30]. The plasma levels of these oxidative markers were markedly increased
in LPS-induced rats and were significantly reduced with ZIN treatment, suggesting the anti-oxidant
potential of ZIN [2,15]. 8-OHdG is one of the principal forms of free radical-induced DNA damage by
oxidation, thus been extensively used as an oxidative stress DNA biomarker [31,32]. The increased levels
of 8-OHdG were suggested that DNA oxidation was aggravated by LPS administration. ZIN treatment
has been found to prevent the LPS-induced oxidative DNA damages as evident by the decreased levels
of 8-OHdG.
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Elevated cytokines are recognized as inflammatory biomarkers in endotoxin-related
pathogenesis [33,34]. TNF-α, IL-β, IL-α, IL-2, IL-6, and IL-10 are known as the key mediators of
inflammation and TNF-α among them is considered to be a principal cytokine regulator [35,36].
Many research studies have identified the function of TNF-α and IL-1 in systemic inflammation,
including both animal models of septic shock and in human sepsis trials [37,38]. Once released
both TNF-α and IL-1 target on different cells e.g., macrophages, neutrophils and endothelial
cells. TNF-α contributed to improved macrophage development which stimulates macrophage
activation, differentiation and survival of these cells and thus enhances proinflammatory responses in
infection [39]. TNF-α and IL-1 enhance inflammatory cascade by activating macrophages to release
certain proinflammatory cytokines such as IL-6 and IL-8, ROS/RNS, and lipid mediators which are
essential to sepsis-induced organ failure [40]. Increased IL-2 plasma levels with gram-negative bacteria
can serve as a septic shock prognostic catalogue. IL-2 receptors are often released from T and B
lymphocytes in biological fluids and tend to contribute to sepsis pathogensis. Inflammatory response
of IL-6 is likely to be an effective mediator [41]. Endogenous IL-10 is an important anti-inflammatory
cytokine, prevents animals from death in sepsis and has been recognized as a key approach for
dealing several inflammatory disorders [42]. IL-10 has been reported to be beneficial in various
inflammatory diseases other than sepsis or systemic inflammation such as inflammatory bowel
disorder, arthritis, sclerosis [41]. In the present study, ZIN treatment to LPS treated rats showed the
marked reduction in plasma cytokine levels significantly as compared to LPS treated rats. It has also
been observed that the treatment with ZIN in normal control rats does not alter the physiological
state. PCT is deemed one of the best biomarkers for sepsis and endotoxemia [43]. LPS toxicity is
followed by its binding to lipopolysaccharide binding protein (LBP), which facilitates binding to
the CD14 co-receptor, activating cell responses through TLR4 signaling. Reducing the circulating
endotoxin in animals handled with ZIN indicates this flavonoid has the potential to enhance LPS
clearance. Endotoxin removal occurs in the liver Kupffer and parenchyma cells where it is catabolized.
The involvement of ZIN against LPS-induced inflammation and oxidative damage in governing this
protective activity further supports this possibility.
LPS-induced rats exhibiting enhanced levels of biochemical parameters were accompanied by
enhanced pathological alterations of brain, lung, liver, and kidney. Staining of the brain cortex in the LPS
group showed degenerated neurons with hyperchromatic nuclei and increased vacuoles which were
prevented by ZIN treatment. The hepatic tissues from the normal control animals exhibited normal
cellular and lobular architecture. Liver tissue from the LPS group exhibited prominent pathological
alterations comprising widespread portal inflammation, hepatic cell necrosis, and infiltration of
inflammatory cells. However, ZIN significantly ameliorated the LPS-induced pathological alterations
as demonstrated by the reduced cell infiltration and restored lobular architecture. Kidney tissues from
ZIN-treated rats showed gradual but sustained recovery in cortex and medulla structure. Although the
recovery is not full, it is easily noticeable in morphology. The thick descending and ascending parts
of Henle loops and collecting coils of small caliber and reduction of interstitial tissue can be seen.
The tubules show considerably lower cubic epithelium tubules were gaining normal morphology
when treated with ZIN. The histopathological evaluation of lung samples indicated a moderate to
severe hemorrhage, thickening of alveolar septa, emphysema, and infiltration of leukocytes in alveoli
walls in the LPS group. Treatment with ZIN ameliorated these aberrations in the architecture of lung
tissues. The improvement in histology is attributed to antioxidant and anti-inflammatory potential of
ZIN as suggested by earlier reports [29,44]. Therefore, this research indicates that ZIN, in addition
to its antioxidant and anti-inflammatory effects, may reduce the amount of circulating endotoxin
from circulation and thereby alleviate the related multi-organ dysfunction syndrome (MODS) when
administered to the animals subjected to LPS-induced sepsis.
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4. Materials and Methods
4.1. Chemicals and Reagents
ZIN (99% pure) and LPS were purchased from Sigma-Aldrich. Biochemical estimation kits like
ALT, ALP, AST, BUN, Cr, Urea, and CKMB were obtained from Human diagnostics. Oxidative stress
markers MDA (K739), GSH (K464), MPO (K747), and (DNA damage marker) 8-OHdG (K4160)
were purchased from (BioVision, Inc. Milpitas, CA, USA). Nitric oxide (NO) was obtained
from Booster Bio, USA. Tumor necrosis factor-alpha (TNF-α, K1052-100), Interleukin (IL) IL-1β
(K4796-100), IL-1α (E4804-100), IL-2 (E4831-100), IL-6 (K4145-100) were procured from (Bio-Vision,
Milpitas, CA, USA), IL-10 (MBS355232) and Procalcitonin (PCT, MBS162052), a septic biomarker was
purchased from (My BioSource, San Diego, CA, USA). All other chemicals were of analytical grade.
4.2. Animals
Six-week-old male Wistar rats (180–200 g) were obtained from an animal facility. The rats
were housed in plastic cages at room temperature (25 ◦C) and humidity of 10% along with 12:12
light–dark cycle. The rats were given free access to water and food. The study was approved
by the ethical committee. The study protocol was approved by the Institutional Review Board
(No. RAKMHSU-REC-08-2019-F-P).
4.3. LPS-Induced Endotoxemia and Survival Study
The rats were divided into four groups (n = 10). The control group was treated with normal saline;
Group II received an intraperitoneal (i.p) injection (10 mg/kg) of LPS as disease control. Rats in Group
III were treated with ZIN 150 mg/kg (p.o) 2 h before LPS challenge. Animals in Group IV were treated
with ZIN 150 mg/kg p.o only. Survival of the rats was monitored up to 96 h post LPS treatment.
4.4. Experimental Model
The animals were divided into four groups of six rats in each group. Animals in Group I served as
normal control and were treated with normal saline. Animals in Group II served as disease control and
IV were treated with LPS (10 mg/kg, i.p). Group III animals were treated with ZIN 150 mg/kg p.o 2 h
before LPS challenge. Group IV served as positive control and were treated with ZIN 150 mg/kg p.o.
4.5. Determination of Biochemical, Oxidative Stress and Inflammatory Markers
Animals were euthanized with isoflurane after six hours of LPS challenge and blood samples
were collected in sterilized EDTA tubes. Different organs like liver, lung, kidney, and brain tissues were
harvested. The plasma samples were stored at −80 ◦C for biochemical, oxidative, and inflammatory
marker analyses. Biochemical parameters like ALT, ALP, AST, BUN, Cr, Urea, LDH, Albumin,
bilirubin, total protein, and CKMB were assessed. Oxidative stress markers MDA, GSH, MPO,
and (DNA damage marker) 8-OHdGlevels were measure by ELISA technique as per the manufacturer
details. Levels of nitric oxide (NO) were measured in plasma by Griess reaction method. The color
intensity was recorded at 540 nm using ELISA plate reader. Inflammatory markers like TNF-α, IL-1β,
IL-1α, IL-2, IL-6, and IL-10 were quantified using ELISA kits as per their manufacturer protocol.
The plasma procalcitonin, a septic biomarker was determined using ELISA kits obtained according to
the manufacturer’s instructions.
4.6. Histological Evaluation
The tissues of liver, lung, kidney, and brain from each animal were extracted and fixed in 12%
formalin for histopathological evaluation. The tissues were gradually dehydrated and embedded
in paraffin, cut into 4 μm sections, and were stained with Hematoxylin and Eosin for histological
examination [45].
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4.7. Statistical Analysis
Animal survival study was checked using Kaplan–Meier analysis plot. The values are represented
as mean ± SEM and the analysis of variance was checked with Dennett’s post hoc test. The analysis
was carried out by using GraphPad Prism. p < 0.05 was considered significant.
5. Conclusions
The present investigation reported the effect of ZIN against LPS-induced oxidative stress,
DNA damage, and cytokine storm on various organs by evaluating the biochemical, inflammatory,
oxidant-antioxidant markers, and histopathological changes. ZIN in regulating its preventive effect
against systemic inflammation further encourages the need to improve it as a more successful
treatment. Since several of the novel, creative approaches to treating sepsis target particular biomarkers,
better strategies to improve the effectiveness of these new treatment methods would benefit. The results
have demonstrated that LPS-induced toxicity and ZIN protects and balances the oxidant-antioxidant
status and regulate the generation of cytokine storm. Therefore, ZIN can be beneficial in MODS.
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Abstract: The NLRP3 (NACHT, LRR and PYD domains-containing protein 3) inflammasome has
been implicated in a variety of diseases, including atherosclerosis, neurodegenerative diseases,
and infectious diseases. Thus, inhibitors of NLRP3 inflammasome have emerged as promising
approaches to treat inflammation-related diseases. The aim of this study was to explore the effects of
juglone (5-hydroxyl-1,4-naphthoquinone) on NLRP3 inflammasome activation. The inhibitory effects
of juglone on nitric oxide (NO) production were assessed in lipopolysaccharide (LPS)-stimulated
J774.1 cells by Griess assay, while its effects on reactive oxygen species (ROS) and NLRP3 ATPase
activity were assessed. The expression levels of NLRP3, caspase-1, and pro-inflammatory cytokines
(IL-1β, IL-18) and cytotoxicity of juglone in J774.1 cells were also determined. Juglone was non-toxic
in J774.1 cells when used at 10 μM (p < 0.01). Juglone treatment inhibited the production of ROS and
NO. The levels of NLRP3 and cleaved caspase-1, as well as the secretion of IL-1β and IL-18, were
decreased by treatment with juglone in a concentration-dependent manner. Juglone also inhibited
the ATPase activities of NLRP3 in LPS/ATP-stimulated J774.1 macrophages. Our results suggested
that juglone could inhibit inflammatory cytokine production and NLRP3 inflammasome activation in
macrophages, and should be considered as a therapeutic strategy for inflammation-related diseases.
Keywords: juglone; NLRP3 inflammasome; caspase-1; IL-1β; IL-18
1. Introduction
Innate immune cells, including macrophages and dendritic cells, play crucial roles in the
initiation of inflammatory immune responses upon activation of inflammasome complexes that
induce the maturation of inflammatory cytokines [1]. Pattern-recognition receptors (PRRs) recognize
pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs),
initiating signaling cascades that lead to inflammation and release of inflammatory cytokines [2,3].
Toll-like receptors (TLRs) and NOD-like receptors (NLRs) called PRR are membrane-bound and
cytoplasmic receptors, respectively, which recognize PAMPs and DAMPs [4]. The immune responses
initiated by the interaction between TLRs and PAMPs are mediated through MyD88-dependent and
TRIF-dependent pathways [2,3,5]. When TLRs recognize and bind lipopolysaccharides (LPS) or
other extracellular PAMPs, the transcription factor nuclear factor (NF)-κB is activated and induces
the expression of several pro-inflammatory cytokines, including interleukin (IL)-1β and IL-18 [6].
On the other hand, NLRs, PRRs found in the cytoplasm, are activated by DAMPs, including adenosine
triphosphate (ATP), monosodium urate crystals, β-amyloid, and nigericin [7].
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P2X7, a membrane-bound PPR that recognizes DAMP, is a membrane-bound receptor that binds
extracellular ATP, promoting the release of K+ [8,9], and subsequently, inducing the formation of
inflammasomes after binding of NLRP3 (NACHT, LRR and PYD domains-containing protein 3) to
ASC (apoptosis-associated speck-like protein containing a C-terminal caspase recruitment domain)
and pro-caspase-1. The formation of NLRP3 inflammasomes activates pro-caspase-1, which induces
pyroptosis by cleaving pro-IL-1β and pro-IL-18 into their active forms, which initiate the innate
immune response [7]. In addition, intracellular danger signals, such as mitochondrial damage
and reactive oxygen species (ROS) production, can promote assembly and activation of NLRP3
inflammasomes [10–12]. Inflammatory factors and cytokines can also prime NLRP3 inflammasomes,
and ROS inhibitors have been reported to suppress NLRP3 priming [13]. Therefore, the treatment of
macrophages with potent antioxidative agents has emerged as a promising strategy to block NLRP3
inflammasome priming.
Juglone (5-hydroxy-1,4-naphthoquinone) is a natural phenolic compound isolated from the
roots, stems, and leaves of walnut trees [14]. Juglone is produced during allelopathy and inhibits
the germination or growth of surrounding plants by inhibiting specific enzymes necessary for
metabolic function, mitochondrial respiration, and photosynthesis [15]. Recent studies have reported
that juglone has a variety of pharmacological effects, including anti-inflammatory, antioxidative,
anticancer, and antimicrobial effects, by inhibiting ROS-producing enzymes and preventing oxidative
stress [14,16–21]. However, the effect of juglone on NLRP3 inflammasome formation and activation
remains elusive. The aim of this study was to investigate the potential of juglone to inhibit the NLRP3
inflammasome-mediated inflammatory effects of LPS and ATP.
2. Results
2.1. Effects of Juglone on Cell Viability
To determine the juglone concentration range that is non-toxic to J774.1 cells, cells were
treated with increasing concentrations of juglone (3.1–50 μM), followed by 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. When juglone was used at 10 μM or less,
no significant cytotoxic effects were observed (p > 0.05; Figure 1). Therefore, juglone was used at 2.5, 5,
or 10 μM in subsequent experiments.
Figure 1. Assessment of the cytotoxic effects of juglone in J774.1 cells using the 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. (a) Chemical structure of juglone. (b) J774.1 cells
were treated with increasing concentrations of juglone (3.1–50 μM) for 24 h, followed by quantification
of cell viability using the MTT assay. Data are presented as mean ± standard deviation (SD) of three
independent experiments. * p < 0.05; ** p < 0.01; vs. control.
2.2. Effects of Juglone on Reactive Oxygen Species (ROS) Production
ROS have a strong oxidative capacity and are essential mediators of NLRP3 (NACHT, LRR and
PYD domains-containing protein 3) inflammasome activation. To determine the ability of juglone to
inhibit lipopolysaccharide (LPS)-induced ROS production in J774.1 cells, we used the cell-permeable
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ROS-sensitive dye DCFH-DA, which is non-fluorescent in a reduced state and emits fluorescence
upon oxidation by ROS. We found that treatment with LPS enhanced ROS production in J774.1
cells. However, when cells were treated with 10 μM juglone, ROS production was significantly
impaired (Figure 2a). The fluorescence intensity in LPS-treated cells was approximately 120%, while
the fluorescence intensity in juglone-treated (10 μM) cells after LPS stimulation was only 84.5%.
Thus, juglone may exert anti-inflammatory effects by suppressing ROS generation by macrophages
during inflammation.
Figure 2. Effects of juglone on the production of inflammatory mediators. (a) reactive oxygen species
(ROS) production in J774.1 cells treated with lipopolysaccharide (LPS). Cells were treated with different
concentrations of juglone (2.5, 5, and 10 μM) for 2 h, followed by treatment with 1 μg/mL LPS for an
additional 24 h. (b) NO production in J774.1 cells treated with LPS. Cells were treated with increasing
concentrations of juglone (3.1–50 μM or 0 μM control) for 2 h, followed by treatment with 1 μg/mL LPS
for an additional 24 h. The levels of NO in the cell culture media were measured using Griess reagent.
(c,d) Effects of juglone on the LPS/ATP-induced secretion of interleukin-1β (IL-1β) and IL-18 in J774.1
cells. J774.1 macrophages were treated with different concentrations of juglone for 2 h, followed by
treatment with 1 μg/mL LPS for 6 h and treatment with 5 mM ATP for 1 h. The levels of IL-1β and
IL-18 secreted in the culture medium were analyzed by enzyme-linked immunosorbent assay (ELISA).
Data are presented as mean ± SD of three independent experiments. * p < 0.05; ** p < 0.01 vs. LPS or
LPS + ATP cells, respectively.
2.3. Effects of Juglone on Nitric Oxide (NO) Production
Inflammatory mediators, such as reactive nitrogen species and ROS, are essential mediators of
inflammatory responses, especially in the initial stages of inflammation. Therefore, we assessed the
effects of juglone in LPS-induced NO production. We found that even though LPS treatment resulted
in a significant increase in NO production in J774.1 cells, juglone treatment suppressed LPS-induced
NO production in a dose-dependent manner (p < 0.05; Figure 2b).
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2.4. Effects of Juglone on the Secretion of the Pro-Inflammatory Cytokines IL-1β and IL-18
Inflammatory cytokines are important mediators of immune responses and orchestrate the initial
stages of inflammation. The pro-inflammatory cytokines IL-1β and IL-18 are known to mediate the
first steps of an inflammatory immune response [22]. Therefore, targeting these upstream mediators
of inflammation has emerged as a promising approach to treat inflammation-related diseases. Thus,
we sought to investigate whether juglone could affect the levels of mRNA, protein, or extracellular
secretion of IL-18 and IL-1β. We found that treatment with juglone suppressed the induction of IL-18
and IL-1β at the mRNA and protein level in response to LPS and ATP in J774.1 cells (Figure 3 and
Figure S1). The secretory inhibition of pro-inflammatory cytokines (IL-1β and IL-18) of juglone on
murine macrophage cells was studied and the results are shown Figure 2c,d. Treatment of macrophage
cells with juglone caused a concentration-dependent reduction in their IL-1β (5 μM, * p < 0.05) and
IL-18 (10 μM, ** p < 0.01). Juglone-treated cell was reduced 25.9% of IL-1β secretion (5 μM, * p < 0.05)
and 22.6% of IL-18 secretion (10 μM, ** p < 0.01) compared to the LPS plus STP-primed control
group. These results suggested that juglone could inhibit the initial steps of the inflammatory immune
response by suppressing the expression and secretion of the pro-inflammatory cytokines IL-1β and
IL-18 in macrophages.
Figure 3. Effects of juglone on IL-1β and IL-18 expression in LPS-treated J774.1 cells. J774.1 macrophages
were treated with different concentrations of juglone (2.5, 5, and 10 μM) for 2 h, followed by treatment
with 1 μg/mL LPS for 6 h and 5 mM ATP for 1 h. (a) The mRNA levels of IL-1β and IL-18 in J774.1
cells were determined with RT-qPCR. Glyceraldehyde 3-phosphate dehydrogenase gene (GAPDH)
was used as a reference gene. (b) The protein levels of IL-1β and IL-18 in J774.1 cells were assessed by
Western blotting and are presented as relative to β-actin intensity. Data are presented as mean ± SD.
* p < 0.05; ** p < 0.01 vs. LPS + ATP treated cells.
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2.5. Effects of Juglone on NLRP3 and Caspase-1 Expression
We then assessed the effects of juglone treatment on the mRNA and protein levels of NLRP3
and caspase-1. We found that even though NLRP3 was induced in J774.1 cells following stimulation
with LPS and ATP, treatment with juglone suppressed the LPS/ATP-mediated NLRP3 induction at the
mRNA level in a dose-dependent manner. The mRNA levels of caspase-1 were not significantly affected
by juglone treatment (Figure 4a). Importantly, juglone treatment suppressed the LPS/ATP-mediated
NLRP3 ATPase upregulation at the protein level in J774.1 macrophages (Figure 4b and Figure S2).
Juglone also reduced the levels of cleaved caspase-1 in a concentration-dependent manner (Figure 4b).
These results suggested that juglone could inhibit the interaction of NLRP3 and apoptosis-associated
speck-like protein containing a C-terminal caspase recruitment domain (ASC) and subsequent NLRP3
inflammasome formation by downregulating the expression of NLRP3. Moreover, the decreased
NLRP3 expression might impair ASC speck formation, leading to reduced cleavage and subsequent
activation of the downstream signaling mediator, caspase-1.
Figure 4. J774.1 cells were treated with various concentrations of juglone for 2 h and then treated with
1 μg/mL LPS for 24 h. (a) The mRNA levels of NACHT, LRR and PYD domains-containing protein 3
(NLRP3) and caspase-1 in J774.1 cells were determined by RT-qPCR. GAPDH was used as a reference
gene. (b) The relative protein levels of NLRP3, procaspase-1, and cleaved caspase-1 were assessed by
Western blotting and are presented as relative to β-actin intensity. Data are presented as the mean ±
SD.* p < 0.05; ** p < 0.01 vs. LPS + ATP treated cells.
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2.6. Effects of Juglone on the ATPase Activity of NLRP3
The pyrin ATP-binding domain of NLRP3 exhibits ATPase activity, which is essential for NLRP3
inflammasome oligomerization. Therefore, we investigated the effects of juglone treatment on the
ATPase activity of NLRP3 in J774.1 cells. Treatment with LPS and ATP in J774.1 macrophages increased
the ATPase activity of NLRP3 (Figure 5). However, treatment with 10 μM of juglone significantly
reduced the ATPase activity of NLRP3 (p < 0.05).
Figure 5. Effects of juglone on the ATPase activity of NLRP3 in LPS/ATP-treated J774.1 cells. J774.1
macrophages were treated with different concentrations of juglone for 2 h, followed by treatment with
1 μg/mL LPS for 6 h and 5 mM ATP for an additional hour. Analysis of the ATPase activity of NLRP3
was performed using a reaction mixture containing 40 mM Tris, 80 mM NaCl, 8 mM MgAc2, 1 mM
EDTA, and 4 mM ATP, pH 7.5. Data are presented as mean ± SD of three independent experiments.
* p < 0.05 vs. LPS/ATP treated cells.
3. Discussion
The NLRP3 (NACHT, LRR and PYD domains-containing protein 3) inflammasome can be activated
by a broad range of stimuli that belong either to pathogen-associated molecular patterns (PAMPs)
released during viral, bacterial, fungal, or protozoa infection [23] or to danger-associated molecular
patterns (DAMPs) of endogenous or exogenous origin, like extracellular ATP and reactive oxygen
species (ROS) [24]. The present study demonstrates that juglone inhibits IL-1b and IL-18 secretion in
activated macrophages by suppressing various pro-inflammatory signaling molecules and pathways.
Juglone has been reported to have potent antioxidative effects and prevent various oxidative
stress-related diseases by inhibiting ROS-producing enzymes [25,26]. Additionally, juglone has been
suggested to have anticancer effects, which are least partly mediated by inhibition of NF-κB signaling
and NF-κB-mediated expression of inflammatory cytokines [27,28]. However, the effects of juglone
NLRP3 inflammasome formation in macrophages are understudied.
IL-1β, IL-18, and NO have been highlighted by numerous studies as essential mediators of
inflammation and have been implicated in autoimmune diseases and other inflammatory conditions [29].
LPS, a major component of Gram-negative bacteria, can induce the expression of inflammatory cytokines
and NO. Herein, we reported that juglone treatment inhibited the production of NO in LPS-stimulated
J774.1 cells in a concentration-dependent manner. ROS are also involved in inflammatory immune
responses and have been shown to induce formation and activation of the NLRP3 inflammasome in
response to various exogenous stimuli [30]. In addition, excessive intracellular ROS levels can lead to
apoptosis or necrosis [31]. To investigate the effects of juglone on ROS production by macrophages,
a DCFH-DA assay was performed in J774.1 cells treated with LPS. Our results suggested that LPS
stimulation induced ROS production and that juglone could suppress LPS-induced ROS generation in
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a dose-dependent manner. Therefore, by reducing ROS production in macrophages, juglone could
potentially inhibit activation of the NLRP3 inflammasome.
ATP-induced P2X7R activation promotes the rapid production of large amounts of ROS, which,
in turn, stimulates activation of the NLRP3 inflammasome [32]. It has been previously reported that
inhibition of the ATPase activity of NLRP3 could decrease the self-oligomerization of NLRP3, as well
as its interaction with ASC, which is critical for inflammasome activation [31].
In this study, we found that juglone treatment suppresses not only the expression of NLRP3
but also the ATPase activity of NLRP3, and these were followed by the inhibition of active caspase-1
(Figure 6). These results suggest that juglone could potentially impair the formation of NLRP3
inflammasome, and, thus, the inhibition of pro-caspase-1 activation in macrophages. We also found
that treatment with juglone could suppress the LPS/ATP-mediated induction of IL-1β and IL-18 in
J774.1 cells, both at the mRNA and protein levels. These correspond to the previous research results
that juglone inhibits pro-inflammatory cytokines (TNF-α, IL-1 β, and IL-6) and adhesion molecules
(VCAM-1 and ICAM-1) expression through the inhibition of IκB-phosphorylation-mediated NF-κB
activation [17,33].
Figure 6. Proposed mechanism underlying the anti-inflammatory effects of juglone in macrophages.
Pre-treatment of macrophages with juglone suppressed ATP-induced IL-1β, IL-18 and NLRP3 secretion
in LPS-primed J774.1 mouse macrophages. Juglone also caused downregulation of ATPase activity and
ROS and NO production. Juglone also reduced the mRNA expression and activation of IL-1β, IL-18,
NLRP3 and caspase-1. The results show that juglone inhibits IL-1β and IL-18 secretion and NLRP3
formation in activated macrophages.
Furthermore, our extended study results showed that the secretion levels of IL-1β and IL-18 in
macrophages were inhibited by juglone treatment in a dose dependent manner. Of note, pro-IL-1β and
pro-IL-18 are cleaved to their active forms by caspase-1 upon activation by NLRP3 inflammasome.
The expression of IL-18 showed relatively small change rather than that of IL-1β. It may be due to
distinct regulation for Il-1β and IL-18. It is reported that there are distinct licensing requirements
for processing of IL-1β and IL-18 activation by NLRP3 inflammasome in mice [34]. Considering that
juglone is natural product, it is valuable that juglone shows anti-inflammatory effects in 10 μM of
concentration. Because juglone might be categorized as a potential anticancer compound based on
the criteria established by the National Cancer Institute [35] that any compound with IC50 value of
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≤4 μg/mL has the potential to be an anticancer compound. In view of these present findings and the
existing reports of its use in traditional folk medicine as an anti-inflammatory agent, juglone deserves
further studies to justify its potential as an anti-inflammatory agent, using a spectrum of preclinical
models. Hence, our results indicate that juglone treatment could reduce the production of mature
inflammatory cytokines IL-1β and IL-18 by suppressing their transcription and translation levels as
well as caspase-1-mediated cleavage to their active forms. Therefore, our findings suggest that juglone
could be used as a potential therapeutic compound for treating inflammatory diseases in the future.
4. Materials and Methods
4.1. Chemical Compounds
Juglone (5-hydroxy-1,4-naphthoquinone; purity > 97%) was purchased from Merck (Darmstadt,
Germany). Adenosine 5′-triphosphate (ATP) and lipopolysaccharide (LPS) were purchased from
Sigma-Aldrich, Inc. (St. Louis, MO, USA).
4.2. Cell Cultures
J774.1 cells were purchased from the Korean Collection for Type Cultures and maintained in
DMEM (Gibco BRL, Gaithersburg, MD, USA) supplemented with 10% fetal bovine serum (Gibco BRL),
100 μg/mL streptomycin, and 100 U/mL penicillin (Gibco BRL). Cells were incubated at 37 ◦C in a
humidified 5% CO2 incubator. J774.1 cells were subjected to the following treatments: (i) control; (ii)
LPS (Escherichia coli O111:b4) + ATP; (iii) 2.5 μM juglone + LPS + ATP; (iv) 5 μM juglone + LPS + ATP;
(v) 10 μM juglone + LPS + ATP. For these treatments, cells were incubated in the presence of juglone
for 2 h, followed by treatment with LPS (1 μg/mL) for 6 h and ATP (5 mM) for 1 h. After treatment,
cells were harvested for further analyses.
4.3. Cell Viability
The cytotoxic effects of juglone were assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) assay. Briefly, J774.1 cells were seeded in 24-well plates (2 × 105 cells/well) in 500 μL of cell
culture medium and incubated in a 37 ◦C and 5% CO2 incubator for 12 h to allow for cell adhesion. After
incubation, cells were treated with increasing concentrations of juglone (3.1–50 μM) for 24 h. Subsequently,
the cell culture medium was replaced with phenol red-free medium, and 50 μL of 5 mg/mL MTT solution
was added to each well. Cells were incubated with MTT for an additional 4 h in a 37 ◦C and 5% CO2
incubator. The supernatant was removed, and 200 μL dimethyl sulfoxide (DMSO) was added to each
well to dissolve the MTT crystals. Optical absorbance was measured at 450 nm using a microplate reader
(Marshall Scientific, Hants, UK). Cell viability was calculated, according to the following Formula (1):
Cell viability (%) = (Abs 450 nm of untreated cells − Abs 450 nm of treated cells/Abs
450 nm of untreated cells) × 100 (1)
4.4. Measurement of Nitric Oxide (NO)
To evaluate the anti-inflammatory effects of juglone in macrophages, NO production was measured
in J774.1 cells. The amount of NO produced in response to LPS stimulation was measured using
the Griess test, which determines the amount of nitrite (NO2−) generated. J774.1 cells were seeded
in 24-well plates (2 × 105 cells/well) and incubated at 37 ◦C for 12 h to allow for cell adhesion.
After incubation, the cell culture medium was replaced with phenol red-free medium. Cells were
treated with different concentrations of juglone for 2 h, followed by stimulation with LPS (1 μg/mL) for
24 h at 37 ◦C and 5% CO2. After incubation, 200 μL of the cell culture solution and 50 μL of Griess
reagent [1% (w/v) sulfanilamide and 0.1% N-1-naphthylethylene diamine in 2.5% (v/v) phosphoric acid]
were mixed in a 96-well plate. After a 10 min incubation at room temperature, the absorbance was
measured at 540 nm. The standard calibration curve was obtained by measuring the optical absorbance
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of serial dilutions of sodium nitrate (NaNO2). The amount of NO produced was determined using the
standard calibration curve.
4.5. Measurement of the Antioxidative Capacity of Juglone
The antioxidative capacity of juglone was measured using the hydrophilic peroxyl radical
scavenging capacity (PSC) assay [36]. To measure ROS in J774.1 cells, 2,7-Dichlorodihydrofluorescein
diacetate (DCFH-DA, Sigma, St. Louis, MO, USA) was used. The cells were seeded into 24-well
plates (2 × 105 cells/well) and incubated for 12 h. Cells were treated with 2.5, 5, and 10 μM juglone.
After 2 h of incubation, cells were exposed to 1 μg/mL LPS for 24 h in a 37 ◦C and 5% CO2 incubator.
After incubation, the cells were washed twice with cold phosphate-buffered saline (PBS) and incubated
with 10 μM of DCFH-DA for 30 min at 37 ◦C. The fluorescence intensity was measured on a fluorescence
microplate reader (Marshall Scientific) using an excitation wavelength of 485 nm and an emission
wavelength of 535 nm.
4.6. Measurement of Cytokine Release
The amounts of IL-1β and IL-18 produced by J774.1 cells were measured using enzyme-linked
immunosorbent assay (ELISA). Briefly, cells were seeded into a 24-well plate (1 × 106 cells/well) and
incubated for 12 h in a 37 ◦C and 5% CO2 incubator. Subsequently, cells were treated with 2.5, 5, and
10 μM of juglone for 2 h, followed by LPS treatment (1 μg/mL) for 6 h and ATP treatment (5 mM) for
1 h. The production of pro-inflammatory cytokines was assessed using commercial ELISA kits (mouse
IL-1β: R&D Systems, Minneapolis, MN, USA; mouse IL-18: Cloud-Clone Co., Katy, TX, USA) according
to the manufacturer’s instructions. The absorbance was measured at 540 nm. All experiments were
performed in triplicate.
4.7. RNA Isolation and cDNA Synthesis
Total cellular RNA from J774.1 cells was isolated using the RNeasy Midi Kit (Qiagen GmbH,
Hilden, Germany) according to the manufacturer’s instructions. Samples were treated with RNase-free
DNase I (Takara, Dalian, China) at 37 ◦C for 30 min to avoid any DNA contamination. The quality and
quantity of the RNA samples were measured using a bioanalyzer (Agilent 2100; Agilent Technologies,
Santa Clara, CA, USA). RNAs with RNA integrity values ≥ 8.0 were used. Complementary DNA was
synthesized from 1 μg total RNA using the iScript cDNA synthesis kit (Bio-Rad Laboratories, Hercules,
CA, USA). cDNA synthesis was performed at 46 ◦C for 20 min, followed by enzyme inactivation at
95 ◦C for 1 min.
4.8. Real-Time Reverse Transcriptase Quantitative Polymerase Chain Reaction (RT-qPCR)
Total RNA was extracted using TRIzol reagent (Life Technologies, Carlsbad, CA, USA) according to
the manufacturer’s instructions. RT-qPCR was performed on a CFX96 Real-time PCR (Bio-Rad
Laboratories Inc., Hercules, CA, USA). RT-qPCR reactions were prepared using 1 μL cDNA,
10 μL SYBR Green master mix (Bio-Rad Laboratories, Inc.), and 2 μL of primer mix in a total
volume of 20 μL. Thermocycling conditions were as follows: 3 min at 95 ◦C, 35 cycles of
denaturation (15 s at 95 ◦C), and combined annealing/extension (30 s at 60 ◦C). GAPDH was used
as a housekeeping gene. Primer sequences and their respective PCR fragment lengths were as
follows: NLRP3 (NACHT, LRR and PYD domains-containing protein 3), forward 5′-GTGGAGATCCT
AGGTTTCTCTG-3′ and reverse 5′-CAGGATCTCATTCTCTTGGATC-3′; Caspase-1, forward
5′-GAGCTGATGTT GACCTCAGAG-3′ and reverse 5′-CTGTCAGAAGTCTTGTGCTCTG-3′; IL-1β,
forward 5′-GTGGAGATCCTAGGTTTCTCTG-3′ and reverse 5′-CAGGATCTCATTCTCTTGGATC-3′;
IL-18, forward 5′-AGGACACTTTCTTGCTTGCC-3′, and reverse 5′-CACAAACCCTCCCCACCTAA-3′;
GAPDH forward 5′-GTGGGGCGCCCCAGGCACCA-3′ and reverse 5′-CTCCTTAATGTCA
CGCACGATTTC-3′. After amplification, a melting curve (0.01 ◦C/s) was used to confirm product purity.
Relative mRNA content was normalized to GAPDH content.
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4.9. Western Blot Analysis
Cells were seeded into 6-well plates (2 × 106 cells/well) and incubated in a 37 ◦C and 5% CO2
incubator for 12 h. Cells were then treated with different concentrations of juglone for 2 h, followed
by treatment with LPS (1 μg/mL) for 6 h and ATP (5 mM) for 1 h. Cells were then washed with cold
PBS and lysed with RIPA buffer (Thermo Scientific, Waltham, MA, USA). Protein concentration was
quantified using a BCA protein assay kit (Sigma). Proteins (40 μg) were separated by SDS-PAGE
(10% and 15% gels) and transferred onto polyvinylidene difluoride membranes using a Mini Tran-Blot
Electrophoretic Transfer Cell (Bio-Rad Laboratories). Membranes were blocked with 5% skimmed
milk at room temperature for 2 h, and washed three times with 1× TBST buffer (20 mM Tris-HCl,
150 mM NaCl, and 5% Tween 20, pH 7.6). Membranes were incubated with the primary antibodies
(1:1000 dilution) at 4 ◦C for at least 10 h. After three washes with 1 × TBST buffer, membranes were
incubated with mouse or rabbit IgG-horseradish peroxidase conjugated secondary antibodies at room
temperature for 2 h. Westsave ECL detection reagent and a chemiluminescent Western blot imaging
instrument (Labgear Australia, Milton, Australia) were used to visualize the signal intensities. NLRP3
(NACHT, LRR and PYD domains-containing protein 3; #13158), and caspase-1 antibody (#24232) were
purchased from Cell Signaling (Danvers, MA, USA). IL-1β (sc-7884) and β-Actin (sc-130656) antibody
were bought from Santa Cruz Biotechnology (Dallas, TX, USA). IL-18 antibody (A16737) was purchased
from ABclonal (Woburn, MA, USA). Mouse anti-rabbit secondary antibody (sc 2357)/or anti-mouse
IgG HRP secondary antibody (sc516102) were bought from bought from Santa Cruz Biotechnology
(Dallas, TX, USA). All antibodies were used at a dilution of 1:1000.
4.10. ATPase Activity Measurement
J774.1 cells were seeded into 6-well plates (2 × 106 cells/well) and incubated at 37 ◦C for 12 h. Cells
were then treated with juglone for 2 h, followed by treatment with LPS (1 μg/mL) for 6 h and ATP
(5 mM) for 1 h. After washing twice with 0.9% NaCl, lysis buffer (40 mM Tris, 80 mM NaCl, 8 mM
MgAc2, and 1 mM EDTA, pH 7.5) was used to lyse the cells. Cells were centrifuged at 15,000 rpm for
15 min at 4 ◦C. After pushing the cell lysate through a 25-gauge needle, the aqueous layer was collected
and analyzed using the ATPase activity assay kit (Sigma), according to the manufacturer’s instructions.
4.11. Statistical Analysis
All the data were analyzed using SPSS Statistics 25 software (International Business Machines,
Armonk, NY, USA). Data are expressed as mean ± standard deviation. Statistical significance was
determined using one-way ANOVA, and P < 0.05 was considered statistically significant; * p < 0.05
and ** p < 0.01
5. Conclusions
Increased ROS, NO, and NLRP3 ATPase activity by LPS and/or ATP treatment causes activation
of the NLRP3 inflammasome in macrophages. Juglone treatment reduced the production of ROS and
NO, and inhibited the ATPase activity of NLRP3 in J774.1 macrophages. Moreover, juglone treatment
suppressed NLRP3 expression and inhibited NLRP3 inflammasome activation, thereby inhibiting the
cleavage of caspase-1. Secretion of the pro-inflammatory cytokines IL-1β and IL-18 was also decreased
by juglone in a concentration-dependent manner. Thus, juglone should be considered as a therapeutic
strategy for inflammation-related diseases.
Supplementary Materials: The following are available online. Figure S1: Original images for Western blots of
IL-1β, IL-18 andβ-actin., Figure S2: Original images for Western blots of NLRP3, pro-caspase and cleaved caspase-1.
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Abstract: Nootkatone (NTK) is a sesquiterpenoid found in essential oils of many species of Citrus
(Rutaceae). Considering previous reports demonstrating that NTK inhibited inflammatory signaling
pathways, this study aimed to investigate the effects of this compound in mice models of acute and
chronic inflammation. Murine models of paw edema induced by carrageenan, dextran, histamine,
and arachidonic acid, as well as carrageenan-induced peritonitis and pleurisy, were used to evaluate
the effects of NTK on acute inflammation. A murine model of granuloma induced by cotton pellets
was used to access the impact of NTK treatment on chronic inflammation. In the acute inflammation
models, NTK demonstrated antiedematogenic effects and inhibited leukocyte recruitment, which was
associated with decreased vascular permeability, inhibition of myeloperoxidase (MPO), interleukin
(IL)1-β, and tumor necrosis factor (TNF)-α production. In silico analysis suggest that NTZ
anti-inflammatory effects may also occur due to inhibition of cyclooxygenase (COX)-2 activity
and antagonism of the histamine receptor type 1 (H1). These mechanisms might have contributed to
the reduction of granuloma weight and protein concentration in the homogenates, observed in the
chronic inflammation model. In conclusion, NTK exerted anti-inflammatory effects that are associated
with inhibition of IL1-β and TNF-α production, possibly due to inhibition of COX-2 activity and
antagonism of the H1 receptor. However, further studies are required to characterize the effects of
this compound on chronic inflammation.
Molecules 2020, 25, 2181; doi:10.3390/molecules25092181 www.mdpi.com/journal/molecules245
Molecules 2020, 25, 2181
Keywords: nootkatone; anti-inflammatory; acute inflammation; granuloma
1. Introduction
Inflammation is the body’s response against tissue damage triggered by a variety of endogenous
and exogenous stimuli. Its purpose is to remove the harmful agent and restore tissue integrity.
The inflammatory reaction involves a series of tissue changes, such as vasodilation with increased
blood flow, increased vascular permeability with plasma exudation and protein extravasation,
and recruitment of leukocytes in response to cytokines and chemokines. In this context, neutrophils
and macrophages, which play critical roles in the early phase of inflammation, also contribute to the
development of many chronic inflammatory diseases [1,2].
Inflammatory mediators include a great diversity of lipids (e.g., eicosanoids), proteins (e.g., cytokines,
chemokines, and adhesion molecules) and other chemically related substances that orchestrate various
cellular and tissue changes through binding to receptors on leukocytes, endothelial cells, and many
other cell types [3]. Some of these mediators are preformed and stored in cytoplasmic granules of mast
cells, basophils, and platelets while others circulate as inactive precursors in the plasma. However,
most of them are produced directly in response to inflammatory stimuli that may cause severe tissue
damage related to the activation of autolytic pathways [4,5]. Persistence of the stimulus, as well as
continuous production of inflammatory mediators, cause significant tissue damage, which is associated
with morphological and functional changes observed in the pathogenesis of several chronic diseases [6].
Cytokines are notable chemical mediators associated with the development of uncountable
inflammatory events. These molecules are produced from gene transcription in immune and
non-immune cells, exerting crucial roles in the host defense against pathogens; however, especially in
response to severe tissue damage, intense production of cytokines can be potentially harmful [7].
In this context, the tumor necrosis factor (TNF)-α and interleukin (IL) and IL-1 have remarkable
local and systemic effects. These cytokines are capable of activating leukocytes and other cell types,
stimulating the production of chemical mediators that amplify the inflammatory response [7,8].
Anti-inflammatory compounds, either synthetic or naturally occurring, are substances capable of
inhibiting inflammatory events by interfering with signaling cascades associated with the production
or action of inflammatory mediators. In most cases, their mechanism of action involves inhibition of
enzymes (such as cyclooxygenase (Cox) -2 and 5- lipoxygenase (LO)), receptors or gene transcription.
Corticosteroids and Non-Steroidal Anti-inflammatory Drugs (NSAIDs) are the main drug classes
used to treat inflammatory symptoms. Nevertheless, they cause severe side effects, indicating the
importance of developing novel, safe, and effective anti-inflammatory drugs [6,9].
(+)–Nootkatone (NTK) is a ketone terpenoid belonging to the largest subclass of sesquiterpenes
(Figure 1) [10]. This naturally occurring organic compound is found as a component of aromatic
species such as Alaskan cedar (Cupressus nootkatensis D.Don) and Java (Cyperus rotundus L.), as well
as in essential oils of Citrus (Rutaceae), Alpinia (Zingiberaceae), Chrysopogon (Poaceae) and many
other genera [11]. Due to its pleasant fragrance, this compound, as well as its biogenetic precursor
valencene, have been industrially used in the chemical, food, and cosmetic sectors [11,12]. Nevertheless,
studies have demonstrated that other components of citrus fruits, such as flavonoids, mainly due
to their antioxidant and anti-inflammatory activities, contribute to the relevance of Citrus species as
sources of natural products with both industrial and medicinal use. Additionally, as flavonoids are
abundant in fruit juices, the consumption of these products represents an easy way to take advantage
of the therapeutic properties of these compounds [12].
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Figure 1. (+)-Nootkatone (NTK) [8].
Previous studies demonstrated that plant extracts containing NTK presented anti-inflammatory
effects. Tsoyi and collaborators demonstrated that NTK and valencene inhibited nitric oxide (NO)
production by inhibiting NO synthase [13]. It was also found that the compound inhibited platelet
activation [14] and lipid peroxidation, in addition to inhibiting systemic oxidative stress, as well
as preventing DNA damage by activating nuclear factor erythroid-derived 2-like 2 and heme
oxygenase 1 [15].
Considering the pharmacological properties of NTK, this study aimed to investigate its effects in
mice models of acute and chronic inflammation.
2. Results
2.1. NTK Inhibits Paw Edema Induced by Different Inflammatory Agents
Because edema is one of the first inflammatory cardinal signs in acute responses, we investigated
the effects of NTK on paw edema induced by different triggering agents. Initially, we analyzed the
effect of a single oral pre-treatment with varying doses of NTK (10, 100, and 300 mg/kg) at different time
points after challenge with carrageenan (Figure 2a) or dextran (Figure 2c). These treatments caused
significant inhibition of the edema caused by both agents at all evaluated time-points. In addition,
as demonstrated by the analysis of the area under the curve (AUC) (Figure 2b,d), no significant










Figure 2. Time-point analysis of treatment with different NTK doses on paw edema formation induced
by carrageenan (a) or dextran (c). These data are also represented as area under the curve (AUC) ((b,d),
respectively). a4 = p < 0.0001 vs. saline; b3 = p < 0.001 vs. NTK 100 mg/kg group; c4 = p < 0.0001 vs.
NTK 10 mg/kg group. Statistical significance was determined with two-way ANOVA (a,c) and post
hoc Tukey test.
Histamine and arachidonic acid (AA)-derived lipid mediators are crucially involved in edema
formation during inflammatory conditions [16]. Therefore, we investigated the participation
of these mediators on NKT-mediated edema inhibition. As shown in Figure 2a, a single oral
pre-treatment with NTK (10 mg/kg) inhibited paw edema formation at 30 and 60 min after challenge
in comparison with vehicle pre-treatment. Promethazine (PTZ) (6 mg/kg), a histamine receptor
antagonist, caused similar inhibition of the edema, suggesting that NTK-mediated antiedematogenic
effects may involve, at least partially, inhibition of histamine vascular actions. Accordingly, the most
significant antiedematogenic effect of NTK was observed in AA-stimulated mice (Figure 3b). Moreover,
indomethacin (IND), an NSAID used as a positive control, caused comparable inhibition at all evaluated










Figure 3. Potential mechanisms associated with NTK-mediated paw edema inhibition.
The antiedematogenic effect is expressed as a percentage of edema induced by histamine (a) or
arachidonic acid (b). a4 = p < 0.0001 vs. saline; a3 = p < 0.001 vs. saline and a2 = p < 0.01 vs. saline.
Statistical significance was determined with two-way ANOVA and post hoc Tukey test.
2.2. The Effects of NTK on Carrageenan-Induced Peritonitis
The intraperitoneal administration of carrageenan (1%) induced an intense influx of leukocytes
associated with elevated myeloperoxidase (MPO) and albumin levels into the peritoneal cavity of mice
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4 h after challenge (Figure 4a–c), indicating the development a peritoneal inflammation associated with
leukocyte migration and activation, and increased vascular permeability. The animals treated with
NTK (10 mg/kg) or indomethacin (25 mg/kg) presented a significant reduction in all these inflammatory
parameters, demonstrating that the treatments exerted anti-inflammatory effects in mice.


















Figure 4. The effects of NTK on carrageenan-induced peritonitis. (a) The number of total leukocytes;
(b) concentrations of myeloperoxidase (MPO), and (c) concentrations of albumin in the peritoneal fluid
of mice. a4 = p < 0.0001 vs. saline and a3 = p < 0.001 vs. saline. Statistical significance was determined
with one-way ANOVA and post hoc Tukey test.
2.3. NTK Inhibits Leukocyte Recruitment and Cytokine Production on Carrageenan-Induced Pleurisy
Interleukin (IL)-1β and Tumor Necrosis Factor (TNF)-α have critical roles in the development
of acute inflammation [17]. The group of mice challenged with carrageenan and pre-treated with
NTK (10 mg/kg) presented a significantly reduced number of total leukocytes associated with lower
concentrations of IL1-β and TNF-α in the pleural lavages in comparison with untreated animals






















Figure 5. The effects of NTK on carrageenan-induced pleurisy. (a) The number of total leukocytes;
(b) concentrations of Interleukin (IL)-1β, and (c) concentrations of Tumor Necrosis Factor (TNF)-α in
the pleural lavages of mice. a4 = p < 0.0001 vs. saline and a2 = p < 0.01 vs. saline. Statistical significance
was determined with one-way ANOVA and post hoc Tukey test.
2.4. Investigation of NTK-Mediated COX-2 and H1 Inhibition in Silico
In the present study, the docking procedure was validated by removing and repositioning
each ligand into the binding site. The root-mean-square deviation (RMSD) resulting from the
X-ray crystallography structures found conformations of 0.87Å and 0.32Å (for COX-2 and histamine,
respectively), demonstrating convergence in the calculated complex formation and attesting the
performance of the docking protocol. The results of docking analysis determine how closely the lowest
energy pose (binding conformation) from the COX-2 enzyme and the H1 receptor.
The docked ligands showed score energies of −8.6 kcal/mol to diclofenac and −8.0 kcal/mol
for nootkatone in the COX-2 binding site. Considering the H1 receptor, the score energies were
−11.5 kcal/mol for doxepin and −8.1 kcal/mol for nootkatone. Of note, these data were useful to analyze
the hydrophobic and polar interactions in the binding site of the complexes. The best conformation of
nootkatone into COX-2 enzyme and H1 receptor binding sites indicate a favorable interaction with both
proteins (Figure 6a,b), as well as their respective control ligands diclofenac and doxepin, suggesting a





Figure 6. The binding poses of best stability between NTK and diclofenac into the cyclooxygenase
(COX)-2 enzyme binding site (a) and between NTK and doxepin into the binding site of the H1
receptor (b).
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Figure 7. Maps of amino acid residues within the binding pocket of COX-2 (a,b) and the H1 receptor (c,d).
The interactions of NKT (a,c), Diclofenac (b), and Doxepin (d) with these amino acids is illustrated.
2.5. The Effects of NTK on Cotton Pellet-Induced Granuloma
The cotton pellet-induced granuloma model was used to evaluate the effects of NTK on chronic
inflammation. Administration of NTK (10 mg/kg) to mice decreased both granuloma weight (Figure 8a)
and concentration of proteins in the homogenates (Figure 8b) in comparison with untreated mice,
indicating that the treatment inhibited, at least partially, the inflammatory response in this model.
  
(a) (b) 
Figure 8. The effects of NTK treatment on cotton pellet-induced granuloma in mice. (a) Final weight
of the granuloma. (b) Protein concentration in the homogenates. a4 = p < 0.0001 vs. saline and
a1 = p < 0.05 vs. saline. Statistical significance was determined with T test.
3. Discussion
The present study demonstrated the anti-inflammatory effects of NTK, an aromatic sesquiterpenoid
widely found in the plant kingdom. A screening evaluating the effect of different doses of this compound
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on paw edema induced by carrageenan or dextran, demonstrated significant antiedematogenic effects
at 10, 100, or 300 mg/kg in mice. Therefore, we chose the lower dose for the following analysis.
Carrageenan and dextran are phlogistic agents that act by triggering an inflammatory reaction
characterized by the release of chemical mediators, such as prostaglandins (e.g., PGE2) and vasoactive
amines (e.g., histamine), which increase the vascular permeability and cause the biochemical, cellular,
and vascular changes observed in acute inflammation [18].
Considering the involvement of vasoactive amines and lipid mediators on edema induction,
we investigated the effects of NTK pre-treatment on edema triggered by histamine and AA
challenge. It was shown that the compound partially inhibited paw edema formation triggered
by histamine administration and promethazine, a histamine receptor antagonist, caused comparable
inhibition, suggesting that NTK-mediated antiedematogenic effects may involve, at least partially,
inhibition of histamine vascular actions. NTK Pre-treatment significantly inhibited edema formation
in AA-stimulated mice. Accordingly, indomethacin, an NSAID used as the positive control,
caused comparable inhibition at all evaluated time-points, suggesting that the effects of NTK in acute
inflammation might involve arachidonic acid metabolism inhibition, possibly through interference
with the enzymatic activity of cyclooxygenase (COX), lipoxygenase (LO), or phospholipase A2 (PLA2),
or even by antagonizing the effects of bioactive eicosanoids on tissue receptors. Nevertheless,
the similarity in magnitude between the effect of NTK and indomethacin, suggests a common action on
the COX pathway [19,20]. Our findings are corroborated by previous research demonstrating that NTK
concentration-dependently inhibited platelet activation induced by AA in vitro. Since prostaglandins
significantly mediate AA-induced platelet activation, we hypothesized that NTK could be acting
through inhibition of COX activation in platelets [14].
To investigate the involvement of COX-2 and H1 receptor inhibition on NTZ-mediated
anti-inflammatory effects, we performed in silico analysis by molecular docking. The COX-2 binding
site shows two important regions of interaction with inhibitors: the hydrophobic pocket formed by
Tyr324, Trp356, Phe487, Phe350, Ala496, Tyr317, and Leu321, and the hydrogen bond pocket formed
by Ser-499 and Tyr-354. The Alkyl and Alkyl-pi stacking interactions work as “anchors”, favoring
the van der Waals interactions and contributing to the formation of a stable bond in the COX-2/NTK
complex. Our results demonstrated a complementarity between the ligands and the active site of
COX-2. The relative contribution of van der Waals interactions has demonstrated to be relevant for
both NTK and diclofenac. In addition, 15 similar interaction points with hydrophobic and hydrophilic
cavities were found between NTK and diclofenac. However, the control drug had relatively better
docking energy, in part, generated by hydrogen bonds. Previous studies with other terpenes derivatives
have demonstrated that these compounds interacted similarly, although no involvement of hydrogen
bonds was shown [21,22]. In the H1 receptor binding site, NTK showed potential Van der Waals
interactions with Ser84, Thr 85, Phe 378, Trp 131, Asn 164 (Figure 7). However, other interactions
such as alkyl, π-sigma, and π-alkyl, contribute to the stabilization of the interaction, as well as to
the formation of the lipophilic pocket in the binding site. According to Keserű, G. M. et al. (2004),
taking part in the lipophilic pocket formation is crucial for the antagonist activity in the binding cavity.
The interactive map shows nine similar stabilization points between the NTK/H1 and the doxepin/H1
complex at the binding site. Therefore, NTK shows favorable docking with the COX-2 enzyme and the
H1 receptor. These amino acid similarities support the hypothesis that NTK occupies the active site in
both targets, corroborating our experimental data using in vivo models.
Carrageenan-induced pleurisy and peritonitis are well-established models used for evaluation of
the systemic anti-inflammatory properties of natural and synthetic drugs. A single oral pre-treatment
with NTK (10 mg/kg) caused significant inhibition of leukocyte recruitment associated with decreased
concentrations of albumin, MPO, IL1-β, and TNF-α, demonstrating that the compound inhibited
hallmark parameters of acute systemic inflammation. The decreased albumin levels found in
NTK-treated animals indicates an inhibitory action by this compound on carrageenan-mediated
increased vascular permeability. Accordingly, the lower concentrations of IL-1β and TNF-α found
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in the NTK group justify, at least partially, the inhibitory effects of this compound on all acute
inflammation parameters demonstrated by this study, since these cytokines were shown to exert
multiple inflammatory actions, leading to increased vascular permeability and leukocyte recruitment
and activation [22]. In this context, in addition to presenting a reduced number of leukocytes in
both pleural and peritoneal lavages, the NTK-treated mice showed significantly reduced MPO levels,
indicating inhibition of leukocyte activity.
In order to evaluate the effects of NTK against a chronic stimulus, we used the cotton pellet-induced
granuloma model in mice. NTK treatment for 10 consecutive days showed positive effects, reducing both
granuloma weight and total proteins in the homogenates. These findings suggest a possible inhibitory
action of the treatment on macrophage migration and activation as well as of the proliferative
response, corroborating the effects of NTK on cytokine production and leukocyte activity. Importantly,
because NTK was found to reduce several inflammatory parameters induced by different noxious
stimuli in different mice models of acute systemic inflammation, we suggest that this sesquiterpene
may be used for further research aimed at the development of new anti-inflammatory drugs.
The results obtained in the present research are corroborated by the findings of previous studies.
Choi et al. [20] demonstrated in vitro that NTK suppressed the expression of chemokines such as
thymus and activation-regulated chemokine (TARC/CCL17) and macrophage-derived chemokine
(MDC/CCL22) in HaCaT cells, by inhibiting the mitogen-activated protein kinases (MAP kinases)
PKC and p38. Since these kinases participate in signaling pathways involved in the activation of the
transcriptional nuclear factor-kappaB (NF-κB) transcriptional factor, these findings suggest that NKT
could modulate the inflammatory response at multiple levels, since NF-κB stimulates the transcription
of numerous genes from cytokines, chemokines and adhesion molecules, supporting the findings of the
present study. According to Qi and collaborators [23], the NKT treatment reduced the levels of TNF-α,
IL-1β, and IL-6 in models of cognitive impairment and dementia in rats, corroborating the data from our
pleurisy model. Moreover, NKT significantly reduced the activities of inflammatory enzymes such as
superoxide dismutase (SOD), glutathione S-transferase (GST), cyclooxygenase-2 (COX-2), and inducible
nitric oxide synthase (iNOS) and levels of glutathione (GSH), in addition to decreasing the total
antioxidant capacity (T-AOC), as well as concentrations of malondialdehyde (MDA) and nitric oxide
(NO) through inhibition of the Toll-like receptor 4/NF-κB/domains-containing-protein-3-inflammasome
(TLR4/NF-κB/NLRP3) pathway [23]. NTK (90 mg Kg) was also shown to reduce the anti-inflammatory
effects of cigarette vapor [24], as well as inhibit lung inflammation parameters via NF-κB inhibition [19].
Nevertheless, the mechanisms underlying the effects of NTK as an anti-inflammatory compound
remain to be fully characterized. Therefore, we will carry out in vitro studies to analyze the impact
of NTK on COX-1 and COX-2 expression and activity, which will be correlated with the levels of
PGE2 in the supernatants of macrophage cultures. Additionally, we will use mast cell cultures will to
analyze the effects of NTK on histamine release in vitro, which will be correlated with the activity of
this compound in combination with agonists and antagonists of the H1 receptor in vivo.
Finally, Kurdi and colleagues demonstrated that NTK (10 mg/kg) treatment exerted
hepatoprotective and antifibrotic effects by suppressing the carbon tetrachloride (CCL4)-induced
lesion, which is characterized by expression of pro-inflammatory cytokines, such as TNF-α,
monocyte chemotactic protein (MCP)-1 and IL-1β in liver tissues. In the same study, histopathological
findings revealed that NTK reduced fibrosis, steatosis, hepatocyte necrosis and leukocyte infiltration [25],
providing evidence that NTK could be useful in the management of chronic inflammation, as indicated
by our findings in the cotton pellet-induced granuloma. However, further research is required to
characterize better the anti-inflammatory effects of NTK, as well as its mechanism of action on chronic
inflammation. To this end, we will carry out experiments to characterize the cell populations, as well
as the expression of chronic inflammation markers in the granuloma model.
In conclusion, NTK presented anti-inflammatory effects in mice models of acute and chronic
inflammation. In acute inflammation, the antiedematogenic effects, as well as leukocyte recruitment
inhibition, may be associated with decreased vascular permeability and inhibition of MPO, IL1-β,
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and TNF-α production, possibly due to inhibition COX-2 activity and antagonism of the H1 receptor.
These mechanisms might have contributed to the anti-inflammatory effects displayed by NTK on the
granuloma model. However, further studies are required to characterize the effects of this compound
on chronic inflammation.
4. Materials and Methods
4.1. Drugs and Reagents
Compound NTK, all inflammatory agents (carrageenan, dextran, histamine, and arachidonic
acid), ELISA kits from eBioscience and compound o-dianisidine (used for myeloperoxidase assay)
were purchased from Sigma-Aldrich (New York, NY, USA); the kits for albumin and total proteins
quantification were supplied by Labtest (Lagoa Santa, Brazil), ketamine was purchased by the VETNIL
(São Paulo, Brazil), and xylazine was purchased by CEVA (São Paulo, Brazil).
4.2. Animals
Swiss mice (Mus musculus) of both sexes, weighing 20–30 g, were randomly assigned into groups
and maintained in polypropylene cages at 22 ± 3 ◦C, under a 12 h light/dark cycle and with free
access to water and food (Labina, Purina®, Euskirchen, Germany). The research was carried out
in accordance with the guidelines animal testing (Guide for the care and use of laboratory animals,
from NIH—National Institute of Health—USA, 1996; Federal Law No. 11,794/2008 and National
Experiment Control Council—CONCEA). The protocols used in this study were approved by the
local institutional review board for animal experimentation (CEUA, Regional University of Cariri,
protocol number 100/2019.2).
4.3. Evaluation of the Anti-Inflammatory Activity
The effects of NTK on acute inflammation were evaluated using the following mice models:
carrageenan-induced peritonitis, carrageenan-induced pleurisy, and paw edema induced by either
carrageenan, dextran, histamine, or arachidonic acid (AA). In all these protocols, the mice received
a single oral treatment one hour before the challenge. Each challenge was performed through a
single administration of an inflammatory agent (carrageenan, histamine, dextran, or AA) to the mice,
triggering an acute inflammatory response, which was monitored immediately after the challenge
at specific time-points, according to standard protocols. The paw edema models were used to
evaluate the local inflammatory response, while pleurisy and peritonitis were used to analyze systemic
inflammatory parameters. In the chronic inflammation protocol, the animals were treated daily for ten
consecutive days, after surgically receiving a persistent stimulus (cotton pellets). This protocol induces
the formation of granuloma, which is considered as a parameter of chronic inflammation.
4.3.1. Evaluation of the Antiedematogenic Activity
The animals (n = 6 per group) were randomly assigned into groups and orally treated with NTK
(10, 100, or 300 mg/kg), vehicle (0.9% saline, negative control) or control drugs (promethazine, 10 mg/kg
or indomethacin, 25 mg/kg) 1 h before challenge with 20 μL of carrageenan, dextran, histamine, or AA
at 1% (w/v). Each inflammatory agent used in the challenge was administered in the hind right paw
and an equal volume of saline was administered in the hind left paw. The volume of both paws was
measured at different time-points according to the type of challenge, using a plethysmometer and the
results were expressed as a percentage of edema, considering the difference between the hind and left
paw of the untreated group as 100% [19,21,22].
4.3.2. Carrageenan-Induced Peritonitis
The mice (n = 6) were orally pre-treated with the vehicle, NTK (10 mg/kg), or indomethacin
(25 mg/kg) 1 h before receiving an intraperitoneal injection of 1 mL of 1% carrageenan (challenge).
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Four hours after challenge, these animals were euthanized by CO2 inhalation, the peritoneal cavity
was washed with 3 mL of heparinized PBS (10 IU/mL), and the peritoneal lavage was collected for
leukocyte counting and quantification of MPO and total proteins [26]. Total leukocyte counts were
performed using the SDH-20 model automatic counter and the differential counts were performed by
optical microscopy, on slides stained using the panoptic method.
4.3.3. Carrageenan-Induced Pleurisy
The mice (n = 6) were orally pre-treated with the vehicle, NTK (10 mg/kg), or indomethacin
(25 mg/kg) 1 h before receiving an intrathoracic injection of 1% carrageenan (challenge). Four hours
later, the animals were anesthetized with ketamine (8 mg/kg) and xylazine (8 mg/kg) and euthanized
by cervical dislocation. The pleural cavity was washed with 1 mL of saline containing 0.9%
Ethylenediaminetetraacetic acid (EDTA, Sigma, New York, NY, USA). The pleural lavages were
centrifuged (5000 rpm, 5 min, at room temperature), and supernatants were stored (at −80 ◦C) for
further analysis. The precipitate was added with 1 mL of PBS, and leukocytes were counted under
light microscopy after diluting the pleural lavage samples in Turk fluid (2% acetic acid) [27].
4.3.4. Quantification of MPO and Total Proteins
Samples of the peritoneal lavage were centrifuged at 6000 RPM for 2 min. Albumin quantification
in the supernatants was performed using a Labtest kit (Lagoa Santa, Brazil) and used as a parameter
of protein extravasation due to increased vascular permeability. In this method, the absorbance
of bromocresol green, which specifically binds albumin, is proportional to the concentration of the
protein in the sample. The readings were performed using a spectrophotometer with absorbance
adjusted between 600 and 640 nm. Leukocyte activity was determined by quantifying the MPO
enzyme. To this end, a tube was added with 40 μL of the supernatant of the pleural lavage and
1960 μL of the o-dianisidine and H2O2 reagent in PBS (pH = 6.0). The readings were performed using
a spectrophotometer at 450 nm.
4.3.5. Cytokine Quantification
The concentrations of TNF-α and IL-1β were determined using enzyme-linked immunosorbent
assay (ELISA) kits (Invitrogen®, California, CA, USA) according to the manufacturer’s instructions.
Briefly, supernatants of pleural lavages were diluted 1:1 (w/w) in the diluent solution provided by the
ELISA kit, and the readings were performed at 450 nm using a microplate reader (ASYS®, New York,
NY, USA). The concentrations were obtained by interpolation from a standard curve and data were
expressed as pg/mL.
4.3.6. Cotton Pellet-Induced Granuloma
Mice (n = 6) previously anesthetized with ketamine (80 mg/kg) and xylazine (20 mg/kg) had
four cotton pellets (0.01 g each) implanted through a small dorsal incision. Twenty-four hours later,
the animals were treated orally with vehicle or NTK (10 mg/kg) for ten consecutive days. On day 11,
the animals were euthanized, and the pellets, as well as the surrounding tissue, were removed, dried at
37 ◦C for 24 h, and weighed. The results were expressed as the difference between the final weight and
the initial weight [28].
For total protein quantification, the pellets were placed in test tubes and homogenized with 1 mL of
0.9% saline. The concentration of total proteins was determined using a specific kit (Labtest, Lagoa Santa,
Brazil) that is based on the reaction with copper ions in an alkaline medium, creating a violet color
complex whose absorbance is proportional to the concentration of proteins in the sample. The readings
were performed at 550 nm using a spectrophotometer.
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4.4. In Silico Analysis of COX-2 Inhibition
Docking simulations were carried out for ligand-bound protein complexes, obtained from the
Protein Data Bank (PDB, ID. 1PXX and 3RZE). The complexed structures were adjusted using a protein
preparation tool provided by the Chimera package, the 3D structures of ligands were obtained using
the corina® 3D structure generator and minimization of energy was achieved using the UCSF Chimera
structure build module. The binding region was defined by a 10 Å × 10 Å × 10 Å box set at the centroid
of the co-crystallized ligand in the crystal complex to explore a large region of the enzyme structure.
The docking analysis was carried out using the UCSF Chimera and AutoDock Vina software based
on the Iterated local search global optimizer. Proteins and ligands were maintained flexible during
the docking process. The selection of flexible residues from proteins was based on the active site at
4.0 Å from the co-crystallized ligands. The most favorable binding free energy was represented by
clustering the positional RMSD results with not more than 1.0 Å. The final docked complexes were
analyzed using Discovery Studio 3.1 visualizer [29].
4.5. Statistical Analyses
Data were analyzed by one-way ANOVA or two-way ANOVA and Tukey post hoc test or T test
using GraphPad Prism software version 7.00 (GraphPad, San Diego, CA, USA, 2016). Values are
expressed as means ± SEM. Statistical significance was considered when p < 0.05.
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Abstract: Considering the global health threat posed by kidney disease burden, a search for new
nephroprotective drugs from our local flora could prove a powerful strategy to respond to this health
threat. In this study we investigated the antihyperuricemic and nephroprotective potential of RA-3,
a plant-derived lanosteryl triterpene. The antihyperuricemic and nephroprotective effect of RA-3 was
investigated using the adenine and gentamicin induced hyperuricemic and nephrotoxicity rat model.
Following the induction of hyperuricemia and nephrotoxicity, the experimental model rats (Sprague
Dawley) were orally administered with RA-3 at 50 and 100 mg/kg body weight, respectively, daily for
14 days. Treatment of the experimental rats with RA-3, especially at 100 mg/kg, effectively lowered
the serum renal dysfunction (blood urea nitrogen and creatinine) and hyperuricemic (uric acid and
xanthine oxidase) biomarkers. These were accompanied by increased antioxidant status with decrease
in malondialdehyde content. A much improved histomorphological structure of the kidney tissues
was also observed in the triterpene treated groups when compared to the model control group. It is
evident that RA-3 possesses the antihyperuricemic and nephroprotective properties, which could be
vital for prevention and amelioration of kidney disease.
Keywords: RA-3; nephrotoxicity; triterpene; antioxidant; hyperuricemia
1. Introduction
The recent massive hike of kidney disease on the global rankings of disease burden signals
public health crisis [1]. Kidney disease (nephropathy) is a product of multiple factors that inflict
damage to nephron, renal parenchyma, and subsequent renal failure, if diagnosis and treatment are
delayed [2]. Amongst various risk factors such as diabetes, hypertension, hyperuricemia, and infections,
drug-induced nephrotoxicity is considered one of the significant contributors to both acute and chronic
kidney disease [3]. This is attributable to increased exposure of the general population to a large
number of prescribed and over-the-counter drugs as well as a variety of other ingested foodstuff and
environmental intoxicants [4]. Hyperuricemia, a condition characterized by abnormally elevated uric
acid levels in the blood, is considered an independent risk factor of kidney disease [5,6]. The underlying
kidney damaging effects of uric acid are associated with tubular toxicity, vasoconstriction, oxidative
stress, and inflammation [6,7].
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Though nephropathy is harmful, with early diagnosis it is treatable to prevent end-stage renal
failure. Depending on the underlying cause and stage of the injury, there are various drugs currently
in clinical use against hyperuricemia and nephropathy. These drugs include captopril, allopurinol,
and some diuretics (loop and thiazide). Despite efficacy of these drugs, they are also associated with
some adverse reactions such as hypersensitivity syndrome, acute interstitial nephritis, and electrolyte
imbalances [8,9]. The discovery of new nephroprotective drugs with improved safety profile and
tolerance are encouraged. Since tissue damages are commonly prone to oxidative stress and excessive
inflammatory response [10], new therapeutic drugs with strong antioxidant and anti-inflammatory
activities would be preferred.
There is substantial evidence on potential role of various medicinal plants, as crude extracts or
pure isolated compounds [2,11–13], in protecting the kidney from various insults thus, maintaining its
integrity and functions. Even though methyl-3β-hydroxylanosta-9,24-dien-21-oate (RA-3), a lanosteryl
triterpene from Protorhus longifolia (Bernh) Engl., has displayed significant various bioactivities such as
antihyperlipidemic [14], antihyperglycemic [15], and cardioprotective [16] effects, its nephroprotective
potential has not been reported. However, the triterpenes from this plant have previously exhibited
lack of cytotoxic effects on human embryonic kidney cell lines [17]. To continue exploring potential
significant bioactivities of this plant-derived bioactive compound, the current study investigated
its antihyperuricemic and nephroprotective potential in adenine-gentamicin induced hyperuricemic
and nephrotoxicity rat model. Adenine and gentamicin induced kidney damage is characterized by
increased renal tubular cell death and increased blood urea nitrogen (BUN), creatinine (Cr), and uric
acid (UA). All these parameters are commonly observed in human clinical subjects of nephropathy.
2. Results
2.1. Confirmation of the Isolated Lanosteryl Triterepene (RA-3)
RA-3 was routinely isolated and purified from the chloroform extract of P. longifolia stem bark
using chromatographic techniques. The physical (white crystals, >95% pure, melting point 204–205 ◦C)
and spectral data (IR (KBr) vmax = 3469, 1683 cm–1, molecular formula C31H50O3) of this compound
were in agreement with previous reports from our laboratory [14,18]. The expected chemical structure
of the compound was confirmed as methyl-3β-hydroxylanosta-9,24-dien-21-oate (Figure 1).
Figure 1. Methyl-3β-hydroxylanosta-9,24-dien-21-oate (RA-3), a lanosteryl triterpene from P. longifolia.
2.2. Body Weight Changes
Body weights of the rats were monitored for the duration of the study. A normal increase in
body was observed in the normal. However, the model group showed a slow increase in body when
compared to the normal rats. A slight difference in body weight increase was also observed in the
RA-3 and allopurinol treated rats (Table 1).
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Table 1. Body weight changes of the rats after 28 days of the experiment.
Group Initial Body Weight (g) Final Body Weight (g) Body Weight Changes (g)
Normal 192.3 ± 9.33 215.0 ± 4.71 22.7 *
Model control 165.8 ± 14.06 176.9 ± 10.32 11.1
Allopurinol (10 mg/kg) 155.2 ± 21.68 173.1 ± 7.77 17.9 *
RA-3 (50 mg/kg) 179.1 ± 6.20 193.7 ± 15.49 14.6
RA-3 (100 mg/kg) 159.6 ± 10.18 176.8 ± 20.17 17.2
Data were expressed as mean ± SD (n = 5). * p < 0.05 vs. model control group.
2.3. Changes on Serum Levels of Some Renal Dysfunction Biomarkers
Changes in serum levels of some common renal dysfunction biomarkers were analyzed following
treatment of the ailing rats with RA-3. Elevated levels of serum creatinine (Cr, 4.8 ± 1.78 mg/dL),
angiotensin converting enzyme (ACE, 138.0 ± 39.61 U/L), and blood urea nitrogen
(BUN, 22.5 ± 1.11 mg/dL), were observed in the model control group (MC). However, treatment
of the rats with RA-3, especially at 100 mg/kg, effectively lowered these renal dysfunction biomarkers
(Cr, 0.92 ± 0.23 mg/dL; ACE 75.5 ± 10.9 U/L; BUN 5.75 ± 0.29 mg/dL) near to the values of the normal
control group (Figure 2). The results (Cr and BUN) obtained from RA-3 (100 mg/kg) treated groups
were also comparable to the group treated with allopurinol.
Figure 2. Effect of RA-3 on serum levels of creatinine (a), blood urea nitrogen (BUN) (b), and angiotensin
converting enzyme (ACE) (c). Data were expressed as mean ± SD (n = 5), * p < 0.05 vs. MC group.
NC—normal control, MC—model control, Allo—allopurinol.
2.4. Serum Levels of Xanthine Oxidase, Uric Acid and Interleukin-6
While higher serum levels of UA (0.61 ± 0.10 mg/dL), xanthine oxidase (XO, 1.48 ± 0.22 mU/mL),
and interleukin-6 (IL-6, 0.71 ± 0.28 pg/mL) were observed in the model control group when compared
to the normal control, RA-3, in a concentration dependent manner, significantly decreased the serum
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levels of UA (0.34 ± 0.08; 0.16 ± 0.02 mg/dL, p < 0.01) and XO (0.62 ± 0.12; 0.44 ± 0.08 mU/mL, p < 0.05).
Though the difference was not significant, a relatively lower serum levels of IL-6 were also observed
in the RA-3 treated groups when compared to the model control. Similar results were observed in
the allopurinol (a known XO inhibitor and hypouricemic drug) treated group (Figure 3) in which a
significant decrease in the serum levels of AU and XO were observed.
Figure 3. Effect of RA-3 on the serum levels of uric acid (a), xanthine oxidase (XO) (b) and interleukin-6
(IL-6) (c). Data were expressed as mean ± SD (n = 5), * p < 0.05 vs. MC group. NC—normal control,
MC—model control, Allo—allopurinol.
2.5. Serum Biomarkers of Oxidative Stress
Decreased serum levels of superoxide dismutase (SOD) activity, reduced glutathione (GSH)
content and thus total antioxidant status along with increased malondialdehyde (MDA) content were
observed in the untreated group (model control) when compared to the normal, RA-3, and allopurinol
treated groups (Table 2), an indication of oxidative stress. Nevertheless, treatment of the animals
with RA-3 at both concentrations (50 and 100 mg/kg) improved the levels of the antioxidants while
decreasing the MDA content.




SOD (Units/mL) Total Antioxidant Status (mM)
MDA
(nmol/μL)
Normal 0.91 ± 0.31 * 71 ± 0.14 * 1.94 ± 0.17 * 0.17 ± 0.06 *
Model control 0.22 ± 0.06 14.3 ± 0.06 0.34 ± 0.02 1.04 ± 0.03
Allopurinol (10 mg/kg) 1.20 ± 0.68 * 21.0 ± 0.03 1.00 ± 0.55 0.20 ± 0. 44 *
RA-3 (50 mg/kg) 0.74 ± 0.22 24. 7± 0.15 * 1.40 ± 0.40 * 0.16 ± 0.04 *
RA-3 (100 mg/kg) 0.80 ± 0.18 * 55.0 ± 0.17 * 1.87 ± 0.20 * 0.14 ± 0.02 *
Data were expressed as mean ± SD (n = 5). * p < 0.05 vs. model control group.
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2.6. Histological Analysis of the Kidney Tissues
The results of histological analysis are presented in Figure 4. The sections of kidneys from the
normal group showed a normal architecture with intact glomerulus and renal tubules. A marked
damage to the kidney indicated by robust display of glomerular congestion, dilated renal tubules and
epithelial degeneration was observed on the kidney sections from the model control group. However,
kidney sections from the rats treated with RA-3, especially at 100 mg/kg showed a much improved
histomorphological structure of the kidney (Figure 4v), characterized by minimal renal tubular dilation
and necrosis, indicative of recovery.
 
Figure 4. Photomicrographs of the kidney sections of the rats. (i) Section of kidney from normal
group, showing normal kidney architecture with intact glomerulus (black arrow) and renal tubules
(black triangle); (ii) section from model control group, showing glomerular congestion, dilated renal
tubules, and epithelial degeneration (red arrow), (iii) section from group treated with allopurinol,
showing minimal improved renal architecture; (iv) section from group treated with RA-3 (50 mg/kg),
showing regeneration of epithelium, (v) section from group treated with RA-3 (100 mg/kg), showing
improved renal architecture characterized by epithelial regeneration and reduced glomerular congestion.
The indicator size for each image is 14X-200 μm (H&E).
3. Discussion
Considering the global health threat posed by kidney disease burden, a search for new
nephroprotective drugs from our local flora could prove a powerful strategy to respond to this health
threat. Potential of plant-derived triterpenes as new nephroprotective agents has been demonstrated
using various animal models [13,19].
This study investigated the antihyperuricemic and nephroprotective potential of RA-3, a lanosteryl
triterpene from P. longifolia. The increased serum levels of these biomarkers along with a robust
display of glomerular congestion and epithelial degeneration in the kidney samples from the MC
group confirmed the induction of hyperuricemia and nephrotoxicity in the rats. It was interesting to
observe the significant decrease in serum levels of these biomarkers (UA, BUN, Cr) with improved
histomorphology of the kidney tissues from the rats treated with RA-3 at both concentrations.
The results served as an indication of the hypouricemic and nephroprotective potential of the triterpene.
Substantial experimental evidence has also demonstrated the significant nephroprotective properties
of some other plant-derived triterpenes [13,19,20].
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While renal toxicity of gentamicin is strongly linked to oxidative stress [3], adenine’s toxicity is
associated with renal tubular obstruction and hyperuricemic effect [21]. Hyperuricemia is considered
an independent risk factor of kidney disease [5]. Blood UA levels are physiologically regulated by XO
activity, an enzyme that catalyzes the formation of UA from xanthine. The XO catalyzed reaction also
generates reactive oxygen species (ROS) which can trigger inflammatory reactions and consequent
tissue damage [22]. The reduced serum levels of UA along with decreased XO activity in the triterpene
treated groups supported the antihyperuricemic effect of RA-3. These observations were also similar
to those of the group treated with allopurinol, a standard hyporuricemic drug. Experimental evidence
has shown that antihyperuricemic compounds do possess nephroprotective effect [19,23].
Hyperuricemia is known to cause, among others, vascular smooth muscle cell proliferation,
endothelial dysfunction, and increased IL-6 synthesis, all of which may contribute to the progression of
chronic kidney disease [9]. Though there was no significant difference between the model control and
the treated nephrotoxic groups, the relatively lower serum levels of IL-6 in the RA-3 and allopurinol
treated groups were observed. This could further be correlated with the suppressed XO activity in
these groups. Since XO activity is known to trigger inflammatory reactions and consequent tissue
damage [22], the observed results further indicated the tissue protective potential of the triterpene.
It has further been demonstrated that even mild elevations in serum UA can cause hypertension and
renal microvascular disease without causing urate crystal deposition in kidneys [24]. The hypertensive
effect of elevated serum UA has been associated with activation of the renin-angiotensin system
(RAS) [7]. The vasoconstrictive effect of RAS is mediated by ACE, an enzyme that catalyzes conversion
of angiotensin I to a bioactive angiotensin II. The observed lower ACE activity in the lanosteryl
triterpene treated groups further suggests the potential role of RA-3 in management of hypertension,
another important risk factor of nephropathy [25]. The role of ACE inhibitors in prevention of renal
function deterioration is well-established [26,27]. The hypouricemic effect exhibited by RA-3 may also
be vital in the prevention of other ailments known to be associated with hyperuricemia [28–30].
Furthermore, despite the ROS-mediated renal toxicity of gentamicin and adenine, the improved
serum total antioxidant status, GSH and SOD along with reduced MDA content in the rats treated
with RA-3 indicated its tissue protective potential against oxidative damage. It is interesting to
note from these results that the ability of RA-3 to enhance endogenous antioxidant defense while
inhibiting lipid peroxidation has previously been demonstrated in streptozotocin (STZ)-induced
diabetes and isoproterenol (ISO)-induced myocardial injury in rat models [15,16]. It is also worth
noting that similar to gentamicin induced renal tubular toxicity, the necrotic toxicity of STZ and ISO
are also associated with oxidative stress [31,32]. Since inflammation and oxidative tissue damage
are common culprits in various pathophysiologies including nephropathy, nephroprotective drugs
with both anti-inflammatory and antioxidant properties are highly desired. The nephroprotective
potential of most medicinal plant extracts and their derived compounds has been associated with their
antioxidant and anti-inflammatory activities [11,33].
4. Materials and Methods
4.1. Reagents
Glutathione assay kit (catalog number: CS0260), xanthine oxidase assay kit (catalog number:
MAK078), superoxide dismutase assay kit (catalog number: 19160), antioxidant assay status kit (catalog
number: CS0790), malondialdehyde assay kit (catalog number: MAK085), rat interleukin-6 assay kit
(catalog number: RAB0333). All the commercial assay kits used were purchased from Sigma Aldrich
(St. Louis, MO, USA)
4.2. Plant Extraction and Isolation of the Lanosteryl Triterpene (RA-3)
Plant extract was prepared from stem bark of P. longifolia collected from KwaHlabisa,
KwaZulu-Natal, South Africa. The plant material (voucher specimen number RA01UZ) was identified
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and confirmed by Dr. NR Ntuli from Botany Department, University of Zululand. The targeted
compound (RA-3) was routinely isolated and purified from the chloroform extract using the method well
established in our laboratory [18]. The lanosteryl triterpene was isolated over silica gel chromatography
and the pure compound was recrystallized in 100% ethyl acetate. Melting point and spectroscopic data
analysis were used, in comparison with literature data [14,18], to confirm chemical structure of the
isolated pure (>95%) lanosteryl triterpene.
4.3. Animals
The University of Zululand Research Ethics Committee (UZREC) granted ethical clearance
(UZREC 171110-030 PGM 2016/321) for use of laboratory animals (Sprague Dawley rats). Sprague
Dawley rats (n = 30) were collected from the animal unit of the Department of Biochemistry, University
of Zululand. The animals were housed in standard cages (maximum of four rats per cage) and
maintained at room temperature (23–25 ◦C; relative humidity ~50%) with a 12:12-h light/dark cycle as
per stipulated national guidelines for the care and use of animals. All the rats were in good state of
health and were allowed to acclimatize to the experimental set-up for a week before the experiment
was conducted. Unless stated otherwise, all the animals had free access to drinking water and normal
rat feed throughout the experimental period.
4.4. Preparation of RA-3 Solution
Fresh working solutions of RA-3 (50 and 100 mg/kg body weight) were prepared in 2% Tween 20.
These concentrations were based on our previous studies on the compound [14–16].
4.5. Investigation of the Antihyperuricemic and Nephroprotective Potential of RA-3
The adenine and gentamicin induced hyperuricemia and nephrotoxicity rat model, slightly
modified from that described by Meng et al. [34] was used to evaluate the antihyperuricemic and
nephroprotective effect of the triterpene (RA-3). Sprague Dawley rats of either sex (150–200 g) were
randomly divided into two major groups; normal and model groups. The rats in the model group
were orally administered with adenine (150 mg/kg body weight) and intraperitoneally injected with
gentamicin (40 mg/kg body weight) daily for fourteen days to induce hyperuricemia and nephrotoxicity.
Following induction of nephrotoxicity, the animals in the model group were randomly divided
into four groups (II-V) of at least five rats per group (n = 5). The normal control (I) and model control
(II) groups received drinking water and 2% Tween 20 (vehicle, p.o), respectively, throughout the
experimental period. While the positive control group (III) received allopurinol (10 mg/kg, body weight,
p.o), the experimental groups IV and V were orally administered with RA-3 at 50 and 100 mg/kg,
respectively. The respective drugs were administered daily for a further fourteen days period. All drug
administrations were performed between 8:00 and 9:00 AM and the animals were treated in the same
order throughout the experimental period. At the end of the experimental period, the rats were
fasted for eight hours and euthanized under anesthesia (Pentobarbital at 30 mg/kg body weight, ip).
A complete loss of sensation was confirmed by pedal withdrawal reflex before any procedure could be
conducted on the rats. The rats were quickly dissected, blood and kidney samples were immediately
collected. The collected tissues samples were used for estimation of some biochemical parameters and
histopathological indications, respectively.
4.5.1. Biochemical Analysis
The collected blood samples were separately allowed to clot and centrifuged at 1200 rpm for 10 min.
Serum was collected and used for estimation of some selected biochemical parameters. The serum
levels of total antioxidant status, GSH, SOD, XO, and MDA were estimated using commercial activity
assay kits (Sigma Aldrich, St. Louis, MO, USA). The total antioxidant status assay kit non-specifically
measures the total concentration of the antioxidant molecules (small molecules and proteins) in a
biological sample (serum, cell and tissue lysate etc.). The serum IL-6 content was measured with ELISA
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kit (Sigma Aldrich, St. Louis, MO, USA). Standard laboratory procedures (Global Clinical & Viral
Laboratory, Kwazulu Natal, South Africa) were followed to estimate the serum levels of Cr, UA, ACE,
and BUN.
4.5.2. Histological Analysis of Kidney Tissues
Kidney tissues, preserved in 10% neutral buffered formalin, were embedded in paraffin and
sectioned according to standard procedures. The sectioned tissues were subjected to Hematoxylin
and Eosin staining for routine histopathological examination (Department of Physiology Department,
University of KwaZulu-Natal, Kwazulu Natal, South Africa).
4.6. Data Analysis
Data were expressed as mean ± standard deviation (SD) of the mean. The results were analyzed
by Kruskal-Wallis test followed by Dunn’s post hoc multiple comparison test using GraphPad Prism
software (version 6). The statistical differences were considered significant at p < 0.05.
5. Conclusions
The results of the current study have indicated and confirmed the antihyperuricemic and
nephroprotective potential of RA-3. The ACE inhibitory effect and hypouricemic potential displayed
by the triterpene are not only crucial in renal protection, but in other related complications such as
cardiovascular disease, hypertension and gout arthritis as well. Investigation of the molecular basis of
its nephroprotective potential will provide an insight into the triterpene’s therapeutic mechanism.
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Abstract: Hesperidin, a secondary orange (Citrus sinensis) metabolite, was extracted from orange
bagasse. No organic solvents or additional energy consumption were used in the clean and sustainable
process. Hesperidin purity was approximately 98% and had a yield of 1%. Hesperidin is a known
supplement due to antioxidant, chelating, and anti-ageing properties. Herein, hesperidin application
to eliminate dark eye circles, which are sensitive and thin skin regions, was studied. In addition,
the proposed method for its aqueous extraction was especially important for human consumption.
Further, the most effective methods for hesperidin nanonization were explored, after which the
nanoemulsions were incorporated into a cream formulation that was formulated for a tropical climate.
Silky cream formulations (oil in water) were tested in vitro on artificial 3D skin from cultured cells
extracted from skin residues after plastic surgery. The proposed in vitro assay avoided tests of the
different formulations in human volunteers and animals. It was shown that one of the nanonized
hesperidin formulations was the most skin-friendly and might be used in cosmetics.
Keywords: hesperidin; new-clean process extraction; nanocrystals; antioxidant; anti-ageing
1. Introduction
Hesperidin (HSD) is a secondary plant metabolite and one of the principal bioflavonoids of
citrus fruits. This flavanone and its aglycone form, hesperetin (HST), are present in relatively high
quantities (1–2%), especially in sweet immature oranges (Citrus sinensis) [1,2]. HSD is known for
valuable bioactivity and can act as an antioxidant [3–10], anti-inflammatory [3,9,10], hypolipidemic [8],
vasoprotective [3,4,8,11], and anticancerogenic [3,9] agent. The great majority of flavanones are
glycosylated mainly with rutinose and neohesperidose [1,12]. HSD (Figure 1) is proposed, after different
in vitro studies, as a plant defense molecule and a potent antioxidant [7,13]. It is water soluble just at
high pH, dimethyl sulfoxide, and pyridine, giving yellow and clear solutions. HSD is partially soluble
in methanol and glacial acetic acid, and almost insoluble in acetone, chloroform, and benzene [12,14].
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Figure 1. Chemical structure of hesperidin (2S)-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-7-[(2S,3R,
4S,5S,6R)-3,4,5-trihydroxy-6-[[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-2-
yl]oxy-2,3-dihydrochromen-4-one). HSD carbon atoms are numbered, and A–C rings are shown.
1.1. Antioxidant Activity of Hesperidin
Bioflavonoids have been known for a long time because of their noticeable antioxidant potential
that mitigates the harmful impact of free radical and reactive oxygen species. Hydroxyl, alkoxyl, peroxyl,
and peroxyl nitrite radicals induce ageing, tissue damage, and contribute to many disease developments
like cancer, hypertension, atherosclerosis, amyloidosis, and senile dementia. Nevertheless, the cited
free radicals are produced in everyday life and neutralized as well by enzymes [1]; with ageing and
increased radical production, their nocive effects are enlarged and become far more potent. The radical
scavenging property inherent to natural bioflavonoids is related to their structure and in HSD, hydroxyl
groups at positions 3′- and 5- demonstrate mild antioxidant activities [15,16]. Hesperetin (HST) has
an additional hydroxyl group (7-), thus showing a stronger antioxidant activity compared to HSD.
Disaccharide in the HSD structure affects its capacity for electronic delocalization and decreases its
antioxidant activity [6]. For example, HSD nano-loaded lipid carrier showed antioxidant effects in
concentrations of 45 μM in 2,2-diphenyl-1-picrylhydrazyl (DPPH) assay, and without any toxic effects
on several cell lines [17].
1.2. Hesperidin and Hesperetin Use in Cosmetics as Anti-Ageing Active Components
Hesperidin and hesperetin are the foci of intensive research for topical application. For example,
sulfonated, acetylated, or phosphorylated HSD derivatives are potent inhibitors of hyaluronidase.
Moreover, HSD can also act on superoxide in electron transfer as well as proton transfer in vivo.
HSD might act as a topical UV-protective agent, by protecting phosphatidylcholine liposomes from UV
irradiation-induced peroxidation. The neohesperidin, for example, demonstrates the capacity to extend
yeast’s chronical lifespan, individually or in synergism with the HST, for 10 different aging factors,
such as scavenging ROS effects, regulation of stress-related enzymes, and maintaining pH cellular value,
favorable for life extension of yeast cells [18]. Hesperidin was also proved as a potent anti-photoageing
factor, through regulation of metalloproteinases MMP-9 via mitogen activation protein kinase (MAPK)
signaling pathways. In the same study, Lee and colleagues [19] approved the positive effect of the
hesperidin on wrinkle depth on a mouse dorsal skin model, and reduction in UVB-induced hydration
changes and trans-epidermal water loss [20]. Different studies demonstrate accelerated cutaneous
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diabetic or venous wounds healing and ameliorate skin epidermal barrier function already after 7 days
of HSD application [20]. On the other side, HST was found to penetrate through the stratum corneum [5]
and assays conducted in vitro showed that the presence of lecithin and d-limonene in formulations may
aid towards faster hesperetin penetration into the skin [21]. Additionally, in vitro studies of the stratum
corneum have demonstrated that flavonoids show differences in penetration capacities, which depend
in a large part on the ingredients/vehicles present in the formulation. Therefore, the penetration rate of
flavonoids, such as catechin, rutin, quercetin, and others, is influenced by moisturizing ingredients
(glycerol, glycols, polyglycols, ethoxylated methyl glucoside, and urea) and by the type of cosmetic
formulation (hydrogel, emulsion, microemulsion, and micellar system) [6]. For example, the water
in oil microemulsion formulations significantly enhances quercetin skin penetration up to 12 h after
application [22–24]. HSD-loaded nanostructured lipid vehicles show burst release in the beginning
and further sustained bioflavonoid release from the lipid nanocarrier [17]. Despite their interesting and
beneficial skin effects, bioflavonoids are very demanding for making effective formulations. In addition,
their insolubility in water complicates their use in cosmetic products and influences greatly on their
extraction from fruits and plants that is usually performed by the use of organic solvents.
Many different protocols are described and used for the extraction of hesperidin from various
starting materials, including maceration [12,25–27], Soxhlet extraction [26,28], assisted extraction
with ultrasound [25], high hydrostatic pressure and microwave assisted extraction [29,30], enzymatic
process [14], and supercritical fluids extraction [31]. All the aforementioned extraction methods require
the use of organic solvents, energy, and/or high-pressure, which makes those processes unfavorable for
an ecologically clean way of treating orange peel. Herein, a new and green method, without using
organic solvents and with low energy consumption, was implemented for the extraction of hesperidin
from fresh orange bagasse. Hesperidin extracted in this manner is safe to use and biocompatible for
topical application.
2. Results
2.1. Yield of Hesperidin Extracted from Humid Orange Peel—Green Method
The obtained hesperidin was pale yellow amorphous powder (Supplementary Information
Figure S1). The yield of HSD extracted in this manner was ~1.2% calculated per dry orange peel
bagasse. The same method was repeated varying calcium(II) chloride solution concentrations—5% and
10%—but HSD yields were significantly lower when compared to one obtained with 7.5% calcium(II)
chloride solution. In addition, the color of the solution with 7.5% calcium(II) chloride was much darker
than obtained with the other two solutions (Figure S1, Supplementary Information). In the case of
5%, there are not enough calcium(II) ions to react the pectin and disrupt interaction of HSD with the
macromolecule, and in the case of 10% of the solution, calcium(II) interactions with HSD are due to
their ability to chelate metal ions.
2.2. Spectral Data and Characterization of Obtained HSD
The chemical structure and purity of the obtained HSD were analyzed applying High-field
Nuclear Magnetic Resonance (NMR) (Supplementary Information Figures S2 and S3), Fourier
Transform-Infrared (FT-IR) spectroscopy and Ultra High-Performance Liquid Chromatography
(UPLC, Supplementary Information Figure S3) techniques. All HSD NMR peak assignments of
proton and carbon signals were in accordance with the literature [32]. From the 1H NMR spectrum of
the obtained HSD, typical flavanone structure signals could be assigned at δ 12.02 (1H, s, 5-OH) and
δ 9.09 (1H), which originate from two hydroxyl groups attached to an aromatic ring, further δ 5.51
(1H, dd, J = 12.1, 3.3 Hz, H-2), from protons of the 1,3,4-trisubstitued ring at δ 6.91 (3H, m), protons of
rhamnose and glucose at δ 4.98 (1H, d, J = 7.3 Hz) and 4.53 (H, m), one methoxy group peak at δ 3.80
(3H, s), and one methyl group peak at δ 1.09 (4H, d, J = 6.2 Hz). The acquired Heteronuclear Single
Quantum Coherence (HSQC) spectra (Figure S2) and Heteronuclear Multiple Bond Coherence (HMBC)
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spectra (Figure S3) of the extracted HSD were used to confirm its structure. HSD was monitored by
UV maximum at 284 nm, caused by the conjugation of the keto group and the other oxygen atoms
with the aromatic ring systems. HSD purity was determined utilizing Ultra High-Performance Liquid
chromatography (UHPLC) with the reverse stationary phase (C18, length 10 cm, 5 μm). HSD analytical
standard (Sigma-Aldrich, 97% of purity) was used for calibration curve construction from the injection
of aliquots of 1, 2, 4, 6, 8, and 10 μL of standard HSD solution in methanol (concentration 100 ppm).
Calibration curves and the analysis of the sample from the extraction were performed in triplicate.
A solution of 100 ppm of HSD in methanol (HPLC grade of purity) was analyzed in UHPLC as to
obtain the area of the peak and to determine the relative concentration of HSD, comparing to the
Sigma-Aldrich standard of HSD with grade purity > 97%. The peak with the retention time of 6.877
min was assigned to HSD (Figure S3) as the same procedure was done with the standard for HSD
(>97%, Sigma-Aldrich). The determined purity was 97.2%, m/m, when compared to the Sigma-Aldrich
analytical standard (> 97%). Therefore, the applied extraction process was adequate and a high HSD
yield was achieved, while purity of the extracted HSD was high. It was observed that low impurities
coming from naringin were present (Supplementary Information Figures S2–S4).
2.3. Chelation Properties of Hesperidin
Hesperidin and copper(II) acetate were dissolved in methanol and mixed to obtain
hesperidin-copper complex. Likewise, with other compounds with a similar structure, HSD possesses
chelation potential when it is mixed with metal(II) ions [33]. Figure 2 presents the FT-IR spectra of
hesperidin, copper(II) acetate, and hesperidin–copper complex.
Figure 2. Fourier transform infrared (FT-IR) spectra of hesperidin (HSD, dotted line), copper(II) acetate
(Cu(II), dashed line), and HSD–Cu(II) complex (full line) on a Cary 630 FT-IR spectrometer equipped
with a monolithic design diamond Attenuated Total Reflectance (ATR) accessory (Agilent Technologies
Inc.). Hesperidin is a chelating agent of metal multivalent ions (Me2+). The creation of the complex
involves -OH groups in ortho- positions that coordinate with divalent cations [1].
The FT-IR spectra of HSD, copper(II) acetate, and the HSD–Cu(II) complex showed HSD band
shift upon complexation with a metal ion [33]. For example, the vibration stretching for -C=O in HSD
at 1644 cm−1 was shifted to 1515 cm−1 in the HSD–Cu(II) complex, due to the coordination with the
metal ion. The absorption bands in HSD for C-O at 1297, 1275, 1242, 1206, 1184, 1154, 1132, 1095,
1054, 1037, and 1009 cm−1 were suppressed, probably because of the Cu(II) bonding with -OH groups.
Therefore, there is a strong indication that hesperidin formed a complex with Cu(II) ions.
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2.4. HSD Interacts with Collagenase
Collagenase enzymes are a group of metalloproteinases responsible for the degradation of
collagen and may cause an ageing effect in skin when present in higher levels in extracellular matrix.
Figure 3 presents suppression of fluorescence quenching—observed for collagenase (Clostridium
histolyticum, Sigma-Aldrich) by the addition of hesperidin in different concentrations (DMSO solution).
Hesperidin, as other flavonoids, can reduce the intensity of tryptophan or other fluorophores of enzyme
fluorescence emissions. Hesperidin chelates zinc(II) ion, which is in the catalytic site of the enzyme,
and changes the conformation of the protein. There are already various studies in which it has been
proven that flavonoids have an inhibitory effect on metalloproteinase (collagenase, elastases, and
hyaluronidases) by chelating their metal ions. Additionally, the temperature of the experiment was
varied as to evaluate and calculate the thermodynamic values of enthalpy (ΔH) and entropy (ΔS) of
collagenase–hesperidin interaction.
(a) (b)
Figure 3. Illustration of fluorescence spectroscopy data: (a) Collagenase (Clostridium hystolicum) at
37 ◦C upon addition of HSD (in DMSO) at concentrations from 0.08 to 0.90 mmol L−1. (b) Diagram of
log((F0−F)/F) in function of log[HSD].
The mechanism of fluorescence suppression can be explained through collision quenching between
the excited enzyme and suppressor (Q), defined by bimolecular quenching constant Kq according to
Stern–Volmer [34]. The reduction in the intensity of the fluorescence emission (F) in relation to the
intensity observed in the absence of suppressor (F0) is given by Equation (1):
(F0/F) = 1 + Kqτ0[Q] = 1 + KS[Q] (1)
[Q] is a concentration of HSD, τ0 is 10−8 s, and Kq is the association constant, 0.29 × 10−3 mol−1 L,
0.32 × 10−3 mol−1 L, or 0.15 × 10−3 mol−1 L obtained for collagenase–HSD at 25 ◦C, 30 ◦C, and 37 ◦C,
respectively. The active site number was estimated at n = 1.2 (1.26, 1.24, and 1.19 for collagenase–HSD
interaction at 25 ◦C, 30 ◦C, and 37 ◦C, respectively). It was possible to calculate Gibbs free energy,
entropy, and enthalpy, ref [35] for collagenase–HSD at 25 ◦C, 30 ◦C, and 37 ◦C, as shown in Table 1.
Table 1. Thermodynamic parameters of collagenase–HSD interaction.
Temperature ◦C ΔG (kJ mol−1) ΔH (kJ mol−1) ΔS (J mol−1 K−1)
Collagenase–Hesperidin
25 20.0
30 22.2 −14.5 −19.0
37 22.6
According to the data (Table 1) and as well to Ross and Subramanian [35], the interaction between
collagenase and HSD is a partial immobilization. This interaction occurs when protein and ligand are
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leaving the state from which the two are separated and when they are hydrophobically associated.
Further, this type of association contributes to the decrease in the ΔS and ΔG values.
2.5. Characterization of HSD Nanocrystals
The obtained HSD was pre-milled and further nanonized on a homogenizer or ultrasound of
high potency. The effectiveness of pre-milling was clearly revealed by the reduction in particle
size distribution observed after applying different analytical methodologies for HSD nanonization.
The average size, zeta potential, and polydispersity index of the HSD nanoparticles are shown in Table 2.
Table 2. Mean size, zeta potential, and polydispersity (PdI) of nanoparticles from different formulations
prepared with various techniques, measured by a Malvern Zetasizer and a NanoSight LM20 microscope.










I 148.0 −36.2 0.181 109.0 39.0 2.03
II 1126 −29.6 0.579 157.0 59.0 0.14
III 265.7 −4.81 0.332 226.0 55.0 0.63
IV 259.7 −32.7 0.370 73.0 15.0 0.27
V 335.6 −30.1 0.375 63.0 18.0 0.43
VI 367.2 −33.6 0.332 111.0 47.0 5.65
VII 287.7 −19.0 0.433 76.0 15.0 2.34
VIII 485.4 −51.6 0.506 33.0 4.00 2.48
The results were obtained after 6 months of preparation of the emulsions. The sizes of the
HSD nanoparticles, after passing through the homogenizer and ultrasound, reduced from 600 to
150–350 nm, depending on the type, concentration of the polymer, and technique used for preparation.
Zeta potentials were very variable, and it was not possible to obtain the desired stability for all
nanoemulsions (for example, III, Table 2) with the best zeta potential being around −30 ± 6 mV. Part of
the particles had sizes up to 400 nm as measured using the Dynamic Light Scattering (DLS) and will
not affect their permeation via stratum corneum.
Scanning and transmission electron micrographs obtained for the formulations I, II, and IV–VIII
are presented in Figure 4 and show particles whose sizes are in accordance with the sizes measured by
(DLS) and NanoTracking Analysis (NTA) techniques. Nanoparticles of formulation I were around
200 nm in size, as shown in Table 2 and Figure 4. The formulation II contained bigger particles,
around 1 μm, probably because of sodium-carboxyl methyl cellulose as surfactant (image not shown).
Formulation IV (Figure 4) had particles with sizes of 250 nm (DLS and NTA), probably due to the
aggregation of poloxamer around the hesperidin particles, whereas NTA experiments showed the
presence of smaller particles of 50–100 nm.
Formulations V and VI were prepared utilizing the technique NANOEDGElike, where hesperidin
was dissolved in small amounts of propylene glycol and glycerol, respectively. SEM experiments were
not adequate to characterize the VI formulation and it was necessary to apply atomic force microscopy
(AFM) to perform such characterization. The particles were in the size range of 50–200 nm, and in the
image of formulation VI, nanofibers of nanocellulose could be seen. Formulations V and VI showed
above average stability for 6 months without any precipitation of the nanoparticles. Their stability
was achieved mostly because of the significant amount of nanocellulose used for their production,
while good dispersibility of hesperidin was achieved because of propylene glycol and glycerol used in
their formulation. As the formulations were prepared in aqueous solutions, there was no observed
HSD binding with CNF, which was also especially important from the point of view of skin permeation.
The stability of the prepared nanoemulsions (I–VIII) was very good (up to 6 months), which despite
showing a small percentage of agglomerates, returned to the initial state by a process involving the use
of an ultrasound bath (5 min).
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Figure 4. Scanning electron micrographs (left; scale bar = 500 nm) of formulation I and transmission
electron micrographs (right; scale bar = 200 nm) of formulation I. Scanning electron micrographs of
formulation III (left; scale bar = 1 μm) and formulation IV (right; scale bar = 500 nm), respectively.
Scanning electron micrographs of formulation V (left; scale bar = 1 μm) and atomic force micrographs
of formulation VI (right; scale bar = 4 μm). Scanning electron micrographs of formulations VII and
VIII (left; scale bar = 2 μm).
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2.6. Stability of HSD Cream Formulations
The stability tests for HSD incorporated in silky cream formulations, kept in plastic boxes made
of polypropylene at 4 ◦C and at room temperature, were carried out 72 h, 30 days, and 12 months after
manufacture. Organoleptic tests included appearance, color, brightness, consistency, and homogeneity
of the creams, evaluated by visual observation. Applied and sensory characteristics of samples,
such as spreadability, absorption, stickiness, and fat film on the skin were assessed after applying the
cream on the skin. Shortly after preparation, creams were homogenous, bright, and easily spreadable on
the skin. During the following 12 months, their consistency did not change, and the cream formulations
maintained odor and color as well. Measurement of the pH value was carried out potentiometrically,
by direct immersion of the glass electrode into the tested samples of creams at room temperature.
Values of the pH were in the range from 5 to 6, as is recommended by pharmacopoeia.
2.7. Evaluation of Toxicity of HSD Nanoemulsions and Cream
Full thickness skin (FTS) models for the toxicity (corrosion) test of hesperidin cream formulations
were synthesized in the Laboratory of Biology of the Skin, Faculty of Pharmaceutical Sciences, University
of Sao Paulo. As the experiment is quite complicated and expensive, just some of the HSD cream
formulations were tested.
Figure 5 presents photomicrographs of histological analysis—eosin stain (samples in paraffin) of the
FTS skin model after the cream application assay (24 h). This model was synthesized from the fibroblast
and keratinocytes isolated from normal human skin cells-donated foreskin samples. The model was
composed from two main skin layers-epidermis and dermis-and used for the evaluation of the toxicity
of cosmetic and other preparations. Epidermis was composed from five layers: stratum corneum,
stratum lucidum, stratum granulosum, stratum spinosum, and stratum basale. The last one was formed
from the undifferentiated cells, with a full metabolic activity, which was lost in later proliferation of the
cells and formation of the corneocytes. It is important to mention that macrophage and Langerhans
cells were not present, which are the first defensive line of the skin [36].
(a) (b) (c) (d)
Figure 5. Photomicrographs of Histological Analysis—Eosin stain (sample in paraffin) of the full
thickness skin (FTS) equivalent skin model after the cream application assay (a) negative control: sodium
chloride 0.9%; (b) positive control: HSD-DMSO, (c) A1 cream, and (d) A2 cream. The skin models were
generated using primary human keratinocytes and fibroblasts—the FTS model; (Scale bar = 500 μm).
In the negative control sample (Figure 5a) photomicrograph, epidermis and dermis layers were
preserved and there was no presence of vacuolization in the stratum basale. After application of the
A1 cream (without HSD-nanoemulsion), the basal layer was preserved, with remaining proliferation
despite some vacuoles’ presence (Figure 5b). The stratum corneum of this sample was preserved
and thicker, and the cream demonstrated good moisturizing effects. HSD in 10% DMSO showed
corrosive and cytotoxic effects on the FTS skin model, and led to complete degradation of the basal layer
(Figure 5b). Further, the formulation with even a small percentage of DMSO was avoided. Application
of nanoemulsion VI showed an irregular basal layer and elevated stratum corneum; therefore, a slight
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corrosive effect for this formulation was observed (Figure 5d). Nanoemulsion VII demonstrated less
cytotoxic effects, inclusively in the basal membrane, compared to the A2 cream. The corrosion test with
the A2 and A3 creams (data not shown) showed moderate hydration effects on the FTS skin model,
probably due to the hygroscopic effect of some of their ingredients. As this skin model is a living organ,
some of the ingredients of the nanoemulsion or the surfactant alone could have led to lower vitality
of the cells and prevented their further proliferation. The A2 cream contained only a Pluronic-F127
as a hygroscopic compound, and therefore, the viability of the cells was much higher than in the
case of the A3 cream. Nanoemulsions VI and VII demonstrated corrosive effects on the skin model
(data not shown) due to the dilution of the buffer solution as well as the inadequate environment for
the development and proliferation of cells. It is important to mention that the generated FTS skin
model does not contain macrophages or Langerhans cells, which are the first defense of the skin tissue’s
immunity, which makes it much more sensitive than normal skin tissue.
3. Discussion
A new, water-based, eco-friendly extraction was performed to yield hesperidin (HSD, 1.2%) with
approximate purity of 98%. This new method explored the use of calcium(II) and changes in the
pH as to isolate HSD from orange peel. The use of calcium(II) enabled the complexation of pectin
within the bagasse and release of HSD, which dissolved at high pH values. NaOH solution at pH
~11.5 deprotonated phenol HSD groups and promoted its better solubility. The next step counted
on HSD protonation (HCl), which caused HSD precipitation on pH ~4.2. Pale yellow powder was
obtained and characterized using different spectroscopic techniques. HSD is usually extracted with
organic solvents [30,32] or by supercritical fluid extraction [31]. The organic solvent extraction for
hesperidin extraction was performed by Cypriano and colleagues [37] in a 1.2% yield, following Ikan’s
method [12]. The method suggested in this work is energy- and organic solvents-free, and calcium(II)
and pH-triggered. The use of calcium(II) facilitated complexation of pectin polysaccharide and at the
same time, liberation of hesperidin from orange bagasse. The suggested process is longer but facilitates
the extraction of hesperidin with greater purity compared to the Sigma-Aldrich analytical standard.
Observing the structure of HSD (Figure 1), it is evident that its B-ring is electron richer than the
A-ring due to the contribution of the ortho methoxy group. The first site of oxidation in HSD is the
3′-phenoxyl group in a one-electron reduction [8,38]. The pKa of HSD -OH groups is 8.9 and 11.2,
respectively. However, the pKa of the hydroxyl radical in the 3′ position drops to a value around 4–5.
Due to this, HSD acts as antioxidant in the pH range of 7 to 10. Therefore, the mechanism of HSD
oxidation involves the transfer of one electron and one proton. The reduction potential of the phenolate
radical is strongly affected by substituents in the B-ring [8]. HSD has an electron-donating group
(methoxy) attached to the B-ring, which elevates its reduction potential (E = 0.72 V) when compared to
other flavonoids with catechol groups in the B-ring (E value from 0.5 to 0.7 V). Nevertheless, its reduction
potential is still smaller than those from alkyl peroxyl radicals (E = 1.05 V) and superoxide radicals
(E = 0.94 V), which confirms that HSD can scavenge and inactivate these harmful radical species in the
organism [8,39–51]. HSD high chemical reactivity can prevent injuries caused by free radicals through
direct interaction with radical oxygen species (ROS), or indirectly by inducing antioxidant enzymes
activation, chelating of metal ions, reduction in α-tocopherol radicals, inhibition of oxidases, reduction
in NO oxidative [4,38] stress, and increases in antioxidant effects of low molecular antioxidants [9,39].
Many other polyphenols, such as phenolic acid, flavonoids, coumarins, stilbenes, and lignans,
are the most important polyphenols used in traditional and modern cosmetic and dermatologic
products [3,52,53]. The antioxidant, anti-ageing, anti-inflammatory, antimicrobial, and anticancer
properties of flavonoids are frequently deployed in skincare products. Their antiradical functions,
as well as the ability to inhibit some enzymes, are some of the most important effects. Flavonoids
have an influence on skin microcirculation and can be used as ingredients in creams for vascular,
oily, and/or atypical skin [3]. Dermal bioavailability and antioxidant activity [54,55] of glycosides is
beneath when compared to their aglycon forms, due to their low permeability [3]. One of the interesting
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physical-chemical properties of bioflavonoids is their ability to absorb ultraviolet radiation due to the
presence of the conjugated double bonds in their structure. They may absorb UV radiations in the range
of 550–300 and 285–240 nm, resulting from phenolic electron-donating substituents, as well as inter- and
intramolecular hydrogen bonds and steric effects. The polyphenol concentrations used in cosmetics
cannot replace conventional UV filters. Moreover, they can act as co-adjuvants in erythema and skin
burns reduction caused by exposures to UVB radiation and IR rays of sunlight [3]. The anti-ageing
properties of flavonoids are associated with their effect on the modulation of matrix metalloproteinases
activities, which are dependent on the Zn2+ ion and involved in connective tissue remodeling. Equally,
by sequestering metal ions or the effects on the expression of endogenous protein tissue inhibitors of
metalloproteinase (TIMPs) [9], flavonoids can act protectively. Flavonoids’ skin whitening activity
relates to their modulation of tyrosinase activity, through their chelating of calcium(II), in the formation
of L-dopaquinone, which is a part of the melanogenesis process [56]. This ability is common to
quercetin, cyanidin, and kaempferol, while their glycoside forms have not shown this capability [3].
Hyaluronic acid, which is an integral part of the dermis and blood vessel wall, is degraded by the
activity of the enzyme hyaluronidase, which can be inhibited by the protective roles of flavonoids [3].
Additionally, phenolic compounds may have antimicrobial properties and assist in the preservation of
cosmetic products against secondary infections [3].
Low drug permeability through human epidermis can be ameliorated using penetration enhancers
(compounds such as surfactants, terpenes, lipophilic solvent, and fatty acids), which modify the
permeability of the skin barrier reversibly. Rutin, catechin, epicatechin, and quercetin have a limited
penetration. Quercetin shows poor permeability even in the presence of the enhancers, due to its
absolute insolubility in water [35]. Several authors suggested that the permeability of this compound
can be increased by uploading flavonoids in liposomes or other kinds of carrier systems. It can
also be affected by the presence of promoters of permeability, such as glycerin and propylene
glycol [3]. In the skin, HSD may significantly stimulate epidermal hyperplasia and improve epidermal
permeability through epidermal proliferation, osteoblasts differentiation, and lipid secretion. Different
skin layers and skin proteins can respond differently to HSD treatment. Involucrin, present in the
stratum spinosum, does not respond to HSD treatment. Filaggrin and loricrin (located in the stratum
granulosum and stratum spinosum) expressions are increased. These beneficial effects that improve
epidermal permeability and regulate filaggrin can be useful in the treatment of certain skin disorders,
such as cutaneous inflammation and atopic dermatitis [52]. In vitro, HSD can inhibit the tyrosinase
in melanocytes and reduce the process of melanogenesis, or influence melanocytes proliferation.
Therefore, the possibility of affecting tyrosinase activity, and the practical application thereof in the
field of anti-ageing preparations designed to prevent lentigo senilis and lentigo solaris makes HSD
remarkably interesting for skin whitening [3]. Daily topical applications of HSD microemulsion have
shown a significant skin whitening effect, reduction in trans-epidermal water loss, and inhibition of
irritation effect after exposure to UV rays after four weeks. In their study, Kim et al. [56] showed that
HSD had a depigmentation effect by blocking the melanophilin, a tripartite protein complex which is
a response for transport of the melanosome into the melanocytes. This was proven by melanosome
aggregation tests in cells. HSD did not inhibit melanin production in melanoma cells, but reduced skin
pigmentation in the reconstruction of human epidermal skin [56]. HSD may also affect polyoxygenase,
cyclooxygenase, hyaluronidase, collagenase, elastase, and tyrosinase; thus, it can contribute to the
reduction in modifications in the skin’s connective tissue remodeling [3]. Hyaluronidase plays a
significant role in regulating the permeability of capillary walls and supporting tissues by causing the
breakdown of hyaluronic acid and increasing the permeability of the tissue [5]. The HSD’s ability to
chelate multivalent metals such as iron(III), iron(II), copper(II), zinc(II), and manganese(II) is as relevant
to the inhibition of enzymes, which contain metal ions in their reaction center or require metal cations
cofactors, as to the inhibition of inflammatory processes and function of vascular vessels [3,15,57,58].
Chelation properties of HSD are particularly important for skin bleaching activities, as well as HSD
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interaction with the tyrosinase during catalytic production of melanin. Tyrosinase has copper(II) in the
active site, which is responsible for tyrosinase oxidation activities [9].
4. Materials and Methods
4.1. Materials
Oranges (Citrus sinensis) and orange peel bagasse were purchased from a local supermarket
in Campinas (Sao Paulo, Brazil). Hesperidin standard was bought from Sigma-Aldrich (St. Louis,
MA, USA) at analytical grade (>97%). Calcium(II) chloride, copper(II) acetate, sodium hydroxide,
and hydrochloric acid were from Labsynth (Diadema, Sao Paulo, Brazil) at practical grade. Deuterated
solvent (DMSO-d6) was purchased from Sigma-Aldrich (St. Louis, MA, USA). Methanol and
phosphoric acid for the UHPLC assays were analytical grade (Avantor “Performance Materials”,
Mexico®, Ecatepec de Morelos, Mexico). ABIL® Care 85 (Bis-PEG/PPg-16/16 PEG/PPG16/16
Dimethicone; Caprylic/Capric Triglyceride) were sampled from the EVONIK® group (Essen, Germany).
Muru muru (Astrocaryum murumuru Seed Butter), Cupuaçu butter (Theobroma grandiflorum Seed Butter),
and Andiroba oil (Carapa Guianensis Seed Oil) were sampled from Amazon oil industry; Glyceryl
monostearate, Mineral oil, Carbopol ULTREZ 10, Triethanolamine, and Vit E-acetate (α-Tocopheryl
acetate) were bought from Fagron® (Rotterdam, The Netherlands).
4.2. Extraction of HSD from Humid Orange Bagasse
The fresh chopped orange peel (Citrus sinensis, 100 g) was milled in a blender and immersed
in 300 mL of aqueous CaCl2 solution (7.5%). The mixture was left to stand for 24 h, then, a NaOH
1 mol L−1 solution was added dropwise until a pH of 11.50 was reached. It was set to stand for 24 h, the
pH was measured, and it dropped to 9.66 overnight. Then, the suspension was filtered, and the pellet
was much harder when compared with the starting material, probably because of the interactions
between calcium(II) ions and pectin. Concentrated HCl was then added to the solution, and pH was
lowered to 4.35. The solution was left to stand at 4 ◦C for 2 days. After 24 h, crystals were formed
at the bottom of the glass. However, for the best yields, two days of precipitation is recommended.
After 48 h, HSD was filtered onto a MILIPORE® (Burlington, MA, USA) apparatus, using a 0.45 μm
pore filter, and dried for 2 h in drying oven (60 ◦C).
4.3. Nuclear Magnetic Resonance—NMR
Nuclear Magnetic Resonance spectra were acquired on a Bruker AVANCE III 600 MHz spectrometer
(Bruker Biospin, Karlsruhe, Germany) equipped with a 5 mm Triple Resonance Broadband Inverse
(TBI) probe at 25 ◦C. 1H NMR (1D, 600.173 MHz) spectra were acquired using a f1 pre-saturation
sequence with 32 transient scanning, 64 k data points, and 13 kHz bandwidth. 13C NMR spectra were
obtained using the 1D sequence with power decoupling. Isolated HSD was dissolved in DMSO-d6
(20 mg mL−1). Two-dimensional spectra (Heteronuclear Single Quantum Coherence—HSQC) were
acquired using the 600.17 MHz frequency domain spectrometer F2 and 150.91 MHz in the F1 domain
with a free induction decay size (FID) of 4096 (F2) and 256 (F1) data points and 16 “ghost” scans were
used. HSQC (hsqcedetgpsp.) spectra were recorded with an acquisition time of 2.129 × 10−1 s (F2) and
4.437 × 10−3 s (F1) pulse sequence. The Heteronuclear Multiple Bond Correlations (HMBC) were
acquired using the 600.17 MHz frequency domain spectrometer F2 and 150.91 MHz in the F1 domain
with a free induction decay size (FID) of 2048 (F2) and 256 (F1) data points and 16 “ghost” scans were
used. HMBC spectra were acquired with an acquisition time of 2.130 × 10−1 s (F2) and 4.437 × 10−3 s
(F1), using the hmbcgplpndgf. pulse sequence. The spectra were processed in MestreNova software,
using LB = 1.00 for F2 and LB = 0.30 for F1.
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4.4. Fourier Transform Infrared Spectroscopy—FT-IR
The Fourier transform infrared spectrum (FT-IR) of HSD was obtained on a Cary 630 FT-IR
spectrometer equipped with a monolithic diamond attenuated total reflection (ATR) accessory
(Agilent Technologies Inc., Santa Clara, CA, USA). The spectra were recorded accumulating 128 scans
at a resolution of 4 cm−1 in the range from 4000 to 400 cm−1.
4.5. UHPLC—Purity of Extracted Hesperidin
The HSD purity was determined utilizing Ultra-High-Performance Liquid (UHPLC—Waters,
Milford, MA, USA) with the reverse stationary phase (Zorbax Eclipse C18, length 10 cm, 5 μm,
Agilent Technologies Inc., Santa Clara, CA, USA). The mobile phase was prepared with methanol
and water (60:40 v/v) with the addition of phosphoric acid (0.1%). A hesperidin analytical standard
(Sigma-Aldrich, >97% of purity, St. Louis, MO, USA) was used for calibration curve construction from
the injection of aliquots of 1, 2, 4, 6, 8, and 10 μL of standard solution, HSD in methanol (100 ppm).
Calibration curves and the analysis of the sample from the extraction were performed in triplicate.
The following method was adapted from Weon et al. (2012) [59].
4.6. Chelation Properties of Hesperidin
Chelation properties of HSD were tested through the interaction of HSD with copper(II), following
the procedure in Selvaraj et al. [58]. For the experiment, HSD (1 mmol L−1) was dissolved in 50 mL of
methanol, mixed with 0.199 g of copper(II) acetate in 25 mL of double distilled water and stirred for
6 h at room temperature. The pale green insoluble precipitate was obtained and filtered and washed
with water and methanol to remove the excess of HSD and copper(II) acetate. The product was then
air-dried. The greenish precipitate obtained was vacuum dried and characterized.
4.7. Fluorescence Suppression—Quenching
The measurements were performed on a Varian spectrofluorometer (Cary Eclipse model, Agilent
Technologies Inc., Santa Clara, CA, USA) by applying a wavelength of 278 nm for excitation of the
collagenase, excitation and emission slits were 5 nm wide, and acquisition of emission spectra occurred
in the range of 300–450 nm, with the sample compartment with a thermostat at 25, 30, and 37 ◦C.
A 10 × 10 mm optical path quartz (Hellma, Mülheim, Germany) cuvette was used. To obtain spectra,
2 mL of collagenase (Sigma-Aldrich) in concentration 0.065 mg mL−1 (water solution) were titrated
with hesperidin solution in DMSO (0.10 mg mL−1 concentration). Additions of aliquots of HSD were
as follow: 0.5 μL up to 4 μL, 1.0 μL up to 50 μL, and 5 μL up to a volume of 110 μL, reaching the final
concentrations of 5.68 mg mL−1 of HSD in solution.
4.8. Preparation of Hesperidin Nanocrystals
HSD was utilized to formulate nanoemulsions. Polymers utilized in preparations were poloxamer
(Pluronic F127, Sigma Aldrich, St. Louis, MO, USA) and nanocellulose, which served as stabilizers
and showed different capacities regarding the preservation of hesperidin nanostructure. These were
dissolved in water and mixed with an Ultra Turrax mixer for 15 min at a speed of 14,000 rpm min−1.
Pre-milling with the mixer avoided blocking the homogenizing gap of the homogenizer present in
the prepared formulation. Hereupon, the formulations I, II, and VII were processed through the
homogenizer (Gea Niro Soavi, Model NS 1001L—Panda 2k, Dusseldorf, Germany) at high pressure
(600 bar) for 5 cycles. During the homogenization process, a pressure decrease was observed, especially
after the third cycle. The process utilized for HSD nanonization for formulations III, IV, V, and VI
was based on the technology NANOEDGE™, where HSD was solubilized in a minimum quantity of
solvent (or homogenous mixture of complex composition). The resulting solution was added to a
mixture of purified water and stabilizers and it underwent a homogenization process with high-potency
ultrasound (Ultronique, Model: DESRUPTOR; Freq. US: 20 kHz; Potency US: 750 W, Indaiatuba SP,
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Brazil), 70% potency for 30 min. Formulations V and VI were prepared through a NANOEDGE-like
technique, where initially HSD was dissolved in the mixture of essential oil (orange peels) and
glycerol and added into the solution of purified water and nanocellulose; afterwards, it was sonicated.
Formulations prepared using two nano-techniques and their ingredients were as follows:
I—H69, combination of pre-milling with an Ultra Turrax and high-pressure homogenization,
ingredients used: hesperidin and water;
II—H69, combination of pre-milling in an Ultra Turrax and high-pressure homogenization,
ingredients used: hesperidin, DMSO, glycerol, sodium-carboxyl methyl cellulose, and water;
III—NANOEDGE-like, combination of microprecipitation and ultrasound, used ingredients:
hesperidin, DMSO, glycerol, poloxamer (Pluronic F127), and water;
IV—NANOEDGE-like, combination of microprecipitation and ultrasound, used ingredients:
hesperidin, DMSO, orange oil, poloxamer (Pluronic F127), and water;
V—NANOEDGE-like, combination of microprecipitation and ultrasound, used ingredients:
hesperidin, propylene glycol, nanocellulose, and water;
VI—NANOEDGE-like, combination of microprecipitation and ultrasound, used ingredients:
hesperidin, glycerol, nanocellulose, and water;
VII—H69, combination of pre-milling in an Ultra Turrax and high-pressure homogenization:
hesperidin, glycerol, orange oil, poloxamer (Pluronic F127), and water;
VIII—Milling in an Ultra Turrax, ingredients used: hesperidin, glycerol, orange oil, poloxamer
(Pluronic F127), and water.
4.9. Formulation of the Silky Cream
Oil-in-water silky cream formulations were prepared following the protocols of the EVONIK®
group (Essen, Germany), for use of the surfactant ABIL® Care 85 (Bis-PEG/PPg-16/16 PEG/PPG16/16
Dimethicone; Caprylic/Capric Triglyceride) and presented in Table 3. Muru muru (Astrocaryum
murumuru Seed Butter), Cupuaçu butter (Theobroma grandiflorum Seed Butter), and Andiroba oil
(Carapa Guianensis Seed Oil) were sampled from Amazon oil industry; Glyceryl monostearate, Mineral
oil, Carbopol ULTREZ 10, Triethanolamine, and Vit E-acetate (α-Tocopheryl acetate) were from Fagron®.
Emulsifier ABIL® Care 85 that gives a velvety-silky skin feel was sampled from EVONIK® and was
used in exceptionally low usage concentration. Ethylhexylglycerin and Phenoxyethanol (Fagron®)
were used for formulation preserving in exceptionally low concentration, instead of the commercial
paraben’s components.
Table 3. Silky velvet cream formulations prepared for application of hesperidin nanoemulsions.
Phase Name A1 (%, g g−1) A2 (%, g g−1) A3 (%, g g−1)
A
Bis-PEG/PPG-16/16 PEG/PPG-16/16
Dimethicone; Caprylic/Capric Triglyceride 1.0 1.0 1.0
Muru muru butter 1.0 1.0 1.0
Cupuaçu butter 1.0 1.0 1.0
Andiroba oil 3.0 3.0 3.0
GMS 2.0 2.0 2.0
Cetostearyl alcohol 3.0 3.0 3.0
Mineral oil 5.0 5.0 5.0
B
Carbopol ULTREZ 10 0.2 0.2 0.2
Aqua (Purified Water) 79.8 - -
Nanoemulsion - 79.8 79.8
C Triethanolamine 5 *gtts 5 *ggts 5 *ggts
B Vit E-acetate 0.5 0.5 0.5
E Ethylhexylglicerin, Phenoxyethanol 0.5 0.5 0.5
*gtts is drops.
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Ingredients of the phases A and B were measured, transferred into two beakers, and heated
to 50 ◦C. When the oil phase was homogenized and all the ingredients were molten, phase A was
added into phase B. The mixture was stirred and homogenized until it cooled down to a temperature
of 25 ◦C. Ingredients of the phases C and E were added at room temperature, along with stirring.
A whitish cream, oil-in-water, silky, with soft consistency, and easy to apply with no greasy film
leftovers after applying was obtained. Nanoemulsion VI was used for the preparation in the A2 cream
and Nanoemulsion VII was used for preparation in the A3 cream formulation.
4.10. Skin Model USP-FTS Skin Corrosion Test of Cream Formulations
Full thickness skin models (FTS) for the toxicity test of hesperidin cream formulations were
prepared in the Laboratory of Biology of the Skin, coordinated by Prof. Silvya Stuchi Maria-Engler,
Faculty of Pharmaceutical Sciences, University of Sao Paulo. Fibroblast and keratinocytes were isolated
from the normal human skin cells, from donated foreskin samples obtained from the University of
Sao Paulo Hospital (Sao Paulo, Brazil). Performed assays were under the approval of the local Ethics
Committee (HU CEP Case No. 943/09 and CEP FCF/USP 534). Isolated cells were seeded on top
of the collagen I matrix model in a 6-well plate containing enough specific medium mixture for the
FTS model as to maintain the skin at the air–liquid interface, as it is described by Catarino et al. [32].
For the corrosion tests, the following system was used: 100 μg mL−1 of hesperidin in 10% DMSO,
cream without the hesperidin nanoemulsion (A1), two formulations of hesperidin nanoemulsions
(Nanoemulsion VI and Nanoemulsion VII), and the last two in the cream formulations as A2 and A3
creams. As a negative control, 0.9% sodium-chloride solution was used. The 100 μg mL−1 of hesperidin
in 10% DMSO were tested by adding 5 mL in the well plate, and the 0.5 mL of cream formulations
were applied over epidermis. Samples were left over night for incubation (37 ◦C, 5% CO2). All tests
were performed in duplicate. After 24 h, skins were washed with 0.9% of sodium-chloride solution
and preserved in paraffin for further microscopic tests.
4.11. Diffraction Light Scattering and Zeta Potential
Mean size, polydispersity, and zeta potential of nanoparticles from each formulation were
determined using diffraction light scattering technique (Nano ZS Zetasizer—Malvern, PANalytical
Almelo, The Netherlands). Known also as Photon Correlation Spectroscopy—PCS, this is the technique
that was used to measure the hydrodynamic diameter of particles in a range from microns up to 1 nm.
4.12. Nanoparticle Tracking Analysis—NTA Analysis
Analysis (NTA) was performed with a NanoSight LM20 microscope (NanoSight, Amesbury, UK),
equipped with a 640 nm laser sample camera and a fluoroelastometer. Samples were diluted and
injected with sterile syringes 57 (BD Discardit II, Jersey, USA) until the liquid reached the tip of the
mouthpiece. All measurements were performed at room temperature, with live monitoring of thermal
stresses. The software used to capture and analyze the data was NTA 2.0 Build 127. The samples were
captured with 60 s time using the parameters predetermined by the manual.
4.13. Electronic Microscopy—Transmission, Scanning, and Atomic Force
Utilizing the microscope SEM JEOL JSM-6360 LV (JEOL, Akishima, Tokyo, Japan) and an
atomic force microscope (Shimadzu, SPM 9500J3), the size of the nanoparticles in the nanoemulsions
was verified. The sonicated hesperidin nanoemulsion was dropped onto a sample holder, dried at
room temperature, and coated with gold or platinum using a MED 020 Sputter (BalTech, Balzers,
Liechtenstein). The images were obtained using an acceleration voltage of 10 kV and a secondary
electron detector.
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5. Conclusions
Hesperidin (HSD) was obtained from citrus peels through a pH-triggered precipitation method
conducted just in water. The extracted hesperidin purity and yield were excellent when compared to
standard methods of its extraction and a commercially available compound. HSD showed chelating
activity toward bivalent ions and interacted with collagenase. HSD was used for the formulation
of a promising anti-ageing face cream. Upon nanonizing, HSD nanoparticles (150 to 400 nm) were
employed into up to 12 months stable nanoemulsions, whose applicability was tested in vitro on
artificial skin. No nocive effects were observed, and the best face cream formulation (cream A2)
showed good results in reducing the black circles in the under eye region. Moreover, daily topical
applications of hesperidin nanoemulsion have shown a significant skin whitening effect, reduction in
trans-epidermal water loss, and inhibition of an irritation effect after exposure to UV rays. This way,
a clean cream active ingredient is proposed, and a promising cosmeceutical was formulated starting
from agro-industrial waste.
Supplementary Materials: The following are available online, Figure S1. Steps of hesperidin water extraction:
(a) squeezing orange peel, alkaline medium solution; (b) acidic solution and first precipitate of hesperidin;
(c) precipitated hesperidin after 7 days at 4 ◦C; (d) filtration of precipitated hesperidin; (e) dried yellow powder
of hesperidin. Figure S2. HSQC contour plot of hesperidin (20 mg mL−1) in DMSO-d6 (2.50 ppm; 39.50 ppm)
as a solvent, on Bruker AVANCE III 600 MHz equipment at 25 ◦C. Figure S3. HMBC contour plot of hesperidin
(20 mg mL−1) in DMSO-d6 (2.50 ppm; 39.50 ppm) as a solvent, on Bruker AVANCE III 600 MHz equipment
at 25 ◦C. Figure S4. Chromatogram obtained from injection of the extracted hesperidin sample by separation
through ultra-high-performance liquid chromatography (UHPLC) with reverse phase C18; the peak with the
retention time at 6.877 min corresponds to hesperidin. Figure S5. Fluorescence suppression - quenching effect of
hesperidin solution in DMSO (concentration from 0.00 to 5.09 mmol L−1) on collagenase (Clostridium histolyticum,
Sigma-Aldrich) at 37 ◦C. Figure S6. Fluorescence suppression—quenching effect of hesperidin solution in DMSO
(concentration from 0.00 to 5.22 mmol L−1) on collagenase (Clostridium histolyticum, Sigma-Aldrich) at 30 ◦C.
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